<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3065466/results/search/disease/results.xml">
   <result pre="are properly credited. Abstract Antiviral drugs dispensed during the 2009" exact="influenza" post="pandemic generally failed to contain transmission. This poses the"/>
   <result pre="transmission should be part of preparedness plans for a future" exact="influenza" post="pandemic. Data on the incidence of the first 350"/>
   <result pre="containment of transmission is unlikely. page-count: Introduction The threat from" exact="avian influenza" post="H1N5 prompted many countries to establish a stockpile of"/>
   <result pre="of transmission is unlikely. page-count: Introduction The threat from avian" exact="influenza" post="H1N5 prompted many countries to establish a stockpile of"/>
   <result pre="because their use to protect against currently circulating strains of" exact="influenza" post="indicates a reduced chance of being infected [5], [6],"/>
   <result pre="modest. In practice, the antiviral drugs dispensed during the 2009" exact="influenza" post="pandemic generally failed to contain transmission. This prompts us"/>
   <result pre="immunity against the new strain from previous exposure to other" exact="influenza" post="strains. Figure 1 Baseline transmission model. Mass vaccination and"/>
   <result pre="SIR transmission model. Our concern is with a strain of" exact="influenza" post="that is newly emerged and so individuals can be"/>
   <result pre="appropriate individuals is possible in practice. In retrospect, pandemic H1N1" exact="influenza" post="in 2009 seemed to satisfy condition (i), but condition"/>
   <result pre="the emerged virus strain is as estimated for currently circulating" exact="influenza" post="strains. The effect of antivirals on reducing transmission is"/>
   <result pre="important because, as reflected in the model, individuals infected with" exact="influenza" post="become infectious prior to onset of symptoms and the"/>
   <result pre="use of antiviral drugs to contain transmission of pandemic H1N1" exact="influenza" post="in 2009 was not successful because the fraction of"/>
   <result pre="drugs is based on their demonstrated effectiveness against currently circulating" exact="influenza" post="strains. There is no guarantee that these drugs will"/>
   <result pre="are motivated by data on antiviral effects for currently circulating" exact="influenza" post="strains, [25]. In the simulations we used for the"/>
   <result pre="to mitigate general transmission following emergence of a future pandemic" exact="influenza" post="strain. The main conclusion is a strong recommendation that"/>
   <result pre="antiviral drugs do reduce transmission of the new strain of" exact="influenza" post="virus. It is concluded that we can expect to"/>
   <result pre="What do we need?Vaccine246793679517167888 4HarrodMEEmerySDwyerDE2006Antivirals in the management of an" exact="influenza" post="pandemic.Med J Aust185S58S6117115954 5HaydenFGTreanorJJBettsRFLoboM EsinhartJDet al.1996Safety and efficacy of"/>
   <result pre="randomized controlled trials for prevention and treatment.JAMA2821240124610517426 7HaydenFGBelsheRVillanuevaCLannoRHughesCet al.2004Management of" exact="influenza" post="in households: a prospective, randomized comparison of Oseltamivir treatment"/>
   <result pre="influenza.N Engl J Med3531363137316192481 9WelliverRMontoASCarewiczOSchattemanEHassmanMet al.2001Effectiveness of oseltamivir in preventing" exact="influenza" post="in household contacts.JAMA28574875411176912 10Hayden FG etal1997Efficacy and safety of"/>
   <result pre="in treating acute influenza.J Am Med Assoc28310161024 13JeffersonTDemicheliVRivettiDJonesMPietrantonjCDet al.2006Antivirals for" exact="influenza" post="in healthy adults: systematic review.Lancet36730331316443037 14JeffersonTJonesMDoshiPDel MarC2009Neuraminidase inhibitors for"/>
   <result pre="adults: systematic review.Lancet36730331316443037 14JeffersonTJonesMDoshiPDel MarC2009Neuraminidase inhibitors for preventing and treating" exact="influenza" post="in healthy adults: systematic review and meta-analysis.BMJ339b510619995812 15FergusonNMCummingsDATCauchemezSFraserCRileySet al.2005Strategies"/>
   <result pre="systematic review and meta-analysis.BMJ339b510619995812 15FergusonNMCummingsDATCauchemezSFraserCRileySet al.2005Strategies for containing an emerging" exact="influenza" post="pandemic in southeast Asia.Nature43720921416079797 16LonginiIMNizamAXuSUngchusakKHanshaoworakulWet al.2005Containing pandemic influenza at"/>
   <result pre="an emerging influenza pandemic in southeast Asia.Nature43720921416079797 16LonginiIMNizamAXuSUngchusakKHanshaoworakulWet al.2005Containing pandemic" exact="influenza" post="at the source.Science3091083108716079251 17BarnesBGlassK2007The role of health care workers"/>
   <result pre="or treatment? Optimal use of an antiviral stockpile during an" exact="influenza" post="pandemic.Math Biosci20933636017416393 19CowlingBJLauMSHoLMChuangSKTsangTet al.2010The effective reproduction number of pandemic"/>
   <result pre="in Brazil.Statist Meth Med Research15481497 25GlassKBeckerNG2009Estimating antiviral effectiveness against pandemic" exact="influenza" post="using household data.J Roy Soc Interface669570319064345 26BaileyNTJ1975The mathematical theory"/>
   <result pre="data needed for an early estimate of transmissibility when an" exact="infectious disease" post="emerges.Euro Surveill15pii = 19603 31MercerGNGlassKBeckerNG2011Effective reproduction numbers are commonly overestimated early"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3136400/results/search/disease/results.xml">
   <result pre="1479-0556-9-11 pmid: 21699699 doi: 10.1186/1479-0556-9-11 : Review Antiviral drugs against" exact="hepatitis" post="C virus RehmanSidra1sidra_cemb@yahoo.comAshfaqUsman A1usmancemb@gmail.comJavedTariq1tjavedpk@gmail.com[1], collection: 2011epub: 2011-6-691111received: 2011-4-21accepted: 2011-6-23(C)"/>
   <result pre="antiviral targets against HCV via Specifically Targeted Antiviral Therapy for" exact="hepatitis" post="C (STAT-C) approach (in which compounds are designed to"/>
   <result pre="have successively infected with chronic infection and 2-5% have developed" exact="hepatocellular carcinoma" post="per annum. HCV has the capacity to stimulate immunopathological"/>
   <result pre="(ROS) impend indirectly fibrogenetic effects [6] leading to steatosis and" exact="cirrhosis" post="[7]. HCV infection commences while interaction of virions instigate"/>
   <result pre="NS5B RdRp have been appraised. Specifically Targeted Antiviral Therapy for" exact="hepatitis" post="C (STAT-C) approach is now being currently used to"/>
   <result pre="ITMN-191 (R7227) is considered to be helpful in curing chronic" exact="hepatitis" post="C [44]. GS-327073, 5-[{3-(4-chlorophenyl)-5-isoxazolyl} methyl]-2-(2, 3-difluorophenyl)-5H-imidazo [4,5-c] pyridine is"/>
   <result pre="replicons [47]. Novel sulfonamide P4-capped ketoamide second generation inhibitors of" exact="hepatitis" post="C virus NS3 serine protease have been discovered. Discovery"/>
   <result pre="manuscript. References BaldoVBaldovinTTrivelloRFloreaniAEpidemiology of HCV infectionCurr Pharm Des2008141646165410.2174/13816120878474677018673187 RajaNSJanjuaNKEpidemiology of" exact="hepatitis" post="C virus infection in Pakistan. J Microbiol Immunol InfectJ"/>
   <result pre="of a cDNA clone derived from a blood-borne non-A, non-B" exact="viral hepatitis" post="genomeScience198924435936210.1126/science.25235622523562 ReedKERiceCMOverview of hepatitis C virus genome structure, polyprotein"/>
   <result pre="a cDNA clone derived from a blood-borne non-A, non-B viral" exact="hepatitis" post="genomeScience198924435936210.1126/science.25235622523562 ReedKERiceCMOverview of hepatitis C virus genome structure, polyprotein"/>
   <result pre="from a blood-borne non-A, non-B viral hepatitis genomeScience198924435936210.1126/science.25235622523562 ReedKERiceCMOverview of" exact="hepatitis" post="C virus genome structure, polyprotein processing, and protein propertiesCurr"/>
   <result pre="interferon alfa-2b and ribavirin on steatosis in patients infected with" exact="hepatitis" post="CHepatology200338758512829989 BurloneMEBudkowskaAHepatitis C virus cell entry: role of lipoproteins"/>
   <result pre="FeldJJHoofnagleJHMechanism of action of interferon and ribavirin in treatment of" exact="hepatitis" post="CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients with chronic hepatitis CN"/>
   <result pre="treatment of hepatitis CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients with chronic" exact="hepatitis" post="CN Engl J Med20003431666167210.1056/NEJM20001207343230111106715 De FrancescoRMigliaccioGChallenges and successes in"/>
   <result pre="Med20003431666167210.1056/NEJM20001207343230111106715 De FrancescoRMigliaccioGChallenges and successes in developing new therapies for" exact="hepatitis" post="CNature200543695396010.1038/nature0408016107835 HaoWHerlihyKJZhangNJFuhrmanSADoanCPatickAKDuggalRDevelopment of a novel dicistronic reporter-selectable hepatitis C"/>
   <result pre="therapies for hepatitis CNature200543695396010.1038/nature0408016107835 HaoWHerlihyKJZhangNJFuhrmanSADoanCPatickAKDuggalRDevelopment of a novel dicistronic reporter-selectable" exact="hepatitis" post="C virus replicon suitable for high-throughput inhibitor screeningAntimicrob Agents"/>
   <result pre="for high-throughput inhibitor screeningAntimicrob Agents Chemother2007519510210.1128/AAC.01008-0617060518 TedescoRShawANBambalRChaiDConchaNODarcyMGDhanakDFitchDMGatesAGerhardtWG3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of" exact="hepatitis" post="C virus RNA-dependent RNA polymeraseJ Med Chem20064997198310.1021/jm050855s16451063 ZuckPMurrayEMStecEGroblerJASimonAJStruloviciBIngleseJFloresOAFerrerMA cell-based"/>
   <result pre="beta-lactamase reporter gene assay for the identification of inhibitors of" exact="hepatitis" post="C virus replicationAnal Biochem200433434435510.1016/j.ab.2004.07.03115494142 WangCGaleMJrKellerBCHuangHBrownMSGoldsteinJLYeJIdentification of FBL2 as a"/>
   <result pre="WangCGaleMJrKellerBCHuangHBrownMSGoldsteinJLYeJIdentification of FBL2 as a geranylgeranylated cellular protein required for" exact="hepatitis" post="C virus RNA replicationMol Cell20051842543410.1016/j.molcel.2005.04.00415893726 WatashiKIshiiNHijikataMInoueDMurataTMiyanariYShimotohnoKCyclophilin B is a"/>
   <result pre="RNA replicationMol Cell20051842543410.1016/j.molcel.2005.04.00415893726 WatashiKIshiiNHijikataMInoueDMurataTMiyanariYShimotohnoKCyclophilin B is a functional regulator of" exact="hepatitis" post="C virus RNA polymeraseMol Cell20051911112210.1016/j.molcel.2005.05.01415989969 ZhangJYamadaOSakamotoTYoshidaHIwaiTMatsushitaYShimamuraHArakiHShimotohnoKDown-regulation of viral replication"/>
   <result pre="replication by adenoviral-mediated expression of siRNA against cellular cofactors for" exact="hepatitis" post="C virusVirology200432013514310.1016/j.virol.2003.11.02315003869 AlRHXieYWangYHagedornCHExpression of recombinant hepatitis C virus non-structural"/>
   <result pre="against cellular cofactors for hepatitis C virusVirology200432013514310.1016/j.virol.2003.11.02315003869 AlRHXieYWangYHagedornCHExpression of recombinant" exact="hepatitis" post="C virus non-structural protein 5B in Escherichia coliVirus Res19985314114910.1016/S0168-1702(97)00147-09620206"/>
   <result pre="non-structural protein 5B in Escherichia coliVirus Res19985314114910.1016/S0168-1702(97)00147-09620206 FerrariEWright-MinogueJFangJWBaroudyBMLauJYHongZCharacterization of soluble" exact="hepatitis" post="C virus RNA-dependent RNA polymerase expressed in Escherichia coliJ"/>
   <result pre="coliJ Virol199973164916549882374 SampathAPadmanabhanRMolecular targets for flavivirus drug discoveryAntiviral Res20098161510.1016/j.antiviral.2008.08.00418796313 BartenschlagerRThe" exact="hepatitis" post="C virus replicon system: from basic research to clinical"/>
   <result pre="025, a cyclophilin binding molecule, is highly efficient in clearing" exact="hepatitis" post="C virus (HCV) replicon-containing cells when used alone or"/>
   <result pre="therapy for HCV (STAT-C) inhibitorsAntimicrob Agents Chemother20095396797610.1128/AAC.00939-0819104013 CoelmontLHanoulleXChatterjiUBergerCSnoeckJBobardtMLimPVliegenIPaeshuyseJVuagniauxGDEB025 (Alisporivir) inhibits" exact="hepatitis" post="C virus replication by preventing a cyclophilin A induced"/>
   <result pre="in domain II of NS5APLoS One5e13687 FlintMMullenSDeatlyAMChenWMillerLZRalstonRBroomCEminiEAHoweAYSelection and characterization of" exact="hepatitis" post="C virus replicons dually resistant to the polymerase and"/>
   <result pre="Agents Chemother20095340141110.1128/AAC.01081-0818936191 LudmererSWGrahamDJBootsEMurrayEMSimcoeAMarkelEJGroblerJAFloresOAOlsenDBHazudaDJLaFeminaRLReplication fitness and NS5B drug sensitivity of diverse" exact="hepatitis" post="C virus isolates characterized by using a transient replication"/>
   <result pre="ShiSTHerlihyKJGrahamJPNonomiyaJRahavendranSVSkorHIrvineRBinfordSTatlockJLiHPreclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the" exact="hepatitis" post="C virus RNA-dependent RNA polymeraseAntimicrob Agents Chemother2009532544255210.1128/AAC.01599-0819307358 KimHJSharonABalCWangJAlluMHuangZMurrayMGBassitLSchinaziRFKorbaBChuCKSynthesis and"/>
   <result pre="analogues with interferon-alpha2b and triple combination with ribavirin in the" exact="hepatitis" post="C virus replicon systemAntivir Chem Chemother200819253118610555 KorbaBEElazarMLuiPRossignolJFGlennJSPotential for hepatitis"/>
   <result pre="the hepatitis C virus replicon systemAntivir Chem Chemother200819253118610555 KorbaBEElazarMLuiPRossignolJFGlennJSPotential for" exact="hepatitis" post="C virus resistance to nitazoxanide or tizoxanideAntimicrob Agents Chemother2008524069407110.1128/AAC.00078-0818710916"/>
   <result pre="C virus resistance to nitazoxanide or tizoxanideAntimicrob Agents Chemother2008524069407110.1128/AAC.00078-0818710916 EinavSSobolHDGehrigEGlennJSThe" exact="hepatitis" post="C virus (HCV) NS4B RNA binding inhibitor clemizole is"/>
   <result pre="synergistic with HCV protease inhibitorsJ Infect Dis2026574 LiuZRobidaJMChinnaswamySYiGRobothamJMNelsonHBIrsiglerAKaoCCTangHMutations in the" exact="hepatitis" post="C virus polymerase that increase RNA binding can confer"/>
   <result pre="AHepatology200950253310.1002/hep.2298719489073 YangWZhaoYFabryckiJHouXNieXSanchezAPhadkeADeshpandeMAgarwalAHuangMSelection of replicon variants resistant to ACH-806, a novel" exact="hepatitis" post="C virus inhibitor with no cross-resistance to NS3 protease"/>
   <result pre="of cholesterol and lipid metabolism on host cell structure and" exact="hepatitis" post="C virus replicationBiochem Cell Biol200684677910.1139/o05-14916462891 PezackiJPSaganSMTonaryAMRouleauYBelangerSSupekovaLSuAITranscriptional profiling of the"/>
   <result pre="hepatocyte metabolism and the antiviral state it conveys against the" exact="hepatitis" post="C virusBMC Chem Biol20099210.1186/1472-6769-9-219149867 ChengYTsouLKCaiJAyaTDutschmanGEGullenEAGrillSPChenAPLindenbachBDHamiltonADChengYCA novel class of meso-tetrakis-porphyrin"/>
   <result pre="ChengYTsouLKCaiJAyaTDutschmanGEGullenEAGrillSPChenAPLindenbachBDHamiltonADChengYCA novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against" exact="hepatitis" post="C virus genotype 1b replicons in vitroAntimicrob Agents Chemother54197206"/>
   <result pre="LinTILenzOFanningGVerbinnenTDelouvroyFScholliersAVermeirenKRosenquistAEdlundMSamuelssonBIn vitro activity and preclinical profile of TMC435350, a potent" exact="hepatitis" post="C virus protease inhibitorAntimicrob Agents Chemother2009531377138510.1128/AAC.01058-0819171797 HopkinsSScorneauxBHuangZMurrayMGWringSSmitleyCHarrisRErdmannFFischerGRibeillYSCY-635, a novel"/>
   <result pre="novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of" exact="hepatitis" post="C virus RNA replication in vitroAntimicrob Agents Chemother54660672 HopkinsSHeumanDGavisELalezariJGlutzerEDiMassimoBRusnakPWringSSafety,"/>
   <result pre="and anti-viral activity of SCY-635 in adult patients with chronic" exact="hepatitis" post="C virus infectionJ Hepatol200950Suppl 1S36Smitley SaRYS, plasma, pharmacokinetics, and"/>
   <result pre="and anti-viral activity of SCY-635 in adult patients with chronic" exact="hepatitis" post="C virus infection ShiSTHerlihyKJGrahamJPFuhrmanSADoanCPargeHHickeyMGaoJYuXChauFIn vitro resistance study of AG-021541,"/>
   <result pre="resistance study of AG-021541, a novel nonnucleoside inhibitor of the" exact="hepatitis" post="C virus RNA-dependent RNA polymeraseAntimicrob Agents Chemother20085267568310.1128/AAC.00834-0718070954 SeiwertSDAndrewsSWJiangYSerebryanyVTanHKossenKRajagopalanPTMisialekSStevensSKStoychevaAPreclinical characteristics"/>
   <result pre="virus RNA-dependent RNA polymeraseAntimicrob Agents Chemother20085267568310.1128/AAC.00834-0718070954 SeiwertSDAndrewsSWJiangYSerebryanyVTanHKossenKRajagopalanPTMisialekSStevensSKStoychevaAPreclinical characteristics of the" exact="hepatitis" post="C virus NS3/4A protease inhibitor ITMN-191 (R7227)Antimicrob Agents Chemother2008524432444110.1128/AAC.00699-0818824605"/>
   <result pre="BogenSLArasappanAVelazquezFBlackmanMHuelgasRPanWSiegelENairLGVenkatramanSGuoZDiscovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of" exact="hepatitis" post="C virus NS3 serine protease with favorable pharmacokinetic profiles"/>
   <result pre="of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in" exact="hepatitis" post="C patientsJ Hepatol20084916316910.1016/j.jhep.2008.03.02718486984 ShanGZPengZGLiYHLiDLiYPMengSGaoLYJiangJDLiZRA novel class of geldanamycin derivatives"/>
   <result pre="helicase inhibitorBiochemistry4918221832 Stankiewicz-DrogonAPalchykovskaLGKostinaVGAlexeevaIVShvedADBoguszewska-ChachulskaAMNew acridone-4-carboxylic acid derivatives as potential inhibitors of" exact="hepatitis" post="C virus infectionBioorg Med Chem2008168846885210.1016/j.bmc.2008.08.07418801660 ChenCSChiouCTChenGSChenSCHuCYChiWKChuYDHwangLHChenPJChenDSStructure-based discovery of triphenylmethane"/>
   <result pre="Med Chem2008168846885210.1016/j.bmc.2008.08.07418801660 ChenCSChiouCTChenGSChenSCHuCYChiWKChuYDHwangLHChenPJChenDSStructure-based discovery of triphenylmethane derivatives as inhibitors of" exact="hepatitis" post="C virus helicaseJ Med Chem2009522716272310.1021/jm801190519419203 BorowskiPDeinertJSchalinskiSBretnerMGinalskiKKulikowskiTShugarDHalogenated benzimidazoles and benzotriazoles"/>
   <result pre="benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of" exact="hepatitis" post="C and related virusesEur J Biochem20032701645165310.1046/j.1432-1033.2003.03540.x12694177 BretnerMBaierAKopanskaKNajdaASchoofAReinholzMLipniackiAPiasekAKulikowskiTBorowskiPSynthesis and biological"/>
   <result pre="specifically inhibit subgenomic HCV replicationBioorg Med Chem1851295136 MagaGGemmaSFattorussoCLocatelliGAButiniSPersicoMKukrejaGRomanoMPChiasseriniLSaviniLSpecific targeting of" exact="hepatitis" post="C virus NS3 RNA helicase. Discovery of the potent"/>
   <result pre="protection screen reveals potent inhibitors of multiple stages of the" exact="hepatitis" post="C virus life cycleProc Natl Acad Sci USA10737643769 GastaminzaPWhitten-BauerCChisariFVUnbiased"/>
   <result pre="cycleProc Natl Acad Sci USA10737643769 GastaminzaPWhitten-BauerCChisariFVUnbiased probing of the entire" exact="hepatitis" post="C virus life cycle identifies clinical compounds that target"/>
   <result pre="antipsychotic drugs at human 5-hydroxytryptamine2C receptorsJ Pharmacol Exp Ther200029522623210991983 ZhangHRothwanglKMesecarADSabahiARongLFongHHLamiridosins," exact="hepatitis" post="C virus entry inhibitors from Lamium albumJ Nat Prod2009722158216210.1021/np900549e19904996"/>
   <result pre="inhibitors from Lamium albumJ Nat Prod2009722158216210.1021/np900549e19904996 RakicBClarkeJTremblayTLTaylorJSchreiberKNelsonKMAbramsSRPezackiJPA small-molecule probe for" exact="hepatitis" post="C virus replication that blocks protein foldingChem Biol2006131051106010.1016/j.chembiol.2006.08.01017052609 SupekovaLSupekFLeeJChenSGrayNPezackiJPSchlapbachASchultzPGIdentification"/>
   <result pre="blocks protein foldingChem Biol2006131051106010.1016/j.chembiol.2006.08.01017052609 SupekovaLSupekFLeeJChenSGrayNPezackiJPSchlapbachASchultzPGIdentification of human kinases involved in" exact="hepatitis" post="C virus replication by small interference RNA library screeningJ"/>
   <result pre="library screeningJ Biol Chem2008283293617951261 RakicBSaganSMNoesthedenMBelangerSNanXEvansCLXieXSPezackiJPPeroxisome proliferator-activated receptor alpha antagonism inhibits" exact="hepatitis" post="C virus replicationChem Biol200613233010.1016/j.chembiol.2005.10.00616426968"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3184032/results/search/disease/results.xml">
   <result pre="drugs target 3 main groups of viruses: herpes, hepatitis, and" exact="influenza" post="viruses. With the exception of the antisense molecule fomivirsen,"/>
   <result pre="substrates for viral DNA polymerase. Drugs for the treatment of" exact="influenza" post="inhibit the ion channel M2 protein or the enzyme"/>
   <result pre="with Interferon-α and ribavirin remains the backbone treatment for chronic" exact="hepatitis" post="C; the addition of serine protease inhibitors improves the"/>
   <result pre="protease inhibitors improves the treatment outcome of patients infected with" exact="hepatitis" post="C virus genotype 1. Chronic hepatitis B can be"/>
   <result pre="of patients infected with hepatitis C virus genotype 1. Chronic" exact="hepatitis" post="B can be treated with interferon or a combination"/>
   <result pre="all the nucleos(t) ide analogues for the treatment of chronic" exact="hepatitis" post="B possess anti-human immunodeficiency virus properties, and they inhibit"/>
   <result pre="possess anti-human immunodeficiency virus properties, and they inhibit replication of" exact="hepatitis" post="B virus by serving as competitive substrates for its"/>
   <result pre="clinical applications, such as ribavirin for the treatment of chronic" exact="hepatitis" post="C and respiratory syncytial virus and cidofovir for the"/>
   <result pre="utility of M2 inhibitors for the prevention and treatment of" exact="influenza" post="infections. This article provides an overview of clinically available"/>
   <result pre="uses, and adverse effects. Abbreviations ALT, alanine aminotransferase CHB, chronic" exact="hepatitis" post="B CHC, chronic hepatitis C CMV, cytomegalovirus CSF, cerebrospinal"/>
   <result pre="Abbreviations ALT, alanine aminotransferase CHB, chronic hepatitis B CHC, chronic" exact="hepatitis" post="C CMV, cytomegalovirus CSF, cerebrospinal fluid EBV, Epstein-Barr virus"/>
   <result pre="EBV, Epstein-Barr virus FDA, US Food and Drug Administration HBeAg," exact="hepatitis" post="B e antigen HBV, hepatitis B virus HCV, hepatitis"/>
   <result pre="Food and Drug Administration HBeAg, hepatitis B e antigen HBV," exact="hepatitis" post="B virus HCV, hepatitis C virus HHV, human herpesvirus"/>
   <result pre="HBeAg, hepatitis B e antigen HBV, hepatitis B virus HCV," exact="hepatitis" post="C virus HHV, human herpesvirus HIV, human immunodeficiency virus"/>
   <result pre="C virus HHV, human herpesvirus HIV, human immunodeficiency virus HSV," exact="herpes simplex" post="virus HSV-1, HSV type 1 HSV-2, HSV type 2"/>
   <result pre="setting target 3 principal groups of viruses—the herpes, hepatitis, and" exact="influenza" post="viruses. This review article is structured to discuss antiviral"/>
   <result pre="DNA viral infections. Nucleos(t)ide analogues for the treatment of chronic" exact="hepatitis" post="B (CHB) may also possess anti-HIV properties, but their"/>
   <result pre="Acyclovir Acyclovir is a synthetic guanosine analogue used for treating" exact="herpes simplex" post="virus (HSV) and varicella zoster virus (VZV) infections.1, 2,"/>
   <result pre="is preferred for severe and disseminated disease Risk of crystalline" exact="nephropathy" post="Acyclovir (oral) 400 mg orally 3 times daily 800"/>
   <result pre="episode of genital herpes Recurrent episodes of genital herpes HSV" exact="encephalitis" post="Acyclovir (IV) 10 mg/kg IV every 8 h Risk"/>
   <result pre="(IV) 10 mg/kg IV every 8 h Risk of crystalline" exact="nephropathy" post="Long-term suppression Acyclovir (oral) 400 mg orally twice daily"/>
   <result pre="mg/kg IV every 8 h Risk of crystalline nephropathy Long-term" exact="suppression" post="Acyclovir (oral) 400 mg orally twice daily (400–800 mg"/>
   <result pre="every 12 h IVtherapy is preferred for severe CMV disease," exact="gastrointestinal disease," post="pneumonia, and encephalitis Transition to oral valganciclovir on clinical"/>
   <result pre="is preferred for severe CMV disease, gastrointestinal disease, pneumonia, and" exact="encephalitis" post="Transition to oral valganciclovir on clinical and virologic improvement"/>
   <result pre="should not be used for treating active CMV infection CMV" exact="retinitis" post="in HIV-infected patients Valganciclovir (oral) Induction: 900 mg orally"/>
   <result pre="requires concomitant hydration and probenecid use CMV disease other than" exact="retinitis" post="in HIV-infected patients Valganciclovir (oral) Induction: 900 mg orally"/>
   <result pre="acute retinal necrosis (which is associated with HSV or VZV)," exact="eczema herpeticum," post="and oral hairy leukoplakia due to EBV. Oral acyclovir"/>
   <result pre="is associated with HSV or VZV), eczema herpeticum, and oral" exact="hairy leukoplakia" post="due to EBV. Oral acyclovir is used to prevent"/>
   <result pre="associated with HSV or VZV), eczema herpeticum, and oral hairy" exact="leukoplakia" post="due to EBV. Oral acyclovir is used to prevent"/>
   <result pre="patients because of intratubular precipitation of acyclovir crystals. Acyclovir crystalline" exact="nephropathy" post="is more common when acyclovir is given as a"/>
   <result pre="It is available in some countries for the treatment of" exact="herpes zoster" post="and herpes simplex. However, concerns about its toxicity halted"/>
   <result pre="in some countries for the treatment of herpes zoster and" exact="herpes simplex." post="However, concerns about its toxicity halted its clinical development"/>
   <result pre="major clinical indication for cidofovir is the treatment of CMV" exact="retinitis" post="in HIV-infected patients (Table 1).31 Cidofovir is also used"/>
   <result pre="HSV disease, condyloma acuminatum, BK virus-associated hemorrhagic cystitis, JC virus-associated" exact="progressive multifocal leukoencephalopathy," post="and other infections due to double-stranded DNA viruses.34, 35,"/>
   <result pre="The major clinical indications for famciclovir use are treatment of" exact="herpes zoster," post="recurrent genital herpes,52 and recurrent herpes labialis.53 Famciclovir can"/>
   <result pre="and recurrent herpes labialis.53 Famciclovir can also be used as" exact="suppression" post="therapy to reduce the risk of recurrent genital herpes"/>
   <result pre="given intravitreally. Its main indication is the treatment of CMV" exact="retinitis" post="in patients with AIDS who have not benefited from"/>
   <result pre="is increased intraocular pressure and inflammation. Blurred vision, conjunctival hemorrhage," exact="retinal detachment," post="and retinal edema are other adverse effects.55, 56, 57"/>
   <result pre="pressure and inflammation. Blurred vision, conjunctival hemorrhage, retinal detachment, and" exact="retinal edema" post="are other adverse effects.55, 56, 57 Foscarnet Foscarnet is"/>
   <result pre="kinase mutations.33 Foscarnet is approved for the treatment of CMV" exact="retinitis" post="in patients with AIDS.58 It has been used to"/>
   <result pre="the glomerular capillary lumen.62, 63 Foscarnet may cause myelosuppression, with" exact="anemia" post="as the most common effect. It can chelate bivalent"/>
   <result pre="against HHV-7.67 Ganciclovir is approved for the treatment of CMV" exact="retinitis" post="in patients with AIDS, the treatment of herpes simplex"/>
   <result pre="of CMV retinitis in patients with AIDS, the treatment of" exact="herpes simplex" post="keratitis, and CMV prophylaxis in transplant recipients. Intravenous ganciclovir"/>
   <result pre="used to treat other forms of CMV disease, such as" exact="colitis" post="or esophagitis. Induction therapy with IV ganciclovir for CMV"/>
   <result pre="colitis or esophagitis. Induction therapy with IV ganciclovir for CMV" exact="retinitis" post="in patients with AIDS has an efficacy of 85%"/>
   <result pre="bone marrow and solid organ transplant recipients.61 Reversible bone marrow" exact="suppression" post="is the most common adverse effect of ganciclovir. Other"/>
   <result pre="the first dose should be started within 48 hours of" exact="rash" post="onset. Treatment can be prolonged, continuing until all lesions"/>
   <result pre="was first approved by the FDA for treatment of CMV" exact="retinitis" post="in patients with AIDS.83 For immediate sight-threatening lesions, valganciclovir"/>
   <result pre="moderate CMV disease in transplant recipients.86, 87, 89 Bone marrow" exact="suppression" post="is the most common adverse effect of valganciclovir. Gastrointestinal"/>
   <result pre="available only as an ophthalmic solution for treating recurrent epithelial" exact="keratitis" post="and acute keratoconjunctivitis.90 Once phosphorylated into its active form,"/>
   <result pre="Amantadine is a symmetric tricyclic amine that inhibits replication of" exact="influenza" post="A virus by impairing the function of the membrane"/>
   <result pre="the function of the membrane protein M2.91 Present only in" exact="influenza" post="A virus, M2 is an acid-activated ion channel required"/>
   <result pre="filtration and tubular secretion. Amantadine is effective for treating susceptible" exact="influenza" post="A virus infection.91 It results in a more rapid"/>
   <result pre="disease onset.91 Amantadine is effective as prophylaxis for preventing symptomatic" exact="influenza" post="A infection in exposed persons.92, 93 It is usually"/>
   <result pre="at least 7 days after the last confirmed illness. Seasonal" exact="influenza" post="vaccination, however, remains the preferred method for prevention. Amantadine"/>
   <result pre="rimantadine. Rimantadine. Rimantadine is a symmetric tricyclic amine that inhibits" exact="influenza" post="virus.93 It is well absorbed after oral administration, reaching"/>
   <result pre="viral uncoating. Rimantadine is indicated for prevention and treatment of" exact="influenza" post="A virus93; however, its clinical utility is currently limited"/>
   <result pre="inhibitor of neuraminidase that is essential in the replication of" exact="influenza" post="A and B viruses.98 Oral oseltamivir is well absorbed"/>
   <result pre="for the treatment of children (≥1 year) and adults with" exact="influenza" post="A or B viral infections.98 Treatment should start within"/>
   <result pre="inhibitor, zanamivir, in reducing the febrile period during infection with" exact="influenza" post="A (H1N1), influenza A (H3N2), and influenza B virus.99"/>
   <result pre="reducing the febrile period during infection with influenza A (H1N1)," exact="influenza" post="A (H3N2), and influenza B virus.99 Oseltamivir is also"/>
   <result pre="during infection with influenza A (H1N1), influenza A (H3N2), and" exact="influenza" post="B virus.99 Oseltamivir is also used for postexposure prophylaxis"/>
   <result pre="B virus.99 Oseltamivir is also used for postexposure prophylaxis against" exact="influenza" post="A and B, including pandemic strains. For this indication,"/>
   <result pre="significant difference between oseltamivir and zanamivir prophylaxis for preventing symptomatic" exact="influenza" post="among immunocompetent adults.100 The most common adverse effects of"/>
   <result pre="including delirium, abnormal behavior, and hallucinations, have been reported. Oseltamivir-resistant" exact="influenza" post="A virus has been reported.101, 102, 103 Mutations in"/>
   <result pre="account for oseltamivir resistance. Surveillance conducted during the 2009 H1N1" exact="influenza" post="pandemic detected sporadic and infrequent incidence of oseltamivir-resistant pandemic"/>
   <result pre="detected sporadic and infrequent incidence of oseltamivir-resistant pandemic (H1N1) 2009" exact="influenza" post="virus. All resistant viruses had neuraminidase mutations (most commonly"/>
   <result pre="resistance to oseltamivir, but not to zanamivir.104 Oseltamivir resistance among" exact="influenza" post="B viruses occurs less frequently.105 Zanamivir. Zanamivir is an"/>
   <result pre="inhibitor that is used for the treatment and prophylaxis of" exact="influenza" post="A and B viruses.106 Zanamivir is not available orally"/>
   <result pre="Inhaled zanamivir produces high concentrations in the respiratory tract where" exact="influenza" post="virus infection occurs. About 4% to 20% of inhaled"/>
   <result pre="given once daily for 10 days as postexposure prophylaxis of" exact="influenza" post="A and B in household or close contacts. Zanamivir"/>
   <result pre="to various cellular responses, such as inhibition of virus replication," exact="suppression" post="of cell proliferation, enhancement of the phagocytic activity of"/>
   <result pre="Interferon-α was the first drug approved for treatment of compensated" exact="liver disease" post="due to CHB; it is not approved for treating"/>
   <result pre="due to CHB; it is not approved for treating acute" exact="hepatitis" post="B. For CHB, IFN α-2a or α-2b is given"/>
   <result pre="113 Interferon was most effective in patients with recently acquired" exact="hepatitis" post="B virus (HBV), high pretreatment levels of alanine aminotransferase"/>
   <result pre="Likewise, SC peginterferon-α may be more effective than lamivudine in" exact="hepatitis" post="B e antigen (HBeAg)-positive and HBeAg-negative patients with CHB,115,"/>
   <result pre="enhance efficacy.118 Interferon-α is effective in patients with HBV and" exact="hepatitis" post="D virus confection,119 although they are less responsive than"/>
   <result pre="Interferon-α-2a and -2b are approved for the treatment of chronic" exact="hepatitis" post="C (CHC); however, they are not approved for acute"/>
   <result pre="hepatitis C (CHC); however, they are not approved for acute" exact="hepatitis" post="C. A meta-analysis found that IFN-α for at least"/>
   <result pre="in patients not infected with HIV is 24 weeks (for" exact="hepatitis" post="C virus [HCV] genotype 2 or 3) or 48"/>
   <result pre="for 48 weeks. Interferons are generally not recommended in acute" exact="viral hepatitis," post="but treatment of acute HCV with IFN-α has resulted"/>
   <result pre="disturbances (eg, confusion and seizures), myelosuppression (neutropenia [most commonly] and" exact="aplastic anemia" post="[rarely]), cardiovascular disorders (eg, arrhythmias), endocrine disorders (eg, thyroid"/>
   <result pre="(eg, confusion and seizures), myelosuppression (neutropenia [most commonly] and aplastic" exact="anemia" post="[rarely]), cardiovascular disorders (eg, arrhythmias), endocrine disorders (eg, thyroid"/>
   <result pre="triphosphate, is a potent competitive inhibitor of inosine monophosphate dehydrogenase," exact="influenza" post="virus RNA polymerase, and mRNA guanylyltransferase. As a result"/>
   <result pre="has been used, off-label, for the treatment of HSV, influenza," exact="severe acute respiratory syndrome" post="coronavirus,154, 155 La Crosse encephalitis,156 Nipah encephalitis,157 Lassa fever,158"/>
   <result pre="Precipitation of inhaled ribavirin may occur in ventilatory tubings. Hemolytic" exact="anemia" post="occurs commonly,154 and ribavirin should not be given to"/>
   <result pre="relapse often occurs after discontinuation of treatment. Severe exacerbation of" exact="hepatitis" post="may also occur on discontinuation of these drugs; hence,"/>
   <result pre="Acyclic nucleotide analogue of adenosine monophosphate Nephrotoxicity Lactic acidosis Rebound" exact="hepatitis" post="rtN236T is most common Emtricitabine 200 mg orally once"/>
   <result pre="lamivudine Used often in combination with tenofovir Lactic acidosis Rebound" exact="hepatitis" post="rtM204V/I provides cross-resistance with lamivudine Entecavir 0.5 mg orally"/>
   <result pre="orally once daily for treatment-experienced patients and patients with decompensated" exact="liver disease" post="Nucleoside analogue of guanosine One of the most potent"/>
   <result pre="the most potent anti-HBV drugs Well tolerated Lactic acidosis Rebound" exact="hepatitis" post="High barrier to resistance; requires 3 mutations for phenotype:"/>
   <result pre="once daily Nucleoside analogue of cytosine Lactic acidosis Myopathy Rebound" exact="hepatitis" post="rtM204V/I is most frequent Telbivudine 600 mg orally once"/>
   <result pre="Synthetic thymidine nucleoside analogue No activity against HIV Myopathy Peripheral" exact="neuropathy" post="Lactic acidosis Rebound hepatitis rtM204I is most frequent mutation;"/>
   <result pre="No activity against HIV Myopathy Peripheral neuropathy Lactic acidosis Rebound" exact="hepatitis" post="rtM204I is most frequent mutation; others include rtL80I/V, rtA181T,"/>
   <result pre="of the most potent anti-HBV drugs Nephrotoxicity Lactic acidosis Rebound" exact="hepatitis" post="Not well-defined; rtN236T is suggested but not yet confirmed"/>
   <result pre="well-defined; rtN236T is suggested but not yet confirmed aHBV =" exact="hepatitis" post="B virus; HIV = human immunodeficiency virus. bAll drugs"/>
   <result pre="B virus; HIV = human immunodeficiency virus. bAll drugs inhibit" exact="hepatitis" post="B replication by acting as a competitive substrate for"/>
   <result pre="except telbivudine have anti-HBV properties, and all patients with chronic" exact="hepatitis" post="B who are considered for treatment should be screened"/>
   <result pre="for HIV. cA common toxicity of the nucleos(t)ide analogues is" exact="lactic acidosis," post="with the potential to cause increases in serum alaninę"/>
   <result pre="anti-HBV drugs, it has been used in adults with decompensated" exact="liver disease," post="or with compensated liver disease with evidence of active"/>
   <result pre="used in adults with decompensated liver disease, or with compensated" exact="liver disease" post="with evidence of active viral replication, persistently elevated ALT"/>
   <result pre="approved for the treatment of CHB in patients with compensated" exact="liver disease" post="and evidence of active viral replication, persistently increased serum"/>
   <result pre="dizziness, fatigue, gastrointestinal symptoms, and rash. Unique adverse effects are" exact="peripheral neuropathy" post="and myopathy with elevation in creatine kinase levels. Telbivudine"/>
   <result pre="fatigue, gastrointestinal symptoms, and rash. Unique adverse effects are peripheral" exact="neuropathy" post="and myopathy with elevation in creatine kinase levels. Telbivudine"/>
   <result pre="symptoms, and rash. Unique adverse effects are peripheral neuropathy and" exact="myopathy" post="with elevation in creatine kinase levels. Telbivudine treatment should"/>
   <result pre="creatine kinase levels. Telbivudine treatment should be discontinued if either" exact="peripheral neuropathy" post="or myopathy is diagnosed. The rate of resistance to"/>
   <result pre="kinase levels. Telbivudine treatment should be discontinued if either peripheral" exact="neuropathy" post="or myopathy is diagnosed. The rate of resistance to"/>
   <result pre="Telbivudine treatment should be discontinued if either peripheral neuropathy or" exact="myopathy" post="is diagnosed. The rate of resistance to telbivudine is"/>
   <result pre="anemia.194 The addition of boceprevir nearly doubled the rate of" exact="anemia" post="compared with the use of standard peginterferon and ribavirin"/>
   <result pre="can be mild to severe, and Stevens-Johnson syndrome and drug" exact="rash" post="with eosinophilia and systemic symptoms have been reported. Telaprevir"/>
   <result pre="mild to severe, and Stevens-Johnson syndrome and drug rash with" exact="eosinophilia" post="and systemic symptoms have been reported. Telaprevir therapy should"/>
   <result pre="if these dermatologic complications occur, especially in cases of severe" exact="rash" post="or even mild to moderate rash if accompanied by"/>
   <result pre="in cases of severe rash or even mild to moderate" exact="rash" post="if accompanied by systemic symptoms. The mechanism underlying rash"/>
   <result pre="moderate rash if accompanied by systemic symptoms. The mechanism underlying" exact="rash" post="development is unknown.199 Fatigue, pruritus, and gastrointestinal sympotoms (eg,"/>
   <result pre="drugs target 3 main groups of viruses: herpes, hepatitis, and" exact="influenza" post="viruses. The antiviral therapeutic armamentarium has evolved over the"/>
   <result pre="their clinical utility for most infections, such as acyclovir for" exact="herpes simplex" post="virus and ganciclovir for CMV. However, other of these"/>
   <result pre="of these &quot;old&quot; antiviral drugs (eg, amantadine and rimantadine for" exact="influenza" post="virus infections) have lost their clinical utility because of"/>
   <result pre="been observed to the neuraminidase inhibitors for the treatment of" exact="influenza" post="viruses and the nucleos(t)ide analogues for the treatment of"/>
   <result pre="treatment of initial and recurrent genital herpesLancet219825715736125728 3SerotaFTStarrSEBryanCKKochPAPlotkinSAAugustCSAcyclovir treatment of" exact="herpes zoster" post="infections: use in children undergoing bone marrow transplantationJAMA2471982213221357038177 4GuptaRWarrenTWaldAGenital"/>
   <result pre="undergoing bone marrow transplantationJAMA2471982213221357038177 4GuptaRWarrenTWaldAGenital herpesLancet37020072127213718156035 5ReichmanRCBadgerGJMertzGJTreatment of recurrent genital" exact="herpes simplex" post="infections with oral acyclovir: a controlled trialJAMA2511984210321076368877 6LubyJPGnannJWJrAlexanderWJA collaborative"/>
   <result pre="with topical acyclovir or placeboJ Infect Dis1501984166086765 7CernikCGallinaKBrodellRTThe treatment of" exact="herpes simplex" post="infections: an evidence-based reviewArch Intern Med16820081137114418541820 8ZuckermanRWaldAHerpes simplex virus"/>
   <result pre="treatment of herpesvirus infectionsJ Antimicrob Chemother32suppl A19931211328407694 10ValenciaIMilesDKMelvinJRelapse of herpes" exact="encephalitis" post="after acyclovir therapy: report of two new cases and"/>
   <result pre="administrationAnn Pharmacother271993145814598305776 21AmosRJAmessJAMegaloblastic haemopoiesis due to acyclovirLancet11983242243 22Danve-SzatanekCAymardMThouvenotDSurveillance network for" exact="herpes simplex" post="virus resistance to antiviral drugs: 3-year follow-upJ Clin Microbiol42200424224914715760"/>
   <result pre="Microbiol Rev16200311412812525428 24MalvyDTreilhaudMBoueeSA retrospective, case-control study of acyclovir resistance in" exact="herpes simplex" post="virusClin Infect Dis41200532032616007528 25SupertiFAmmendoliaMGMarchettiMNew advances in anti-HSV chemotherapyCurr Med"/>
   <result pre="diseaseAnn Pharmacother321998118111929825085 32CherringtonJMFullerMDLamyPDIn vitro antiviral susceptibilities of isolates from cytomegalovirus" exact="retinitis" post="patients receiving first- or second-line cidofovir therapy: relationship to"/>
   <result pre="for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia," exact="herpes simplex" post="and its potential use in smallpoxDermatol Clin21200330130912757253 38LalezariJPDrewWLGlutzerETreatment with"/>
   <result pre="Clin21200330130912757253 38LalezariJPDrewWLGlutzerETreatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with" exact="herpes simplex" post="virus in a patient with AIDSJ Infect Dis17019945705728077713 39BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful"/>
   <result pre="a patient with AIDSJ Infect Dis17019945705728077713 39BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant" exact="herpes simplex" post="stomatitis with intravenous cidofovir in a childPediatr Infect Dis"/>
   <result pre="with AIDSJ Infect Dis17019945705728077713 39BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant herpes simplex" exact="stomatitis" post="with intravenous cidofovir in a childPediatr Infect Dis J2020011083108611734717"/>
   <result pre="a childPediatr Infect Dis J2020011083108611734717 40KoppTGeusauARiegerAStinglGSuccessful treatment of an aciclovir-resistant" exact="herpes simplex" post="type 2 infection with cidofovir in an AIDS patientBr"/>
   <result pre="cidofovir: a case seriesAIDS20200679179316514320 42MarraCMRajicicNBarkerDEA pilot study of cidofovir for" exact="progressive multifocal leukoencephalopathy" post="in AIDSAIDS1620021791179712218391 43RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of progressive multifocal leukoencephalopathy in"/>
   <result pre="cidofovir for progressive multifocal leukoencephalopathy in AIDSAIDS1620021791179712218391 43RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of" exact="progressive multifocal leukoencephalopathy" post="in a patient receiving highly active antiretroviral therapyMayo Clin"/>
   <result pre="44Segarra-NewnhamMVodoloKMUse of cidofovir in progressive multifocal leukoencephalopathyAnn Pharmacother35200174174411408993 45ViallardJFLazaroEEllieEImprovement of" exact="progressive multifocal leukoencephalopathy" post="after cidofovir therapy in a patient with a destructive"/>
   <result pre="and acute renal failure associated with cidofovirJ Antimicrob Chemother60200719319417496056 49AmbatiJWynneKBAngerameMCRobinsonMRAnterior" exact="uveitis" post="associated with intravenous cidofovir use in patients with cytomegalovirus"/>
   <result pre="new single-day dosing indicationsCutis802007778117725069 54SaltzmanRJurewiczRBoonRSafety of famciclovir in patients with" exact="herpes zoster" post="and genital herpesAntimicrob Agents Chemother381994245424577840587 55GrilloneLRLanzRFomivirsenDrugs Today (Barc)37200124525512768225 56Vitravene"/>
   <result pre="of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus" exact="retinitis" post="in patients with AIDSAm J Ophthalmol133200246747411931780 57HighleymanLFomivirsenBETA29199831 58ChrispPClissoldSPFoscarnet: a"/>
   <result pre="dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus" exact="retinitis" post="in AIDSJ Infect Dis16819934444488393058 63BeaufilsHDerayGKatlamaCFoscarnet and crystals in glomerular"/>
   <result pre="therapy and prevention of CMV infectionsJ Clin Virol162000254010680738 66FrankKBChiouJFChengYCInteraction of" exact="herpes simplex" post="virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphateJ Biol Chem2591984156615696319402 67RazonableRRPayaCVThe"/>
   <result pre="randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral" exact="retinitis" post="in patients with AIDSJ Infect Dis16819935575638394858 69DrewWLIvesDLalezariJPSyntex Cooperative Oral"/>
   <result pre="Oral Ganciclovir Study GroupOral ganciclovir as maintenance treatment for cytomegalovirus" exact="retinitis" post="in patients with AIDSN Engl J Med33319956156207637721 70GaneESalibaFValdecasasGJOral Ganciclovir"/>
   <result pre="outcomesClin Transplant22200816217018339135 72SariskyRTBaconTHBoonRJProfiling penciclovir susceptibility and prevalence of resistance of" exact="herpes simplex" post="virus isolates across eleven clinical trialsArch Virol14820031757176914505088 73BaconTHBoydMRActivity of"/>
   <result pre="74SpruanceSLReaTLThomingCTuckerRSaltzmanRBoonRTopical Penciclovir Collaborative Study GroupPenciclovir cream for the treatment of" exact="herpes simplex" post="labialis: a randomized, multicenter, double-blind, placebo-controlled trialJAMA2771997137413799134943 75AcostaEPFletcherCVValacyclovirAnn Pharmacother3119971851919034421"/>
   <result pre="in solid organ transplant recipientsAm J Transplant720072106211317640310 90WilhelmusKRTherapeutic interventions for" exact="herpes simplex" post="virus epithelial keratitisCochrane Database Syst Rev2008CD00289818254009 91De ClercqEAntiviral drugs"/>
   <result pre="Clin Virol30200411513315125867 92TappendenPJacksonRCooperKAmantadine, oseltamivir and zanamivir for the prophylaxis of" exact="influenza" post="(including a review of existing guidance no. 67): a"/>
   <result pre="Technol Assess131120091246iii, ix-xii 93BettsRFAmantadine and rimantadine for the prevention of" exact="influenza" post="ASemin Respir Infect419893043102697053 94KrumbholzASchmidtkeMBergmannSHigh prevalence of amantadine resistance among"/>
   <result pre="Infect419893043102697053 94KrumbholzASchmidtkeMBergmannSHigh prevalence of amantadine resistance among circulating European porcine" exact="influenza" post="A virusesJ Gen Virol90200990090819223487 95HigginsRREshaghiABurtonLMazzulliTDrewsSJDifferential patterns of amantadine-resistance in"/>
   <result pre="influenza A virusesJ Gen Virol90200990090819223487 95HigginsRREshaghiABurtonLMazzulliTDrewsSJDifferential patterns of amantadine-resistance in" exact="influenza" post="A (H3N2) and (H1N1) isolates in Toronto, CanadaJ Clin"/>
   <result pre="isolates in Toronto, CanadaJ Clin Virol442009919319019729 96HaydenFGHayAJEmergence and transmission of" exact="influenza" post="A viruses resistant to amantadine and rimantadineCurr Top Microbiol"/>
   <result pre="to amantadine and rimantadineCurr Top Microbiol Immunol17619921191301600749 97HaydenFGSperberSJBelsheRBCloverRDHayAJPykeSRecovery of drug-resistant" exact="influenza" post="A virus during therapeutic use of rimantadineAntimicrob Agents Chemother351991174117471952841"/>
   <result pre="and its potential for use in the event of an" exact="influenza" post="pandemicJ Antimicrob Chemother55suppl 12005i5i2115709056 99SugayaNTamuraDYamazakiMComparison of the clinical effectiveness"/>
   <result pre="99SugayaNTamuraDYamazakiMComparison of the clinical effectiveness of oseltamivir and zanamivir against" exact="influenza" post="virus infection in childrenClin Infect Dis47200833934518582202 100KhazeniNBravataDMHoltyJEUyekiTMStaveCDGouldMKSystematic review: safety"/>
   <result pre="antiviral chemoprophylaxis against pandemic and seasonal influenzaAnn Intern Med151200946447319652173 101KisoMMitamuraKSakai-TagawaYResistant" exact="influenza" post="A viruses in children treated with oseltamivir: descriptive studyLancet364200475976515337401"/>
   <result pre="with oseltamivir: descriptive studyLancet364200475976515337401 102de JongMDTranTTTruongHKOseltamivir resistance during treatment of" exact="influenza" post="A (H5N1) infectionN Engl J Med35320052667267216371632 103LeQMKisoMSomeyaKAvian flu: isolation"/>
   <result pre="103LeQMKisoMSomeyaKAvian flu: isolation of drug-resistant H5N1 virusNature4372005110816228009 104DharanNJGubarevaLVMeyerJJInfections with oseltamivir-resistant" exact="influenza" post="A(H1N1) virus in the United StatesJAMA30120091034104119255110 105HatakeyamaSSugayaNItoMEmergence of influenza"/>
   <result pre="oseltamivir-resistant influenza A(H1N1) virus in the United StatesJAMA30120091034104119255110 105HatakeyamaSSugayaNItoMEmergence of" exact="influenza" post="B viruses with reduced sensitivity to neuraminidase inhibitorsJAMA29720071435144217405969 106FreundBGravensteinSElliottMMillerIZanamivir:"/>
   <result pre="of clinical safetyDrug Saf21199926728110514019 107GaurAHBaggaBBarmanSIntravenous zanamivir for oseltamivir-resistant 2009 H1N1" exact="influenza" post="[letter]N Engl J Med36212010888920032317 108KiddIMDownJNastouliEH1N1 pneumonitis treated with intravenous"/>
   <result pre="Liver Dis23suppl 12003192212934164 112WongDKCheungAMO'RourkeKNaylorCDDetskyASHeathcoteJEffect of alpha-interferon treatment in patients with" exact="hepatitis" post="B e antigen-positive chronic hepatitis B: a meta-analysisAnn Intern"/>
   <result pre="alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic" exact="hepatitis" post="B: a meta-analysisAnn Intern Med11919933123238328741 113HariaMBenfieldPInterferon-alpha-2a: a review of"/>
   <result pre="and therapeutic use in the management of viral hepatitisDrugs5019958738968586031 114LokASMcMahonBJChronic" exact="hepatitis" post="B: update 2009Hepatology50200966166219714720 115MarcellinPAsselahTBoyerNTreatment of chronic hepatitis BJ Viral"/>
   <result pre="viral hepatitisDrugs5019958738968586031 114LokASMcMahonBJChronic hepatitis B: update 2009Hepatology50200966166219714720 115MarcellinPAsselahTBoyerNTreatment of chronic" exact="hepatitis" post="BJ Viral Hepat12200533334515985003 116LauGKPiratvisuthTLuoKXPeginterferon alfa-2a, lamivudine, and the combination"/>
   <result pre="Hepat12200533334515985003 116LauGKPiratvisuthTLuoKXPeginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic" exact="hepatitis" post="BN Engl J Med35220052682269515987917 117MarcellinPLauGKBoninoFPeginterferon alfa-2a alone, lamivudine alone,"/>
   <result pre="and the two in combination in patients with HBeAg-negative chronic" exact="hepatitis" post="BN Engl J Med35120041206121715371578 118JanssenHLvan ZonneveldMSenturkHPegylated Interferon alfa-2b alone"/>
   <result pre="alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic" exact="hepatitis" post="B: a randomised trialLancet365200512312915639293 119FarciPMandasACoianaATreatment of chronic hepatitis D"/>
   <result pre="HBeAg-positive chronic hepatitis B: a randomised trialLancet365200512312915639293 119FarciPMandasACoianaATreatment of chronic" exact="hepatitis" post="D with interferon alfa-2aN Engl J Med330199488948259188 120FarciPRoskamsTChessaLLong-term benefit"/>
   <result pre="J Med330199488948259188 120FarciPRoskamsTChessaLLong-term benefit of interferon alpha therapy of chronic" exact="hepatitis" post="D: regression of advanced hepatic fibrosisGastroenterology12620041740174915188169 121SorianoVPuotiMBonaciniMCare of patients"/>
   <result pre="regression of advanced hepatic fibrosisGastroenterology12620041740174915188169 121SorianoVPuotiMBonaciniMCare of patients with chronic" exact="hepatitis" post="B and HIV co-infection: recommendations from an HIV-HBV International"/>
   <result pre="the first European Consensus Conference on the treatment of chronic" exact="hepatitis" post="B and C in HIV co-infected patientsJ Hepatol42200561562415916745 123PoynardTLeroyVCohardMMeta-analysis"/>
   <result pre="Hepatol42200561562415916745 123PoynardTLeroyVCohardMMeta-analysis of interferon randomized trials in the treatment of" exact="viral hepatitis" post="C: effects of dose and durationHepatology2419967787898855176 124ZeuzemSFeinmanSVRasenackJPeginterferon alfa-2a in"/>
   <result pre="123PoynardTLeroyVCohardMMeta-analysis of interferon randomized trials in the treatment of viral" exact="hepatitis" post="C: effects of dose and durationHepatology2419967787898855176 124ZeuzemSFeinmanSVRasenackJPeginterferon alfa-2a in"/>
   <result pre="of dose and durationHepatology2419967787898855176 124ZeuzemSFeinmanSVRasenackJPeginterferon alfa-2a in patients with chronic" exact="hepatitis" post="CN Engl J Med34320001666167211106715 125PerryCMJarvisBPeginterferon-alpha-2a (40 kD): a review"/>
   <result pre="a review of its use in the management of chronic" exact="hepatitis" post="CDrugs6120012263228811772139 126HeathcoteEJShiffmanMLCooksleyWGPeginterferon alfa-2a in patients with chronic hepatitis C"/>
   <result pre="of chronic hepatitis CDrugs6120012263228811772139 126HeathcoteEJShiffmanMLCooksleyWGPeginterferon alfa-2a in patients with chronic" exact="hepatitis" post="C and cirrhosisN Engl J Med34320001673168011106716 127BrokJGluudLLGluudCRibavirin plus interferon"/>
   <result pre="Engl J Med34320001673168011106716 127BrokJGluudLLGluudCRibavirin plus interferon versus interferon for chronic" exact="hepatitis" post="CCochrane Database Syst Rev12010CD00544520091577 128FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for"/>
   <result pre="CCochrane Database Syst Rev12010CD00544520091577 128FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infectionN Engl J Med347200297598212324553 129MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus"/>
   <result pre="with interferon alfa-2b plus ribavirin for initial treatment of chronic" exact="hepatitis" post="C: a randomised trialLancet358200195896511583749 130GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of"/>
   <result pre="hepatitis C: a randomised trialLancet358200195896511583749 130GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of" exact="hepatitis" post="C: an updateHepatology4920091335137419330875 131CarratFBani-SadrFPolSPegylated interferon alfa-2b vs standard interferon"/>
   <result pre="interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic" exact="hepatitis" post="C in HIV-infected patients: a randomized controlled trialJAMA29220042839284815598915 132TorrianiFJRodriguez-TorresMRockstrohJKPeginterferon"/>
   <result pre="a randomized controlled trialJAMA29220042839284815598915 132TorrianiFJRodriguez-TorresMRockstrohJKPeginterferon Alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infection in HIV-infected patientsN Engl J Med351200443845015282351"/>
   <result pre="Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C in HIV-coinfected personsN Engl J Med351200445145915282352 134JaeckelECornbergMWedemeyerHTreatment of"/>
   <result pre="C in HIV-coinfected personsN Engl J Med351200445145915282352 134JaeckelECornbergMWedemeyerHTreatment of acute" exact="hepatitis" post="C with interferon alfa-2bN Engl J Med34520011452145711794193 135SantantonioTFasanoMSinisiEEfficacy of"/>
   <result pre="24-week course of PEG-interferon alpha-2b monotherapy in patients with acute" exact="hepatitis" post="C after failure of spontaneous clearanceJ Hepatol42200532933315710214 136EronLJJudsonFTuckerSInterferon therapy"/>
   <result pre="the treatment of genital herpesDrugs6020001329135211152015 138HuangSSSkolaskyRLDal PanGJRoyalWIIIMcArthurJCSurvival prolongation in HIV-associated" exact="progressive multifocal leukoencephalopathy" post="treated with alpha-interferon: an observational studyJ Neurovirol419983243329639075 139GeschwindMDSkolaskyRIRoyalWSMcArthurJCThe relative"/>
   <result pre="139GeschwindMDSkolaskyRIRoyalWSMcArthurJCThe relative contributions of HAART and alpha-interferon for therapy of" exact="progressive multifocal leukoencephalopathy" post="in AIDSJ Neurovirol7200135335711517416 140RenaultPFHoofnagleJHParkYPsychiatric complications of long-term interferon alfa"/>
   <result pre="long-term interferon alfa therapyArch Intern Med1471987157715803307672 141DieperinkEWillenbringMHoSBNeuropsychiatric symptoms associated with" exact="hepatitis" post="C and interferon19 alpha: a reviewAm J Psychiatry157200086787610831463 142MidturiJSierra-HoffmanMHurleyDWinnRBeissnerRCarpenterJSpectrum"/>
   <result pre="pulmonary toxicity associated with the use of interferon therapy for" exact="hepatitis" post="C: case report and review of the literatureClin Infect"/>
   <result pre="J Med344200196196611274622 145DurandJMKaplanskiGPortalIScheinerCBerlandYSoubeyrandJLiver failure due to recombinant alpha interferonLancet338199112681269 146AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute" exact="interstitial nephritis" post="with the nephrotic syndrome following recombinant leukocyte a interferon"/>
   <result pre="Med344200196196611274622 145DurandJMKaplanskiGPortalIScheinerCBerlandYSoubeyrandJLiver failure due to recombinant alpha interferonLancet338199112681269 146AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute interstitial" exact="nephritis" post="with the nephrotic syndrome following recombinant leukocyte a interferon"/>
   <result pre="due to recombinant alpha interferonLancet338199112681269 146AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute interstitial nephritis with the" exact="nephrotic syndrome" post="following recombinant leukocyte a interferon therapy for mycosis fungoidesN"/>
   <result pre="the nephrotic syndrome following recombinant leukocyte a interferon therapy for" exact="mycosis" post="fungoidesN Engl J Med310198432356689738 147AgestaNZabalaRDiaz-PerezJLAlopecia areata during interferon alpha-2b/ribavirin"/>
   <result pre="during interferon alpha-2b/ribavirin therapyDermatology205200230030112399683 148WadeJRSnoeckEDuffFLambMJorgaKPharmacokinetics of ribavirin in patients with" exact="hepatitis" post="C virusBr J Clin Pharmacol62200671071417118126 149KramerTHGaarGGRayCGMinnichLCopelandJGConnorJDHemodialysis clearance of intravenously"/>
   <result pre="and ribavirin-like moleculesJ Antimicrob Chemother57200681316293677 151GluudLLMarchesiniEIorioAPeginterferon plus ribavirin for chronic" exact="hepatitis" post="C in patients with human immunodeficiency virusAm J Gastroenterol10420092335234119513022"/>
   <result pre="154KnowlesSRPhillipsEJDresserLMatukasLCommon adverse events associated with the use of ribavirin for" exact="severe acute respiratory syndrome" post="in CanadaClin Infect Dis3720031139114214523782 155MullerMPDresserLRaboudJAdverse events associated with high-dose"/>
   <result pre="acute respiratory syndromePharmacotherapy27200749450317381375 156McJunkinJEKhanRde los ReyesECTreatment of severe La Crosse" exact="encephalitis" post="with intravenous ribavirin following diagnosis by brain biopsyPediatrics9919972612679024460 157ChongHTKamarulzamanATanCTTreatment"/>
   <result pre="ribavirin following diagnosis by brain biopsyPediatrics9919972612679024460 157ChongHTKamarulzamanATanCTTreatment of acute Nipah" exact="encephalitis" post="with ribavirinAnn Neurol49200181081311409437 158McCormickJBKingIJWebbPALassa fever: effective therapy with ribavirinN"/>
   <result pre="Med329199317448232482 164DandoTPloskerGAdefovir dipivoxil: a review of its use in chronic" exact="hepatitis" post="BDrugs6320032215223414498759 165RivkinAMAdefovir dipivoxil in the treatment of chronic hepatitis"/>
   <result pre="chronic hepatitis BDrugs6320032215223414498759 165RivkinAMAdefovir dipivoxil in the treatment of chronic" exact="hepatitis" post="BAnn Pharmacother38200462563314990784 166MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of hepatitis"/>
   <result pre="chronic hepatitis BAnn Pharmacother38200462563314990784 166MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of" exact="hepatitis" post="B e antigen-positive chronic hepatitis BN Engl J Med348200380881612606735"/>
   <result pre="dipivoxil for the treatment of hepatitis B e antigen-positive chronic" exact="hepatitis" post="BN Engl J Med348200380881612606735 167HadziyannisSJTassopoulosNCHeathcoteEJAdefovir dipivoxil for the treatment"/>
   <result pre="BN Engl J Med348200380881612606735 167HadziyannisSJTassopoulosNCHeathcoteEJAdefovir dipivoxil for the treatment of" exact="hepatitis" post="B e antigen-negative chronic hepatitis BN Engl J Med348200380080712606734"/>
   <result pre="dipivoxil for the treatment of hepatitis B e antigen-negative chronic" exact="hepatitis" post="BN Engl J Med348200380080712606734 168HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with adefovir dipivoxil"/>
   <result pre="J Med348200380080712606734 168HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with adefovir dipivoxil for HBeAg-negative chronic" exact="hepatitis" post="BN Engl J Med35220052673268115987916 169DelaneyWEProgress in the treatment of"/>
   <result pre="BN Engl J Med35220052673268115987916 169DelaneyWEProgress in the treatment of chronic" exact="hepatitis" post="B: long-term experience with adefovir dipivoxilJ Antimicrob Chemother59200782783217332007 170LimSGNgTMKungNA"/>
   <result pre="Antimicrob Chemother59200782783217332007 170LimSGNgTMKungNA double-blind placebo-controlled study of emtricitabine in chronic" exact="hepatitis" post="BArch Intern Med1662006495616401810 171SimsKAWoodlandAMEntecavir: a new nucleoside analog for"/>
   <result pre="171SimsKAWoodlandAMEntecavir: a new nucleoside analog for the treatment of chronic" exact="hepatitis" post="B infectionPharmacotherapy2620061745175717125436 172MatthewsSJEntecavir for the treatment of chronic hepatitis"/>
   <result pre="chronic hepatitis B infectionPharmacotherapy2620061745175717125436 172MatthewsSJEntecavir for the treatment of chronic" exact="hepatitis" post="B virus infectionClin Ther28200618420316678641 173ScottLJKeatingGMEntecavir: a review of its"/>
   <result pre="infectionClin Ther28200618420316678641 173ScottLJKeatingGMEntecavir: a review of its use in chronic" exact="hepatitis" post="BDrugs6920091003103319496629 174JohnsonMAMooreKHYuenGJByeAPakesGEClinical pharmacokinetics of lamivudineClin Pharmacokinet3619994166 175DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial"/>
   <result pre="of lamivudineClin Pharmacokinet3619994166 175DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial of lamivudine for chronic" exact="hepatitis" post="B infectionN Engl J Med3331995165716617477217 176DienstagJLSchiffERWrightTLLamivudine as initial treatment"/>
   <result pre="infectionN Engl J Med3331995165716617477217 176DienstagJLSchiffERWrightTLLamivudine as initial treatment for chronic" exact="hepatitis" post="B in the United StatesN Engl J Med34119991256126310528035 177LaiCLChienRNLeungNWAsia"/>
   <result pre="Hepatitis Lamivudine Study GroupA one-year trial of lamivudine for chronic" exact="hepatitis" post="BN Engl J Med339199861689654535 178HonkoopPde ManRAHeijtinkRASchalmSWHepatitis B reactivation after"/>
   <result pre="impairmentJ Clin Pharmacol49200972573419395586 180KimJWParkSHLouieSGTelbivudine: a novel nucleoside analog for chronic" exact="hepatitis" post="BAnn Pharmacother40200647247816507625 181JonesRNelsonMNovel anti-hepatitis B agents: a focus on"/>
   <result pre="J Clin Pract6020061295129916981973 182LaiCLGaneELiawYFTelbivudine versus lamivudine in patients with chronic" exact="hepatitis" post="BN Engl J Med35720072576258818094378 183ChanHLHeathcoteEJMarcellinPTreatment of hepatitis B e"/>
   <result pre="patients with chronic hepatitis BN Engl J Med35720072576258818094378 183ChanHLHeathcoteEJMarcellinPTreatment of" exact="hepatitis" post="B e antigen positive chronic hepatitis with telbivudine or"/>
   <result pre="J Med35720072576258818094378 183ChanHLHeathcoteEJMarcellinPTreatment of hepatitis B e antigen positive chronic" exact="hepatitis" post="with telbivudine or adefovir: a randomized trialAnn Intern Med147200774575417909201"/>
   <result pre="186GallantJEDeresinskiSTenofovir disoproxil fumarateClin Infect Dis37200394495013130407 187WongSNLokASTenofovir disoproxil fumarate: role in" exact="hepatitis" post="B treatmentHepatology44200630931316871562 188ReijndersJGJanssenHLPotency of tenofovir in chronic hepatitis B:"/>
   <result pre="role in hepatitis B treatmentHepatology44200630931316871562 188ReijndersJGJanssenHLPotency of tenofovir in chronic" exact="hepatitis" post="B: mono or combination therapy?J Hepatol48200838338618191272 189GitmanMDHirschwerkDBaskinCHSinghalPCTenofovir-induced kidney injuryExpert"/>
   <result pre="the FDA adverse event reporting systemAIDS Patient Care STDS2220089910318260800 191SchmidSOpravilMModdelMAcute" exact="interstitial nephritis" post="of HIV-positive patients under atazanavir and tenofovir therapy in"/>
   <result pre="FDA adverse event reporting systemAIDS Patient Care STDS2220089910318260800 191SchmidSOpravilMModdelMAcute interstitial" exact="nephritis" post="of HIV-positive patients under atazanavir and tenofovir therapy in"/>
   <result pre="PP. Boceprevir: a protease inhibitor for the treatment of chronic" exact="hepatitis" post="C [Epub ahead of print August 9, 2011]. Ann"/>
   <result pre="treated chronic HCV genotype 1 infectionN Engl J Med36420111207121721449784 197PawlotskyJMChevaliezSMcHutchisonJGThe" exact="hepatitis" post="C virus life cycle as a target for new"/>
   <result pre="life cycle as a target for new antiviral therapiesGastroenterology13220071979199817484890 198SarrazinCKiefferTLBartelsDDynamic" exact="hepatitis" post="C virus genotypic and phenotypic changes in patients treated"/>
   <result pre="HCV infectionN Engl J Med36020091839185019403903 201JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic" exact="hepatitis" post="C virus infectionN Engl J Med36420112405241621696307 202ZeuzemSAndreonePPolSTelaprevir for retreatment"/>
   <result pre="herpesviruses; (2) discuss options for the prevention and treatment of" exact="influenza" post="virus, including infections with resistant strains; and (3) discuss"/>
   <result pre="and (3) discuss antiviral drugs for the treatment of chronic" exact="hepatitis" post="B and C infections, including novel nucleos(t)ide analogues and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3764029/results/search/disease/results.xml">
   <result pre="ribavirin mono-therapy regimens have minimal effect on patients with chronic" exact="hepatitis" post="C virus (HCV) infections, they can be efficacious when"/>
   <result pre="NS5B) (reviewed in reference [1]). Human HCV infection causes chronic" exact="liver disease," post="cirrhosis, and is associated with hepatocellular carcinoma [2]. It"/>
   <result pre="infection causes chronic liver disease, cirrhosis, and is associated with" exact="hepatocellular carcinoma" post="[2]. It is estimated that 180 million people worldwide"/>
   <result pre="infection it is expected that the number of patients with" exact="hepatocellular carcinoma" post="will increase in the coming years. The standard therapy"/>
   <result pre="[13]. 5-Fluorouracil is broadly used in the clinic to treat" exact="cancer" post="[14] including HCV associated hepatocellular carcinoma [15]. 5-Fluorouracil displays"/>
   <result pre="in the clinic to treat cancer [14] including HCV associated" exact="hepatocellular carcinoma" post="[15]. 5-Fluorouracil displays mutagenic activity leading to viral extinction"/>
   <result pre="MarinosG, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infection. N Engl J Med347: 975–982doi:;10.1056/NEJMoa020047;347/13/97512324553 5ShermanKE,"/>
   <result pre="NelsonDR, SulkowskiMS, et al. (2011) Response-guided telaprevir combination treatment for" exact="hepatitis" post="C virus infection. N Engl J Med365: 1014–1024doi:10.1056/NEJMoa101446321916639 6LimayeAR,"/>
   <result pre="tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in" exact="hepatitis" post="C. Hepatology. 55: 749–758doi:10.1002/hep.24744 8ZeuzemS, AsselahT, AngusP, ZarskiJP, LarreyD,"/>
   <result pre="(2008) Mechanisms of action of interferon and ribavirin in chronic" exact="hepatitis" post="C: Summary of a workshop. Hepatology47: 306–320.18161743 10FeldJJ, LutchmanGA,"/>
   <result pre="EvansMJ, SyderAJ, WolkB, TellinghuisenTL, et al. (2005) Complete replication of" exact="hepatitis" post="C virus in cell culture. Science309: 623–626.15947137 12FeigelstockDA, MihalikKB,"/>
   <result pre="cell culture. Science309: 623–626.15947137 12FeigelstockDA, MihalikKB, FeinstoneSM (2011) Selection of" exact="hepatitis" post="C virus resistant to ribavirin. Virol J 8402: 1743–422X-8-402doi:10.1186/1743-422X-8-402"/>
   <result pre="survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced" exact="hepatocellular carcinoma." post="J Gastroenterol42: 845–853doi:10.1007/s00535-007-2099-817940838 16MorenoH, TejeroH, de la TorreJC, DomingoE,"/>
   <result pre="MorelV, WychowskiC, et al. (2007) Effect of ribavirin on the" exact="hepatitis" post="C virus (JFH-1) and its correlation with interferon sensitivity."/>
   <result pre="are region specific and increased by ribavirin in a full-length" exact="hepatitis" post="C virus replication system. J Virol76: 8505–8517.12163570 25HofmannWP, PoltaA,"/>
   <result pre="MihmU, KronenbergerB, et al. (2007) Mutagenic effect of ribavirin on" exact="hepatitis" post="C nonstructural 5B quasispecies in vitro and during antiviral"/>
   <result pre="YokosukaO, ImazekiF, TanakaM, ShinoY, et al. (2004) Inhibition of subgenomic" exact="hepatitis" post="C virus RNA in Huh-7 cells: ribavirin induces mutagenesis"/>
   <result pre="SongBC, LiangTJ, HoofnagleJH, et al. (2007) Mutation rate of the" exact="hepatitis" post="C virus NS5B in patients undergoing treatment with ribavirin"/>
   <result pre="Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of" exact="hepatitis" post="C virus genotype 1-infected patients. J Virol 876172–6181: JVI.02778–12doi:10.1128/JVI.02778-12"/>
   <result pre="JacobsonI, GeorgeS (2008) Recent progress in the development of selected" exact="hepatitis" post="C virus NS3.4A protease and NS5B polymerase inhibitors. Current"/>
   <result pre="(2004) First clinical results for a novel antiviral treatment for" exact="hepatitis" post="C: a phase I/III dose escalation trial assessing tolerance,"/>
   <result pre="efficacy upon administration of a HepDirect prodrug of 2′-C-methylcytidine to" exact="hepatitis" post="C virus-infected chimpanzees. Antimicrob Agents Chemother 553854–3860: AAC.01152–10doi:10.1128/AAC.01152-10 36Le"/>
   <result pre="YoungKC, LaiMM (2003) Mutagenic and inhibitory effects of ribavirin on" exact="hepatitis" post="C virus RNA polymerase. Biochemistry42: 10462–10471.12950173 40SierraM, AiraksinenA, Gonzalez-LopezC,"/>
   <result pre="al. (1999) Crystal structure of the RNA-dependent RNA polymerase from" exact="hepatitis" post="C virus reveals a fully encircled active site. Nature"/>
   <result pre="Crystal structures of the RNA-dependent RNA polymerase genotype 2a of" exact="hepatitis" post="C virus reveal two conformations and suggest mechanisms of"/>
   <result pre="344–348.16327776 46TellinghuisenTL, MarcotrigianoJ, GorbalenyaAE, RiceCM (2004) The NS5A protein of" exact="hepatitis" post="C virus is a zinc metalloprotein. J Biol Chem"/>
   <result pre="EggerD, LohmannV, BartenschlagerR, BlumHE, et al. (2003) Identification of the" exact="hepatitis" post="C virus RNA replication complex in Huh-7 cells harboring"/>
   <result pre="protein into nonstructural protein 5A allows direct visualization of functional" exact="hepatitis" post="C virus replication complexes. J Virol78: 7400–7409.78/14/7400doi:10.1128/JVI.78.14.7400-7409.200415220413 49MacdonaldA, HarrisM"/>
   <result pre="al. (1995) Comparison of full-length sequences of interferon-sensitive and resistant" exact="hepatitis" post="C virus 1b. Sensitivity to interferon is conferred by"/>
   <result pre="Clin Invest96: 224–230doi:10.1172/JCI1180257542279 51HsuHH, DonetsM, GreenbergHB, FeinstoneSM (1993) Characterization of" exact="hepatitis" post="C virus structural proteins with a recombinant baculovirus expression"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3854647/results/search/disease/results.xml">
   <result pre=": Research Article Prescription of antiviral drugs during the 2009" exact="influenza" post="pandemic: an observational study using electronic medical files of"/>
   <result pre="accordance with the recommendations, what proportion of patients diagnosed with" exact="influenza" post="had been prescribed antiviral drugs, and to what extent"/>
   <result pre="had been prescribed antiviral medication (n = 351) or were diagnosed with" exact="influenza" post="(n = 3293). Results Of all antiviral prescriptions, 69% were in"/>
   <result pre="accordance with the recommendations. Only 5% of patients diagnosed with" exact="influenza" post="were prescribed antiviral drugs. This percentage increased to 12%"/>
   <result pre="were prescribed antiviral drugs. This percentage increased to 12% among" exact="influenza" post="patients belonging to the designated high risk groups. On"/>
   <result pre="designated high risk groups. On the other hand, 2.5% of" exact="influenza" post="patients not at high risk of complications received antiviral"/>
   <result pre="Netherlands have been restrictive in prescribing antiviral drugs during the" exact="influenza" post="pandemic, even when patients met the criteria for antiviral"/>
   <result pre="topic Background On April 30th 2009, the first case of" exact="influenza" post="A(H1N1)pdm09 was identified in the Netherlands, while it eventually"/>
   <result pre="in the Netherlands, while it eventually caused an epidemic with" exact="influenza" post="activity above baseline in the period 12 October through"/>
   <result pre="hemisphere) [1]. During the emerging pandemic, all patients suspected of" exact="influenza" post="were indicated for treatment with antiviral drugs and their"/>
   <result pre="on morbidity and mortality appeared to be similar to seasonal" exact="influenza" post="virus, based on its so far documented relatively mild"/>
   <result pre="for severe disease and patients having a complicated course of" exact="influenza" post="[5]. Prophylactic prescriptions were no longer recommended. High risk"/>
   <result pre="patients were defined as the same patients eligible for seasonal" exact="influenza" post="vaccination, i.e. all patients of 60 years or above"/>
   <result pre="women in their third trimester, and patients having symptoms of" exact="influenza" post="in whom the infection occurred to be unusually severe"/>
   <result pre="first choice for treatment of high risk patients suspected of" exact="influenza" post="during the pandemic. Treatment with zanamivir was reserved for"/>
   <result pre="reserved for patients suspected for an infection with a resistant" exact="influenza" post="virus. Oseltamivir was only available as a prescription drug,"/>
   <result pre="practices’ characteristics, and 2) what proportion of patients diagnosed with" exact="influenza" post="received oseltamivir and which factors determined this prescription. Methods"/>
   <result pre="registered at the same day. We specifically considered diagnoses of" exact="influenza" post="(ICPC-code R80, which will be used by GPs for"/>
   <result pre="for patients with influenza-like illness in the context of an" exact="influenza" post="epidemic, or upon virological confirmation of an influenza virus),"/>
   <result pre="of an influenza epidemic, or upon virological confirmation of an" exact="influenza" post="virus), another acute respiratory infection (ARI, defined by ICPC-codes"/>
   <result pre="used by GPs for patients with influenza-like illness outside the" exact="influenza" post="season). Patients who did not receive oseltamivir were evaluated"/>
   <result pre="on age (&amp;lt;2 years or ≥60 years), co-morbidity (cardiac disease," exact="respiratory disease," post="diabetes mellitus, chronic renal insufficiency, reduced resistance against infections"/>
   <result pre="(&amp;lt;2 years or ≥60 years), co-morbidity (cardiac disease, respiratory disease," exact="diabetes mellitus," post="chronic renal insufficiency, reduced resistance against infections and children"/>
   <result pre="using salicylates), a complicated course of illness (the occurrence of" exact="pneumonia" post="within 7 days before or after the diagnosis of"/>
   <result pre="pneumonia within 7 days before or after the diagnosis of" exact="influenza" post="or ARI, or the need to prescribe antibiotics –"/>
   <result pre="or a third trimester pregnancy (an oseltamivir prescription or an" exact="influenza" post="diagnosis between 20 to 34 weeks after a first"/>
   <result pre="be no more than 14 weeks after oseltamivir prescription or" exact="influenza" post="diagnosis). Details on ICPC- and ATC-codes used to classify"/>
   <result pre="Half of the patients receiving oseltamivir had a diagnosis of" exact="influenza" post="(n = 181; 51.6%). The most frequently registered diagnoses in 105"/>
   <result pre="infection were general disease (21 patients), fever (17 patients), other" exact="viral disease" post="(12 patients), and ‘no disease’ (11 patients). No valid"/>
   <result pre="3,293 patients (1.3% of the study population) were diagnosed with" exact="influenza" post="and oseltamivir was prescribed to 181 (5.5%). The weekly"/>
   <result pre="oseltamivir was prescribed to 181 (5.5%). The weekly number of" exact="influenza" post="patients followed well the epidemiologic curve of the Dutch"/>
   <result pre="influenza-like illness (IAZ) surveillance (data not shown) [1]. Of all" exact="influenza" post="patients, 1,051 (31.9%) belonged to the designated high risk"/>
   <result pre="of age. On the other hand, 2,242 patients diagnosed with" exact="influenza" post="did not belong to the high risk groups and"/>
   <result pre="in 2009 were determinants of the prescription of oseltamivir among" exact="influenza" post="patients (Table 3). Patients with underlying co-morbidity had the"/>
   <result pre="were observed for other underlying diseases. Ten percent of all" exact="influenza" post="patients had a complicated course of illness, but this"/>
   <result pre="influencing the prescription of oseltamivir by general practitioners to 3,293" exact="influenza" post="patients Prescription of oseltamivir, n of patients (%) Univariate"/>
   <result pre="prescriptions was positively associated with the prescription of oseltamivir. Among" exact="influenza" post="patients who did not belong to the designated high"/>
   <result pre="4 Potential factors influencing the prescription of oseltamivir to 2,242" exact="influenza" post="patients not at high risk Prescription of oseltamivir, n"/>
   <result pre="the Netherlands have been restrained in prescribing oseltamivir during the" exact="influenza" post="pandemic. Only 5% of all patients diagnosed with influenza"/>
   <result pre="the influenza pandemic. Only 5% of all patients diagnosed with" exact="influenza" post="were prescribed oseltamivir, and only 12% of those who"/>
   <result pre="followed the recommendations in the national guidelines. Only 2.5% of" exact="influenza" post="patients not at high risk were prescribed oseltamivir, and"/>
   <result pre="are used in general practices to select patients eligible for" exact="influenza" post="vaccination [10,11]. This method has been used to monitor"/>
   <result pre="[10,11]. This method has been used to monitor the Dutch" exact="influenza" post="vaccination rate in different high risk groups for several"/>
   <result pre="by Hersh and colleagues, antivirals were prescribed in 58% of" exact="influenza" post="visits to US ambulatory physicians [15]. The prescription rate"/>
   <result pre="have been very restrained in prescribing antiviral drugs during the" exact="influenza" post="pandemic. Where GPs have used antiviral medication, they have"/>
   <result pre="den WijngaardCCHaagsmaJADonkerGAMeijerAvan der HoekWLugnérAKKretzschmarMEvan der SandeMAThe burden of 2009 pandemic" exact="influenza" post="A(H1N1) in the NetherlandsEur J Public Health20122215015710.1093/eurpub/ckq18721183472 van ‘t"/>
   <result pre="WijngaardCCvan der SandeMAvan der HoekWSurveillance of hospitalisations for 2009 pandemic" exact="influenza" post="A(H1N1) in the Netherlands, 5 June – 31 December"/>
   <result pre="Norwegian Institute of Public Health TackenMMulderJVisscherSTiersmaWDonkersJVerheijRBraspenningJMonitoring vaccination rate Dutch national" exact="influenza" post="prevention program 2009 [in Dutch]2010LINH: Nijmegen/Utrecht Van EssenGABuevingHJVoordouwACGBergHFVan der"/>
   <result pre="Van EssenGABuevingHJVoordouwACGBergHFVan der LaanJRde Jeude CPVLBoomsmaLJOpsteltenWDutch College of General Practitioners-guideline" exact="influenza" post="and influenza vaccination (first revision) [in Dutch]Huisarts Wet200851appendix 1–2"/>
   <result pre="der LaanJRde Jeude CPVLBoomsmaLJOpsteltenWDutch College of General Practitioners-guideline influenza and" exact="influenza" post="vaccination (first revision) [in Dutch]Huisarts Wet200851appendix 1–2 TackenMAJBBraspenningJCCBerendeAHakEDe BakkerDHGroenewegenPPGrolRPVaccination"/>
   <result pre="TackenMBraspenningJSpreeuwenbergPVan den HoogenHVan EssenGDe BakkerDGrolRPatient characteristics determine differences in the" exact="influenza" post="vaccination rate more so than practice featuresPrev Med20023540140610.1006/pmed.2002.108312453719 FietjéEHPhilbertDvan"/>
   <result pre="than practice featuresPrev Med20023540140610.1006/pmed.2002.108312453719 FietjéEHPhilbertDvan GeffenECWintersNABouvyMLAdherence to oseltamivir guidelines during" exact="influenza" post="pandemic, the NetherlandsEmerg Infect Dis20121853453510.3201/eid1803.11135122377063 HershALStaffordRSAntiviral prescribing by office-based"/>
   <result pre="Assess20101410918220630123 AzizMVasooSAzizZPatelSEltoukhyNSinghKOseltamivir overuse at a Chicago hospital during the 2009" exact="influenza" post="pandemic and the poor predictive value of influenza-like illness"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC3898391/results/search/disease/results.xml">
   <result pre="pmid: 24433304 doi: 10.1186/1471-2458-14-41 : Research Article Influenza vaccines and" exact="influenza" post="antiviral drugs in Africa: are they available and do"/>
   <result pre="morbidity and mortality in Africa, particularly among high-risk groups, but" exact="influenza" post="vaccines and antiviral drugs may not be commonly available"/>
   <result pre="this study was to determine the availability and use of" exact="influenza" post="vaccines and antiviral drugs as well as to describe"/>
   <result pre="in Africa. Methods A self-administered survey was distributed among key" exact="influenza" post="experts in 40 African countries. Results Of the 40"/>
   <result pre="surveyed, 31 (78%) responded; 14/31 (45%) reported availability of seasonal" exact="influenza" post="vaccine, and 19/31 (65%) reported availability of antiviral drugs"/>
   <result pre="available for 4/14 (29%) countries that reported availability of seasonal" exact="influenza" post="vaccine and ranged from &amp;lt;0.5% to 2% of the"/>
   <result pre="and identifying funding are essential to encourage countries to use" exact="influenza" post="vaccine more widely. Influenza Vaccine Antiviral Drugs Policy Recommendations"/>
   <result pre="of inpatient and outpatient respiratory cases, respectively, tested positive for" exact="influenza" post="between 2006–2010 [2]. For many years, influenza epidemiology has"/>
   <result pre="tested positive for influenza between 2006–2010 [2]. For many years," exact="influenza" post="epidemiology has been described in countries with temperate climates"/>
   <result pre="Morocco [3,4] but there are now data that comprehensively describe" exact="influenza" post="viruses in tropical countries like Kenya and Zambia [5,6]."/>
   <result pre="in tropical countries like Kenya and Zambia [5,6]. In Africa," exact="influenza" post="causes severe illness and deaths in both temperate and"/>
   <result pre="and limited access to health care. For example, outbreaks of" exact="influenza" post="A(H3N2), which circulates widely across the globe, have caused"/>
   <result pre="Africa are four times more likely to die from an" exact="influenza" post="infection than their counterparts in the United States [11]."/>
   <result pre="The high prevalence of comorbidities including human immunodeficiency virus and" exact="tuberculosis" post="contribute to increased influenza-associated mortality in Africa [7]. Vaccination"/>
   <result pre="Africa [7]. Vaccination is the most effective way to prevent" exact="influenza" post="illness and antiviral drugs help treat viral infection [12]."/>
   <result pre="countries in the African Region have capacity to produce seasonal" exact="influenza" post="vaccines [13] and that only 2 of the 54"/>
   <result pre="combined receive only 1% to 4% of the global seasonal" exact="influenza" post="vaccine supply each year [15]. With growing data on"/>
   <result pre="each year [15]. With growing data on the burden of" exact="influenza" post="across the African continent, many countries are considering introducing"/>
   <result pre="are considering introducing or expanding strategies to prevent and manage" exact="influenza" post="infection. We conducted this study to gather more data"/>
   <result pre="this study to gather more data on the availability of" exact="influenza" post="vaccines and antiviral drugs in Africa as well as"/>
   <result pre="of Defense. We approached these institutions to identify key in-country" exact="influenza" post="experts in Africa who could answer the survey. In"/>
   <result pre="be public health research. The survey included 22 questions regarding" exact="influenza" post="vaccines, antiviral drugs and related policies and guidelines and"/>
   <result pre="determine a valid response via personal communication with an in-country" exact="influenza" post="expert. Results Of the 54 countries on the African"/>
   <result pre="the 31 countries surveyed, 14 (45%) reported availability of seasonal" exact="influenza" post="vaccine (Figure 1); six in the private sector only"/>
   <result pre="anyone to respond to this survey in Algeria, WHO reports" exact="influenza" post="vaccine is available there [14]. La Réunion also reported"/>
   <result pre="both the private and public sectors. Figure 1 Availability of" exact="influenza" post="vaccine and antiviral drugs in Africa. Table 1 Availability"/>
   <result pre="vaccine and antiviral drugs in Africa. Table 1 Availability of" exact="influenza" post="vaccine and antiviral drugs for the treatment of influenza"/>
   <result pre="of influenza vaccine and antiviral drugs for the treatment of" exact="influenza" post="in Africa* Country Region World Bank income level Vaccine"/>
   <result pre="available for 4/14 (29%) countries that reported availability of seasonal" exact="influenza" post="vaccine and ranged from &amp;lt;0.5% to 2% of the"/>
   <result pre="from &amp;lt;0.5% to 2% of the population. Countries that had" exact="influenza" post="vaccine available were from all regions of Africa and"/>
   <result pre="(chi-square = 0.19; p-value = 0.57). Among the 14 countries that reported having any" exact="influenza" post="vaccine, four (Côte d’Ivoire, Egypt, Mauritius, and Morocco) reported"/>
   <result pre="Africa has standing guidelines for the prevention and treatment of" exact="influenza" post="[19]but a national public policy regarding vaccination is yet"/>
   <result pre="as most important in influencing decision-makers to introduce and promote" exact="influenza" post="vaccine; evidence that illnesses and deaths can be prevented"/>
   <result pre="vaccine; evidence that illnesses and deaths can be prevented by" exact="influenza" post="vaccination and evidence that the national health system will"/>
   <result pre="31 respondent countries, 23 (74%) reported receiving and/or purchasing pandemic" exact="influenza" post="vaccine in or after 2009, and 19 (83%) of"/>
   <result pre="Mali, Senegal and South Africa) and La Réunion reported conducting" exact="influenza" post="vaccine research in the years 2012 and/or 2013. Lastly,"/>
   <result pre="Over the last few years, the Northern and Southern hemisphere" exact="influenza" post="vaccine formulations have been identical albeit the time in"/>
   <result pre="distributed is different. Several countries that do not currently have" exact="influenza" post="vaccine available are likely to consider doing so in"/>
   <result pre="underutilized vaccines [20], many of the countries in Africa without" exact="influenza" post="vaccine are low income. The Global Alliance for Vaccines"/>
   <result pre="for Vaccines and Immunisation (GAVI) is a public-private partnership that" exact="aids" post="low income countries in procuring vaccines. Currently, there are"/>
   <result pre="of these countries are in Africa [21]. Before the 2009" exact="influenza" post="A(H1N1) pandemic, most countries in Africa had inadequate data"/>
   <result pre="countries in Africa had inadequate data on the burden of" exact="influenza" post="disease and high risk groups to inform influenza public"/>
   <result pre="burden of influenza disease and high risk groups to inform" exact="influenza" post="public health policies [22]. Since then, influenza surveillance systems"/>
   <result pre="groups to inform influenza public health policies [22]. Since then," exact="influenza" post="surveillance systems have been strengthened and many countries are"/>
   <result pre="surveillance systems have been strengthened and many countries are studying" exact="influenza" post="incidence and seasonality, particularly among sub-groups [1,2]. Networks like"/>
   <result pre="[2] and AfriFlu [23] have increased the scientific dialogue among" exact="influenza" post="experts in Africa. Globally, one of the main concerns"/>
   <result pre="Africa. Globally, one of the main concerns is whether seasonal" exact="influenza" post="vaccine supply is adequate to meet the needs of"/>
   <result pre="[13,24,25]. A survey among 10 countries in Southeast Asia, where" exact="influenza" post="pandemics are likely to emerge, found seasonal influenza vaccine"/>
   <result pre="Asia, where influenza pandemics are likely to emerge, found seasonal" exact="influenza" post="vaccine sales in the private sector average &amp;lt;1000 doses"/>
   <result pre="[20]. In contrast, 5/15 (33%) of the African countries with" exact="influenza" post="vaccine reported having national guidelines for influenza vaccines. Investment"/>
   <result pre="African countries with influenza vaccine reported having national guidelines for" exact="influenza" post="vaccines. Investment in influenza research to promote evidence-based influenza"/>
   <result pre="vaccine reported having national guidelines for influenza vaccines. Investment in" exact="influenza" post="research to promote evidence-based influenza public health policies in"/>
   <result pre="for influenza vaccines. Investment in influenza research to promote evidence-based" exact="influenza" post="public health policies in Africa is essential to encouraging"/>
   <result pre="be low. As additional data emerge on the burden of" exact="influenza" post="disease in Africa, the identification of groups at risk"/>
   <result pre="in Africa, 2006–2010J Infect Dis2012206Suppl 1S14S2110.1093/infdis/jis60623169960 McAnerneyJMCohenCMoyesJBesselaarTGBuysASchoubBDBlumbergLTwenty-five years of outpatient" exact="influenza" post="surveillance in South Africa, 1984–2008J Infect Dis2012206Suppl 1S153S15810.1093/infdis/jis57523169963 BarakatAIhazmadHBenkaroumSCherkaouiIBenmamounAYoubiMEl"/>
   <result pre="in Morocco, 1996–2009PLoS One20116e2457910.1371/journal.pone.002457921931764 KatzMALeboEEmukuleGNjugunaHNAuraBCosmasLAudiAJunghaeMWaibociLWOlackBet al.Epidemiology, seasonality, and burden of" exact="influenza" post="and influenza-like illness in urban and rural Kenya, 2007–2010J"/>
   <result pre="mortality associated with the first 12 months of 2009 pandemic" exact="influenza" post="A H1N1 virus circulation: a modelling studyLancet Infect Dis20121268769510.1016/S1473-3099(12)70121-422738893"/>
   <result pre="Dis20121268769510.1016/S1473-3099(12)70121-422738893 NairHBrooksWAKatzMRocaABerkleyJAMadhiSASimmermanJMGordonASatoMHowieSet al.Global burden of respiratory infections due to seasonal" exact="influenza" post="in young children: a systematic review and meta-analysisLancet20113781917193010.1016/S0140-6736(11)61051-922078723 collab:"/>
   <result pre="Dis2010511362136910.1086/65731421070141 Fact sheet on influenzahttp://www.who.int/mediacentre/factsheets/fs211/en/index.html PartridgeJKienyMPGlobal production capacity of seasonal" exact="influenza" post="vaccine in 2011Vaccine20133172873110.1016/j.vaccine.2012.10.11123149268 Back to immunization surveillance, assessment and"/>
   <result pre="2011Vaccine20133172873110.1016/j.vaccine.2012.10.11123149268 Back to immunization surveillance, assessment and monitoring datahttp://www.who.int/immunization/monitoring_surveillance/en/ PalacheASeasonal" exact="influenza" post="vaccine provision in 157 countries (2004–2009) and the potential"/>
   <result pre="of national public health policiesVaccine2011299459946610.1016/j.vaccine.2011.10.03022024174 Third annual African network for" exact="influenza" post="surveillance and epidemiology (ANISE) meetinghttps://www.team-psa.com/anise/2012/home.asp OpenEpihttp://www.openepi.com The World Bank"/>
   <result pre="in southeast Asia: 2008–2011PLoS One20127e5284210.1371/journal.pone.005284223285200 Countries eligible for supporthttp://www.gavialliance.org/support/apply/countries-eligible-for-support/ GessnerBDShindoNBriandSSeasonal" exact="influenza" post="epidemiology in sub-Saharan Africa: a systematic reviewLancet Infect Dis20111122323510.1016/S1473-3099(11)70008-121371656"/>
   <result pre="sub-Saharan Africa: a systematic reviewLancet Infect Dis20111122323510.1016/S1473-3099(11)70008-121371656 SteffenCDiopOMGessnerBDHacenMMHassarMKatzMAMillerMAPagetWJSchoubBDVernetGNdumbePMAfriflu--international conference on" exact="influenza" post="disease burden in Africa, 1–2 June 2010, Marrakech, MoroccoVaccine20112936336910.1016/j.vaccine.2010.11.02921111779"/>
   <result pre="Africa, 1–2 June 2010, Marrakech, MoroccoVaccine20112936336910.1016/j.vaccine.2010.11.02921111779 KienyMPCostaAHombachJCarrascoPPervikovYSalisburyDGrecoMGustILaForceMFranco-ParedesCet al.A global pandemic" exact="influenza" post="vaccine action planVaccine2006246367637010.1016/j.vaccine.2006.07.02117240560 collab: Members of the Western Pacific"/>
   <result pre="of the Western Pacific Region Global Influenza S, System RSeasonal" exact="influenza" post="vaccine policies, recommendations and use in the world health"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4195804/results/search/disease/results.xml">
   <result pre="the development of coronavirus specific therapeutics. However, the emergence of" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome"/>
   <result pre="(MERS-CoV), was isolated as the causative agent of a severe" exact="pneumonia" post="in several patients in the Middle East [1]. Globally,"/>
   <result pre="of America (http://www.who.int/csr/don/2014_05_16_mers/en/, http://www.cdc.gov/coronavirus/mers/). This CoV is closely related to" exact="severe acute respiratory syndrome" post="CoV (SARS-CoV), an epidemic that was short-lived but alarming"/>
   <result pre="fevers, indications similar to influenza, but later progresses to atypical" exact="pneumonia" post="in most cases [16]. Although, many antiviral agents have"/>
   <result pre="effect was specific for SARS-CoV replication because no effect on" exact="influenza" post="virus replication was observed with up to 50 μM"/>
   <result pre="a broad-spectrum activity against other coronaviruses, including MERS-CoV and mouse" exact="hepatitis" post="virus (MHV) [47]. Entry inhibitors Viral entry is an"/>
   <result pre="used for the treatment of some viral infections, such as" exact="hepatitis" post="C virus, albeit with some adverse side effects including"/>
   <result pre="hepatitis C virus, albeit with some adverse side effects including" exact="hemolytic anemia," post="elevated transaminase levels and bradycardia [83], depression, suicide, relapse"/>
   <result pre="1ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med36720121814182023075143 2••RotaP.A.ObersteM.S.MonroeS.S.NixW.A.CampagnoliR.IcenogleJ.P.PenarandaS.BankampB.MaherK.ChenM.H.Characterization of a"/>
   <result pre="Cell Biol13119953393497593163 7HonC.C.LamT.Y.ShiZ.L.DrummondA.J.YipC.W.ZengF.LamP.Y.LeungF.C.Evidence of the recombinant origin of a bat" exact="severe acute respiratory syndrome" post="(SARS)-like coronavirus and its implications on the direct ancestor"/>
   <result pre="BoheemenS.de GraafM.LauberC.BestebroerT.M.RajV.S.ZakiA.M.OsterhausA.D.HaagmansB.L.GorbalenyaA.E.SnijderE.J.Genomic characterization of a newly discovered coronavirus associated with" exact="acute respiratory distress syndrome" post="in humansMBio20123 15ItheteN.L.StoffbergS.CormanV.M.CottontailV.M.RichardsL.R.SchoemanM.C.DrostenC.DrexlerJ.F.PreiserW.Close relative of human Middle East respiratory"/>
   <result pre="basis for design of anti-SARS drugsScience30020031763176712746549 21••YangH.YangM.DingY.LiuY.LouZ.ZhouZ.SunL.MoL.YeS.PangH.The crystal structures of" exact="severe acute respiratory syndrome" post="virus main protease and its complex with an inhibitorProc"/>
   <result pre="This is the first report on the crystal structures of" exact="severe acute respiratory syndrome" post="virus main protease at different pH and its complex"/>
   <result pre="complexes as SARS-CoV 3C-like protease inhibitorsFEBS Lett58120075454545817981158 28WuC.Y.JanJ.T.MaS.H.KuoC.J.JuanH.F.ChengY.S.HsuH.H.HuangH.C.WuD.BrikA.Small molecules targeting" exact="severe acute respiratory syndrome" post="human coronavirusProc Natl Acad Sci U S A1012004100121001715226499 29ShaoY.M.YangW.B.PengH.P.HsuM.F.TsaiK.C.KuoT.H.WangA.H.LiangP.H.LinC.H.YangA.S.Structure-based"/>
   <result pre="of highly potent SARS-CoV 3CL protease inhibitorsChembiochem820071654165717722121 30ShieJ.J.FangJ.M.KuoT.H.KuoC.J.LiangP.H.HuangH.J.WuY.T.JanJ.T.ChengY.S.WongC.H.Inhibition of the" exact="severe acute respiratory syndrome" post="3CL protease by peptidomimetic alpha,beta-unsaturated estersBioorg Med Chem1320055240525215994085 31ShieJ.J.FangJ.M.KuoC.J.KuoT.H.LiangP.H.HuangH.J.YangW.B.LinC.H.ChenJ.L.WuY.T.Discovery"/>
   <result pre="estersBioorg Med Chem1320055240525215994085 31ShieJ.J.FangJ.M.KuoC.J.KuoT.H.LiangP.H.HuangH.J.YangW.B.LinC.H.ChenJ.L.WuY.T.Discovery of potent anilide inhibitors against the" exact="severe acute respiratory syndrome" post="3CL proteaseJ Med Chem4820054469447315974598 32WuC.Y.KingK.Y.KuoC.J.FangJ.M.WuY.T.HoM.Y.LiaoC.L.ShieJ.J.LiangP.H.WongC.H.Stable benzotriazole esters as mechanism-based"/>
   <result pre="Med Chem4820054469447315974598 32WuC.Y.KingK.Y.KuoC.J.FangJ.M.WuY.T.HoM.Y.LiaoC.L.ShieJ.J.LiangP.H.WongC.H.Stable benzotriazole esters as mechanism-based inactivators of the" exact="severe acute respiratory syndrome" post="3CL proteaseChem Biol13200626126816638531 33TsaiK.C.ChenS.Y.LiangP.H.LuI.L.MahindrooN.HsiehH.P.ChaoY.S.LiuL.LiuD.LienW.Discovery of a novel family of"/>
   <result pre="inhibitors of SARS-CoV 3CL proteaseBioorg Med Chem Lett2020103569357220494577 37HarcourtB.H.JuknelieneD.KanjanahaluethaiA.BechillJ.SeversonK.M.SmithC.M.RotaP.A.BakerS.C.Identification of" exact="severe acute respiratory syndrome" post="coronavirus replicase products and characterization of papain-like protease activityJ"/>
   <result pre="characterization of papain-like protease activityJ Virol782004136001361215564471 38BarrettoN.JuknelieneD.RatiaK.ChenZ.MesecarA.D.BakerS.C.The papain-like protease of" exact="severe acute respiratory syndrome" post="coronavirus has deubiquitinating activityJ Virol792005151891519816306590 39FriemanM.BasuD.MatthewsK.TaylorJ.JonesG.PicklesR.BaricR.EngelD.A.Yeast based small molecule"/>
   <result pre="nuclei acid unwinding by SARS-CoV helicase. 42PaoliniC.De FrancescoR.GallinariP.Enzymatic properties of" exact="hepatitis" post="C virus NS3-associated helicaseJ Gen Virol8120001335134510769077 43KimM.K.YuM.S.ParkH.R.KimK.B.LeeC.ChoS.Y.KangJ.YoonH.KimD.E.ChooH.2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral"/>
   <result pre="NS3-associated helicaseJ Gen Virol8120001335134510769077 43KimM.K.YuM.S.ParkH.R.KimK.B.LeeC.ChoS.Y.KangJ.YoonH.KimD.E.ChooH.2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both" exact="hepatitis" post="C virus (HCV) and SARS-associated coronavirus (SCV)Eur J Med"/>
   <result pre="soluble receptorBiochem Biophys Res Commun31920041216122115194496 67••SimmonsG.GosaliaD.N.RennekampA.J.ReevesJ.D.DiamondS.L.BatesP.Inhibitors of cathepsin L prevent" exact="severe acute respiratory syndrome" post="coronavirus entryProc Natl Acad Sci U S A1022005118761188116081529 First"/>
   <result pre="domain within the SARS-CoV envelope. 70YangZ.Y.HuangY.GaneshL.LeungK.KongW.P.SchwartzO.SubbaraoK.Nabel GJ: pH-dependent entry of" exact="severe acute respiratory syndrome" post="coronavirus is mediated by the spike glycoprotein and enhanced"/>
   <result pre="Commun31220031159116414651994 73ShahP.P.WangT.KaletskyR.L.MyersM.C.PurvisJ.E.JingH.HurynD.M.GreenbaumD.C.SmithA.B.IIIBatesP.A small-molecule oxocarbazate inhibitor of human cathepsin L blocks" exact="severe acute respiratory syndrome" post="and ebola pseudotype virus infection into human embryonic kidney"/>
   <result pre="of viral entry and possible antiviral targets. 77••AdedejiA.O.SeversonW.JonssonC.SinghK.WeissS.R.SarafianosS.G.Novel inhibitors of" exact="severe acute respiratory syndrome" post="coronavirus entry that act by three distinct mechanismsJ Virol8720138017802823678171"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4247767/results/search/disease/results.xml">
   <result pre="of new drugs have been developed for HIV, HCV and" exact="influenza" post="virus, the optimal combinations of multiple drugs are incompletely"/>
   <result pre="drugs targeting HIV [5–13], HCV [14–18], HBV [19, 20] and" exact="influenza" post="virus [21, 22]. These studies have elucidated the key"/>
   <result pre="experience severe side effects such as lipodystrophy, hepatotoxicity, renal dysfunction," exact="peripheral neuropathy" post="and cardiovascular diseases (reviewed in [28]). By optimizing drug"/>
   <result pre="severe side effects such as lipodystrophy, hepatotoxicity, renal dysfunction, peripheral" exact="neuropathy" post="and cardiovascular diseases (reviewed in [28]). By optimizing drug"/>
   <result pre="we discuss how drug combination theory might be applied to" exact="cancer" post="chemotherapies and antiviral therapies. Combining mathematical models of viral"/>
   <result pre="usefulness of combining the Loewe additivity with mathematical modeling of" exact="hepatitis" post="C virus (HCV) replication. The aim is to optimize"/>
   <result pre="drug targets are decided. For example, using computational modeling of" exact="cancer" post="signaling networks and animal experiments, Kirouac et al.[46] identified"/>
   <result pre="the optimal inhibitor combination for suppressing the growth of ERBB2-amplified" exact="breast cancer." post="They adopted Bliss independence as a synergy criterion. Supplementing"/>
   <result pre="a biological system. The above research potentially benefits not only" exact="cancer" post="chemotherapy, but also antiviral therapy development. For instance, Owens"/>
   <result pre="interferon-alpha therapyScience199828210310710.1126/science.282.5386.1039756471 16.DixitNMLayden-AlmerJELaydenTJPerelsonASModelling how ribavirin improves interferon response rates in" exact="hepatitis" post="C virus infectionNature200443292292410.1038/nature0315315602565 17.DahariHRibeiroRMPerelsonASTriphasic decline of hepatitis C virus"/>
   <result pre="response rates in hepatitis C virus infectionNature200443292292410.1038/nature0315315602565 17.DahariHRibeiroRMPerelsonASTriphasic decline of" exact="hepatitis" post="C virus RNA during antiviral therapyHepatology200746162110.1002/hep.2165717596864 18.DahariHSainzBPerelsonASUprichardSLModeling subgenomic hepatitis"/>
   <result pre="of hepatitis C virus RNA during antiviral therapyHepatology200746162110.1002/hep.2165717596864 18.DahariHSainzBPerelsonASUprichardSLModeling subgenomic" exact="hepatitis" post="C virus RNA kinetics during treatment with alpha interferonJ"/>
   <result pre="RNA kinetics during treatment with alpha interferonJ Virol2009836383639010.1128/JVI.02612-0819369346 19.LewinSRRibeiroRMWaltersTLauGKBowdenSLocarniniSPerelsonASAnalysis of" exact="hepatitis" post="B viral load decline under potent therapy: complex decay"/>
   <result pre="therapy: complex decay profiles observedHepatology2001341012102010.1053/jhep.2001.2850911679973 20.DahariHShudoERibeiroRMPerelsonASModeling complex decay profiles of" exact="hepatitis" post="B virus during antiviral therapyHepatology200949323810.1002/hep.2258619065674 21.BeaucheminCAAMcSharryJJDrusanoGLNguyenJTWentGTRibeiroRMPerelsonASModeling amantadine treatment of"/>
   <result pre="hepatitis B virus during antiviral therapyHepatology200949323810.1002/hep.2258619065674 21.BeaucheminCAAMcSharryJJDrusanoGLNguyenJTWentGTRibeiroRMPerelsonASModeling amantadine treatment of" exact="influenza" post="A virus in vitroJ Theor Biol200825443945110.1016/j.jtbi.2008.05.03118653201 22.DobrovolnyHMGieschkeRDaviesBEJumbeNLBeaucheminCAANeuraminidase inhibitors for"/>
   <result pre="reservoir, and viral blipsJ Theor Biol200926030833110.1016/j.jtbi.2009.06.01119539630 26.GuedjJRongLDahariHPerelsonASA perspective on modelling" exact="hepatitis" post="C virus infectionJ Viral Hepat20101782583310.1111/j.1365-2893.2010.01348.x20723038 27.ChatterjeeAGuedjJPerelsonASMathematical modelling of HCV"/>
   <result pre="to evaluate interactions between drugsBiochem Pharmacol19965163564410.1016/S0006-2952(95)02230-98615900 37.DahariHRibeiroRMRiceCMPerelsonASMathematical modeling of subgenomic" exact="hepatitis" post="C virus replication in Huh-7 cellsJ Virol20078175076010.1128/JVI.01304-0617035310 38.McLeanAKLucianiFTanakaMMTrade-offs in"/>
   <result pre="Virol20078175076010.1128/JVI.01304-0617035310 38.McLeanAKLucianiFTanakaMMTrade-offs in resource allocation in the intracellular life-cycle of" exact="hepatitis" post="C virusJ Theor Biol201026756557210.1016/j.jtbi.2010.09.03120883700 39.NakabayashiJA compartmentalization model of hepatitis"/>
   <result pre="of hepatitis C virusJ Theor Biol201026756557210.1016/j.jtbi.2010.09.03120883700 39.NakabayashiJA compartmentalization model of" exact="hepatitis" post="C virus replication: an appropriate distribution of HCV RNA"/>
   <result pre="Theor Biol201230011011710.1016/j.jtbi.2012.01.02322286015 40.BinderMSulaimanovNClausznitzerDSchulzeMHüberCMLenzSMSchlöderJPTripplerMBartenschlagerRLohmannVKaderaliLReplication vesicles are load- and choke-points in the" exact="hepatitis" post="C virus lifecyclePLoS Pathog20139e100356110.1371/journal.ppat.100356123990783 41.JonkerDMVisserSAvan der GraafPHVoskuylRADanhofMTowards a mechanism-based"/>
   <result pre="sum of the partsDrug Discov Today200712344210.1016/j.drudis.2006.11.00817198971 46.KirouacDCDuJYLahdenrantaJOverlandRYararDParagasVPaceEMcDonaghCFNielsenUBOnsumMDComputational modeling of ERBB2-amplified" exact="breast cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
   <result pre="of the partsDrug Discov Today200712344210.1016/j.drudis.2006.11.00817198971 46.KirouacDCDuJYLahdenrantaJOverlandRYararDParagasVPaceEMcDonaghCFNielsenUBOnsumMDComputational modeling of ERBB2-amplified breast" exact="cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
   <result pre="and regulation relevant to Hepatitis C replicationMol Syst Biol2010637510.1038/msb.2010.3220531405 50.GuedjJPerelsonASSecond-phase" exact="hepatitis" post="C virus RNA decline during telaprevir-based therapy increases with"/>
   <result pre="therapy increases with drug effectiveness: implications for treatment durationHepatology2011531801180810.1002/hep.2427221384401 51.GuedjJNeumannAUUnderstanding" exact="hepatitis" post="C viral dynamics with direct-acting antiviral agents due to"/>
   <result pre="modes of action and yields a shorter estimate of the" exact="hepatitis" post="C virus half-lifeProc Natl Acad Sci U S A20131103991399610.1073/pnas.120311011023431163"/>
   <result pre="virus half-lifeProc Natl Acad Sci U S A20131103991399610.1073/pnas.120311011023431163 53.RongLGuedjJDahariHCoffieldDJLeviMSmithPPerelsonASAnalysis of" exact="hepatitis" post="C virus decline during treatment with the protease inhibitor"/>
   <result pre="multiscale modelPLoS Comput Biol20139e100295910.1371/journal.pcbi.100295923516348 54.RongLPerelsonASMathematical analysis of multiscale models for" exact="hepatitis" post="C virus dynamics under therapy with direct-acting antiviral agentsMath"/>
   <result pre="antiviral agentsMath Biosci2013245223010.1016/j.mbs.2013.04.01223684949 55.RongLDahariHRibeiroRMPerelsonASRapid emergence of protease inhibitor resistance in" exact="hepatitis" post="C virusSci Transl Med2010230ra3210.1126/scitranslmed.300054420445200"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4313645/results/search/disease/results.xml">
   <result pre="method for optimizing pharmacy-based distribution of antiviral drugs during an" exact="influenza" post="pandemic in terms of overall access for a target"/>
   <result pre="state of Texas, USA. We found that during the 2009" exact="influenza" post="pandemic, the Texas Department of State Health Services achieved"/>
   <result pre="State Health Services at a Web-based interface. Keywords: antiviral drugs" exact="influenza" post="influenza virus viruses 2009 pandemic influenza A(H1N1)pdm09 virus pandemic"/>
   <result pre="Health Services at a Web-based interface. Keywords: antiviral drugs influenza" exact="influenza" post="virus viruses 2009 pandemic influenza A(H1N1)pdm09 virus pandemic influenza"/>
   <result pre="interface. Keywords: antiviral drugs influenza influenza virus viruses 2009 pandemic" exact="influenza" post="A(H1N1)pdm09 virus pandemic influenza optimization control pharmacies pharmacy-based drug"/>
   <result pre="influenza influenza virus viruses 2009 pandemic influenza A(H1N1)pdm09 virus pandemic" exact="influenza" post="optimization control pharmacies pharmacy-based drug distribution underinsured populations ZIP"/>
   <result pre="codes Texas Influenza pandemics occur when novel strains of the" exact="influenza" post="virus emerge in human populations and spread worldwide ("/>
   <result pre="populations and spread worldwide ( 1 ). There were 3" exact="influenza" post="pandemics in the 20th century (1918, 1957, and 1968),"/>
   <result pre="several emerging threats are already under surveillance. A highly pathogenic" exact="avian influenza" post="A (H5N1) virus has occasionally been infecting humans in"/>
   <result pre="emerging threats are already under surveillance. A highly pathogenic avian" exact="influenza" post="A (H5N1) virus has occasionally been infecting humans in"/>
   <result pre="trying to contain an ongoing outbreak of a highly pathogenic" exact="avian influenza" post="(H7N9) virus ( 7 , 8 ). The primary"/>
   <result pre="to contain an ongoing outbreak of a highly pathogenic avian" exact="influenza" post="(H7N9) virus ( 7 , 8 ). The primary"/>
   <result pre="7 , 8 ). The primary control measures for pandemic" exact="influenza" post="are antiviral medications and vaccines ( 9 ), as"/>
   <result pre="and hygienic precautions ( 10 ). Although the efficacy of" exact="influenza" post="vaccines depends on factors such as patient age and"/>
   <result pre="because development and deployment of effective vaccines for a new" exact="influenza" post="virus may take several months ( 12 ), antiviral"/>
   <result pre="transmission ( 16 , 17 ). In preparation for future" exact="influenza" post="pandemics, the US Department of Health and Human Services"/>
   <result pre="response plans ( 19–22 ). After detection of the new" exact="influenza" post="A(H1N1)pdm09 virus in April 2009, the US government declared"/>
   <result pre="health emergency, and the World Health Organization declared a global" exact="influenza" post="pandemic. Vaccines became widely available after 6 months of"/>
   <result pre="commercial pharmacy distribution network established in Texas during the 2009" exact="influenza" post="pandemic. Methods Data Texas has 1,939 US postal code"/>
   <result pre="to dispense antiviral drugs to underinsured populations during the 2009" exact="influenza" post="pandemic; these pharmacies were in 723 ZIP code areas."/>
   <result pre="antiviral drugs sufficient for a course of treatment during an" exact="influenza" post="pandemic (model described below). We created a willingness-to-travel model,"/>
   <result pre="simplifying assumption that health care–seeking behavior in Texas during an" exact="influenza" post="pandemic will resemble national willingness to travel by privately"/>
   <result pre="1 Willingness-to-travel curve for receiving antiviral drugs during the 2009" exact="influenza" post="pandemic given by equation (2) (in Methods section) fit"/>
   <result pre="by the Texas antiviral drug distribution network during the 2009" exact="influenza" post="A pandemic and by optimized antiviral drug distribution networks,"/>
   <result pre="and in small ZIP code areas. Results During the 2009" exact="influenza" post="pandemic, the Texas DSHS recruited 1,393 pharmacies from 6"/>
   <result pre="Table 2 Expected access for antiviral drugs during the 2009" exact="influenza" post="pandemic provided by 3 drug distribution networks, Texas, USA*"/>
   <result pre="Walmart, and independent retail pharmacies (henceforth independents). During the 2009" exact="influenza" post="pandemic, the Texas DSHS distributed antiviral drugs from the"/>
   <result pre="for single-chain and 2-chain pharmacy distribution networks during the 2009" exact="influenza" post="pandemic, Texas, USA. Each network contains a maximum of"/>
   <result pre="sites in the antiviral drug distribution network during the 2009" exact="influenza" post="pandemic that contained only independent pharmacies (independents; i.e., no"/>
   <result pre="pharmacies in the dispensing of SNS antiviral drugs during future" exact="influenza" post="pandemics ( 20–22,34 ). We have developed and demonstrated"/>
   <result pre="the antiviral drug distribution decision support tool during the 2009" exact="influenza" post="pandemic ( 28 ), Texas, USA. Figure 6 Screenshot"/>
   <result pre="antiviral drug distribution decision support tool used during the 2009" exact="influenza" post="pandemic ( 28 ), Texas, USA. The optimization model"/>
   <result pre="Gutfraind A, Galvani AP, et al. Optimizing distribution of pandemic" exact="influenza" post="antiviral drugs. Emerg Infect Dis. 2015 Feb [ date"/>
   <result pre="on deployment of SNS antiviral drugs in Texas during the" exact="influenza" post="pandemic during 2009. This study was supported by the"/>
   <result pre="References 1.collab: Centers for Disease Control and Prevention . Seasonal" exact="influenza" post="(flu), 2013 [cited 2014 Jan 23]. http://www.cdc.gov/flu/antivirals/whatyoushould.htm 2.InternationalSOS ."/>
   <result pre="[cited 2014 Jan 23]. http://www.cdc.gov/flu/antivirals/whatyoushould.htm 2.InternationalSOS . Pandemic preparedness: past" exact="influenza" post="pandemics, 2013 [cited 2014 Jan 23]. https://www.internationalsos.com/pandemicpreparedness/SubCatLevel.aspx?li=11&amp;amp;language-ID=eng&amp;amp;subCatID=5 3.DawoodFS ,"/>
   <result pre="mortality associated with the first 12 months of 2009 pandemic" exact="influenza" post="A H1N1 virus circulation: a modelling study.Lancet Infect Dis"/>
   <result pre=". 10.1016/S1473-3099(12)70121-422738893 4.collab: US Agency for International Development . Pandemic" exact="influenza" post="and other emerging threats, 2013 [cited 2014 Jan 23]."/>
   <result pre="http://www.who.int/mediacentre/factsheets/avian_influenza/en/ 6.collab: Centers for Disease Control and Prevention . Avian" exact="influenza" post="current situation, 2014 [cited 2014 Jan 23]. http://www.cdc.gov/flu/avianflu/avian-flu-summary.htm 7.collab:"/>
   <result pre="http://www.cdc.gov/flu/avianflu/avian-flu-summary.htm 7.collab: Centers for Disease Control and Prevention . Avian" exact="influenza" post="A (H7N9) virus, 2014 [cited 2014 Jan 23]. http://www.cdc.gov/flu/avianflu/h7n9-virus.htm"/>
   <result pre="10.2165/00019053-199916001-0000610623375 10.RothDZ , HenrB . Social distancing as a pandemic" exact="influenza" post="prevention measure, 2011 [cited 2014 January 23]. http://www.nccid.ca/files/Evidence_Reviews/H1N1_3_final.pdf 11.collab:"/>
   <result pre="Control and Prevention (CDC) . Prevention and control of seasonal" exact="influenza" post="with vaccines. Recommendations of the Advisory Committee on Immunization"/>
   <result pre="13.LonginiIM , HalloranME , NizamA , YangY . Containing pandemic" exact="influenza" post="with antiviral agents.Am J Epidemiol . 2004 ; 159"/>
   <result pre=", UngchusakK , HanshaoworakulW , CummingsDA , et al.Containing pandemic" exact="influenza" post="at the source.Science . 2005 ; 309 : 1083"/>
   <result pre="RileyS , MeeyaiA , et al.Strategies for containing an emerging" exact="influenza" post="pandemic in Southeast Asia.Nature . 2005 ; 437 :"/>
   <result pre="10.1038/nature0401716079797 16.BeckerNG , WangD . Can antiviral drugs contain pandemic" exact="influenza" post="transmission?PLoS ONE . 2011 ; 6 : e17764 ."/>
   <result pre="US Department of Health and Human Services . HHS pandemic" exact="influenza" post="plan, 2005 [cited 2013 Nov 11]. http://www.cdc.gov/flu/pdf/professionals/hhspandemicinfluenzaplan.pdf 19.collab: Virginia"/>
   <result pre="State of Louisiana Department of Health and Hospitals . Pandemic" exact="influenza" post="guidance annex 4: antiviral, 2011 [cited 2013 Dec 9]."/>
   <result pre="and public health preparedness for catastrophic events. The 2009 H1N1" exact="influenza" post="vaccination campaign: summary of a workshop series, 2010 [cited"/>
   <result pre="ChouJY , RamonMM . Response to the novel H1N1 pandemic" exact="influenza" post="(2009 and 2010): final report to the Texas Department"/>
   <result pre="among community pharmacists, pharmacies, and health departments to improve pandemic" exact="influenza" post="response.Biosecur Bioterror . 2014 ; 12 : 76 –"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4353273/results/search/disease/results.xml">
   <result pre="for practitioners on the use of antiviral drugs to control" exact="influenza" post="outbreaks in long-term care facilities in Canada, 2014–2015 season"/>
   <result pre="to inform health care professionals of the increased risk for" exact="influenza" post="in long-term care facilities due to a documented mismatch"/>
   <result pre="the components chosen for this season’s vaccine and currently circulating" exact="influenza" post="strains. Adjusted recommendations for the use of antiviral drugs"/>
   <result pre="strains. Adjusted recommendations for the use of antiviral drugs for" exact="influenza" post="in long-term care facilities for this season are provided."/>
   <result pre="and other health care practitioners of an increased risk of" exact="influenza" post="outbreaks in long-term care facilities (LTCF) during the 2014–2015"/>
   <result pre="influenza outbreaks in long-term care facilities (LTCF) during the 2014–2015" exact="influenza" post="season in Canada, and to provide recommendations for adjustment"/>
   <result pre="of Canada regarding early data indicating a mismatch of the" exact="influenza" post="vaccine H3N2 component to an emerging H3N2 seasonal strain."/>
   <result pre="special supplement are: Influenza A(H3N2) viruses are dominating (&amp;gt;90%) among" exact="influenza" post="detections so far in 2014–2015, and have been associated"/>
   <result pre="susceptible to the neuraminidase inhibitor (NI) drugs. The majority of" exact="influenza" post="A(H3N2) viruses (&amp;gt;95%) characterized thus far in Canada this"/>
   <result pre="key antigenic sites of the hemagglutinin (H) protein of the" exact="influenza" post="virus, and number and location of genetic differences are"/>
   <result pre="for antiviral use during LTCF outbreak control are needed while" exact="influenza" post="A(H3N2) activity shows signs of spiking in several parts"/>
   <result pre="for all staff working at the site of a declared" exact="influenza" post="A(H3N2) LTCF outbreak regardless of whether they have received"/>
   <result pre="outbreak regardless of whether they have received this year’s 2014–2015" exact="influenza" post="vaccine. C. VIROLOGICAL CONTEXT 1. Dominant influenza A(H3N2) activity"/>
   <result pre="this year’s 2014–2015 influenza vaccine. C. VIROLOGICAL CONTEXT 1. Dominant" exact="influenza" post="A(H3N2) activity early in the 2014–2015 season To date"/>
   <result pre="as of week 50, ending December 13, 2014), 4283 (96%)" exact="influenza" post="A viruses and 168 (4%) influenza B viruses have"/>
   <result pre="13, 2014), 4283 (96%) influenza A viruses and 168 (4%)" exact="influenza" post="B viruses have been detected (4). The number of"/>
   <result pre="influenza B viruses have been detected (4). The number of" exact="influenza" post="A detections in week 50 nearly doubled from the"/>
   <result pre="primarily by increased detection of A(H3N2) viruses. Of the 2011" exact="influenza" post="A viruses detected in Canada thus far with subtype"/>
   <result pre="descended from the 2009 pandemic virus, was instead the dominant" exact="influenza" post="A epidemic strain (4). 2. Evidence for antigenic drift/vaccine"/>
   <result pre="drift/vaccine mismatch among H3N2 viruses detected in Canada Of 61" exact="influenza" post="A(H3N2) viruses characterized so far this season by Canada’s"/>
   <result pre="influenza A(H3N2) viruses characterized so far this season by Canada’s" exact="influenza" post="reference laboratory, the National Microbiology Laboratory (NML), 59 (97%)"/>
   <result pre="have to be considered in declaring whether a care facility" exact="influenza" post="outbreak is facility-wide or specific to a ward/unit. When"/>
   <result pre="influenza outbreak is facility-wide or specific to a ward/unit. When" exact="influenza" post="virus is causing illness in the community, it may"/>
   <result pre="medical conditions and, in some residents, older age (21). Annual" exact="influenza" post="immunization is recommended for these individuals because of these"/>
   <result pre="high among residents. Among health care workers and other staff," exact="influenza" post="immunizations rates are more variable but generally lower than"/>
   <result pre="response associated with aging and other comorbidity. Controlling outbreaks of" exact="influenza" post="in LTCF requires a multi-faceted approach including: Surveillance for"/>
   <result pre="Control and Prevention (22). For control of an outbreak of" exact="influenza" post="among residents of a LTCF, surveillance for ILI is"/>
   <result pre="years and older, fever may not be prominent (4). Where" exact="influenza" post="is suspected, laboratory testing can confirm the diagnosis. The"/>
   <result pre="testing can confirm the diagnosis. The preferred sample for individual" exact="influenza" post="diagnosis is a nasopharyngeal specimen obtained using a flocked"/>
   <result pre="oropharyngeal secretions obtained with a throat swab are suboptimal for" exact="influenza" post="diagnosis. The preferred testing methods are, in order of"/>
   <result pre="testing methods are, in order of declining preference: RT-PCR, rapid" exact="influenza" post="diagnostic tests and viral culture. For surveillance purposes, FluWatch"/>
   <result pre="tests and viral culture. For surveillance purposes, FluWatch defines an" exact="influenza" post="outbreak on the basis of two or more cases"/>
   <result pre="a seven-day period, including at least one laboratory-confirmed case of" exact="influenza" post="(4). However, this is for surveillance purposes and the"/>
   <result pre="this is for surveillance purposes and the declaration of an" exact="influenza" post="outbreak and the enactment of control measures is at"/>
   <result pre="Officer of Health in accordance with provincial guidance. When an" exact="influenza" post="outbreak is suspected in a LTCF, this should be"/>
   <result pre="with health care and infection control practitioners, to declare an" exact="influenza" post="outbreak in a LTCF and to recommend specific interventions"/>
   <result pre="is generally accepted that antiviral drugs to treat and prevent" exact="influenza" post="in residents, together with other infection control measures, are"/>
   <result pre="other infection control measures, are important for the control of" exact="influenza" post="outbreaks in LTCF. Recommended practices with respect to antiviral"/>
   <result pre="should be administered as soon as the clinical diagnosis of" exact="influenza" post="has been made because residents of LTCF are, by"/>
   <result pre="2. Antiviral drug prophylaxis i. Residents: Upon diagnosis of an" exact="influenza" post="outbreak, all residents becoming ill should be treated (vide"/>
   <result pre="where they may have the potential to acquire or transmit" exact="influenza" post="(21) should also take prophylactic antiviral medication during the"/>
   <result pre="outbreak, regardless of whether they have received the current season’s" exact="influenza" post="vaccine. This is because, despite some vaccine protection anticipated,"/>
   <result pre="antiviral agent need to be considered for treatment doses if" exact="influenza" post="is diagnosed or considered likely. Residents or staff receiving"/>
   <result pre="current virus, another viral agent or an oseltamivir- (or zanamavir)-resistant" exact="influenza" post="virus. Expert consultation is suggested to address: the cause,"/>
   <result pre="Michel Laverdiere and Dr Danuta Skowronski: None. References REFERENCES 1.SchanzerDLSevenhuysenCWinchesterBMersereauTEstimating" exact="influenza" post="deaths in Canada, 1992–2009PLoS ONE20138e8048124312225 2.ThompsonWWShayDKWeintraubEet al.Mortality associated with"/>
   <result pre="influenza deaths in Canada, 1992–2009PLoS ONE20138e8048124312225 2.ThompsonWWShayDKWeintraubEet al.Mortality associated with" exact="influenza" post="and respiratory syncytial virus in the United StatesJAMA20032891798612517228 3.ThompsonWWShayDKWeintraubEet"/>
   <result pre="2015). 5.collab: World Health OrganizationWHO recommendations on the composition of" exact="influenza" post="virus vaccines&amp;lt;www.who.int/influenza/vaccines/virus/recommendations/en/index.html&amp;gt; (Accessed December 19, 2015). 6.AokiFYAllenUDStiverHGLaverdièreMEvansGAThe use of"/>
   <result pre="Infect Dis Med Microbiol201324Suppl C1C15C 7.BushRMBenderCASubbaraoKCoxNJFitchWMPredicting the evolution of human" exact="influenza" post="AScience19992861921510583948 8.CoxNJBenderCAThe molecular epidemiology of influenza virusesSemin Virol1995635970 9.NdifonWWingreenNSLevinSADifferential"/>
   <result pre="the evolution of human influenza AScience19992861921510583948 8.CoxNJBenderCAThe molecular epidemiology of" exact="influenza" post="virusesSemin Virol1995635970 9.NdifonWWingreenNSLevinSADifferential neutralization efficiency of hemagglutinin epitopes, antibody"/>
   <result pre="efficiency of hemagglutinin epitopes, antibody interference, and the design of" exact="influenza" post="vaccinesProc Natl Acad Sci USA20091068701619439657 10.PopovaLSmithKWestAHet al.Immunodominance of antigenic"/>
   <result pre="site B over site A of hemagglutinin of recent H3N2" exact="influenza" post="virusesPLoS One20127e4189522848649 11.KoelBFBurkeDFBestebroerTMet al.Substitutions near the receptor binding site"/>
   <result pre="near the receptor binding site determine major antigenic change during" exact="influenza" post="virus evolutionScience2013342976924264991 12.JinHZhouHLiuHet al.Two residues in the hemagglutinin of"/>
   <result pre="virus evolutionScience2013342976924264991 12.JinHZhouHLiuHet al.Two residues in the hemagglutinin of A/Fujian/411/02-like" exact="influenza" post="viruses are responsible for antigenic drift from A/Panama/2007/99Virology2005336113915866076 13.SkowronskiDMJanjuaNZDe"/>
   <result pre="drift from A/Panama/2007/99Virology2005336113915866076 13.SkowronskiDMJanjuaNZDe SerresGet al.A sentinel platform to evaluate" exact="influenza" post="vaccine effectiveness and new variant circulation, Canada 2010–11 seasonClin"/>
   <result pre="community and the householdClin Infect Dis2013561363923413420 15.SkowronskiDMJanjuaNZDe SerresGet al.Low 2012–13" exact="influenza" post="vaccine effectiveness associated with mutation in the egg-adapted H3N2"/>
   <result pre="drift in circulating virusesPLoS One20149e9215324667168 16.AndrewsNMcMenaminJDurnallHet al.Effectiveness of trivalent seasonal" exact="influenza" post="vaccine in preventing laboratory-confirmed influenza in primary care in"/>
   <result pre="16.AndrewsNMcMenaminJDurnallHet al.Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed" exact="influenza" post="in primary care in the United Kingdom: 2012/13 end"/>
   <result pre="(Accessed December 19, 2015). 20.CastillaJMartinez-BazINavascuesAet al.Vaccine effectiveness in preventing laboratory-confirmed" exact="influenza" post="in Navarre, Spain: 2013/14 mid-season analysisEuro Surveill201419pii:2070024556347 21.collab: Advisory"/>
   <result pre="Statement – National Advisory Committee on Immunization (NACI)Statement on seasonal" exact="influenza" post="vaccine for 2014–2015 22.collab: United States Centers for Disease"/>
   <result pre="United States Centers for Disease Control &amp;amp; PreventionInterim guidance for" exact="influenza" post="outbreak management in long-term care facilities(last updated December 19,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4353274/results/search/disease/results.xml">
   <result pre="Canada Guidelines Guidance on the use of antiviral drugs for" exact="influenza" post="in acute care facilities in Canada, 2014–2015 StiverH GrantMD1EvansGerald"/>
   <result pre="to inform health care professionals of the increased risk for" exact="influenza" post="in long-term care facilities due to a documented mismatch"/>
   <result pre="the components chosen for this season’s vaccine and currently circulating" exact="influenza" post="strains. Adjusted recommendations for the use of antiviral drugs"/>
   <result pre="strains. Adjusted recommendations for the use of antiviral drugs for" exact="influenza" post="in the acute care setting for this season are"/>
   <result pre="management of patients in the acute care setting infected with" exact="influenza" post="viruses circulating in Canada during the 2014–2015 influenza season."/>
   <result pre="infected with influenza viruses circulating in Canada during the 2014–2015" exact="influenza" post="season. A. PROCESS STATEMENT The development of this updated"/>
   <result pre="of Canada regarding early data indicating a mismatch of the" exact="influenza" post="vaccine H3N2 component to an emerging H3N2 seasonal strain."/>
   <result pre="to 48 h of symptom onset to low-risk outpatients with" exact="influenza" post="(where placebo-controlled trials were ethically safe) have shown that"/>
   <result pre="investigating the efficacy of NIs in treating mild to moderate" exact="influenza" post="illness in out-patients have not adequately addressed the significantly"/>
   <result pre="3.6 days (5). Inhaled zanamivir shortened the duration of major" exact="influenza" post="symptoms by 3 days compared with placebo in individuals"/>
   <result pre="30 h (3). In low-risk outpatients, NI treatment of mild" exact="influenza" post="illness may be considered but is optional (6). On"/>
   <result pre="the other hand, observational cohort-controlled studies of patients with severe" exact="influenza" post="due to the H3N2 subtype and H1N1 pandemic subtype"/>
   <result pre="persons with no discernable risk factors. In the current 2014–2015" exact="influenza" post="season, A(H3N2) influenza has accounted for the majority of"/>
   <result pre="discernable risk factors. In the current 2014–2015 influenza season, A(H3N2)" exact="influenza" post="has accounted for the majority of influenza cases documented"/>
   <result pre="influenza season, A(H3N2) influenza has accounted for the majority of" exact="influenza" post="cases documented by testing. In addition, a significant antigenic"/>
   <result pre="significant antigenic drift has occurred in the majority of H3N2" exact="influenza" post="strains obtained from ill patients, resulting in a clinically"/>
   <result pre="in a clinically relevant mismatch between the predominant circulating H3N2" exact="influenza" post="virus and the H3N2 vaccine strain. The WHO Global"/>
   <result pre="System laboratories have tested &amp;gt;96,535 specimens: 23,421 were positive for" exact="influenza" post="viruses, of which 22,129 (94.5%) were typed as influenza"/>
   <result pre="for influenza viruses, of which 22,129 (94.5%) were typed as" exact="influenza" post="A and 1292 (5.5%) as influenza B. Of the"/>
   <result pre="(94.5%) were typed as influenza A and 1292 (5.5%) as" exact="influenza" post="B. Of the subtyped influenza A viruses, 163 (1.7%)"/>
   <result pre="A and 1292 (5.5%) as influenza B. Of the subtyped" exact="influenza" post="A viruses, 163 (1.7%) were influenza A (H1N1) pdm09,"/>
   <result pre="B. Of the subtyped influenza A viruses, 163 (1.7%) were" exact="influenza" post="A (H1N1) pdm09, and 9211 (98.3%) were influenza A"/>
   <result pre="(1.7%) were influenza A (H1N1) pdm09, and 9211 (98.3%) were" exact="influenza" post="A (H3N2) (9). Although the vaccine may still provide"/>
   <result pre="date, the majority of the predominating H3N2 virus isolates of" exact="influenza" post="are susceptible to oseltamivir and zanamivir. All isolates of"/>
   <result pre="of H1N1 are oseltamivir- and zanamivir-susceptible. Almost all isolates of" exact="influenza" post="B are also susceptible to oseltamivir and zanamivir. C."/>
   <result pre="WITH ILI TO AN ACUTE CARE FACILITY? During peaks of" exact="influenza" post="activity in the community, a case definition in older"/>
   <result pre="of 86% and a negative predictive value of 39.3% for" exact="influenza" post="in patients attending an outpatient clinic (10). Of course,"/>
   <result pre="Of course, these values vary depending on the prevalence of" exact="influenza" post="in the community relative to other respiratory infections. In"/>
   <result pre="community relative to other respiratory infections. In older patients with" exact="chronic obstructive pulmonary disease," post="who have been vaccinated for influenza, only the presence"/>
   <result pre="may account for those with non-influenza infection. The use of" exact="influenza" post="polymerase chain reaction (PCR) is preferred to direct fluorescent"/>
   <result pre="to its greater sensitivity. A nasopharyngeal swab is preferred for" exact="influenza" post="PCR testing, particularly if the patient requires hospital admission."/>
   <result pre="with mild illness without risk factors for severe or complicated" exact="influenza" post="with antiviral drugs is not recommended if &amp;gt;48 h"/>
   <result pre="patients on ventilators may not improve and continue to shed" exact="influenza" post="viruses for prolonged periods, even after five days on"/>
   <result pre="discussion of the appropriate antibiotic management of patients with suspected" exact="bacterial pneumonia" post="is beyond the scope of this document. However, if"/>
   <result pre="of the appropriate antibiotic management of patients with suspected bacterial" exact="pneumonia" post="is beyond the scope of this document. However, if"/>
   <result pre="with an acute respiratory infection on a background of an" exact="influenza" post="outbreak, and a chest radiograph demonstrates pulmonary infiltrates, primary"/>
   <result pre="influenza outbreak, and a chest radiograph demonstrates pulmonary infiltrates, primary" exact="influenza" post="or secondary bacterial pneumonia, or both, are possibilities. Primary"/>
   <result pre="a chest radiograph demonstrates pulmonary infiltrates, primary influenza or secondary" exact="bacterial pneumonia," post="or both, are possibilities. Primary influenza pneumonia typically presents"/>
   <result pre="influenza or secondary bacterial pneumonia, or both, are possibilities. Primary" exact="influenza" post="pneumonia typically presents with severe shortness of breath and"/>
   <result pre="or secondary bacterial pneumonia, or both, are possibilities. Primary influenza" exact="pneumonia" post="typically presents with severe shortness of breath and occurs"/>
   <result pre="both, are possibilities. Primary influenza pneumonia typically presents with severe" exact="shortness" post="of breath and occurs within one to three days"/>
   <result pre="illness with reappearance of fever after defervesence from a typical" exact="influenza" post="illness might represent a complicating secondary bacterial pneumonia. Bacterial"/>
   <result pre="from a typical influenza illness might represent a complicating secondary" exact="bacterial pneumonia." post="Bacterial pneumonia should be strongly suspected when a typical"/>
   <result pre="influenza illness might represent a complicating secondary bacterial pneumonia. Bacterial" exact="pneumonia" post="should be strongly suspected when a typical influenza illness"/>
   <result pre="pneumonia. Bacterial pneumonia should be strongly suspected when a typical" exact="influenza" post="illness is resolving, usually around the fifth day, and"/>
   <result pre="severely ill patients, appropriate antibiotics for community-acquired or nursing home-acquired" exact="pneumonia" post="should be instituted immediately, as well as NI antiviral"/>
   <result pre="infection control measures for the management of patients with suspected" exact="influenza" post="is beyond the scope of this document. However, the"/>
   <result pre="the following measures are generally employed. Patient isolation During an" exact="influenza" post="outbreak, all individuals with ILI admitted to the emergency"/>
   <result pre="PROPHYLAXIS FOR PATIENTS AND HCWs? Post-exposure prophylaxis: Secondary cases of" exact="influenza" post="in family members of an index case can be"/>
   <result pre="(oseltamivir) to 10 (zanamivir) days to reduce the chance of" exact="influenza" post="illness. This is especially important this influenza season in"/>
   <result pre="the chance of influenza illness. This is especially important this" exact="influenza" post="season in the face of the vaccine mismatch. Post-exposure"/>
   <result pre="influenza: A randomized controlled trialLancet200035518455010866439 2.collab: The MIST (Management of" exact="influenza" post="in the Southern Hemisphere Trialists) Study GroupRandomised trial of"/>
   <result pre="of efficacy and safety of inhaled zanamivir in treatment of" exact="influenza" post="A and B virus infectionsLancet19983521877819863784 3.HaydenFGOsterhausADMETreanorJJet al.Efficacy and safety"/>
   <result pre="the treatment of influenzaviris infectionsNew Engl J Med1997337874809302301 4.JeffersonTJonesMDoshiPSpencerEAOnakpoyaIHeneghanCJOseltamivir for" exact="influenza" post="in adults and children: Systematic review of clinical study"/>
   <result pre="5.AokiFYMacleodMDPaggiaroPet al.Early administration of oral oseltamivir increases the benefits of" exact="influenza" post="treatmentJ Antimicrob Ther2003511239 6.AokiFYAllenUDStiverHGLaverdièreMEvansGAThe use of antiviral drugs for"/>
   <result pre="Did Med Microbiol201324Suppl C1C15C 7.McGeerAGreenKPlevneshiAet al.Antiviral therapy and outcomes of" exact="influenza" post="requiring hospitalization in Ontario, CanadaClin Infect Dis20074515687518190317 8.LouieJKYangSAcostaMet al.Treatment"/>
   <result pre="8.LouieJKYangSAcostaMet al.Treatment with neuraminidase inhibitors for critically ill patients with" exact="influenza" post="(H1N1) pdmo9Clin Infect Dis2012551198120422843781 9.collab: World Health OrganizationInfluenza update1212015–"/>
   <result pre="update1212015– Update number 228. &amp;lt;www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en&amp;gt; (Accessed January 13, 2015). 10.BoivinGHardyITellierGMaziadeJPredicting" exact="influenza" post="infections during epidemics with the use of a clinical"/>
   <result pre="the use of a clinical case definitionClin Infect Dis2000311166911073747 11.NeuzilKMO’ConnorTZGorseGJNicholKLRecognizing" exact="influenza" post="in older patients with chronic obstructive pulmonary disease who"/>
   <result pre="case definitionClin Infect Dis2000311166911073747 11.NeuzilKMO’ConnorTZGorseGJNicholKLRecognizing influenza in older patients with" exact="chronic obstructive pulmonary disease" post="who have received influenza vaccineClin Infect Dis2003361697412522748 12.BisnoALGriffinJPVan EppsKANiellHBRytelMWPneumonia"/>
   <result pre="older patients with chronic obstructive pulmonary disease who have received" exact="influenza" post="vaccineClin Infect Dis2003361697412522748 12.BisnoALGriffinJPVan EppsKANiellHBRytelMWPneumonia and Hong Kong influenza:"/>
   <result pre="for oral suspension&amp;lt;www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062_tamiflu_toc.cfm&amp;gt; (Accessed January 13, 2015). 16.HalloranMEHaydenFGYangYLonginiIMJrMontoASAntiviral effects on" exact="influenza" post="viral transmission and pathogenicity: Observation-based trialsAm J Epidemiol20071652122117088311 TABLE"/>
   <result pre="trialsAm J Epidemiol20071652122117088311 TABLE 1 Oseltamivir and zanamivir treatment of" exact="influenza" post="Updated from: The use of antiviral drugs for influenza:"/>
   <result pre="antivirals are not authorized for the routine treatment of seasonal" exact="influenza" post="illness in infants &amp;lt;1 year of age. Such use"/>
   <result pre="weight is not known, dosing by age for treatment of" exact="influenza" post="(give two doses per day) or prophylaxis (give one"/>
   <result pre="25 mg per dose. 3.It is strongly suggested that an" exact="infectious disease" post="physician or clinical pharmacist be consulted in the case"/>
   <result pre="not recommended for persons with chronic respiratory diseases such as" exact="asthma" post="or chronic obstructive pulmonary disease that increase the risk"/>
   <result pre="for persons with chronic respiratory diseases such as asthma or" exact="chronic obstructive pulmonary disease" post="that increase the risk of bronchospasm. TABLE 2 Recommended"/>
   <result pre="a framework for guidance, it is strongly suggested that an" exact="infectious disease" post="physician, a specialist in renal insufficiency or clinical pharmacist"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4531042/results/search/disease/results.xml">
   <result pre="of CMV after transplantation, is commonly complicated by bone marrow" exact="suppression" post="that limits its use particularly as prophylaxis in HSCT"/>
   <result pre="and with symptom resolution.41 Reduction in the degree of immune" exact="suppression" post="may also have facilitated the virological and clinical response"/>
   <result pre="also as common in the placebo group). The rate of" exact="neutropenia" post="was very low (when indirectly compared with the neutropenia"/>
   <result pre="of neutropenia was very low (when indirectly compared with the" exact="neutropenia" post="associated with the use of VGCV, 6% versus 58%,"/>
   <result pre="antiviral drugs for the prevention of other herpesviruses such as" exact="herpes simplex." post="Phase III trials are currently underway, and there is"/>
   <result pre="and elevation in serum creatinine Stoelben et al40 No reported" exact="neutropenia" post="or other major laboratory alterations Chemaly et al42 Pharmacokinetic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4539848/results/search/disease/results.xml">
   <result pre="combination with other antiviral or non-antiviral drugs in patients with" exact="hepatitis" post="B and hepatic fibrosis. Objectives: The current randomized controlled"/>
   <result pre="indexes of liver function and liver fibrosis in patients with" exact="hepatitis" post="B. Data Sources: Published literatures in Chinese and English"/>
   <result pre="in Chinese and English on hepatoprotective treatment strategies for chronic" exact="hepatitis" post="B and liver fibrosis were searched in three databases"/>
   <result pre="improve liver function and liver fibrosis parameters in patients with" exact="hepatitis" post="B. Hepatitis B Liver Cirrhosis Meta-Analysis Ursodeoxycholic Acid (UDCA)"/>
   <result pre="Hepatitis B can lead to serious liver diseases, including cirrhosis," exact="liver cancer." post="In China, approximately 120 million people are infected with"/>
   <result pre="in Iran, and 15% to 40% of the patients with" exact="hepatitis" post="B may develop cirrhosis or liver cancer (2). Liver"/>
   <result pre="to 40% of the patients with hepatitis B may develop" exact="cirrhosis" post="or liver cancer (2). Liver fibrosis is a healing"/>
   <result pre="of the patients with hepatitis B may develop cirrhosis or" exact="liver cancer" post="(2). Liver fibrosis is a healing response, but the"/>
   <result pre="the patients with hepatitis B may develop cirrhosis or liver" exact="cancer" post="(2). Liver fibrosis is a healing response, but the"/>
   <result pre="often leads to severe forms of liver fibrosis, and ultimately" exact="cirrhosis" post="with liver dysfunction (3-5). Early cirrhosis may be reversible."/>
   <result pre="liver fibrosis, and ultimately cirrhosis with liver dysfunction (3-5). Early" exact="cirrhosis" post="may be reversible. Therefore, prompt diagnosis and intervention are"/>
   <result pre="acid, and improves cholestasis. UDCA is mainly used to treat" exact="primary biliary cirrhosis," post="hepatitis B associated liver fibrosis, and cholestatic liver disease,"/>
   <result pre="cholestasis. UDCA is mainly used to treat primary biliary cirrhosis," exact="hepatitis" post="B associated liver fibrosis, and cholestatic liver disease, the"/>
   <result pre="primary biliary cirrhosis, hepatitis B associated liver fibrosis, and cholestatic" exact="liver disease," post="the efficacy is certain. Some studies reported that UDCA"/>
   <result pre="the United States and Europe, about 65% of patients with" exact="liver disease" post="use Chinese medical preparations which include milk thistle as"/>
   <result pre="used to treat liver cirrhosis, hepatitis, liver fibrosis and alcoholic" exact="liver disease" post="(15). N-acetylcysteine (NAC) is an intracellular glutathione precursor, which"/>
   <result pre="caused by excessive acetaminophen (paracetamol), but is also useful for" exact="liver disease" post="arising from other causes (18). NAC reduces serum Total"/>
   <result pre="and increases Prothrombin activity (PTA) in patients with severe chronic" exact="hepatitis" post="B (19). 2. Objectives The current study aimed to"/>
   <result pre="indexes of liver function and liver fibrosis in patients with" exact="hepatitis" post="B. 3. Data Sources Papers written in either English"/>
   <result pre="or Chinese describing the use of hepatoprotective agents to treat" exact="hepatitis" post="and liver fibrosis were retrieved. Using &quot;chronic hepatitis B,"/>
   <result pre="to treat hepatitis and liver fibrosis were retrieved. Using &quot;chronic" exact="hepatitis" post="B, hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin,"/>
   <result pre="hepatitis and liver fibrosis were retrieved. Using &quot;chronic hepatitis B," exact="hepatitis" post="B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine),"/>
   <result pre="4.1.1. Inclusion Criteria Hepatitis B infection or liver fibrosis; chronic" exact="hepatitis" post="B was diagnosed if HBV history or HBV markers"/>
   <result pre="Studies in which non-protective liver drugs were used to treat" exact="viral hepatitis" post="or liver fibrosis; animal experiments and reviewed papers that"/>
   <result pre="in which non-protective liver drugs were used to treat viral" exact="hepatitis" post="or liver fibrosis; animal experiments and reviewed papers that"/>
   <result pre="not contain clinical data; pregnant and lactating female patients with" exact="liver disease." post="The therapy course was less than three weeks; liver"/>
   <result pre="drug in combination with an antiviral agent treatment of chronic" exact="hepatitis" post="B. The test and control groups included 741 and"/>
   <result pre="ALT, AST, ALP and TBIL Levels In patients with chronic" exact="hepatitis" post="B infection treated with combination hepatoprotective and antiviral drug"/>
   <result pre="with placebo on liver function indexes in patients with chronic" exact="hepatitis" post="B, including ALT and TBIL. In these trials, the"/>
   <result pre="three hepatoprotective agents significantly decreased ALT levels in patients with" exact="hepatitis" post="B. NAC was associated with greater efficacy compared to"/>
   <result pre="of UDCA and silibinin on ALT levels in patients with" exact="hepatitis" post="B were considerable: NAC (WMD = -25.66; P ="/>
   <result pre="Plots Indicating Reduced Amounts of ALT In patients with chronic" exact="hepatitis" post="B infection treated with hepatoprotective drugs vs. placebo. Data"/>
   <result pre="over NAC and silibinin to reduce TBIL in patients with" exact="hepatitis" post="B. Meta-analysis showed that NAC (WMD = -2.56; P"/>
   <result pre="Agents vs. Placebo on TBIL Levels In patients with chronic" exact="hepatitis" post="B infection. Data are presented as pooled relative risks"/>
   <result pre="agents compared to only one to treat patients with chronic" exact="hepatitis" post="B. There were 618 subjects in the two hepatoprotective"/>
   <result pre="ALT, AST, GGT, ALP and TBIL levels in patients with" exact="hepatitis" post="B. ALT (WMD=-31.44; 95% CI [-48.57,-14.32]), AST (WMD ="/>
   <result pre="4. Meta-Analysis Forest Plots for Effects In patients with chronic" exact="hepatitis" post="B infection treated with the combination of two liver"/>
   <result pre="on the recovery rate of liver indicators in patients with" exact="hepatitis" post="B; 173 subjects who used a combination of two"/>
   <result pre="Normalization Rates of ALT and TBIL In patients with chronic" exact="hepatitis" post="B infection treated with two vs. one hepatoprotective agent."/>
   <result pre="of ALT, AST and TBIL was conducted, in patients with" exact="hepatitis" post="B (Figure 8). The Funnel plot showed that the"/>
   <result pre="on normalization of ALT, AST and TBIL, in patients with" exact="hepatitis" post="B 7. Discussion The current model is expected to"/>
   <result pre="current model is expected to maximize long-term treatment of severe" exact="liver disease" post="caused by HBV infection to suppress the virus, improve"/>
   <result pre="in drug tolerance due to hepatoprotective agents in patients with" exact="hepatitis" post="B (34, 40). In 2006, Qureshi et al reported"/>
   <result pre="doses of ursodeoxycholic acid reduces ALT levels in patients with" exact="hepatitis" post="B (28). The meta-analysis of the current study showed"/>
   <result pre="ALT, and were a liver function marker in patients with" exact="hepatitis" post="B. The reduction in ALT levels by acetylcysteine was"/>
   <result pre="of serum II-18, IFN-γ and NO in the patients with" exact="hepatitis" post="B. Some studies stated that acetylcysteine should be used,"/>
   <result pre="and that it was more beneficial in early stages of" exact="liver disease" post="(21). The limitations of the study included the retrospective"/>
   <result pre="1LiangGNChenLHGlycyrrhizin injection combined with Danshen injection observe the effect of" exact="hepatitis" post="B liver fibrosis.J Tibetan Med.2010311245 2AlavianSMTabatabaeiSVGhadimiTBeedrapourFKafi-AbadSAGharehbaghianAet al.Seroprevalence of Hepatitis"/>
   <result pre="with other simple noninvasive indices for predicting liver fibrosis and" exact="cirrhosis" post="in hepatitis B virus-infected patients.Liver Int.20103045465310.1111/j.1478-3231.2009.02192.x20074094 6LimYSKimWRThe global impact"/>
   <result pre="simple noninvasive indices for predicting liver fibrosis and cirrhosis in" exact="hepatitis" post="B virus-infected patients.Liver Int.20103045465310.1111/j.1478-3231.2009.02192.x20074094 6LimYSKimWRThe global impact of hepatic"/>
   <result pre="adenosine combine with ursodeoxycholic acid in the treatment of chronic" exact="hepatitis" post="B with severe jaundice.Chin Hosp Pharm J Dis.20033264813 8GaoYSongMZLiangCRClinical"/>
   <result pre="controlled study.BMC Surg.2013133810.1186/1471-2482-13-3824053627 11BobergKMWisloffTKjollesdalKSStovringHKristiansenISCost and health consequences of treatment of" exact="primary biliary cirrhosis" post="with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the treatment"/>
   <result pre="Surg.2013133810.1186/1471-2482-13-3824053627 11BobergKMWisloffTKjollesdalKSStovringHKristiansenISCost and health consequences of treatment of primary biliary" exact="cirrhosis" post="with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the treatment"/>
   <result pre="silymarin and its combination therapy for the treatment of chronic" exact="hepatitis" post="B.Eur J Clin Microbiol Infect Dis.20133256576910.1007/s10096-012-1789-123247631 14RenBRZhaoYYXuBHWuJLChenJLiangCYResearch of silymarin"/>
   <result pre="Gastroenterol Rep.19991142910980926 19WangNShiXFGuoSHZhangDZRenH[A clinical study of N-acetylcysteine treatment in chronic" exact="hepatitis" post="B patients].Zhonghua Gan Zang Bing Za Zhi.2008167487918647523 20XiaGThe clinical"/>
   <result pre="observation of acetylcysteine injection on 58 cases of chronic severe" exact="hepatitis" post="B.West Chin Med J.2009245123940 21ShiXFGuoSHWuGWangZYRenHLiuQThe clinical curative effect observation"/>
   <result pre="effect observation of acetylcysteine injection on 40 cases of chronic" exact="hepatitis" post="B.J Chongqing Med Univ.200530111521 22ShohratiMDermanakiFBabaeiFAlavianSMEvaluation of the effects of"/>
   <result pre="in paraclinical and oxidative stress parameters of patients with chronic" exact="hepatitis" post="B.Hepat Mon.20101029510022312380 23WuGGuoSHThe Clinic Study of N-Acetylcysteine Injection Therapy"/>
   <result pre="Hepatitis B.Chongqing Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on liver" exact="cirrhosis" post="with hepatitis B].Zhong Nan Da Xue Xue Bao Yi"/>
   <result pre="Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on liver cirrhosis with" exact="hepatitis" post="B].Zhong Nan Da Xue Xue Bao Yi Xue Ban.2010352171510.3969/j.issn.1672-7347.2010.02.01420197618"/>
   <result pre="methionine combined with ursodeoxycholic acid in the treatment of chronic" exact="hepatitis" post="B with severe jaundice.Chinese J Hos Pharm.20136019 28QureshiHMehdiIAhmedWUAlamSERole of"/>
   <result pre="30FlisiakRProkopowiczDEffect of misoprostol on serum beta2-microglobulin in the course of" exact="viral hepatitis" post="B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the"/>
   <result pre="of misoprostol on serum beta2-microglobulin in the course of viral" exact="hepatitis" post="B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the"/>
   <result pre="J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the course of" exact="viral hepatitis" post="B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect of oxymatrine on specific cytotoxic T"/>
   <result pre="Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the course of viral" exact="hepatitis" post="B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect of oxymatrine on specific cytotoxic T"/>
   <result pre="lymphocyte surface programmed death receptor-1 expression in patients with chronic" exact="hepatitis" post="B.Chin Med J (Engl).201212581434822613649 33BaoFYXieJSilybin phospholipid complex combinated with"/>
   <result pre="Med J (Engl).201212581434822613649 33BaoFYXieJSilybin phospholipid complex combinated with interferon treating" exact="hepatitis" post="B.J Cent Plains Med.20063315701 34BaoFYQiuPYAnalyzing the adjunctive therapy of"/>
   <result pre="34BaoFYQiuPYAnalyzing the adjunctive therapy of silibinin phospholipid complex treat chronic" exact="hepatitis" post="B in 86 cases.Shandong Med.2006262631 35KimMYChoMYBaikSKJeongPHSukKTJangYOet al.Beneficial effects of"/>
   <result pre="Capsule combined lamivudine on hepatic fibrosis in patients with chronic" exact="hepatitis" post="B].Zhongguo Zhong Xi Yi Jie He Za Zhi.200626119788017186724 37WuYYaoDKZhuL[Clinical"/>
   <result pre="Oxymatrine combined therapy on liver function in patients with chronic" exact="hepatitis" post="B and liver fibrosis.Pract Clin Med.2014152213 39ZhouXYGaoCGaoXCLiuXLLiLHWangXClinical effects of"/>
   <result pre="effect of interferon α-2b combined with silymarin to treat chronic" exact="hepatitis" post="B.Clin Hepatol.20045302"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4542094/results/search/disease/results.xml">
   <result pre="chemotherapy is likely to be associated with the development of" exact="cancer" post="stem cell-like phenotypes. This chemical stress can force the"/>
   <result pre="to induce a wide HCT8 subpopulation of cells (HCT8RETO) with" exact="cancer" post="stem cell features (CSCs) in a very short time."/>
   <result pre="(CRC). Nevertheless, this drug is associated with the induction of" exact="cancer" post="stem cell characteristics in several tumors as previously described."/>
   <result pre="expressed in colon carcinomas, probably due to the presence of" exact="cancer" post="stem cells. The expression of different HERVs and a"/>
   <result pre="have an impact on tumor biology and/or proliferation of chemorefractory" exact="cancer" post="cells in vitro. Enhanced cytotoxic effect of antiviral compounds"/>
   <result pre="indicating unspecific cytotoxic effects of antiviral compounds rather than additional" exact="suppression" post="of HERV-protein expression. Fig. 6 Cytotoxic effect of antiviral"/>
   <result pre="expression of various HERV proteins is not only detectable in" exact="colon cancer" post="cells, but might also have therapeutic implications for CRC"/>
   <result pre="of various HERV proteins is not only detectable in colon" exact="cancer" post="cells, but might also have therapeutic implications for CRC"/>
   <result pre="[22, 23]. Recently, we described a method to induce multi-resistant" exact="cancer" post="cells that express several CSC tissue-related markers as well"/>
   <result pre="has been also linked to stemness in both normal and" exact="cancer" post="cells [36]. Colon adenocarcinoma paraffin sections showed significant expression"/>
   <result pre="proteins to promote cell-cell fusion and generation of multinucleated giant" exact="cancer" post="cells could represent an alternative membrane-mediated defense mechanism [12,"/>
   <result pre="anti-HERV-K-specific monoclonal antibodies inhibited tumor growth and induced apoptosis of" exact="breast cancer" post="cells [39]. These data served as a rationale to"/>
   <result pre="monoclonal antibodies inhibited tumor growth and induced apoptosis of breast" exact="cancer" post="cells [39]. These data served as a rationale to"/>
   <result pre="downregulation of HERV proteins in a panel of HERV-expressing chemoresistant" exact="cancer" post="cell lines. Among these compounds, the structurally unrelated amantadine,"/>
   <result pre="PPAPs were recently described as selective agents in highly resistant" exact="neuroblastoma" post="entities [40–43], exerting a pleiotropic effect that involves the"/>
   <result pre="expression of various HERV proteins might have therapeutic implications in" exact="colorectal cancer." post="Therefore, the introduction of antiviral compounds to the current"/>
   <result pre="al.Atypical cell populations associated with acquired resistance to cytostatics and" exact="cancer" post="stem cell features: the role of mitochondria in nuclear"/>
   <result pre="in nuclear encapsulationDNA Cell Biol201433117497410.1089/dna.2014.237525126674 2.MezhirJJAdvaniSJSmithKDDargaTEPoonAPSchmidtHet al.Ionizing radiation activates late" exact="herpes simplex" post="virus 1 promoters via the p38 pathway in tumors"/>
   <result pre="of human endogenous retroviral long terminal repeat sequences in human" exact="cancer" post="(Review)Int J Mol Med20133247556223900638 6.PacesJHuangYTPačesVRídlJChangCMNew insight into transcription of"/>
   <result pre="non-coding spliced transcripts from human endogenous retrovirus HERV-H elements in" exact="colon cancer." post="PLoS One. 7(1):e29950. 23.LeeSHKangYJJoJOOckMSBaekKWEoJet al.Elevation of human ERV3-1 env"/>
   <result pre="of eIF4E with ribavirin cooperates with common chemotherapies in primary" exact="acute myeloid leukemia" post="specimensLeukemia2011257119720010.1038/leu.2011.5721455212 26.BordenKLCuljkovic-KraljacicBRibavirin as an anti-cancer therapy: acute myeloid leukemia"/>
   <result pre="eIF4E with ribavirin cooperates with common chemotherapies in primary acute" exact="myeloid leukemia" post="specimensLeukemia2011257119720010.1038/leu.2011.5721455212 26.BordenKLCuljkovic-KraljacicBRibavirin as an anti-cancer therapy: acute myeloid leukemia"/>
   <result pre="with ribavirin cooperates with common chemotherapies in primary acute myeloid" exact="leukemia" post="specimensLeukemia2011257119720010.1038/leu.2011.5721455212 26.BordenKLCuljkovic-KraljacicBRibavirin as an anti-cancer therapy: acute myeloid leukemia"/>
   <result pre="primary acute myeloid leukemia specimensLeukemia2011257119720010.1038/leu.2011.5721455212 26.BordenKLCuljkovic-KraljacicBRibavirin as an anti-cancer therapy:" exact="acute myeloid leukemia" post="and beyond?Leuk Lymphoma2010511018051510.3109/10428194.2010.49650620629523 27.BordenKLTargeting the oncogene eIF4E in cancer:"/>
   <result pre="acute myeloid leukemia specimensLeukemia2011257119720010.1038/leu.2011.5721455212 26.BordenKLCuljkovic-KraljacicBRibavirin as an anti-cancer therapy: acute" exact="myeloid leukemia" post="and beyond?Leuk Lymphoma2010511018051510.3109/10428194.2010.49650620629523 27.BordenKLTargeting the oncogene eIF4E in cancer:"/>
   <result pre="myeloid leukemia specimensLeukemia2011257119720010.1038/leu.2011.5721455212 26.BordenKLCuljkovic-KraljacicBRibavirin as an anti-cancer therapy: acute myeloid" exact="leukemia" post="and beyond?Leuk Lymphoma2010511018051510.3109/10428194.2010.49650620629523 27.BordenKLTargeting the oncogene eIF4E in cancer:"/>
   <result pre="Invest Med2011346E31522129918 28.AssoulineSCuljkovicBCocolakisERousseauCBesluNAmriAet al.Molecular targeting of the oncogene eIF4E in" exact="acute myeloid leukemia" post="(AML): a proof-of-principle clinical trial with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase"/>
   <result pre="Med2011346E31522129918 28.AssoulineSCuljkovicBCocolakisERousseauCBesluNAmriAet al.Molecular targeting of the oncogene eIF4E in acute" exact="myeloid leukemia" post="(AML): a proof-of-principle clinical trial with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase"/>
   <result pre="28.AssoulineSCuljkovicBCocolakisERousseauCBesluNAmriAet al.Molecular targeting of the oncogene eIF4E in acute myeloid" exact="leukemia" post="(AML): a proof-of-principle clinical trial with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase"/>
   <result pre="and low-dose cytarabine for the treatment of relapsed and refractory" exact="acute myeloid leukemia" post="with elevated eIF4EHaematologica20151001e7910.3324/haematol.2014.11124525425688 30.Díaz-CarballoDMalakSBardenheuerWFreistuehlerMReuschHPCytotoxic activity of nemorosone in neuroblastoma"/>
   <result pre="low-dose cytarabine for the treatment of relapsed and refractory acute" exact="myeloid leukemia" post="with elevated eIF4EHaematologica20151001e7910.3324/haematol.2014.11124525425688 30.Díaz-CarballoDMalakSBardenheuerWFreistuehlerMReuschHPCytotoxic activity of nemorosone in neuroblastoma"/>
   <result pre="cytarabine for the treatment of relapsed and refractory acute myeloid" exact="leukemia" post="with elevated eIF4EHaematologica20151001e7910.3324/haematol.2014.11124525425688 30.Díaz-CarballoDMalakSBardenheuerWFreistuehlerMReuschHPCytotoxic activity of nemorosone in neuroblastoma"/>
   <result pre="myeloid leukemia with elevated eIF4EHaematologica20151001e7910.3324/haematol.2014.11124525425688 30.Díaz-CarballoDMalakSBardenheuerWFreistuehlerMReuschHPCytotoxic activity of nemorosone in" exact="neuroblastoma" post="cellsJ Cell Mol Med2008126B259860810.1111/j.1582-4934.2008.00232.x18194446 31.TallaridaRJAn overview of drug combination"/>
   <result pre="with isobologramsJ Pharmacol Exp Ther200631911710.1124/jpet.106.10411716670349 32.Díaz-CarballoDAcikelliAHGustmannSBardenheuerWStrumbergDAcquired resistance to cytostatics triggers" exact="cancer" post="stem-cell-like phenotype in different tumor entitiesJ Stem Cells Regen"/>
   <result pre="cancerOncogene2003221015283510.1038/sj.onc.120624112629516 35.GolanMHiziAResauJHYaal-HahoshenNReichmanHKeydarIet al.Human endogenous retrovirus (HERV-K) reverse transcriptase as a" exact="breast cancer" post="prognostic markerNeoplasia20081065213310.1593/neo.0798618516289 36.OhnukiMTanabeKSutouKTeramotoISawamuraYNaritaMet al.Dynamic regulation of human endogenous retroviruses"/>
   <result pre="35.GolanMHiziAResauJHYaal-HahoshenNReichmanHKeydarIet al.Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast" exact="cancer" post="prognostic markerNeoplasia20081065213310.1593/neo.0798618516289 36.OhnukiMTanabeKSutouKTeramotoISawamuraYNaritaMet al.Dynamic regulation of human endogenous retroviruses"/>
   <result pre="43.Díaz-CarballoDAcikelliAHBardenheuerWGustmannSMalakSStollRet al.Identification of compounds that selectively target highly chemotherapy refractory" exact="neuroblastoma" post="cancer stem cellsInt J Clin Pharmacol Ther201452978780110.5414/CP20215424902844 44.YuHLiuTZhaoZChenYZengJLiuSet al.Mutations"/>
   <result pre="al.Identification of compounds that selectively target highly chemotherapy refractory neuroblastoma" exact="cancer" post="stem cellsInt J Clin Pharmacol Ther201452978780110.5414/CP20215424902844 44.YuHLiuTZhaoZChenYZengJLiuSet al.Mutations in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4574619/results/search/disease/results.xml">
   <result pre="of wild poliovirus (WPV) transmission to eliminate the risks of" exact="poliomyelitis" post="disease associated with continued OPV use [1, 2]. Given"/>
   <result pre="OPV use include the relatively predictable cases of vaccine-associated paralytic" exact="poliomyelitis" post="(VAPP) in a small fraction of OPV recipients and"/>
   <result pre="the 73 known long-term excretors, 13 (17 %) presented with" exact="common variable immunodeficiency" post="disease (CVID), while the remainder presented with other PIDs"/>
   <result pre="with other PIDs (oPIDs), including not further specified PIDs (16)," exact="severe combined immunodeficiency" post="disease (SCID)(14), hypogammaglobulinemia (11), X-linked agammaglobulinemia (8), agammaglobulinemia (6),"/>
   <result pre="not further specified PIDs (16), severe combined immunodeficiency disease (SCID)(14)," exact="hypogammaglobulinemia" post="(11), X-linked agammaglobulinemia (8), agammaglobulinemia (6), major histocompatibility complex"/>
   <result pre="with any disruptions exposing patients to a risk of developing" exact="infectious disease" post="complications [34]. Although the acute flaccid paralysis surveillance system"/>
   <result pre="fraction of new PID cases, excluding IgA deficiency and transient" exact="hypogammaglobulinemia" post="in infancy  - CVID 1/32,000  - oPIDs 1/8,500 Potential"/>
   <result pre="combined immunodeficiency disease SIA Supplemental immunization activity VAPP Vaccine-associated paralytic" exact="poliomyelitis" post="WPV(1,2,3) Wild poliovirus (serotype 1, 2, or 3, respectively)"/>
   <result pre="of polioviruses isolated from a child with agammaglobulinemia and paralytic" exact="poliomyelitis" post="after Sabin vaccine administrationMicrobiol Immunol19812599051310.1111/j.1348-0421.1981.tb00095.x6273701 29.MartinJVaccine-derived poliovirus from long"/>
   <result pre="an immunodeficient patientVirology199926521788410.1006/viro.1999.000310600590 33.MacLennanCADunnGWoodPChronic infection with vaccine-derived poliovirus in a" exact="common variable immunodeficiency" post="and implications for world healthJ Allergy Clin Immunol2001107SupplS3045 34.DeVriesASHarperJMurrayALexauCBahtaLChristensenJCebelinskiEFullerSKlineSWallaceGSet"/>
   <result pre="and implications for world healthJ Allergy Clin Immunol2001107SupplS3045 34.DeVriesASHarperJMurrayALexauCBahtaLChristensenJCebelinskiEFullerSKlineSWallaceGSet al.Vaccine-derived" exact="poliomyelitis" post="12 years after infection in MinnesotaN Engl J Med20113642423162310.1056/NEJMoa100867721675890"/>
   <result pre="decision tool to measure cost benefit of newborn screening for" exact="severe combined immunodeficiency" post="(SCID) and related T-cell lymphopeniaImmunol Res20146011455210.1007/s12026-014-8485-424599744 41.JoshiAYIyerVNHaganJBSt SauverJLBoyceTGIncidence and"/>
   <result pre="studyMayo Clin Proc2009841162210.4065/84.1.1619121249 42.AlexanderLNSewardJFSantibanezTAPallanschMAKewOMPrevotsDRStrebelPMConoJWhartonMOrensteinWAet al.Vaccine policy changes and epidemiology of" exact="poliomyelitis" post="in the United StatesJAMA200429214169670110.1001/jama.292.14.169615479934 43.AbolhassaniHAghamohammadiAAbolhassaniFEftekharHHeidarniaMRezaeiNHealth policy for common variable"/>
   <result pre="York, 2013; Report No.: ST/ESA/SER.A/336. 57.MinorPVaccine-derived poliovirus (VDPV): Impact on" exact="poliomyelitis" post="eradicationVaccine2009272026495210.1016/j.vaccine.2009.02.07119428874 58.ModellVGeeBLewisDBOrangeJSRoifmanCMRoutesJMSorensenRUNotarangeloLDModellFGlobal study of primary immunodeficiency diseases (PI)—diagnosis, treatment,"/>
   <result pre="attenuated polio viruses is prolongedJ Clin Microbiol1988828994 66.ShahmahmoodiSMamishiSAghamohammadiAAghazadehNTabatabaieHGooyaMMZahraeiSMMousaviTYousefiMFarrokhiKet al.Vaccine-associated paralytic" exact="poliomyelitis" post="in immunodeficient children, Iran, 1995–2008Emerg Infect Dis20101671133610.3201/eid1607.09160620587188"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4623666/results/search/disease/results.xml">
   <result pre="prophylactic vaccines. Analysis of the individual risk perception time evolution" exact="aids" post="in understanding risk perception dynamics. HIV transmission and natural"/>
   <result pre="which has all-or-none efficacy . Similar to the practice with" exact="hepatitis" post="B vaccine in some jurisdictions, we assume that individuals"/>
   <result pre="disease epidemics. Ration Soc.14, 353–383 (2002). AuldM. C.Choices, beliefs, and" exact="infectious disease" post="dynamics. J. Health Econ.22, 361–377 (2003).12683957 do Espirito Santo,"/>
   <result pre="Journal of Public Health11, 251–256 (2001).11582601 National center for HIV/AIDS," exact="viral hepatitis," post="STD and TB prevention HIV in the United States"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4654359/results/search/disease/results.xml">
   <result pre="there was no observable trend. Drugs initially licensed to treat" exact="hepatitis" post="C had a longer duration of clinical development than"/>
   <result pre="now are radically changing the care of those infected by" exact="hepatitis" post="C.4 However, concerns have been expressed about the increasing"/>
   <result pre="and 2014 (inclusive) and specifically indicated for the treatment of" exact="viral disease" post="were identified along with their initial approved indication(s) from"/>
   <result pre="for HIV infection. The next most frequent initial indication was" exact="hepatitis" post="C infection (15%), followed by infection with cytomegalovirus (13%),"/>
   <result pre="hepatitis C infection (15%), followed by infection with cytomegalovirus (13%)," exact="hepatitis" post="B (8%), herpes simplex virus (4%), influenza virus (4%)"/>
   <result pre="(15%), followed by infection with cytomegalovirus (13%), hepatitis B (8%)," exact="herpes simplex" post="virus (4%), influenza virus (4%) and respiratory syncytial virus"/>
   <result pre="with cytomegalovirus (13%), hepatitis B (8%), herpes simplex virus (4%)," exact="influenza" post="virus (4%) and respiratory syncytial virus (2%, full details"/>
   <result pre="the initial indications for new drugs, those licensed to treat" exact="hepatitis" post="C infection had a longer duration of clinical development"/>
   <result pre="time taken for regulatory approval. In addition, drugs licensed for" exact="hepatitis" post="C appeared to spend longer in development than those"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC4865845/results/search/disease/results.xml">
   <result pre="10.1038/ncomms11320 : Article A human genome-wide loss-of-function screen identifies effective" exact="chikungunya" post="antiviral drugs KarlasAlexander12*BerreStefano34*CoudercThérèse34VarjakMargus5BraunPeter12MeyerMichael2GangneuxNicolas34Karo-AstoverLiis5WeegeFriderike1RafteryMartin6SchönrichGünther6KlemmUwe7WurzlbauerAnne8BracherFranz8MeritsAndres5MeyerThomas F.a12†LecuitMarcb349†[1], Max Planck Institute for Infection"/>
   <result pre="identified inhibitors have prophylactic antiviral effects in mouse models of" exact="chikungunya" post="infection. Two of them, the calmodulin inhibitor pimozide and"/>
   <result pre="perform a host genome-wide loss-of-function screen to identify targets for" exact="chikungunya" post="antiviral drugs and validate hits using a mouse model"/>
   <result pre="antiviral drugs and validate hits using a mouse model of" exact="chikungunya" post="infection. Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that"/>
   <result pre="infection. Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes" exact="chikungunya" post="fever, an acute infection characterized by arthralgia and frequently"/>
   <result pre="of drugs available to treat human immunodeficiency virus (HIV)-infected or" exact="hepatitis" post="C virus (HCV)-infected patients, deciphering that the biology of"/>
   <result pre="these proviral genes have been identified in previous screens with" exact="influenza" post="A virus (IAV)914, HCV1819, sindbis virus (SINV)1011, dengue virus"/>
   <result pre="(DENV)20, West Nile virus (WNV)21, HIV-1 (refs 13, 22) or" exact="vaccinia virus" post="(VACV)23 (Fig. 1c; see Supplementary Data 3 for details"/>
   <result pre="titre VRPs. GFP-expressing recombinant viruses used in Fig. 4 were" exact="cowpox" post="virus strain Brighton Red vBRFseR (CPXV; provided by K."/>
   <result pre="vBRFseR (CPXV; provided by K. Tischer, Freie Universität Berlin, Germany)," exact="herpes simplex" post="virus 1 strain KOS K26GFP (HSV-1; provided by P."/>
   <result pre="were performed as described above. To analyse primary infection of" exact="herpes simplex" post="type 1 strain KOS (HSV-1), cowpox strain Brighton Red"/>
   <result pre="primary infection of herpes simplex type 1 strain KOS (HSV-1)," exact="cowpox" post="strain Brighton Red (CPXV) or adenovirus strain 5 (Ad5),"/>
   <result pre="A. et al. A human genome-wide loss-of-function screen identifies effective" exact="chikungunya" post="antiviral drugs. Nat. Commun. 7:11320 doi: 10.1038/ncomms11320 (2016). Supplementary"/>
   <result pre="Drug Discov.6, 1001–1018 (2007).18049474 ScheelT. K. &amp;amp; RiceC. M.Understanding the" exact="hepatitis" post="C virus life cycle paves the way for highly"/>
   <result pre="E.et al.. Therapeutic silencing of microRNA-122 in primates with chronic" exact="hepatitis" post="C virus infection. Science327, 198–201 (2010).19965718 LinK. &amp;amp; GallayP.Curing"/>
   <result pre="al.. Genome-wide RNAi screen identifies human host factors crucial for" exact="influenza" post="virus replication. Nature463, 818–822 (2010).20081832 OoiY. S., StilesK. M.,"/>
   <result pre="Science319, 921–926 (2008).18187620 KonigR.et al.. Human host factors required for" exact="influenza" post="virus replication. Nature463, 813–817 (2010).20027183 BoutrosM., BrasL. P. &amp;amp;"/>
   <result pre="W.et al.. A functional genomic screen identifies cellular cofactors of" exact="hepatitis" post="C virus replication. Cell Host Microbe5, 298–307 (2009).19286138 LiQ.et"/>
   <result pre="Host Microbe5, 298–307 (2009).19286138 LiQ.et al.. Integrative functional genomics of" exact="hepatitis" post="C virus infection identifies host dependencies in complete viral"/>
   <result pre="Nucleic Acids Res.40, D1100–D1107 (2012).21948594 SourisseauM.et al.. Characterization of reemerging" exact="chikungunya" post="virus. PLoS Pathog.3, e89 (2007).17604450 YasunagaA.et al.. Genome-wide RNAi"/>
   <result pre="STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous" exact="leukemia" post="driven by FLT3 mutations. Genes Cancer3, 503–511 (2012).23264850 KangS.,"/>
   <result pre="Res.112, 125–133 (2013).23701975 ZieglerS. A.et al.. In vivo imaging of" exact="chikungunya" post="virus in mice and Aedes mosquitoes using a Renilla"/>
   <result pre="Dis.11, 1471–1477 (2011).21668347 MorrisonT. E.et al.. A mouse model of" exact="chikungunya" post="virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis,"/>
   <result pre="VanlandinghamD. L.et al.. Development and characterization of a double subgenomic" exact="chikungunya" post="virus infectious clone to express heterologous genes in Aedes"/>
   <result pre="HobomG. &amp;amp; WebsterR. G.A DNA transfection system for generation of" exact="influenza" post="A virus from eight plasmids. Proc. Natl Acad. Sci."/>
   <result pre="Sorafenib 1.11 18.24 16.42 Linifanib 2.15 &amp;gt; 60 NT CHIKV," exact="chikungunya" post="virus; CLK1, CDC-like kinase 1; FLT4, fms-related tyrosine kinase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5065164/results/search/disease/results.xml">
   <result pre="combination with peginterferon and ribavirin, stratified by the presence of" exact="cirrhosis" post="and prior treatment experience. Tolerability was assessed at each"/>
   <result pre="severe adverse events leading to treatment discontinuations, hospitalizations or severe" exact="anemia" post="and a substantially higher cost per SVR when compared"/>
   <result pre="US population.[5] Untreated HCV is likely to progress to liver" exact="cirrhosis" post="and is strongly associated with the development of hepatocellular"/>
   <result pre="submitted (Clinicaltrials.gov registration: NCT02113631). Patients Patients were recruited from the" exact="hepatitis" post="C outpatient clinic. The trial was conducted as a"/>
   <result pre="GT1 infection and evidence of chronic hepatitis. The presence of" exact="cirrhosis" post="was confirmed by a liver biopsy completed within 3"/>
   <result pre="a liver biopsy was not available, a clinical assessment of" exact="cirrhosis" post="risk was performed by the two independent hepatologists (YFY"/>
   <result pre="creatinine ≤ 1.5 mg/dL; patients needed to demonstrate adequately controlled" exact="diabetes mellitus" post="and normal or adequately controlled TSH on prescription medication."/>
   <result pre="adequately controlled TSH on prescription medication. Patients with compensated liver" exact="cirrhosis" post="were eligible to participate in the study. Patients who"/>
   <result pre="4 weeks of treatment. Prior non-responders or patients with compensated" exact="cirrhosis" post="received boceprevir for 44 weeks and Peg-IFN/RBV for 48"/>
   <result pre="after 4 weeks of treatment. Non-responders and patients with compensated" exact="cirrhosis" post="were prescribed telaprevir for 12 weeks and Peg-IFN/RBV for"/>
   <result pre="early after a number of serious adverse events (in particular" exact="rash" post="with telaprevir) were increasingly reported. Resource use was prospectively"/>
   <result pre="Hispanic or Latino. Liver biopsy results revealed advanced fibrosis or" exact="cirrhosis" post="(F3 and F4) in 10/50 (20%), and 2/50 (4%)"/>
   <result pre="and F4) in 10/50 (20%), and 2/50 (4%) patients had" exact="cirrhosis" post="determined with clinical assessment by the two independent hepatologists."/>
   <result pre=" • Male 25 (100) 24 (96) Advanced fibrosis (3/4) or" exact="cirrhosis" post="[n (%)] 6 (24) 6 (24) Treatment exposure [n"/>
   <result pre="hospitalization due to progressive maculopapular rash, and another developed severe" exact="anemia" post="(Hb ≤8 g/dL). Of the two patients on boceprevir"/>
   <result pre="on boceprevir who stopped treatment early, one experienced a severe" exact="rash" post="and the other had severe dysgeusia. Four patients (3"/>
   <result pre="0.04  • Hospitalization 0 (0) 1 (4) 0.77  • Severe" exact="anemia" post="(&amp;lt;8 g/dL) 0 (0) 1 (4) 0.77  • Total"/>
   <result pre="two novel protease inhibitors in 2011 sparked an interest in" exact="hepatitis" post="C treatment. Given the lack of evidence-based guidelines concerning"/>
   <result pre="hepatitis C treatment. Given the lack of evidence-based guidelines concerning" exact="hepatitis" post="C treatment when these drugs were approved, clinicians preferred"/>
   <result pre="a third are older than 60 years. As a result," exact="hepatitis" post="C is an important disease of aging; especially since"/>
   <result pre="detect any differences among important sub-populations, such as patients with" exact="cirrhosis" post="or women. Additionally, the FDA approved two new DAAs,"/>
   <result pre="Pragmatic RCTs in the context of the newer generation of" exact="hepatitis" post="C therapies merits discussion. These newer antiviral treatments achieve"/>
   <result pre="sicker and aging population can be particularly useful in guiding" exact="hepatitis" post="C treatment choices. Based on our findings and the"/>
   <result pre="References References 1Mohd HanafiahK, GroegerJ, FlaxmanAD, WiersmaST. Global epidemiology of" exact="hepatitis" post="C virus infection: new estimates of age-specific antibody to"/>
   <result pre="Guidelines for the screening, care and treatment of persons with" exact="hepatitis" post="C infection. World Health Organization Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 3ArmstrongGL,"/>
   <result pre="http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 3ArmstrongGL, WasleyA, SimardEP, McQuillanGM, KuhnertWL, AlterMJ. The prevalence of" exact="hepatitis" post="C virus infection in the United States, 1999 through"/>
   <result pre="2006;144(10):705–14. .16702586 4DennistonMM, JilesRB, DrobeniucJ, KlevensRM, WardJW, McQuillanGM, et al.Chronic" exact="hepatitis" post="C virus infection in the United States, National Health"/>
   <result pre="5DominitzJA, BoykoEJ, KoepsellTD, HeagertyPJ, MaynardC, SporlederJL, et al.Elevated prevalence of" exact="hepatitis" post="C infection in users of United States veterans medical"/>
   <result pre="2005;41(1):88–96. 10.1002/hep.20502 .15619249 6PradatP, VoirinN, TillmannHL, ChevallierM, TrepoC. Progression to" exact="cirrhosis" post="in hepatitis C patients: an age-dependent process. Liver international:"/>
   <result pre=".15619249 6PradatP, VoirinN, TillmannHL, ChevallierM, TrepoC. Progression to cirrhosis in" exact="hepatitis" post="C patients: an age-dependent process. Liver international: official journal"/>
   <result pre="al.Hepatitis C virus infection is associated with the development of" exact="hepatocellular carcinoma." post="Proceedings of the National Academy of Sciences of the"/>
   <result pre="Falck-YtterY, HoltzmanD, TeoCG, et al.Recommendations for the identification of chronic" exact="hepatitis" post="C virus infection among persons born during 1945–1965. MMWR"/>
   <result pre="risk of long-term morbidity and mortality in patients with chronic" exact="hepatitis" post="C: results from an analysis of data from a"/>
   <result pre="or in combination with ribavirin as initial treatment for chronic" exact="hepatitis" post="C. Hepatitis Interventional Therapy Group. The New England journal"/>
   <result pre="placebo for 48 weeks for treatment of chronic infection with" exact="hepatitis" post="C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet."/>
   <result pre="HeathcoteEJ, LaiMY, GaneE, et al.Peginterferon alfa-2a in patients with chronic" exact="hepatitis" post="C. The New England journal of medicine. 2000;343(23):1666–72. 10.1056/NEJM200012073432301"/>
   <result pre="McCulloughAJ. Surprisingly small effect of antiviral treatment in patients with" exact="hepatitis" post="C. Annals of internal medicine. 2002;136(4):288–92. .11848726 14BrokJ, GluudLL,"/>
   <result pre="14BrokJ, GluudLL, GluudC. Ribavirin plus interferon versus interferon for chronic" exact="hepatitis" post="C. The Cochrane database of systematic reviews. 2010;(1):CD00544510.1002/14651858.CD005445.pub2 .20091577"/>
   <result pre="Di BisceglieAM, ReddyKR, BzowejNH, et al.Telaprevir for previously untreated chronic" exact="hepatitis" post="C virus infection. The New England journal of medicine."/>
   <result pre="al.Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated" exact="hepatitis" post="C virus patients. World journal of hepatology. 2014;6(9):660–9. 10.4254/wjh.v6.i9.66025276282"/>
   <result pre="KowdleyKV, ZeuzemS, AgarwalK, et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for" exact="hepatitis" post="C with cirrhosis. N Engl J Med. 2014;370(21):1973–82. 10.1056/NEJMoa1402869"/>
   <result pre="et al.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for" exact="hepatitis" post="C in patients co-infected with HIV-1: a randomized trial."/>
   <result pre="30http://www.hepatitisc.uw.edu/page/treatment/drugs/ledipasvir-sofosbuvir. 31ChhatwalJ, KanwalF, RobertsMS, DunnMA. Cost-effectiveness and budget impact of" exact="hepatitis" post="C virus treatment with sofosbuvir and ledipasvir in the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5228644/results/search/disease/results.xml">
   <result pre="28072684MD-D-16-04055 doi: 10.1097/MD.000000000000532105321 : 4500: Research ArticleObservational Study Assessment of" exact="hepatocellular carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
   <result pre="new era of highly effective oral antiviral drugs for chronic" exact="hepatitis" post="C virus (HCV), indications for antiviral treatment may be"/>
   <result pre="suitable candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating" exact="hepatocellular carcinoma" post="(HCC) risk in patients with chronic HCV treated or"/>
   <result pre="(P &amp;lt; 0.01 and P &amp;lt; 0.01, respectively). In all study subjects, presence of" exact="cirrhosis" post="(hazard ratio [HR], 9.92, P &amp;lt; 0.01), age (HR 1.03, P &amp;lt; 0.01),"/>
   <result pre="In the no-treatment group, age, male, and the presence of" exact="cirrhosis" post="were independent predictors for HCC development. HCC risk increased"/>
   <result pre="needs to be considered in these patients. Keywords age chronic" exact="hepatitis" post="C hepatocellular carcinoma liver cirrhosis sustained virologic response 1"/>
   <result pre="be considered in these patients. Keywords age chronic hepatitis C" exact="hepatocellular carcinoma" post="liver cirrhosis sustained virologic response 1 Introduction Hepatitis C"/>
   <result pre="these patients. Keywords age chronic hepatitis C hepatocellular carcinoma liver" exact="cirrhosis" post="sustained virologic response 1 Introduction Hepatitis C virus (HCV)"/>
   <result pre="million population worldwide and is the major cause of liver" exact="cirrhosis" post="(LC) and hepatocellular carcinoma (HCC).[1,2] Since these diseases are"/>
   <result pre="and is the major cause of liver cirrhosis (LC) and" exact="hepatocellular carcinoma" post="(HCC).[1,2] Since these diseases are associated with high mortality"/>
   <result pre="initially positive for HCV antibody and had no other chronic" exact="liver disease," post="such as hepatitis B virus (HBV) infection, alcoholic liver"/>
   <result pre="antibody and had no other chronic liver disease, such as" exact="hepatitis" post="B virus (HBV) infection, alcoholic liver disease, autoimmune hepatitis,"/>
   <result pre="liver disease, such as hepatitis B virus (HBV) infection, alcoholic" exact="liver disease," post="autoimmune hepatitis, primary biliary cirrhosis, or Wilson disease (Fig."/>
   <result pre="such as hepatitis B virus (HBV) infection, alcoholic liver disease," exact="autoimmune hepatitis," post="primary biliary cirrhosis, or Wilson disease (Fig. 1). Anti-HCV"/>
   <result pre="hepatitis B virus (HBV) infection, alcoholic liver disease, autoimmune hepatitis," exact="primary biliary cirrhosis," post="or Wilson disease (Fig. 1). Anti-HCV and HCV RNA"/>
   <result pre="serum albumin or bilirubin, serum alpha-fetoprotein (AFP) level, Child-Turcotte-Pugh classification," exact="hepatitis" post="B surface antigen or antibody, HCV RNA (IU/mL), HCV"/>
   <result pre="of LC. LC was clinically diagnosed based on evidence of" exact="portal hypertension" post="(encephalopathy, esophageal varices, ascites, or splenomegaly), low platelet count"/>
   <result pre="was clinically diagnosed based on evidence of portal hypertension (encephalopathy," exact="esophageal varices," post="ascites, or splenomegaly), low platelet count (&amp;lt;100,000/mm3), or liver"/>
   <result pre="who developed HCC (P &amp;lt; 0.01), males (P = 0.03), and the rate of" exact="cirrhosis" post="(P &amp;lt; 0.01) were significantly higher in patients who developed HCC"/>
   <result pre="greater than those with other genotypes (P = 0.09) (C). HCC =" exact="hepatocellular carcinoma," post="LC = liver cirrhosis, PEG-IFN/RBV = peg-interferon plus ribavirin,"/>
   <result pre="that of those with other genotypes (P = 0.047) (B). HCC =" exact="hepatocellular carcinoma," post="LC = liver cirrhosis. In the no-treatment group, HCC"/>
   <result pre="1 or another genotype were similar (P = 0.59) (C). HCC =" exact="hepatocellular carcinoma," post="LC = liver cirrhosis. 3.5 Factors predictive of HCC"/>
   <result pre="that older age (hazard ratio [HR] 1.06, P &amp;lt; 0.01), presence of" exact="cirrhosis" post="(HR 14.89, P &amp;lt; 0.01), higher serum HCV RNA levels (HR"/>
   <result pre="analysis showed that older age (HR 1.03, P &amp;lt; 0.01), presence of" exact="cirrhosis" post="(HR 9.92, P &amp;lt; 0.01), SVR (−) (HR 7.02, P &amp;lt; 0.01), and"/>
   <result pre="the treatment group, older age (HR 1.05, P = 0.02), presence of" exact="cirrhosis" post="(HR 6.35, P &amp;lt; 0.01), and SVR (−) (HR 10.73, P &amp;lt; 0.01)"/>
   <result pre="(HR 1.03, P &amp;lt; 0.01), male (HR 1.68, P = 0.02), and presence of" exact="cirrhosis" post="(HR 11.64, P &amp;lt; 0.01) independently predicted HCC development (Table 4)."/>
   <result pre="a well-known risk factor of HCC development regardless of underlying" exact="liver disease," post="and thus, cirrhotic patients are candidates for active surveillance"/>
   <result pre="In addition, according to current guidelines, HCV patients with decompensated" exact="cirrhosis" post="can also be treated with new DAA agents,[7–9] and"/>
   <result pre="associated with the risk of HCV-related HCC, such as, obesity," exact="diabetes mellitus," post="and insulin resistance, were not addressed in the present"/>
   <result pre="CHC, an older age, a male gender, and presence of" exact="cirrhosis" post="were found to predict HCC development. In our opinion,"/>
   <result pre="CHC = chronic HCV, DAA = direct-acting antiviral, HBV =" exact="hepatitis" post="B virus, HCC = hepatocellular carcinoma, HCV = hepatitis"/>
   <result pre="= direct-acting antiviral, HBV = hepatitis B virus, HCC =" exact="hepatocellular carcinoma," post="HCV = hepatitis C virus, IFN = interferon, LC"/>
   <result pre="= hepatitis B virus, HCC = hepatocellular carcinoma, HCV =" exact="hepatitis" post="C virus, IFN = interferon, LC = liver cirrhosis,"/>
   <result pre="to disclose. References References [1]GhanyMGStraderDBThomasDLet al.Diagnosis, management, and treatment of" exact="hepatitis" post="C: an update. Hepatology2009;49:1335–74.19330875 [2]ShepardCWFinelliLAlterMJGlobal epidemiology of hepatitis C"/>
   <result pre="treatment of hepatitis C: an update. Hepatology2009;49:1335–74.19330875 [2]ShepardCWFinelliLAlterMJGlobal epidemiology of" exact="hepatitis" post="C virus infection. Lancet Infect Dis2005;5:558–67.16122679 [3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b"/>
   <result pre="with interferon alfa-2b plus ribavirin for initial treatment of chronic" exact="hepatitis" post="C: a randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus"/>
   <result pre="randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infection. N Engl J Med2002;347:975–82.12324553 [5]KhurooMSKhurooMSDahabSTMeta-analysis: a"/>
   <result pre="of peginterferon plus ribavirin for the initial treatment of chronic" exact="hepatitis" post="C genotype 4. Aliment Pharmacol Ther2004;20:931–8.15521839 [6]NguyenMHTrinhHNGarciaRet al.Higher rate"/>
   <result pre="Ther2004;20:931–8.15521839 [6]NguyenMHTrinhHNGarciaRet al.Higher rate of sustained virologic response in chronic" exact="hepatitis" post="C genotype 6 treated with 48 weeks versus 24"/>
   <result pre="AASLD-IDSA recommendations for testing, managing, and treating adults infected with" exact="hepatitis" post="C virus. Hepatology2015;62:932–54.26111063 [8]collab: European Association for Study of"/>
   <result pre="Association for Study of LiverEASL clinical practice guidelines: management of" exact="hepatitis" post="C virus infection. J Hepatol2014;60:392–420.24331294 [9]collab: Korean Association for"/>
   <result pre="the Study of the LiverKASL clinical practice guidelines: management of" exact="hepatitis" post="C. Clin Mol Hepatol2016;22:76–139.27044763 [10]HungCHLeeCMLuSNet al.Long-term effect of interferon"/>
   <result pre="effect of interferon alpha-2b plus ribavirin therapy on incidence of" exact="hepatocellular carcinoma" post="in patients with hepatitis C virus-related cirrhosis. J Viral"/>
   <result pre="ribavirin therapy on incidence of hepatocellular carcinoma in patients with" exact="hepatitis" post="C virus-related cirrhosis. J Viral Hepat2006;13:409–14.16842444 [11]BrunoSStroffoliniTColomboMet al.Sustained virological"/>
   <result pre="national surveillance program of cirrhotic and noncirrhotic patients with chronic" exact="hepatitis" post="C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis"/>
   <result pre="[13]NishiguchiSKurokiTNakataniSet al.Randomised trial of effects of interferon-alpha on incidence of" exact="hepatocellular carcinoma" post="in chronic active hepatitis C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet"/>
   <result pre="of interferon-alpha on incidence of hepatocellular carcinoma in chronic active" exact="hepatitis" post="C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet al.Risk factors for hepatocellular"/>
   <result pre="active hepatitis C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet al.Risk factors for" exact="hepatocellular carcinoma" post="and its incidence after interferon treatment in patients with"/>
   <result pre="and its incidence after interferon treatment in patients with chronic" exact="hepatitis" post="C. Osaka Liver Disease Study Group. Hepatology1998;27:1394–402.9581697 [15]ToyodaHKumadaTTadaTet al.Risk"/>
   <result pre="Osaka Liver Disease Study Group. Hepatology1998;27:1394–402.9581697 [15]ToyodaHKumadaTTadaTet al.Risk factors of" exact="hepatocellular carcinoma" post="development in non-cirrhotic patients with sustained virologic response for"/>
   <result pre="development in non-cirrhotic patients with sustained virologic response for chronic" exact="hepatitis" post="C virus infection. J Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower"/>
   <result pre="virus infection. J Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower incidence of" exact="hepatocellular carcinoma" post="and cirrhosis in hepatitis C patients with sustained virological"/>
   <result pre="Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower incidence of hepatocellular carcinoma and" exact="cirrhosis" post="in hepatitis C patients with sustained virological response by"/>
   <result pre="[16]MoonCJungKSKim doYet al.Lower incidence of hepatocellular carcinoma and cirrhosis in" exact="hepatitis" post="C patients with sustained virological response by pegylated interferon"/>
   <result pre="Dis Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of peginterferon alfa-2b and ribavirin on" exact="hepatocellular carcinoma" post="prevention in older patients with chronic hepatitis C. J"/>
   <result pre="ribavirin on hepatocellular carcinoma prevention in older patients with chronic" exact="hepatitis" post="C. J Gastroenterol Hepatol2015;30:321–8.25091027 [18]LeeSSJeongSHJangESet al.Prospective cohort study on"/>
   <result pre="Gastroenterol Hepatol2015;30:321–8.25091027 [18]LeeSSJeongSHJangESet al.Prospective cohort study on the outcomes of" exact="hepatitis" post="C virus-related cirrhosis in South Korea. J Gastroenterol Hepatol2015;30:1281–7.25778783"/>
   <result pre="al.Prospective cohort study on the outcomes of hepatitis C virus-related" exact="cirrhosis" post="in South Korea. J Gastroenterol Hepatol2015;30:1281–7.25778783 [19]OgawaEFurusyoNKajiwaraEet al.Efficacy of"/>
   <result pre="pegylated interferon alpha-2b and ribavirin treatment on the risk of" exact="hepatocellular carcinoma" post="in patients with chronic hepatitis C: a prospective, multicenter"/>
   <result pre="on the risk of hepatocellular carcinoma in patients with chronic" exact="hepatitis" post="C: a prospective, multicenter study. J Hepatol2013;58:495–501.23099187 [20]Fernandez-RodriguezCMAlonsoSMartinezSMet al.Peginterferon"/>
   <result pre="and ribavirin therapy on hepatocellular carcinoma: incidence and survival in" exact="hepatitis" post="C patients with advanced fibrosis. J Hepatol2010;52:652–7.20346533 [22]BruixJCastellsABoschJet al.Surgical"/>
   <result pre="patients with advanced fibrosis. J Hepatol2010;52:652–7.20346533 [22]BruixJCastellsABoschJet al.Surgical resection of" exact="hepatocellular carcinoma" post="in cirrhotic patients: prognostic value of preoperative portal pressure."/>
   <result pre="N Engl J Med2014;370:1889–98.24725239 [25]LawitzEMangiaAWylesDet al.Sofosbuvir for previously untreated chronic" exact="hepatitis" post="C infection. N Engl J Med2013;368:1878–87.23607594 [26]FriedMWSide effects of"/>
   <result pre="infection. N Engl J Med2013;368:1878–87.23607594 [26]FriedMWSide effects of therapy of" exact="hepatitis" post="C and their management. Hepatology2002;36:S237–44.12407599 [27]RussoMWFriedMWSide effects of therapy"/>
   <result pre="and their management. Hepatology2002;36:S237–44.12407599 [27]RussoMWFriedMWSide effects of therapy for chronic" exact="hepatitis" post="C. Gastroenterology2003;124:1711–9.12761728 [28]MannsMPolSJacobsonIMet al.All-oral daclatasvir plus asunaprevir for hepatitis"/>
   <result pre="chronic hepatitis C. Gastroenterology2003;124:1711–9.12761728 [28]MannsMPolSJacobsonIMet al.All-oral daclatasvir plus asunaprevir for" exact="hepatitis" post="C virus genotype 1b: a multinational, phase 3, multicohort"/>
   <result pre="al.Efficacy of Ledipasvir plus Sofosobuvir with or without ribavirin in" exact="hepatitis" post="C genotype 1 patients who failed previous treatment with"/>
   <result pre="ribavirin in patients aged 65 years and older with chronic" exact="hepatitis" post="C. Liver Int2010;30:527–37.19523048 [33]ThabutDLe CalvezSThibaultVet al.Hepatitis C in 6,865"/>
   <result pre="with or without ribavirin in patients with decompensated genotype 1" exact="hepatitis" post="C cirrhosis. Liver Transplant2016;22:281–6. [36]MorenoCLasserLDelwaideJet al.Sofosbuvir in combination with"/>
   <result pre="al.Sofosbuvir in combination with simeprevir +/− ribavirin in genotype 4" exact="hepatitis" post="C patients with advanced fibrosis or cirrhosis: real-life experience"/>
   <result pre="an update. Hepatology2011;53:1020–2.21374666 [38]TerraultNABzowejNHChangKMet al.AASLD guidelines for treatment of chronic" exact="hepatitis" post="B. Hepatology2016;63:261–83.26566064 [39]ContiFBuonfiglioliFScuteriAet al.Early occurrence and recurrence of hepatocellular"/>
   <result pre="chronic hepatitis B. Hepatology2016;63:261–83.26566064 [39]ContiFBuonfiglioliFScuteriAet al.Early occurrence and recurrence of" exact="hepatocellular carcinoma" post="in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol2016;65:727–33.27349488"/>
   <result pre="[39]ContiFBuonfiglioliFScuteriAet al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related" exact="cirrhosis" post="treated with direct-acting antivirals. J Hepatol2016;65:727–33.27349488 [40]ReigMMarinoZPerelloCet al.Unexpected high"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5319548/results/search/disease/results.xml">
   <result pre="(Baltimore)MEDIMedicine0025-79741536-5964Wolters Kluwer Health MD-D-17-00766 doi: 10.1097/MD.000000000000619306193 : Erratum Assessment of" exact="hepatocellular carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
   <result pre="work is properly cited. http://creativecommons.org/licenses/by/4.0medi-96-e6193.pdf In the article &quot;Assessment of" exact="hepatocellular carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
   <result pre="an Inha University Research grant&quot;. References Reference [1]LeeSHJinY-JShinJYet al.Assessment of" exact="hepatocellular carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5440157/results/search/disease/results.xml">
   <result pre="(Baltimore)MEDIMedicine0025-79741536-5964Wolters Kluwer Health MD-D-17-02763 doi: 10.1097/MD.000000000000695806958 : Erratum Assessment of" exact="hepatocellular carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
   <result pre="work is properly cited. http://creativecommons.org/licenses/by/4.0medi-96-e6958.pdf In the article, &quot;Assessment of" exact="hepatocellular carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
   <result pre="by an Inha University Research grant.&quot; References Reference [1]LeeS-HJinY-JShinJ-YAssessment of" exact="hepatocellular carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5490823/results/search/disease/results.xml">
   <result pre="types belonging to species B, C, and E usually cause" exact="respiratory disease," post="species F Ads cause enteric infection, and some of"/>
   <result pre="B Ads is endemic among military recruits, causing severe acute" exact="respiratory disease" post="(for Ad pathology, see [3,5,6]). However, it is immunocompromised"/>
   <result pre="mixed dsDNA viral infectionJ. Clin. Virol.2016831410.1016/j.jcv.2016.07.02127513204 22.VoigtS.HofmannJ.EdelmannA.SauerbreiA.KuhlJ.S.Brincidofovir clearance of acyclovir-resistant" exact="herpes simplex" post="virus-1 and adenovirus infection after stem cell transplantationTranspl. Infect."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5549007/results/search/disease/results.xml">
   <result pre="and 4 had de novo neoplasia, none of them had" exact="hepatocellular carcinoma." post="The outcomes of the different variables analyzed were similar"/>
   <result pre="worldwide; It is also being a major cause of end-stage" exact="liver disease" post="leading to liver transplantation [1, 2]. The prevalence of"/>
   <result pre="[1, 2]. The prevalence of HCV infection in patients with" exact="chronic kidney disease" post="(CKD) exceeds that in the general population [3]. In"/>
   <result pre="in dialysis was 79 months; only one patient had clinical" exact="liver disease" post="before the transplantation. This patient had HCV and HBV"/>
   <result pre="after renal transplantation. Causes of graft failure were chronic allograft" exact="nephropathy" post="(n=8), vascular or urological problems (n=2), undetermined (n=8), and"/>
   <result pre="nephropathy (n=8), vascular or urological problems (n=2), undetermined (n=8), and" exact="membranous glomerulonephritis" post="(n=1). Death with a functioning graft (DWFG) occurred in"/>
   <result pre="(n=8), vascular or urological problems (n=2), undetermined (n=8), and membranous" exact="glomerulonephritis" post="(n=1). Death with a functioning graft (DWFG) occurred in"/>
   <result pre="developed neoplasia during the follow-up period, none of which was" exact="hepatocellular carcinoma" post="(Table 4). Table 4 Post-transplantation complications Complication n Acute"/>
   <result pre="some patients from the analysis, because the status of chronic" exact="hepatitis" post="C was unknown. The natural history of the HCV"/>
   <result pre="hepatitis C was unknown. The natural history of the HCV" exact="hepatitis" post="in post-renal transplantation has not been well established. Some"/>
   <result pre="believe that the immunosuppressive therapy facilitates viral proliferation and aggravates" exact="liver disease" post="[19, 20]. However, an increase in viremia may not"/>
   <result pre="viremia may not be associated with a higher risk of" exact="liver disease" post="after the renal transplantation [21, 22]. Patients with HCV"/>
   <result pre="the post-transplantation period. HCV infection is the leading cause of" exact="liver disease" post="after kidney transplantation and is associated with an increase"/>
   <result pre="and is associated with an increase in mortality [23]. Chronic" exact="hepatitis" post="and its sequelae are the main forms of liver"/>
   <result pre="Chronic hepatitis and its sequelae are the main forms of" exact="liver disease" post="in these patients. HCV-induced cirrhosis is associated with a"/>
   <result pre="the main forms of liver disease in these patients. HCV-induced" exact="cirrhosis" post="is associated with a high risk of hepatocellular carcinoma"/>
   <result pre="patients. HCV-induced cirrhosis is associated with a high risk of" exact="hepatocellular carcinoma" post="[17]. The incidence of hepatocellular carcinoma may be higher"/>
   <result pre="a high risk of hepatocellular carcinoma [17]. The incidence of" exact="hepatocellular carcinoma" post="may be higher in kidney transplant recipients compared to"/>
   <result pre="was in line with the literature. None had progressed to" exact="hepatocellular carcinoma." post="The risk factors that were most consistently associated with"/>
   <result pre="most consistently associated with progression of fibrosis were severity of" exact="liver disease" post="before transplantation and duration of follow-up after transplantation [25]."/>
   <result pre="epidemiological, clinical, and experimental data linking chronic HCV infection to" exact="glomerulonephritis" post="in native as well as transplanted kidneys [26-28]. Both"/>
   <result pre="allografts, HCV may cause a variety of glomerular patterns. Membranoproliferative" exact="glomerulonephritis" post="is the most common condition and is sometimes difficult"/>
   <result pre="study lost his graft due to glomerulopathy, specifically de novo" exact="membranous glomerulonephritis," post="which also can be linked to the virus. HCV"/>
   <result pre="infection has been associated with insulin resistance [29, 30], and" exact="diabetes mellitus" post="in the general population [31-33]. Some authors have shown"/>
   <result pre="A meta-analysis found a 5.7-fold increase in risk for non-Hodgkin" exact="lymphoma" post="in HCV-infected patients [37]. Four of our patients developed"/>
   <result pre="patients developed neoplasia post-transplantation, but none of them had developed" exact="lymphoma" post="or hepatocellular carcinoma. In this miscellaneous group of patients"/>
   <result pre="neoplasia post-transplantation, but none of them had developed lymphoma or" exact="hepatocellular carcinoma." post="In this miscellaneous group of patients transplanted from 1985"/>
   <result pre="conclusion, HCV infection has long been recognized as the main" exact="liver disease" post="in kidney transplantation. Despite the lack of efficacious and"/>
   <result pre="of a cDNA clone derived from a blood-borne non-A, non-B" exact="viral hepatitis" post="genome Science1989244359622523562 2AlterHJSeeffLBRecovery, persistence, and sequelae in hepatitis C"/>
   <result pre="a cDNA clone derived from a blood-borne non-A, non-B viral" exact="hepatitis" post="genome Science1989244359622523562 2AlterHJSeeffLBRecovery, persistence, and sequelae in hepatitis C"/>
   <result pre="non-B viral hepatitis genome Science1989244359622523562 2AlterHJSeeffLBRecovery, persistence, and sequelae in" exact="hepatitis" post="C virus infection: A perspective on long-term outcome Semin"/>
   <result pre="A perspective on long-term outcome Semin Liver Dis200020173510895429 3TsuiJIVittinghoffEShlipakMGO’HareAMRelationship between" exact="hepatitis" post="C and chronic kidney disease: Results from the Third"/>
   <result pre="multifaceted disease. Reviewof extrahepatic manifestations Ann Intern Med1995123615207677303 10JohnsonRJGretchDRYamabeHet al.Membranoproliferative" exact="glomerulonephritis" post="associated with hepatitis C virus infection N Engl J"/>
   <result pre="extrahepatic manifestations Ann Intern Med1995123615207677303 10JohnsonRJGretchDRYamabeHet al.Membranoproliferative glomerulonephritis associated with" exact="hepatitis" post="C virus infection N Engl J Med1993328465707678440 11D’AmicoGRenal involvement"/>
   <result pre="C virus infection N Engl J Med1993328465707678440 11D’AmicoGRenal involvement in" exact="hepatitis" post="C infection: Cryoglobulinemic glomerulonephritis Kidney Int199854650719690235 12SabryAASobhMAIrvingWLet al.A comprehensive"/>
   <result pre="Engl J Med1993328465707678440 11D’AmicoGRenal involvement in hepatitis C infection: Cryoglobulinemic" exact="glomerulonephritis" post="Kidney Int199854650719690235 12SabryAASobhMAIrvingWLet al.A comprehensive study of the association"/>
   <result pre="Kidney Int199854650719690235 12SabryAASobhMAIrvingWLet al.A comprehensive study of the association between" exact="hepatitis" post="C virus and glomerulopathy Nephrol Dial Transplant2002172394511812873 13RothD1GaynorJJReddyKRet al.Effect"/>
   <result pre="of immunosuppressive regimen on survival of kidney transplant recipients with" exact="hepatitis" post="C Transplantation2008851601618551066 16TangIYWalzerNAggarwalNet al.Management of the kidney transplant patient"/>
   <result pre="Transplantation2008851601618551066 16TangIYWalzerNAggarwalNet al.Management of the kidney transplant patient with chronic" exact="hepatitis" post="C infection Int J Nephrol20112011245823doi: 10.4061/2011/245823. Epub 2011 Apr"/>
   <result pre="new? Am J Transplant201414220620doi: 10.1111/ajt.12835. Epub 2014 Aug 425091274 18SperlJFrankováSSpicákJ[Viral" exact="hepatitis" post="in immunosuppressed patients] Klin Mikrobiol Infekc Lek201016120123[in Czech]20809462 19MangaSahin"/>
   <result pre="in renal transplant patients Transplant Proc2005372086815964346 25KamarNRostaingLSelvesJet al.Natural history of" exact="hepatitis" post="C virus-related liver fibrosis after renal transplantation Am J"/>
   <result pre="renal transplantation Am J Transplant2005517041215943629 26BaidSCosimiABTolkoff-RubinNet al.Renal disease associated with" exact="hepatitis" post="C infection after kidney and liver transplantation Transplantation2000702556110933143 27CruzadoJMBestardOGrinyoJMImpact"/>
   <result pre="Transplantation2000702556110933143 27CruzadoJMBestardOGrinyoJMImpact of extrahepatic complications (diabetes and glomerulonephritis) associated with" exact="hepatitis" post="C virus infection after renal transplantation Contrib Nephrol20121761081622310786 28TangSCLaiKNHepatitis"/>
   <result pre="virus infection after renal transplantation Contrib Nephrol20121761081622310786 28TangSCLaiKNHepatitis C virus-associated" exact="glomerulonephritis" post="Contrib Nephrol201318119420623689581 29MilnerKLvander Poorten DTrenellMet al.Chronic hepatitis C is"/>
   <result pre="28TangSCLaiKNHepatitis C virus-associated glomerulonephritis Contrib Nephrol201318119420623689581 29MilnerKLvander Poorten DTrenellMet al.Chronic" exact="hepatitis" post="C is associated with peripheral rather than hepatic insulin"/>
   <result pre="10.1053/j.gastro.2009.11.050. Epub 2009 Dec 4.19962985 30MoucariRAsselahTCazals-HatemDet al.Insulin resistance in chronic" exact="hepatitis" post="C: Association with genotypes 1 and 4, serum HCV"/>
   <result pre="RNA level, and liver fibrosis200813441623 31MehtaSHBrancatiFLSulkowskiMSet al.Prevalence of type 2" exact="diabetes mellitus" post="among persons with hepatitis C virus infection in the"/>
   <result pre="31MehtaSHBrancatiFLSulkowskiMSet al.Prevalence of type 2 diabetes mellitus among persons with" exact="hepatitis" post="C virus infection in the United States Ann Intern"/>
   <result pre="virus infection in the United States Ann Intern Med2000133592911033586 32ZeinCOLevyCBasuAZeinNNChronic" exact="hepatitis" post="C and type II diabetes mellitus: A prospective cross-sectional"/>
   <result pre="systematic review and meta-analysis J Hepatol2008498314418814931 34PereiraBJWrightTLSchmidCHLeveyASThe impact of pretransplantation" exact="hepatitis" post="C infection on the outcome of renal transplantation Transplantation1995607998057482738"/>
   <result pre="C infection on the outcome of renal transplantation Transplantation1995607998057482738 35RaoKVMaJChronic" exact="viral hepatitis" post="enhances the risk of infection but not acute rejection"/>
   <result pre="infection on the outcome of renal transplantation Transplantation1995607998057482738 35RaoKVMaJChronic viral" exact="hepatitis" post="enhances the risk of infection but not acute rejection"/>
   <result pre="rejection in renal transplant recipients Transplantation199662176598990359 36RothDZuckerKCiroccoRet al.The impact of" exact="hepatitis" post="C virus infection on renal allograft recipients Kidney Int199445238447510350"/>
   <result pre="infection on renal allograft recipients Kidney Int199445238447510350 37MatsuoKKusanoASugumarAet al.Effect of" exact="hepatitis" post="C virus infection on the risk of non-Hodgkin’s lymphoma:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5644647/results/search/disease/results.xml">
   <result pre="and prolong life expectancy [16]. In placebo-controlled trials, zidovudine improved" exact="stomatitis" post="and increased the CD4/CD8 ratio in naturally FIV-infected cats."/>
   <result pre="blood cell counts are necessary during zidovudine treatment because non-regenerative" exact="anemia" post="is a common side effect [28]. Cats with bone"/>
   <result pre="is a common side effect [28]. Cats with bone marrow" exact="suppression" post="should not be treated with zidovudine. Most FIV-infected cats"/>
   <result pre="hematocrit drops below 20%, discontinuation of treatment is recommended, and" exact="anemia" post="usually resolves within a few days. Other side effects"/>
   <result pre="didanosine, but treatment contributed to the development of antiretroviral toxic" exact="neuropathy" post="[39]. 2.4. Lamivudine Lamivudine (2R,cis-4-amino-l-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, 3TC) is also an"/>
   <result pre="oral formulation (bis-POM PMEA) approved for the treatment of chronic" exact="hepatitis" post="B. Adefovir belongs to the acyclic nucleoside phosphonates, in"/>
   <result pre="agent and for the treatment of some tumors, such as" exact="prostate cancer" post="[58]. It also has an inhibitory effect on the"/>
   <result pre="and for the treatment of some tumors, such as prostate" exact="cancer" post="[58]. It also has an inhibitory effect on the"/>
   <result pre="classified as an NNRTI [60]. Suramin is effective against feline" exact="leukemia" post="virus (FeLV) in vivo [61,62], and thus, could potentially"/>
   <result pre="peripheral neuritis leading to palmar-plantar hyperesthesia, photophobia, skin reactions, agranulocytosis," exact="hemolytic anemia," post="and destruction of the adrenal cortex as later side"/>
   <result pre="It is FDA-approved for the treatment of HIV-associated cytomegalo and" exact="herpes simplex" post="virus infections in humans [67]. Foscarnet is usually administered"/>
   <result pre="chelates various cations, which can lead to hypocalcemia, hypomagnesemia, and" exact="hypokalemia" post="[69,70]. In vitro, foscarnet has been shown to be"/>
   <result pre="toxic effect on bone marrow, primarily on megakaryocytes, resulting in" exact="thrombocytopenia" post="and hemorrhage. With prolonged ribavirin treatment or at higher"/>
   <result pre="which prevents the spread of virus from infected cells and" exact="aids" post="in the clearance of virus infection [97]. Human IFNs"/>
   <result pre="36.TavaresL.RonekerC.PostieL.de NoronhaF.Testing of nucleoside analogues in cats infected with feline" exact="leukemia" post="virus: A modelIntervirology19893026352540111 37.MitsuyaH.BroderS.Inhibition of the in vitro infectivity"/>
   <result pre="immunodeficiency virus resistant to 2',3'-dideoxycytidineAntimicrob. Agents Chemother.1996409539578849258 39.ZhuY.AntonyJ.M.MartinezJ.A.GlerumD.M.BrusseeV.HokeA.ZochodneD.PowerC.Didanosine causes sensory" exact="neuropathy" post="in an HIV/AIDS animal model: Impaired mitochondrial and neurotrophic"/>
   <result pre="9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and mdl 74,968] in cell cultures and murine" exact="sarcoma" post="virus-infected newborn nmri miceAntimicrob. Agents Chemother.1997416116169056002 46.BalzariniJ.NaesensL.SlachmuyldersJ.NiphuisH.RosenbergI.HolyA.SchellekensH.de ClercqE.9-(2-phosphonylmethoxyethyl)adenine (PMEA)"/>
   <result pre="presenting as Kaposi’s Sarcoma or AIDS-related complex: Clinical pharmacology and" exact="suppression" post="of virus replication in vivoLancet1985262763010.1016/S0140-6736(85)90002-92863631 60.De ClercqE.Suramin: A potent"/>
   <result pre="Lett.1979892210.1016/0304-3835(79)90017-X92362 61.CoganD.C.CotterS.M.KitchenL.W.Effect of suramin on serum viral replication in feline" exact="leukemia" post="virus-infected pet catsAm. J. Vet. Res.198647223022323022623 62.AbkowitzJ.L.Retrovirus-induced feline pure"/>
   <result pre="polymerasesAm. J. Med.1992923S7S10.1016/0002-9343(92)90329-A 67.WangY.SmithK.P.Safety of alternative antiviral agents for neonatal" exact="herpes simplex" post="virus encephalitis and disseminated infectionJ. Pediatr. Pharmacol. Ther.201419728210.5863/1551-6776-19.2.7225024666 68.StrawJ.A.LooT.L.de"/>
   <result pre="67.WangY.SmithK.P.Safety of alternative antiviral agents for neonatal herpes simplex virus" exact="encephalitis" post="and disseminated infectionJ. Pediatr. Pharmacol. Ther.201419728210.5863/1551-6776-19.2.7225024666 68.StrawJ.A.LooT.L.de VeraC.C.NelsonP.D.TompkinsW.A.BaiS.A.Pharmacokinetics of"/>
   <result pre="induced by raltegravir resistance mutationsJ. Mol. Recognit.20092248049410.1002/jmr.97019623602 90.CattoriV.WeibelB.LutzH.Inhibition of feline" exact="leukemia" post="virus replication by the integrase inhibitor raltegravirVet. Microbiol.201115216516810.1016/j.vetmic.2011.03.03921570781 91.GreggsW.M.3rdClouserC.L.PattersonS.E.ManskyL.M.Discovery"/>
   <result pre="raltegravirVet. Microbiol.201115216516810.1016/j.vetmic.2011.03.03921570781 91.GreggsW.M.3rdClouserC.L.PattersonS.E.ManskyL.M.Discovery of drugs that possess activity against feline" exact="leukemia" post="virusJ. Gen. Virol.20129390090510.1099/vir.0.039909-022258856 92.TogamiH.ShimuraK.OkamotoM.YoshikawaR.MiyazawaT.MatsuokaM.Comprehensive in vitro analysis of simian"/>
   <result pre="integrase inhibitor raltegravir (Isentress) on the course of progressive feline" exact="leukemia" post="virus infectionVet. Microbial.201517516717810.1016/j.vetmic.2014.10.03125500005 94.DomenechA.MiroG.ColladoV.M.BallesterosN.SanjoseL.EscolarE.MartinS.Gomez-LuciaE.Use of recombinant interferon omega in"/>
   <result pre="melanoma: Final results of a phase I–II study of the" exact="cancer" post="biotherapy research group and the mid-atlantic oncology programCancer1998821677168110.1002/(SICI)1097-0142(19980501)82:9&amp;lt;1677::AID-CNCR13&amp;gt;3.0.CO;2-19576288 96.GilS.LealR.O.DuarteA.McGahieD.SepulvedaN.SiborroI.CravoJ.CartaxeiroC.TavaresL.M.Relevance"/>
   <result pre="in combination with zidovudine for the treatment of presymptomatic feline" exact="leukemia" post="virus-induced immunodeficiency syndromeAntimicrob. Agents Chemother.1990341749175610.1128/AAC.34.9.17492178336 101.CantellK.PyhalaL.Circulating interferon in rabbits"/>
   <result pre="Immunopathol.200610924525410.1016/j.vetimm.2005.08.02016169599 107.De MariK.MaynardL.SanquerA.LebreuxB.EunH.M.Therapeutic effects of recombinant feline interferon-omega on feline" exact="leukemia" post="virus (FELV)-infected and FELV/feline immunodeficiency virus (FIV)-coinfected symptomatic catsJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5753465/results/search/disease/results.xml">
   <result pre="that could be used to treat antihistamine and relieve other" exact="allergy" post="symptoms [10]. Additionnaly, ReDuNing (RDN) medicine a patented traditional"/>
   <result pre="activation and inhibition of endogenous miRNAs try to fight against" exact="dengue fever" post="that includes effects on the initial Immune reaction. The"/>
   <result pre="with RDN as an herbal drug in the treatment of" exact="dengue fever," post="all active expression miRNAs and their targets were utilized"/>
   <result pre="of DDX3X may lead to treat dengue infection [35]. The" exact="suppression" post="of PTEN gene represents a powerful strategy for ESCC"/>
   <result pre="that influence to inflammation [46]. Herbal medicine probably controls the" exact="infectious disease" post="mainly based on immunomodulatory agents stimulation (such as GSK3B,"/>
   <result pre="DENV is presently a global infection and it is a" exact="viral disease" post="for which there is no licensed therapeutic agent [53]."/>
   <result pre="the most important factors transmitted by mosquitoes worldwide and causing" exact="viral disease," post="almost 100 million cases of dangerous DENV each year,"/>
   <result pre="life-threatening [54]. Direct anti-virus treatment that reduces the risk of" exact="dengue fever" post="can be helpful although this may need to keep"/>
   <result pre="in mammals, revealed that the miRNAs profiles were reshaped by" exact="hepatitis" post="C virus and miRNAs of human might have been"/>
   <result pre="targeting viral transcripts with host miRNAs [62]. To reduce the" exact="dengue fever" post="impact using a potential anti-dengue medicine, we administered several"/>
   <result pre="C [63], whereas Acetaminophen treatment may have little effect during" exact="dengue fever" post="treatment. Furthermore the potential of RDN and LRD against"/>
   <result pre="[64, 65] Reported that RDN could inhibit the susceptibility of" exact="influenza" post="in restraint-stressed mice, through RDN down-regulating NF-kB activation to"/>
   <result pre="flatus, and detoxification, clinically used in the curative of hyperpyrexia," exact="influenza" post="and body pain, cough, yellow sputum, and other symptoms"/>
   <result pre="that lowering viremia may reduce morbidity and the risk of" exact="dengue hemorrhagic fever" post="or dengue shock syndrome. Infected mice by dengue showing"/>
   <result pre="12.TangL-PMaoZ-FLiX-XChenMLiS-BTsoiBCaoL-FLiLZengJ-MWangZ-WReDuNing, a patented Chinese medicine, reduces the susceptibility to H1N1" exact="influenza" post="of mice loaded with restraint stressEuropean J Integrative Med20146663764510.1016/j.eujim.2014.07.018"/>
   <result pre="site gene, is involved in cellular stress responseOncogene200625202901290810.1038/sj.onc.120931416462772 38.FriesenhagenJViemannDBörgelingYSchmolkeMSpiekermannCKirschnekSLudwigSRothJHighly pathogenic" exact="influenza" post="viruses inhibit inflammatory response in Monocytes via activation of"/>
   <result pre="dengue in childrenTropical Med Health201442413710.2149/tmh.2014-09 46.ThalhamerTMcGrathMHarnettMMAPKs and their relevance to" exact="arthritis" post="and inflammationRheumatology200847440941410.1093/rheumatology/kem29718187523 47.YangHZhangWHuangCZhouWYaoYWangZLiYXiaoWWangYA novel systems pharmacology model for herbal"/>
   <result pre="212(12):2011–2020. 50.YuexiaMWeiZZhongpengZMinLJianLYuguangWCombination of ribavirin and reduning protects mice against severe" exact="pneumonia" post="induced by H1N1 influenza a virusJ Tradit Chin Med201636218118610.1016/S0254-6272(16)30025-527400472"/>
   <result pre="and reduning protects mice against severe pneumonia induced by H1N1" exact="influenza" post="a virusJ Tradit Chin Med201636218118610.1016/S0254-6272(16)30025-527400472 51.MairuhuAMac GillavryMSetiatiTSoemantriATen CateHBrandjesDvan GorpEIs"/>
   <result pre="by targeting microRNAN Engl J Med2013368181685169410.1056/NEJMoa120902623534542 63.CastroEFFabianLECaputtoMEGageyDFinkielszteinLMMoltrasioGYMoglioniAGCamposRHCavallaroLVInhibition of bovine viral" exact="diarrhea" post="virus RNA synthesis by thiosemicarbazone derived from 5, 6-dimethoxy-1-indanoneJ"/>
   <result pre="lipopolysaccharide-induced acute lung injury of ratsChinese J Integrative Med201420859159910.1007/s11655-014-1758-x 66.SchulWLiuWXuH-YFlamandMVasudevanSGA" exact="dengue fever" post="viremia model in mice shows reduction in viral replication"/>
   <result pre="viremia model in mice shows reduction in viral replication and" exact="suppression" post="of the inflammatory response after treatment with antiviral drugsJ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC5923505/results/search/disease/results.xml">
   <result pre="herpesviruses, zidovudine for human immunodeficiency virus (HIV), and sofosbuvir for" exact="hepatitis" post="C virus (HCV)) have been successful in clinical trials"/>
   <result pre="of RNA viruses, including Middle East respiratory syndrome coronavirus (MERS-CoV)," exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV), Zika virus (ZIKV), HCV, poliovirus (PV), influenza"/>
   <result pre="respiratory syndrome coronavirus (SARS-CoV), Zika virus (ZIKV), HCV, poliovirus (PV)," exact="influenza" post="A virus (IAV), HIV, and enteroviruses (EV) [13,14,15,16,17,18]. The"/>
   <result pre="can infect pregnant women and cause congenital abnormalities such as" exact="microcephaly" post="in infants, which has attracted increasing public attention as"/>
   <result pre="respectively [17,19], which were lower concentrations than those used in" exact="cancer" post="therapy [20]. In the case of HIV, the combination"/>
   <result pre="gemcitabine with decitabine, another nucleoside analog in clinical use for" exact="cancer" post="therapy, synergistically reduced HIV infectivity by increasing the viral"/>
   <result pre="reported the antiviral effect of gemcitabine against HIV-related retrovirus, murine" exact="leukemia" post="virus (MuLV), in vitro (EC50 of 1.6 nM) and"/>
   <result pre="and found its strong inhibitory effect on Sindbis virus and" exact="herpes simplex" post="virus-1 (HSV-1) (&amp;gt;2 log reduction in virus titer) but"/>
   <result pre="and human echovirus 6, and minimal effects on Bunyamwera virus," exact="measles" post="virus (MeV), and vaccinia virus [16]. The antiviral effect"/>
   <result pre="and minimal effects on Bunyamwera virus, measles virus (MeV), and" exact="vaccinia virus" post="[16]. The antiviral effect of gemcitabine on EVs, initially"/>
   <result pre="low nanomolar EC50, which was lower than that used in" exact="cancer" post="therapy [14,20]. Even for other viruses with a relatively"/>
   <result pre="decades. Both have antiviral activities against viruses such as HCV," exact="hepatitis" post="E virus (HEV), MERS-CoV, dengue virus, yellow fever, hepatitis"/>
   <result pre="such as HCV, hepatitis E virus (HEV), MERS-CoV, dengue virus," exact="yellow fever," post="hepatitis B virus, West Nile virus (WNV), Chikungunya virus"/>
   <result pre="HCV, hepatitis E virus (HEV), MERS-CoV, dengue virus, yellow fever," exact="hepatitis" post="B virus, West Nile virus (WNV), Chikungunya virus (CHIKV),"/>
   <result pre="1.JordheimL.P.DurantelD.ZoulimF.DumontetC.Advances in the development of nucleoside and nucleotide analogues for" exact="cancer" post="and viral diseasesNat. Rev. Drug Discov.20131244746410.1038/nrd401023722347 2.ElionG.B.The purine path"/>
   <result pre="2.ElionG.B.The purine path to chemotherapyScience1989244414710.1126/science.26499792649979 3.WhitleyR.J.AlfordC.A.HirschM.S.SchooleyR.T.LubyJ.P.AokiF.Y.HanleyD.NahmiasA.J.SoongS.J.Vidarabine versus acyclovir therapy in" exact="herpes simplex" post="encephalitisN. Eng. J. Med.198631414414910.1056/NEJM1986011631403033001520 4.KahnJ.O.LagakosS.W.RichmanD.D.CrossA.PettinelliC.LiouS.H.BrownM.VolberdingP.A.CrumpackerC.S.BeallG.et al.A controlled trial comparing"/>
   <result pre="zidovudine with didanosine in human immunodeficiency virus infection. The niaid" exact="aids" post="clinical trials groupN. Eng. J. Med.199232758158710.1056/NEJM1992082732709011353607 5.LawitzE.MangiaA.WylesD.Rodriguez-TorresM.HassaneinT.GordonS.C.SchultzM.DavisM.N.KayaliZ.ReddyK.R.et al.Sofosbuvir for"/>
   <result pre="groupN. Eng. J. Med.199232758158710.1056/NEJM1992082732709011353607 5.LawitzE.MangiaA.WylesD.Rodriguez-TorresM.HassaneinT.GordonS.C.SchultzM.DavisM.N.KayaliZ.ReddyK.R.et al.Sofosbuvir for previously untreated chronic" exact="hepatitis" post="C infectionN. Eng. J. Med.20133681878188710.1056/NEJMoa121485323607594 6.ThomasE.FeldJ.J.LiQ.HuZ.FriedM.W.LiangT.J.Ribavirin potentiates interferon action"/>
   <result pre="6.ThomasE.FeldJ.J.LiQ.HuZ.FriedM.W.LiangT.J.Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in" exact="hepatitis" post="c virus cell culture modelsHepatology201153324110.1002/hep.2398521254160 7.LeyssenP.BalzariniJ.de ClercqE.NeytsJ.The predominant mechanism"/>
   <result pre="by inhibition of imp dehydrogenaseJ. Virol.2005791943194710.1128/JVI.79.3.1943-1947.200515650220 8.DebingY.EmersonS.U.WangY.PanQ.BalzariniJ.DallmeierK.NeytsJ.Ribavirin inhibits in vitro" exact="hepatitis" post="e virus replication through depletion of cellular gtp pools"/>
   <result pre="talk between nucleotide synthesis pathways with cellular immunity in constraining" exact="hepatitis" post="e virus replicationAntimicrob. Agents Chemother.2016602834284810.1128/AAC.02700-1526926637 11.HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG.A.ToddG.C.GrindeyG.B.Evaluation of the antitumor"/>
   <result pre="antipoliovirus agentACS Infect. Dis.20173455310.1021/acsinfecdis.6b0011627733043 16.DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.et al.Obatoclax, saliphenylhalamide, and gemcitabine inhibit" exact="influenza" post="a virus infectionJ. Biol. Chem.2012287353243533210.1074/jbc.M112.39214222910914 17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel"/>
   <result pre="inhibitor from an hsp90 inhibitor as a selective inhibitor of" exact="hepatitis" post="C virusPLoS ONE20127e3028610.1371/journal.pone.003028622347373 20.GrunewaldR.KantarjianH.DuM.FaucherK.TarassoffP.PlunkettW.Gemcitabine in leukemia: A phase I"/>
   <result pre="and broad-spectrum in vitro antiviral activity against pandemic, seasonal and" exact="avian influenza" post="viruses affecting humansJ. Gen. Virol.2016971807181710.1099/jgv.0.00051227259985 25.MorreyJ.D.SmeeD.F.SidwellR.W.TsengC.Identification of active antiviral"/>
   <result pre="broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian" exact="influenza" post="viruses affecting humansJ. Gen. Virol.2016971807181710.1099/jgv.0.00051227259985 25.MorreyJ.D.SmeeD.F.SidwellR.W.TsengC.Identification of active antiviral"/>
   <result pre="enzyme activity is a potential target for the inhibition of" exact="chikungunya" post="virus replication and virus induced apoptosis in cultured mammalian"/>
   <result pre="der LaanL.J.NeytsJ.JanssenH.L.MetselaarH.J.PeppelenboschM.P.PanQ.Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of" exact="hepatitis" post="E virusGastroenterology20141461775178310.1053/j.gastro.2014.02.03624582714 30.PanQ.de RuiterP.E.MetselaarH.J.KwekkeboomJ.de JongeJ.TilanusH.W.JanssenH.L.van der LaanL.J.Mycophenolic acid augments"/>
   <result pre="JongeJ.TilanusH.W.JanssenH.L.van der LaanL.J.Mycophenolic acid augments interferon-stimulated gene expression and inhibits" exact="hepatitis" post="C virus infection in vitro and in vivoHepatology2012551673168310.1002/hep.2556222213147 31.PanattoniA.D’AnnaF.TrioloE.Antiviral"/>
   <result pre="Sci. USA20111086739674410.1073/pnas.101714210821502533 41.WangQ.Y.BushellS.QingM.XuH.Y.BonaviaA.NunesS.ZhouJ.PohM.K.Florez de SessionsP.NiyomrattanakitP.et al.Inhibition of dengue virus through" exact="suppression" post="of host pyrimidine biosynthesisJ. Virol.2011856548655610.1128/JVI.02510-1021507975 42.SmeeD.F.HurstB.L.DayC.W.D282, a non-nucleoside inhibitor"/>
   <result pre="of host pyrimidine biosynthesisJ. Virol.2011856548655610.1128/JVI.02510-1021507975 42.SmeeD.F.HurstB.L.DayC.W.D282, a non-nucleoside inhibitor of" exact="influenza" post="virus infection that interferes with de novo pyrimidine biosynthesisAntivir."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6025560/results/search/disease/results.xml">
   <result pre="occurring during childhood and usually asymptomatic. However, EBV can cause" exact="infectious mononucleosis" post="in approximately 35–50% cases when infection occurs during adolescence"/>
   <result pre="by the commonest infection caused by EBV in Western countries:" exact="infectious mononucleosis" post="(IM). First, its onset is insidious with nondescript sore"/>
   <result pre="with antiviral and immunosuppressive drugs might have an impact on" exact="infectious mononucleosis." post="However, in trials in which corticosteroid and antiviral drugs"/>
   <result pre="latent infection have materialized over the decades. Accordingly, despite prolonged" exact="suppression" post="of viral replication, some latently infected cells will persist"/>
   <result pre="with brivudin (BVDU), they are approved for the therapy of" exact="herpes simplex" post="virus 1 (HSV-1) and varicella-zoster virus (VZV) associated diseases."/>
   <result pre="clinical symptoms or development of EBV-specific cellular immunity [1,7]. The" exact="hepatitis" post="associated with IM has been shown to be accompanied"/>
   <result pre="with VALM (http://www.epiphanybio.com) include a randomized, placebo-controlled, double-blind trial for" exact="infectious mononucleosis" post="[ClinicalTrials.gov Trial: NCT00575185]. Subjects over the age of 15"/>
   <result pre="through a mechanism that remains unclear. In experiments with EBV-positive" exact="nasopharyngeal carcinoma" post="(NPC) xenografts in nude mice, injection into the tumor"/>
   <result pre="enhanced cidofovir-induced apoptosis in EBV-transformed epithelial cells and in EBV-positive" exact="nasopharyngeal carcinoma" post="xenografts [31]. 10. Thymidine Derivatives L-dioxolane thymidine derivatives were"/>
   <result pre="K. Acad. Geneeskd. Belg.2001639312011436421 30.YoshizakiT.WakisakaN.KondoS.MuronoS.ShimizuY.NakashimaM.TsujiA.FurukawaM.Treatment of locally recurrent Epstein-Barr virus-associated" exact="nasopharyngeal carcinoma" post="using the anti-viral agent cidofovirJ. Med. Virol.20088087988210.1002/jmv.2116518360900 31.WakisakaN.YoshizakiT.Raab-TraubN.PaganoJ.S.Ribonucleotide reductase"/>
   <result pre="Med. Virol.20088087988210.1002/jmv.2116518360900 31.WakisakaN.YoshizakiT.Raab-TraubN.PaganoJ.S.Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive" exact="nasopharyngeal carcinoma" post="xenograftsInt. J. Cancer200511664064510.1002/ijc.2109615818619 32.CoenN.SinghU.VuyyuruV.Van den OordJ.J.BalzariniJ.DuraffourS.SnoeckR.ChengY.C.ChuC.K.AndreiG.Activity and mechanism of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6027266/results/search/disease/results.xml">
   <result pre="(ABCC1 or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and" exact="breast cancer" post="resistance protein (ABCG2 or BCRP). Inhibitors of AETs may"/>
   <result pre="or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and breast" exact="cancer" post="resistance protein (ABCG2 or BCRP). Inhibitors of AETs may"/>
   <result pre="Herpes Simplex Virus type 1 (HSV-1) can cause potentially fatal" exact="encephalitis" post="in developed countries [5,6]. Finally, mice intra-nasally infected by"/>
   <result pre="Encephalitis Virus (VEEV) show a CNS phase that results in" exact="encephalitis" post="and death [7,8,9]. Human Immunodeficiency Virus type-1 (HIV-1) belongs"/>
   <result pre="The presence of HIV in the brain can lead to" exact="dementia" post="in the more severe cases [13,14]. The CNS therefore"/>
   <result pre="can cause severe side effects, such as lipodystrophy, diabetes, and" exact="cardiovascular disease" post="[21]. 2. Active Efflux Transporters Do Not Allow the"/>
   <result pre="aspects into account, it has been suggested that the targeted" exact="suppression" post="of P-gp expression in the HIV-1-infected reservoirs of the"/>
   <result pre="against neurotropic viral effects was tested on mice infected by" exact="herpes simplex" post="virus type 1 (HSV-1). In particular, mice models of"/>
   <result pre="virus type 1 (HSV-1). In particular, mice models of HSV-1" exact="encephalitis" post="received an intranasal pretreatment with the immunostimulant polyinosinic:polycytidylic acid"/>
   <result pre="canine distemper virus (CDV) and also indicated for treatment of" exact="hepatitis" post="C [84], allowed investigators to obtain drug concentrations in"/>
   <result pre="induces a reduction in viral replication as evidenced by the" exact="suppression" post="of supernatant HIV-1 p24 levels and by the reduction"/>
   <result pre="United States and CanadaClin. Microbiol. Rev.199478911610.1128/CMR.7.1.898118792 2.HuneycuttB.S.BiZ.AokiC.J.ReissC.S.Central neuropathogenesis of vesicular" exact="stomatitis" post="virus infection of immunodeficient miceJ. Virol.199367669867068105106 3.Van den PolA.N.DaltonK.P.RoseJ.K.Relative"/>
   <result pre="fluorescent envelope glycoproteinJ. Virol.2002761309132710.1128/JVI.76.3.1309-1327.200211773406 4.Van den PolA.N.DavisJ.N.Highly attenuated recombinant vesicular" exact="stomatitis" post="virus VSV-12’GFP displays immunogenic and oncolytic activityJ. Virol.2013871019103410.1128/JVI.01106-1223135719 5.TylerK.L.Update"/>
   <result pre="virus VSV-12’GFP displays immunogenic and oncolytic activityJ. Virol.2013871019103410.1128/JVI.01106-1223135719 5.TylerK.L.Update on" exact="herpes simplex" post="encephalitisRev. Neurol. Dis.2004116917816400278 6.WhitleyR.J.KimberlinD.W.Herpes simplex encephalitis: Children and adolescentsSemin."/>
   <result pre="vivo define early steps in the pathogenesis of Venezuelan equine" exact="encephalitis" post="virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of Venezuelan equine encephalitis"/>
   <result pre="equine encephalitis virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of Venezuelan equine" exact="encephalitis" post="virus-induced disease in the mouseVirology200128419020210.1006/viro.2001.087811384219 9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach"/>
   <result pre="9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach to the study of Venezuelan equine" exact="encephalitis" post="virus pathogenesisArch. Virol. Suppl.19949991098032286 10.PomerantzR.J.Reservoirs, sanctuaries and residual disease:"/>
   <result pre="into the central nervous system?Curr. Pharm. Des.2011173560357610.2174/13816121179819448622074427 28.PavanB.PaganettoG.RossiD.DalpiazA.Multidrug resistance in" exact="cancer" post="or inefficacy of neuroactive agents: Innovative strategies to inhibit"/>
   <result pre="protease inhibitors are inhibitors but not substrates of the human" exact="breast cancer" post="resistance protein (BCRP/ABCG2)J. Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein"/>
   <result pre="inhibitors are inhibitors but not substrates of the human breast" exact="cancer" post="resistance protein (BCRP/ABCG2)J. Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein"/>
   <result pre="drugs in human brain microvessel endothelial cellsAntimicrob. Agents Chemother.2013574481448810.1128/AAC.00486-1323836171 65.ShuklaS.OhnumaS.AmbudkarS.V.Improving" exact="cancer" post="chemotherapy with modulators of ABC drug transportersCurr. Drug Targets20111262163010.2174/13894501179537854021039338"/>
   <result pre="pretreatment with toll-like receptor agonists in a mouse model of" exact="herpes simplex" post="virus type 1 encephalitisJ. Infect. Dis.200819866467210.1086/59067118662130 84.EliaG.BelloliC.CironeF.LucenteM.S.CarusoM.MartellaV.DecaroN.BuonavogliaC.OrmasP.In vitro efficacy"/>
   <result pre="potent humoural immunityArtif. Cells Nanomed. Biotechnol.2018151910.1080/21691401.2018.143845029447484 92.HuliszD.Efficacy of zinc against" exact="common cold" post="viruses: An overviewJ. Am. Pharm. Assoc.20044459460310.1331/1544-3191.44.5.594.Hulisz 93.SeremetaK.P.ChiappettaD.A.SosnikA.Poly(ε-caprolactone), Eudragit® RS"/>
   <result pre="Res.1992933233810.1023/A:10158347011361614966 112.CunninghamA.L.NaifH.SaksenaN.LynchG.ChangJ.LiS.JozwiakR.AlaliM.WangB.FearW.et al.HIV infection of macrophages and pathogenesis of AIDS" exact="dementia" post="complex: Interaction of the host cell and viral genotypeJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6439212/results/search/disease/results.xml">
   <result pre="S1319-0164(18)30213-5 doi: 10.1016/j.jsps.2018.12.008 : Article Plant-derived antiviral drugs as novel" exact="hepatitis" post="B virus inhibitors: Cell culture and molecular docking study"/>
   <result pre="causes acute and chronic liver diseases, including fulminant liver failure," exact="cirrhosis" post="and hepatocellular carcinoma, affecting about two billion of world"/>
   <result pre="and chronic liver diseases, including fulminant liver failure, cirrhosis and" exact="hepatocellular carcinoma," post="affecting about two billion of world population (Teo and"/>
   <result pre="2010). Of these, an estimated 240 million individuals with chronic" exact="hepatitis" post="B (CHB) live in high to moderate endemic regions"/>
   <result pre="all the approved drugs against human immunodeficiency virus (HIV) and" exact="herpes simplex" post="virus (HSV) have been proved effective against HBV. Unfortunately,"/>
   <result pre="standard (positive control). 2.2 Cell culture HBV-reporter cells, HepG2.2.15 (human" exact="hepatoblastoma" post="line, HepG2-derived) were kindly obtained from Dr. S. Jameel"/>
   <result pre="active principle of Embelia schimperi, embelin is shown to inhibit" exact="hepatitis" post="C virus (HCV) serine protease activity (Hussein et al.,"/>
   <result pre="flavonol has been reported for in vitro antiviral activities against" exact="avian influenza" post="virus (H5N1) and murine norovirus (MNV) (Carvalho et al.,"/>
   <result pre="has been reported for in vitro antiviral activities against avian" exact="influenza" post="virus (H5N1) and murine norovirus (MNV) (Carvalho et al.,"/>
   <result pre="reported to have in vitro inhibitory activities against human and" exact="avian influenza" post="A viruses (Saha et al., 2009). Our present data"/>
   <result pre="to have in vitro inhibitory activities against human and avian" exact="influenza" post="A viruses (Saha et al., 2009). Our present data"/>
   <result pre="of novel antiviral activities of 60 medicinal plants extract against" exact="hepatitis" post="B virusExp. Ther. Med.14201762663428672977 ArnoldK.BordoliL.KoppJ.SchwedeT.The Swiss-Model workspace: a web-based"/>
   <result pre="antiviral designRes. Vet. Sci.95201371772423664014 ChangJ.S.LiuH.-W.WangK.-C.ChenM.-C.ChiangL.-C.Ethanol extract of polygonum cuspidatum inhibits" exact="hepatitis" post="B virus in a stable HBV-producing cell lineAntiviral Res.662005293415781129"/>
   <result pre="Viral Hep.202013445452 ChenH.C.ChouC.K.LeeS.D.WangJ.C.YehS.F.Active compounds from saussurea lappa clarks that suppress" exact="hepatitis" post="B virus surface antigen gene expression in human hepatoma"/>
   <result pre="antigen gene expression in human hepatoma cellsAntiviral Res.271995991097486962 ChengZ.SunG.GuoW.HuangY.SunW.ZhaoF.HuK.Inhibition of" exact="hepatitis" post="B virus replication by quercetin in human hepatoma cell"/>
   <result pre="replicationArch. Virol.16020152353235826112762 ChoiH.J.KimJ.H.LeeC.H.AhnY.J.Antiviral activity of quercetin 7-rhamnoside against porcine epidemic" exact="diarrhea" post="virusAntiviral Res.812009778118992773 ChiowK.H.PhoonM.C.PuttiT.TanB.K.ChowV.T.Evaluation of antiviral activities of Houttuynia cordata"/>
   <result pre="infection and AIDSJ. Acquir. Immune Defic. Syndr.61993S32S358426300 DagaP.R.DuanJ.S.DoerksenR.J.Computational model of" exact="hepatitis" post="B virus DNA polymerase: Molecular dynamics and docking to"/>
   <result pre="guangxienseChem. Biodivers.920121508151622899611 HusseinG.MiyashiroH.NakamuraN.HattoriM.KakiuchiN.ShimotohnoK.Inhibitory effects of sudanese medicinal plant extracts on" exact="hepatitis" post="C virus (HCV) proteasePhytother. Res.14200051051611054840 HussainW.HaleemK.S.KhanI.TauseefI.QayyumS.AhmedB.RiazM.N.Medicinal plants: a repository"/>
   <result pre="Juss) leaves on dengue virus type-2 replicationJ. Ethnopharmacol.79200227327811801392 ParvezM.K.SehgalD.SarinS.K.BasirS.F.JameelS.Inhibition of" exact="hepatitis" post="B virus DNA replicative intermediate forms by recombinant interferon-gammaWorld"/>
   <result pre="by recombinant interferon-gammaWorld J. Gastroenterol.1220063006301416718779 ParvezM.K.ArabA.H.Al-DosariM.S.Al-RehailyA.J.Antiviral natural products against chronic" exact="hepatitis" post="B: recent developmentsCurr. Pharm. Des.32016286293 QiuL.P.ChenK.-P.Anti-HBV agents derived from"/>
   <result pre="Inhibition of viral sialidaseBiol. Pharm. Bull.3220091188119219571383 ShafritzD.A.LiebermanH.M.The molecular biology of" exact="hepatitis" post="B virusAnnu. Rev. Med.3519842192326326660 TeoC.G.LocarniniS.A.Potential threat of drug-resistant and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6444013/results/search/disease/results.xml">
   <result pre="activity by different RdRps, illustrated here using purified RdRps from" exact="hepatitis" post="C virus and foot-and-mouth disease virus. The potential of"/>
   <result pre="of this family also include the human pathogens dengue virus," exact="yellow fever" post="virus, West Nile virus, tick-borne encephalitis virus, Japanese encephalitis"/>
   <result pre="human pathogens dengue virus, yellow fever virus, West Nile virus," exact="tick-borne encephalitis" post="virus, Japanese encephalitis virus and hepatitis C virus (HCV)1."/>
   <result pre="pathogens dengue virus, yellow fever virus, West Nile virus, tick-borne" exact="encephalitis" post="virus, Japanese encephalitis virus and hepatitis C virus (HCV)1."/>
   <result pre="yellow fever virus, West Nile virus, tick-borne encephalitis virus, Japanese" exact="encephalitis" post="virus and hepatitis C virus (HCV)1. ZIKV is an"/>
   <result pre="West Nile virus, tick-borne encephalitis virus, Japanese encephalitis virus and" exact="hepatitis" post="C virus (HCV)1. ZIKV is an arthropod-borne virus and"/>
   <result pre="in newborns. An increase in the incidence of GBS and" exact="microcephaly" post="has been associated with outbreaks of ZIKV in Micronesia"/>
   <result pre="RdRps from two distinct viruses: foot-and-mouth disease virus (FMDV) and" exact="hepatitis" post="C virus (HCV). The implications of these results for"/>
   <result pre="against non-RdRp viral polymerases, such as human immunodeficiency virus and" exact="hepatitis" post="B virus reverse transcriptases, and herpes virus DNA polymerase,"/>
   <result pre="dengue virusProc Natl Acad Sci USA2009106204352043910.1073/pnas.090701010619918064 23.GotteMFeldJJDirect-acting antiviral agents for" exact="hepatitis" post="C: structural and mechanistic insightsNat Rev Gastroenterol Hepatol20161333835110.1038/nrgastro.2016.6027147491 24.MaletHet"/>
   <result pre="a target for drug discoveryAntiviral Res2015119576710.1016/j.antiviral.2015.04.01025912817 26.EyerLet al.Nucleoside inhibitors of" exact="tick-borne encephalitis" post="virusAntimicrob Agents Chemother2015595483549310.1128/AAC.00807-1526124166 27.ChenHet al.Selective inhibition of the West"/>
   <result pre="target for drug discoveryAntiviral Res2015119576710.1016/j.antiviral.2015.04.01025912817 26.EyerLet al.Nucleoside inhibitors of tick-borne" exact="encephalitis" post="virusAntimicrob Agents Chemother2015595483549310.1128/AAC.00807-1526124166 27.ChenHet al.Selective inhibition of the West"/>
   <result pre="methyltransferase by nucleoside analogsAntiviral Res20139723223910.1016/j.antiviral.2012.12.01223267828 28.JulanderJGet al.Efficacy of 2′-C-methylcytidine against" exact="yellow fever" post="virus in cell culture and in a hamster modelAntiviral"/>
   <result pre="complex with a template-primer RNAJ Biol Chem2004279472124722110.1074/jbc.M40546520015294895 37.MarukianSet al.Cell culture-produced" exact="hepatitis" post="C virus does not infect peripheral blood mononuclear cellsHepatology2008481843185010.1002/hep.2255019003912"/>
   <result pre="screen to identify small compound inhibitors of the genotype 3a" exact="hepatitis" post="C virus RNA polymeraseJ Biomol Screen2013181027103410.1177/108705711348988323708123 62.NiyomrattanakitPet al.A fluorescence-based"/>
   <result pre="RNA polymerase inhibitorsAntiviral Res20119124125110.1016/j.antiviral.2011.06.00621722674 65.SuCYet al.High-throughput identification of compounds targeting" exact="influenza" post="RNA-dependent RNA polymerase activityProc Natl Acad Sci USA2010107191511915610.1073/pnas.101359210720974907 66.MadhviAet"/>
   <result pre="activityProc Natl Acad Sci USA2010107191511915610.1073/pnas.101359210720974907 66.MadhviAet al.A screen for novel" exact="hepatitis" post="C virus RdRp inhibitor identifies a broad-spectrum antiviral compoundSci"/>
   <result pre="antiviral compoundSci Rep20177581610.1038/s41598-017-04449-328725041 67.VoNVYoungKCLaiMMMutagenic and inhibitory effects of ribavirin on" exact="hepatitis" post="C virus RNA polymeraseBiochemistry200342104621047110.1021/bi034468112950173 68.Bassi, M. R., Sempere, R."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6702965/results/search/disease/results.xml">
   <result pre="of LG against African swine fever virus (ASFV), foot and" exact="mouth disease" post="virus (FMDV), vesicular stomatitis virus (VSV), and swine vesicular"/>
   <result pre="fever virus (ASFV), foot and mouth disease virus (FMDV), vesicular" exact="stomatitis" post="virus (VSV), and swine vesicular disease virus (SVDV), as"/>
   <result pre="different cell lines infected with African swine fever virus (ASFV)," exact="herpes simplex" post="virus (HSV-1), vaccinia virus (VV), influenza virus, transmissible gastroenteritis"/>
   <result pre="with African swine fever virus (ASFV), herpes simplex virus (HSV-1)," exact="vaccinia virus" post="(VV), influenza virus, transmissible gastroenteritis virus and Sindbis virus"/>
   <result pre="fever virus (ASFV), herpes simplex virus (HSV-1), vaccinia virus (VV)," exact="influenza" post="virus, transmissible gastroenteritis virus and Sindbis virus (Hurtado et"/>
   <result pre="herpes simplex virus (HSV-1), vaccinia virus (VV), influenza virus, transmissible" exact="gastroenteritis" post="virus and Sindbis virus (Hurtado et al., 2008). VPA"/>
   <result pre="enveloped viruses (Vazquez-Calvo et al., 2011). VPA treatment of vesicular" exact="stomatitis" post="virus (VSV)-infected cells reduced viral production without significantly affecting"/>
   <result pre="economic importance, such as those caused by ASFV, foot and" exact="mouth disease" post="virus (FMDV), VSV, or swine vesicular disease virus (SVDV),"/>
   <result pre="available (Sanchez-Cordon et al., 2018). Likewise, FMD is the animal" exact="viral disease" post="with the largest economic impact worldwide. Conventional vaccines have"/>
   <result pre="contributes significantly to establishment of a bioenergetically favorable environment for" exact="vaccinia virus" post="infection. PLoS Pathog.10:e1004021. 10.1371/journal.ppat.1004021, PMID: 24651651 HakobyanA.ArabyanE.AvetisyanA.AbroyanL.HakobyanL.ZakaryanH. (2016). Apigenin"/>
   <result pre="23415476 NovellaI. S.CilnisM.ElenaS. F.KohnJ.MoyaA.DomingoE.et al.. (1996). Large-population passages of vesicular" exact="stomatitis" post="virus in interferon-treated cells select variants of only limited"/>
   <result pre="Sanchez-CordonP. J.MontoyaM.ReisA. L.DixonL. K. (2018). African swine fever: a re-emerging" exact="viral disease" post="threatening the global pig industry. Vet. J.233, 41–48. 10.1016/j.tvjl.2017.12.025,"/>
   <result pre="21106740 YamasakiH.UozakiM.KatsuyamaY.UtsunomiyaH.ArakawaT.HiguchiM.et al.. (2007). Antiviral effect of octyl gallate against" exact="influenza" post="and other RNA viruses. Int. J. Mol. Med.19, 685–688."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6755163/results/search/disease/results.xml">
   <result pre="hNTCP-expressing primary pig hepatocytes are a valuable tool for investigating" exact="hepatitis" post="B virus infection and antiviral drugs ZhouMing12*QinBo3*DengXue-Song4ZengXiao-Li5LuYing1HuangZi-Gang2WuChun-Chen6MouLi-Sha1[1], [2], [3],"/>
   <result pre="Primary human hepatocytes (PHHs) are the ‘gold standard’ for investigating" exact="hepatitis" post="B virus (HBV) infection and antiviral drugs. However, poor"/>
   <result pre="Following hNTCP complementation and HBV infection, PPHs and Huh7D human" exact="hepatocellular carcinoma" post="cells, but not PRHs, exhibited increased hepatitis B surface"/>
   <result pre="Huh7D human hepatocellular carcinoma cells, but not PRHs, exhibited increased" exact="hepatitis" post="B surface antigen and hepatitis B e-antigen secretion, covalently"/>
   <result pre="but not PRHs, exhibited increased hepatitis B surface antigen and" exact="hepatitis" post="B e-antigen secretion, covalently closed circular DNA formation and"/>
   <result pre="be valuable tool for investigating HBV infection and antiviral drugs." exact="hepatitis" post="B virus sodium taurocholate co-transporting polypeptide primary pig hepatocyte"/>
   <result pre="mg/kg pentobarbital sodium (7). Death was confirmed by respiratory arrest," exact="cardiac arrest" post="and reflex deficiency. The liver was removed as quickly"/>
   <result pre="Cell Counting Kit-8 according to the manufacturer's instructions. ELISA Secreted" exact="hepatitis" post="B surface antigen (HBsAg) and hepatitis B e-antigen (HBeAg)"/>
   <result pre="manufacturer's instructions. ELISA Secreted hepatitis B surface antigen (HBsAg) and" exact="hepatitis" post="B e-antigen (HBeAg) were detected in medium collected from"/>
   <result pre="of HBV and HCCAnn Epidemiol19231234200910.1016/j.annepidem.2009.01.01719344859 2SheahanTJonesCTPlossAAdvances and challenges in studying" exact="hepatitis" post="C virus in its native environmentExpert Rev Gastroenterol Hepatol4541550201010.1586/egh.10.5320932139"/>
   <result pre="al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human" exact="hepatitis" post="B and D virusElife1e00049201210.7554/eLife.0004923150796 5HeWRenBMaoFJingZLiYLiuYPengBYanHQiYSunYet al.Hepatitis D virus infection"/>
   <result pre="by co-culture with non-parenchymal cellsJ Virol Methods195185193201410.1016/j.jviromet.2013.10.01024134944 9ZhouMHuangYChengZZhaoFLiJZhiXTianXSunWHuKRevival, characterization, and" exact="hepatitis" post="B virus infection of cryopreserved human fetal hepatocytesJ Virol"/>
   <result pre="hNTCP-expressing human hepatoma-derived (Huh7) cellsVirol Sin32465475201710.1007/s12250-017-3983-x28971350 11LadnerSKOttoMJBarkerCSZaifertKWangGHGuoJTSeegerCKingRWInducible expression of human" exact="hepatitis" post="B virus (HBV) in stably transfected hepatoblastoma cells: A"/>
   <result pre="expression of human hepatitis B virus (HBV) in stably transfected" exact="hepatoblastoma" post="cells: A novel system for screening potential inhibitors of"/>
   <result pre="of primary tupaia hepatocytes with purified human and woolly monkey" exact="hepatitis" post="B virusJ Virol7550845089200110.1128/JVI.75.11.5084-5089.200111333889 13KöckJRöslerCZhangJJBlumHENassalMThomaCGeneration of covalently closed circular DNA"/>
   <result pre="B virusJ Virol7550845089200110.1128/JVI.75.11.5084-5089.200111333889 13KöckJRöslerCZhangJJBlumHENassalMThomaCGeneration of covalently closed circular DNA of" exact="hepatitis" post="B viruses via intracellular recycling is regulated in a"/>
   <result pre="Pathog6e1001082201010.1371/journal.ppat.100108220824087 14GlebeDAliakbariMKrassPKnoopEVValeriusKPGerlichWHPre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human" exact="hepatitis" post="B virusJ Virol7795119521200310.1128/JVI.77.17.9511-9521.200312915565 15DoitshGShaulYA long HBV transcript encoding pX"/>
   <result pre="the 2(-Delta Delta C(T)) MethodMethods25402408200110.1006/meth.2001.126211846609 17NassalMThe arginine-rich domain of the" exact="hepatitis" post="B virus core protein is required for pregenome encapsidation"/>
   <result pre="Cell14352365201510.1111/acel.1228325677554 19DrexlerJFGeipelAKönigACormanVMvan RielDLeijtenLMBremerCMRascheACottontailVMMagangaGDet al.Bats carry pathogenic hepadnaviruses antigenically related to" exact="hepatitis" post="B virus and capable of infecting human hepatocytesProc Natl"/>
   <result pre="commercial abattoirsBMC Microbiol14315201410.1186/s12866-014-0315-225495746 21LiWSheRLiuLYouHYinJPrevalence of a virus similar to human" exact="hepatitis" post="B virus in swineVirol J760201010.1186/1743-422X-7-6020233455 22TangHZhouSZhaoLWangJLeiBCaoZPrimary serologic investigation of"/>
   <result pre="Ke Da Xue Xue Bao211811841990(In Chinese)2391101 23YeXZhouMHeYWanYBaiWTaoSRenYZhangXXuJLiuJet al.Efficient inhibition of" exact="hepatitis" post="B virus infection by a preS1-binding peptideSci Rep629391201610.1038/srep2939127384014 24GlebeDUrbanSKnoopEVCagNKrassPGrünSBulavaiteASasnauskasKGerlichWHMapping"/>
   <result pre="virus infection by a preS1-binding peptideSci Rep629391201610.1038/srep2939127384014 24GlebeDUrbanSKnoopEVCagNKrassPGrünSBulavaiteASasnauskasKGerlichWHMapping of the" exact="hepatitis" post="B virus attachment site by use of infection-inhibiting preS1"/>
   <result pre="preS1 lipopeptides and tupaia hepatocytesGastroenterology129234245200510.1053/j.gastro.2005.03.09016012950 25DoongSLTsaiCHSchinaziRFLiottaDCChengYCInhibition of the replication of" exact="hepatitis" post="B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analoguesProc"/>
   <result pre="polypeptide; PPH, primary pig hepatocyte; PRH, primary rabbit hepatocyte; HBV," exact="hepatitis" post="B virus; dpi, days post-infection; HBsAg, hepatitis B surface"/>
   <result pre="rabbit hepatocyte; HBV, hepatitis B virus; dpi, days post-infection; HBsAg," exact="hepatitis" post="B surface antigen; HBeAG, hepatitis B e-antigen; ns, not"/>
   <result pre="virus; dpi, days post-infection; HBsAg, hepatitis B surface antigen; HBeAG," exact="hepatitis" post="B e-antigen; ns, not significant. Figure 4. Anti-HBV drugs"/>
   <result pre="human sodium taurocholate co-transporting polypeptide; PPH, primary pig hepatocyte; HBV," exact="hepatitis" post="B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis"/>
   <result pre="polypeptide; PPH, primary pig hepatocyte; HBV, hepatitis B virus; HBsAg," exact="hepatitis" post="B surface antigen; HBeAg, hepatitis B e-antigen; ns, not"/>
   <result pre="HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg," exact="hepatitis" post="B e-antigen; ns, not significant. Table I. Primers used"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6780377/results/search/disease/results.xml">
   <result pre="arthropod-borne viruses 1. Introduction Dengue is an important arthropod-borne viral" exact="infectious disease" post="caused by any one of the four-dengue virus (DENV-1"/>
   <result pre="regions, which has led to its categorization as an emerging" exact="infectious disease" post="[1,2]. The genus includes more than 70 small-enveloped viruses"/>
   <result pre="genus includes more than 70 small-enveloped viruses related to Japanese" exact="encephalitis" post="(JEV), Zika viruses (ZIKV), West Nile (WNV), yellow fever"/>
   <result pre="to Japanese encephalitis (JEV), Zika viruses (ZIKV), West Nile (WNV)," exact="yellow fever" post="virus (YFV), DENV, or tick-borne encephalitis (TBEV), and other"/>
   <result pre="(ZIKV), West Nile (WNV), yellow fever virus (YFV), DENV, or" exact="tick-borne encephalitis" post="(TBEV), and other medically-important arboviruses [3]. Most importantly, DENV"/>
   <result pre="West Nile (WNV), yellow fever virus (YFV), DENV, or tick-borne" exact="encephalitis" post="(TBEV), and other medically-important arboviruses [3]. Most importantly, DENV"/>
   <result pre="symptoms (asymptomatic or only mildly symptomatic). In the case of" exact="dengue fever" post="(DF), patients may experience headache, myalgia, rash, leukopenia, arthralgia,"/>
   <result pre="arthralgia, retro-orbital pain, and hemorrhagic manifestations. Thereafter, patients suffering from" exact="dengue hemorrhagic fever" post="(DHF) may develop petechiae, bruising, thrombocytopenia, and shock. Ultimate"/>
   <result pre="transmission process was akin to the &quot;jungle cycle&quot; of the" exact="yellow fever" post="virus [14,15,16]. From 1922 to 1945, many outbreaks were"/>
   <result pre="to 1944, a major breakthrough occurred in the treatment of" exact="dengue fever," post="when Dr. R. Kimura (Japan) and Dr. S. Hotta"/>
   <result pre="of needle injuries [25,26,27,28,29], while vertical transmission is responsible for" exact="dengue fever" post="cases in infants born to a DHF-diagnosed mother [30]."/>
   <result pre="complete their life cycles. For example, RNA replication of the" exact="hepatitis" post="C virus (HCV) depends on the human homologue of"/>
   <result pre="4 (CXCR-4)—chemokine receptors as mediators of HIV infections [52,53,54]. The" exact="influenza" post="virus requires post-entry steps for its replication and, for"/>
   <result pre="for biosynthetic processes (Figure 2), such as in the case" exact="cancer" post="cells and human cytomegalovirus (HCMV) cells [3,4,5,6]. As DENV"/>
   <result pre="that using brequinar (a known DHODH inhibitor), an anti-metabolite in" exact="cancer" post="and immune-suppression, can inhibit DENV type 1,2,3 (DENV-1,2,3) serotypes."/>
   <result pre="infected mouse. The efficacy analyses were performed in patients with" exact="dengue fever" post="[115]. The compound celgosivir is generally safe and well-tolerated"/>
   <result pre="from Uncaria tomentosa, Norantea brasiliensis Choisy, Uncaria guianensis [196,197], promyelocytic" exact="leukemia" post="protein intrinsic, Ivermectin [198], extracts from Cissampelos pareira Linn"/>
   <result pre="Walter Reed Army Institute of ResearchWashington, DC, USA1984 45.GermainM.MouchetJ.CordellierR.ChippauxA.CornetM.HerveJ.P.SureauP.FabreJ.RobinY.Epidemiology of" exact="yellow fever" post="in AfricaMed. Infect. Dis.197886977 46.RudnickA.L.B.E.R.T.Ecology of Dengue VirusAsian J."/>
   <result pre="1996Epidemiol. Bull.1996171214 50.TaiA.W.BenitaY.PengL.F.KimS.SakamotoN.XavierR.J.ChungR.T.A functional genomic screen identifies cellular cofactors of" exact="hepatitis" post="C virus replicationCell Host Microbe2009529830710.1016/j.chom.2009.02.00119286138 51.LiuH.M.AizakiH.MachidaK.OuJ.-H.J.LaiM.M.C.Hepatitis C Virus Translation"/>
   <result pre="Hydrolysis of Synthetic Fluorescent SubstratesArch. Biochem. Biophys.200745718719610.1016/j.abb.2006.11.00517184724 103.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of" exact="tick-borne encephalitis" post="virus by furinJ. Virol.199771847584819343204 104.ChambersT.NestorowiczA.AmbergS.RiceC.Mutagenesis of the Yellow Fever"/>
   <result pre="of Synthetic Fluorescent SubstratesArch. Biochem. Biophys.200745718719610.1016/j.abb.2006.11.00517184724 103.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne" exact="encephalitis" post="virus by furinJ. Virol.199771847584819343204 104.ChambersT.NestorowiczA.AmbergS.RiceC.Mutagenesis of the Yellow Fever"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6792045/results/search/disease/results.xml">
   <result pre="properly cited.TEMI_8_1673135.pdf Abstract ABSTRACT Coxsackievirus A4 (CVA4) infection can cause" exact="hand, foot and mouth disease" post="(HFMD), an epidemic illness affecting neonatal and paediatric cohorts,"/>
   <result pre="ABSTRACT Coxsackievirus A4 (CVA4) infection can cause hand, foot and" exact="mouth disease" post="(HFMD), an epidemic illness affecting neonatal and paediatric cohorts,"/>
   <result pre="linear, non-enveloped, positive polarity single-stranded RNA viruses, which principally cause" exact="herpangina" post="and hand, foot and mouth disease (HFMD) in children"/>
   <result pre="positive polarity single-stranded RNA viruses, which principally cause herpangina and" exact="hand, foot and mouth disease" post="(HFMD) in children [1]. Prior to 2009, viral pathogens"/>
   <result pre="RNA viruses, which principally cause herpangina and hand, foot and" exact="mouth disease" post="(HFMD) in children [1]. Prior to 2009, viral pathogens"/>
   <result pre="as erythematous maculopapular exanthema [12] to severe outcomes such as" exact="aseptic meningitis," post="myocarditis and acute flaccid paralysis [14, 15]. Given the"/>
   <result pre="maculopapular exanthema [12] to severe outcomes such as aseptic meningitis," exact="myocarditis" post="and acute flaccid paralysis [14, 15]. Given the increased"/>
   <result pre="Laboratory Animal Management Committee. Cells and CVA4 viral strain Human" exact="rhabdomyosarcoma" post="(RD) cells were kindly provided by the Shandong Center"/>
   <result pre="IL-6, IL-10, IL-13, and IFN-γ, are associated with brain stem" exact="encephalitis" post="and pulmonary oedema caused by EVA71 infection [41–43.] In"/>
   <result pre="[2]UpalaP, ApidechkulT, SuttanaW, et al.Molecular epidemiology and clinical features of" exact="hand, foot and mouth disease" post="in northern Thailand in 2016: a prospective cohort study."/>
   <result pre="et al.Molecular epidemiology and clinical features of hand, foot and" exact="mouth disease" post="in northern Thailand in 2016: a prospective cohort study."/>
   <result pre="[3]GaoL, ZouG, LiaoQ, et al.Spectrum of enterovirus serotypes causing uncomplicated" exact="hand, foot, and mouth disease" post="and enteroviral diagnostic yield of different clinical samples. Clin"/>
   <result pre="et al.Spectrum of enterovirus serotypes causing uncomplicated hand, foot, and" exact="mouth disease" post="and enteroviral diagnostic yield of different clinical samples. Clin"/>
   <result pre="10.1093/cid/ciy34129688329 [4]WengY, ChenW, HeW, et al.Serotyping and genetic characterization of" exact="hand, foot, and mouth disease" post="(HFMD)-associated enteroviruses of no-EV71 and non-CVA16 Circulating in Fujian,"/>
   <result pre="HeW, et al.Serotyping and genetic characterization of hand, foot, and" exact="mouth disease" post="(HFMD)-associated enteroviruses of no-EV71 and non-CVA16 Circulating in Fujian,"/>
   <result pre="et al.Etiology of multiple non-EV71 and Non-CVA16 enteroviruses associated with" exact="hand, foot and mouth disease" post="in Jinan, China, 2009-June 2013. PLoS One. 2015;10(11):e0142733. doi:"/>
   <result pre="multiple non-EV71 and Non-CVA16 enteroviruses associated with hand, foot and" exact="mouth disease" post="in Jinan, China, 2009-June 2013. PLoS One. 2015;10(11):e0142733. doi:"/>
   <result pre="LiJ, YaoMX, et al.Genome analysis of coxsackievirus A4 isolates from" exact="hand, foot, and mouth disease" post="cases in Shandong, China. Front Microbiol. 2019;10:1001. doi: 10.3389/fmicb.2019.0100131134033"/>
   <result pre="al.Genome analysis of coxsackievirus A4 isolates from hand, foot, and" exact="mouth disease" post="cases in Shandong, China. Front Microbiol. 2019;10:1001. doi: 10.3389/fmicb.2019.0100131134033"/>
   <result pre="surveillance of the epidemiological and serotype characteristics of hand, foot," exact="mouth disease" post="in Neijiang city, China, 2010-2017: A retrospective study. PLoS"/>
   <result pre="2019;14(6):e0217474. doi: 10.1371/journal.pone.021747431170178 [8]ZhaoY, ZhangH, LiuH, et al.Molecular characteristics of" exact="hand, foot, and mouth disease" post="for hospitalized pediatric patients in Yunnan. China. Medicine (Baltimore."/>
   <result pre="[8]ZhaoY, ZhangH, LiuH, et al.Molecular characteristics of hand, foot, and" exact="mouth disease" post="for hospitalized pediatric patients in Yunnan. China. Medicine (Baltimore."/>
   <result pre="2018;97(31):e11610. doi: 10.1097/MD.000000000001161030075535 [9]JiH, FanH, LuPX, et al.Surveillance for severe" exact="hand, foot, and mouth disease" post="from 2009 to 2015 in Jiangsu province: epidemiology, etiology,"/>
   <result pre="[9]JiH, FanH, LuPX, et al.Surveillance for severe hand, foot, and" exact="mouth disease" post="from 2009 to 2015 in Jiangsu province: epidemiology, etiology,"/>
   <result pre="characterization of enterovirus infections among pediatric patients with hand foot" exact="mouth disease," post="herpangina and influenza like illness in Thailand, 2012. PLoS"/>
   <result pre="enterovirus infections among pediatric patients with hand foot mouth disease," exact="herpangina" post="and influenza like illness in Thailand, 2012. PLoS One."/>
   <result pre="among pediatric patients with hand foot mouth disease, herpangina and" exact="influenza" post="like illness in Thailand, 2012. PLoS One. 2014;9(6):e98888. doi:"/>
   <result pre="BrittonPN, BurrellR, et al.A complex mosaic of enteroviruses shapes community-acquired" exact="hand, foot and mouth disease" post="transmission and evolution within a single hospital. Virus Evol."/>
   <result pre="al.A complex mosaic of enteroviruses shapes community-acquired hand, foot and" exact="mouth disease" post="transmission and evolution within a single hospital. Virus Evol."/>
   <result pre="Evol. 2018;4(2):vey020. doi: 10.1093/ve/vey02030026965 [12]DragoF, CiccareseG, GariazzoL, et al.Acute localized" exact="exanthem" post="due to coxsackievirus A4. Infez Med. 2017;25(3):274–276.28956547 [13]LauSKP, ZhaoPSH,"/>
   <result pre="2018;108:43–49. doi: 10.1016/j.jcv.2018.09.00230237097 [14]AkuzawaN, HaradaN, HatoriT, et al.Myocarditis, hepatitis, and" exact="pancreatitis" post="in a patient with coxsackievirus A4 infection: a case"/>
   <result pre="YeoA, PhoonMC, et al.The largest outbreak of hand; foot and" exact="mouth disease" post="in Singapore in 2008: the role of enterovirus 71"/>
   <result pre="WeiR, et al.The cytokine and chemokine profiles in patients with" exact="hand, foot and mouth disease" post="of different severities in Shanghai, China, 2010. PLoS Negl"/>
   <result pre="cytokine and chemokine profiles in patients with hand, foot and" exact="mouth disease" post="of different severities in Shanghai, China, 2010. PLoS Negl"/>
   <result pre="of an inactivated enterovirus 71 vaccine administered simultaneously with recombinant" exact="hepatitis" post="B vaccine and group A meningococcal polysaccharide vaccine: a"/>
   <result pre="al.Two-year efficacy and immunogenicity of Sinovac enterovirus 71 vaccine against" exact="hand, foot and mouth disease" post="in children. Expert Rev Vaccines. 2016;15(1):129–137. doi: 10.1586/14760584.2016.109678226460695 [29]HuY,"/>
   <result pre="immunogenicity of Sinovac enterovirus 71 vaccine against hand, foot and" exact="mouth disease" post="in children. Expert Rev Vaccines. 2016;15(1):129–137. doi: 10.1586/14760584.2016.109678226460695 [29]HuY,"/>
   <result pre="al.Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71" exact="encephalomyelitis" post="against disease. J Virol. 2010;84(1):661–665. doi: 10.1128/JVI.00999-0919864378 [34]KhongWX, YanB,"/>
   <result pre="doi: 10.1128/JVI.00333-1728424287 [39]DuZ, ZhaoY, LuoY, et al.Ongoing change of severe" exact="hand, foot, and mouth disease" post="pathogens in Yunnan, China, 2012 to 2016. J Med"/>
   <result pre="ZhaoY, LuoY, et al.Ongoing change of severe hand, foot, and" exact="mouth disease" post="pathogens in Yunnan, China, 2012 to 2016. J Med"/>
   <result pre="et al.Cerebrospinal fluid and cytokines in enterovirus 71 brain stem" exact="encephalitis" post="and echovirus meningitis infections of varying severity. Clin Microbiol"/>
   <result pre="and cytokines in enterovirus 71 brain stem encephalitis and echovirus" exact="meningitis" post="infections of varying severity. Clin Microbiol Infect. 2007;13:677–682. doi:"/>
   <result pre="FranzidouF, et al.Genetic variation of coxsackievirus B5 strains associated with" exact="aseptic meningitis" post="in Greece. Clin Microbiol Infect. 2006;12:688–691. doi: 10.1111/j.1469-0691.2006.01476.x16774571 [48]GraciJD,"/>
   <result pre="et al.Genetic variation of coxsackievirus B5 strains associated with aseptic" exact="meningitis" post="in Greece. Clin Microbiol Infect. 2006;12:688–691. doi: 10.1111/j.1469-0691.2006.01476.x16774571 [48]GraciJD,"/>
   <result pre="al.Clinical efficacy of therapy with recombinant human interferon α1b in" exact="hand, foot, and mouth disease" post="with enterovirus 71 infection. PLoS One. 2016;11:e0148907. doi: 10.1371/journal.pone.014890726882102"/>
   <result pre="therapy with recombinant human interferon α1b in hand, foot, and" exact="mouth disease" post="with enterovirus 71 infection. PLoS One. 2016;11:e0148907. doi: 10.1371/journal.pone.014890726882102"/>
   <result pre="and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71," exact="poliomyelitis" post="I-III and HIV-1 antibodies. Sci Rep. 2016;6:38874. doi: 10.1038/srep3887427934956"/>
   <result pre="2016;6:38874. doi: 10.1038/srep3887427934956 [52]XingW, LiaoQ, ViboudC, et al.Hand, foot, and" exact="mouth disease" post="in China, 2008-12: an epidemiological study. Lancet Infect Dis."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6843332/results/search/disease/results.xml">
   <result pre="issue. We analyzed the conservation rates of all proteins in" exact="herpes simplex" post="virus 1 (HHV-1), a representative of the HHV family"/>
   <result pre="of drugs to treat a wide range of HHVs. herpesviruses" exact="herpes simplex" post="virus 1 HHV-1 DNA packaging terminase pUL15 DNA packaging"/>
   <result pre="associated with several cancers. Epstein–Barr virus (EBV) causes Burkett’s lymphoma," exact="nasopharyngeal carcinoma," post="and Hodgkin’s disease, and has been detected in approximately"/>
   <result pre="disease, and has been detected in approximately 70% of advance" exact="breast cancer" post="tumors [12,13]. Kaposi’s sarcoma-associated herpesvirus (KSHV) can result in"/>
   <result pre="and has been detected in approximately 70% of advance breast" exact="cancer" post="tumors [12,13]. Kaposi’s sarcoma-associated herpesvirus (KSHV) can result in"/>
   <result pre="number of papers published on HIV compared to HHV and" exact="influenza" post="is likely a result of the high mortality rate"/>
   <result pre="Programme on AIDS [81,82]. The increase in the publication of" exact="influenza" post="research papers correlates with flu outbreaks; this is especially"/>
   <result pre="lack the dramatic peaks in transmission that are seen in" exact="influenza" post="and the widespread mortality rate of HIV to spur"/>
   <result pre="post-transplant infections, neurological disabilities in infants, chicken pox, shingles, lymphoma," exact="nasopharyngeal carcinoma," post="Hodgkin’s disease, and infectious blisters on the lips and"/>
   <result pre="genitals. HHV-1 and HHV-2 alone can result in neonatal infection," exact="keratitis" post="meningitis, encephalitis, and HHV-2 increases the likelihood of HIV"/>
   <result pre="human cancerJ. Natl. Cancer Inst.2002941832183610.1093/jnci/94.24.183212488476 14.SchulzT.F.The pleiotropic effects of Kaposi’s" exact="sarcoma" post="herpesvirusJ. Pathol.200620818719810.1002/path.190416362980 15.SunilM.ReidE.LechowiczM.J.Update on HHV-8-Associated MalignanciesCurr. Infect. Dis. Rep.20101214715410.1007/s11908-010-0092-520461118"/>
   <result pre="sequence of the long unique region in the genome of" exact="herpes simplex" post="virus type 1J. Gen. Virol.1988691531157410.1099/0022-1317-69-7-15312839594 17.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of herpes"/>
   <result pre="herpes simplex virus type 1J. Gen. Virol.1988691531157410.1099/0022-1317-69-7-15312839594 17.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of" exact="herpes simplex" post="virus 1 strain KOSJ. Virol.2012866371637210.1128/JVI.00646-1222570244 18.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of herpes"/>
   <result pre="herpes simplex virus 1 strain KOSJ. Virol.2012866371637210.1128/JVI.00646-1222570244 18.MacdonaldS.J.MostafaH.H.MorrisonL.A.DavidoD.J.Genome sequence of" exact="herpes simplex" post="virus 1 strain McKraeJ. Virol.2012869540954110.1128/JVI.01469-1222879612 19.DavisonA.J.Comparative analysis of the"/>
   <result pre="antiviral drugs against human cytomegalovirusInfect. Drug Resist.2015826927726345608 33.YangK.DangX.BainesJ.D.A domain of" exact="herpes simplex" post="virus pUL33 required to release monomeric viral genomes from"/>
   <result pre="Virol.200579146601466710.1128/JVI.79.23.14660-14667.200516282466 41.ZhouB.YangK.WillsE.TangL.BainesJ.D.A mutation in the DNA polymerase accessory factor of" exact="herpes simplex" post="virus 1 restores viral DNA replication in the presence"/>
   <result pre="https://inkscape.org/.(accessed on 9 October 2019) 62.Selvarajan SigamaniS.ZhaoH.KamauY.N.BainesJ.D.TangL.The structure of the" exact="herpes simplex" post="virus DNA-packaging terminase pUL15 nuclease domain suggests an evolutionary"/>
   <result pre="Switzerland2016 83.JohnstonC.GottliebS.L.WaldA.Status of vaccine research and development of vaccines for" exact="herpes simplex" post="virusVaccine2016342948295210.1016/j.vaccine.2015.12.07626973067 84.DeshpandeS.P.KumaraguruU.RouseB.T.Why do we lack an effective vaccine against"/>
   <result pre="simplex virusVaccine2016342948295210.1016/j.vaccine.2015.12.07626973067 84.DeshpandeS.P.KumaraguruU.RouseB.T.Why do we lack an effective vaccine against" exact="herpes simplex" post="virus infections?Microbes. Infect.2000297397810.1016/S1286-4579(00)00339-710962281 85.LookerK.J.MagaretA.S.TurnerK.M.VickermanP.GottliebS.L.NewmanL.M.Global estimates of prevalent and incident"/>
   <result pre="simplex virus infections?Microbes. Infect.2000297397810.1016/S1286-4579(00)00339-710962281 85.LookerK.J.MagaretA.S.TurnerK.M.VickermanP.GottliebS.L.NewmanL.M.Global estimates of prevalent and incident" exact="herpes simplex" post="virus type 2 infections in 2012PLoS ONE201510e11498910.1371/journal.pone.011498925608026 86.World Health"/>
   <result pre="2015-2016NCHS Data Brief.201830418 88.PrzechA.J.YuD.WellerS.K.Point mutations in exon I of the" exact="herpes simplex" post="virus putative terminase subunit, UL15, indicate that the most"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC6925545/results/search/disease/results.xml">
   <result pre="CMV infection. The risk factors for viral infections were allo-HCT," exact="acute leukemia," post="acute and chronic graft versus host disease (a/cGVHD), and"/>
   <result pre="factor for death from viral infection were CMV-IgG seropositivity in" exact="acute lymphoblastic leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
   <result pre="for death from viral infection were CMV-IgG seropositivity in acute" exact="lymphoblastic leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
   <result pre="death from viral infection were CMV-IgG seropositivity in acute lymphoblastic" exact="leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
   <result pre="(allo-HCT)4 and in 21% of children with solid tumor or" exact="lymphoma" post="in pediatric auto-HCT setting.5 The incidence of viral infection"/>
   <result pre="result of a reactivation event.6 In the early post-transplant period" exact="herpes simplex" post="virus (HSV) reactivation was the most frequent viral infection"/>
   <result pre="HSV, VZV, polyoma BK virus (BKV), while episodic viruses included" exact="influenza" post="A and B (FLUAV and FLUBV, respectively) and other"/>
   <result pre="(741 allo-HCT; 230 auto-HCT) were performed. Indications for HCTs were:" exact="acute lymphoblastic leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
   <result pre="allo-HCT; 230 auto-HCT) were performed. Indications for HCTs were: acute" exact="lymphoblastic leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
   <result pre="230 auto-HCT) were performed. Indications for HCTs were: acute lymphoblastic" exact="leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
   <result pre="for HCTs were: acute lymphoblastic leukemia (ALL, n=233), acute myeloblastic" exact="leukemia" post="(AML, n=151), neuroblastoma (n=138), primary immunodeficiencies (n=113), bone marrow"/>
   <result pre="acute lymphoblastic leukemia (ALL, n=233), acute myeloblastic leukemia (AML, n=151)," exact="neuroblastoma" post="(n=138), primary immunodeficiencies (n=113), bone marrow failure syndromes (n=101),"/>
   <result pre="syndromes (n=101), Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65), Ewing" exact="sarcoma" post="(n=44), myelodysplastic syndrome (n=38) and other indications (n=88). Incidence"/>
   <result pre="Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65), Ewing sarcoma (n=44)," exact="myelodysplastic syndrome" post="(n=38) and other indications (n=88). Incidence of Infection A"/>
   <result pre="cytomegalovirus; CMV-CTL, cytomegalovirus specific T lymphocytes; EBV, Epstein–Barr virus; FLUAV," exact="influenza" post="A virus; HBV, hepatitis B virus; HHV-6, human herpesvirus"/>
   <result pre="T lymphocytes; EBV, Epstein–Barr virus; FLUAV, influenza A virus; HBV," exact="hepatitis" post="B virus; HHV-6, human herpesvirus 6; hMPV, human metapneumovirus;"/>
   <result pre="than auto-HCT. In allo-HCT patients, the risk was higher in" exact="acute leukemia" post="patients vs other (HR=1.9; p&amp;lt;0.001), MUD vs MSD (HR=2.6;"/>
   <result pre="auto-HCT. In allo-HCT patients, the risk was higher in acute" exact="leukemia" post="patients vs other (HR=1.9; p&amp;lt;0.001), MUD vs MSD (HR=2.6;"/>
   <result pre="&amp;lt;0.001 allo-HCT Sex male vs female 0.9 (0.7–1.1) 0.698 Acute" exact="leukemia" post="vs other 1.9 (1.4–2.4) &amp;lt;0.001 NHL/HD vs other 1.2"/>
   <result pre="bold font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; D, days;"/>
   <result pre="font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; D, days;"/>
   <result pre="(1.1–2.0) 0.045 Sex male vs female 1.1 (0.8–1.5) 0.829 Acute" exact="leukemia" post="vs other 1.5 (0.8–2.4) 0.413 NHL/HD vs other 0.9"/>
   <result pre="bold font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; CMV, cytomegalovirus;"/>
   <result pre="font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; CMV, cytomegalovirus;"/>
   <result pre="rate of 90.7%. Cesaro et al. reported that BKV-related hemorrhagic" exact="cystitis" post="occurred in 8–25% of pediatric and 7–54% of adult"/>
   <result pre="the lack of significant effects on BKV replication and hemorrhagic" exact="cystitis" post="severity, and the selection of antibiotic resistance.19 In our"/>
   <result pre="clinical manifestations of ADV infections in immunocompetent hosts include upper" exact="respiratory disease," post="gastroenteritis or (kerato-)conjunctivitis and are self-limited in most cases,"/>
   <result pre="of ADV infections in immunocompetent hosts include upper respiratory disease," exact="gastroenteritis" post="or (kerato-)conjunctivitis and are self-limited in most cases, although"/>
   <result pre="in most cases, although severe manifestations including encephalitis, myocarditis, and" exact="pneumonia" post="have been sporadically observed. In immunocompromised patients, ADV can"/>
   <result pre="a significant cause of morbidity and mortality in patients with" exact="leukemia" post="and those undergoing HCT.12,21 In the late 1990s the"/>
   <result pre="and RhV.12 We observed a relatively low (1.2%) rate of" exact="influenza" post="A infection, with no cases of influenza B infection,"/>
   <result pre="(1.2%) rate of influenza A infection, with no cases of" exact="influenza" post="B infection, which may be due to environmental prophylaxis"/>
   <result pre="contacts, and hospital and prophylactic use of neuraminidase inhibitors during" exact="influenza" post="season in some cases). The current guidelines of the"/>
   <result pre="for influenza.23 RV and NoV are important pathogens of viral" exact="gastroenteritis" post="in children. We observed that cumulative incidence of RV"/>
   <result pre="pediatric allo-HCT recipients.24,25 In pediatric HCT, the incidence of NoV-associated" exact="gastroenteritis" post="was reported in 12.9% with no NoV-related mortality.26 PCR"/>
   <result pre="no therapy.8 However, it may be manifested as encephalitis/myelitis, pneumonia," exact="hepatitis" post="and EBV-associated tumors as PTLD.8,29 After transplantation 14–65% of"/>
   <result pre="response rate (50–88%) and fewer relapse.28 We found that allo-HCT," exact="acute leukemia," post="a/cGVHD, MUD/MMUD-HCT were the risk factors for viral infections."/>
   <result pre="viral infection. The risk factors for viral infections were allo-HCT," exact="acute leukemia," post="a/cGVHD, MUD/MMUD vs MSD. The risk factor for death"/>
   <result pre="factor for death from viral infection were CMV-IgG seropositivity in" exact="acute lymphoblastic leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
   <result pre="for death from viral infection were CMV-IgG seropositivity in acute" exact="lymphoblastic leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
   <result pre="death from viral infection were CMV-IgG seropositivity in acute lymphoblastic" exact="leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
   <result pre="aciclovir; ADV, adenovirus; a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="allo-, allogeneic; AML, acute myeloblastic leukemia; ANC, absolute neutrophil"/>
   <result pre="ADV, adenovirus; a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="allo-, allogeneic; AML, acute myeloblastic leukemia; ANC, absolute neutrophil"/>
   <result pre="ECIL, European Conference on Infections in Leukaemia; FCV, foscarnet; FLUAV," exact="influenza" post="A virus; FLUBV, influenza B virus; GCV, ganciclovir; HBV,"/>
   <result pre="Infections in Leukaemia; FCV, foscarnet; FLUAV, influenza A virus; FLUBV," exact="influenza" post="B virus; GCV, ganciclovir; HBV, hepatitis B virus; HCT,"/>
   <result pre="influenza A virus; FLUBV, influenza B virus; GCV, ganciclovir; HBV," exact="hepatitis" post="B virus; HCT, hematopoietic cell transplantation; HD, Hodgkin lymphoma;"/>
   <result pre="6; hMPV, human metapneumovirus; HPIV, parainfluenza; HR, hazard ratio; HSV," exact="herpes simplex" post="virus; IQR, quartiles; MAC, myeloablative conditioning; MEL, melphalan; MMUD,"/>
   <result pre="serostatus on the incidence of graft-versus-host disease in patients with" exact="acute leukemia" post="after hematopoietic stem-cell transplantation: a study from the acute"/>
   <result pre="on the incidence of graft-versus-host disease in patients with acute" exact="leukemia" post="after hematopoietic stem-cell transplantation: a study from the acute"/>
   <result pre="acute leukemia after hematopoietic stem-cell transplantation: a study from the" exact="acute leukemia" post="and infectious diseases working parties of the European society"/>
   <result pre="leukemia after hematopoietic stem-cell transplantation: a study from the acute" exact="leukemia" post="and infectious diseases working parties of the European society"/>
   <result pre="for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic" exact="cystitis" post="in haematopoietic stem cell transplant recipients. J Antimicrob Chemother."/>
   <result pre="European guidelines for diagnosis and treatment of adenovirus infection in" exact="leukemia" post="and stem cell transplantation: summary of ECIL-4 (2011). Transpl"/>
   <result pre="CamaraR, CordonnierC, LjungmanP. European guidelines for prevention and management of" exact="influenza" post="in hematopoietic stem cell transplantation and leukemia patients: summary"/>
   <result pre="and management of influenza in hematopoietic stem cell transplantation and" exact="leukemia" post="patients: summary of ECIL-4 (2011), on behalf of ECIL,"/>
   <result pre="Biol Blood Marrow Transplant. 2012;18(12):1883–1889. doi:10.1016/j.bbmt.2012.07.00522796532 27.WilliamsD. Treatment of rotavirus-associated" exact="diarrhea" post="using enteral immunoglobulins for pediatric stem cell transplant patients."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7026129/results/search/disease/results.xml">
   <result pre="does not comply with these terms. Abstract Severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) is an emerging tick-borne infectious disease caused"/>
   <result pre="Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne" exact="infectious disease" post="caused by SFTS virus (SFTSV), which is a novel"/>
   <result pre="recent advances in antiviral drugs against SFTSV. severe fever with" exact="thrombocytopenia" post="syndrome severe fever with thrombocytopenia syndrome virus antiviral ribavirin"/>
   <result pre="against SFTSV. severe fever with thrombocytopenia syndrome severe fever with" exact="thrombocytopenia" post="syndrome virus antiviral ribavirin favipiravir Funding Ministry of Health,"/>
   <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) is an emerging tick-borne infectious disease caused"/>
   <result pre="Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne" exact="infectious disease" post="caused by SFTS virus (SFTSV), a novel bunyavirus classified"/>
   <result pre="immunodeficiency virus, Lassa virus, and [in combination with interferon (IFN)-α]" exact="hepatitis" post="C virus. Ribavirin can be administered orally, intravenously, or"/>
   <result pre="broad spectrum of activity against various RNA viruses, including the" exact="influenza" post="virus, arenaviruses, bunyaviruses, West Nile virus, yellow fever virus,"/>
   <result pre="viruses, including the influenza virus, arenaviruses, bunyaviruses, West Nile virus," exact="yellow fever" post="virus, and foot-and-mouth disease virus (Furuta et al., 2009)."/>
   <result pre="of thrombopoietin receptor (c-Mpl) for the treatment of immune thrombocytopenic" exact="purpura" post="and aplastic anemia (eltrombopag), and an antiprotozoal agent (broxyquinoline)."/>
   <result pre="receptor (c-Mpl) for the treatment of immune thrombocytopenic purpura and" exact="aplastic anemia" post="(eltrombopag), and an antiprotozoal agent (broxyquinoline). Of them, hexachlorophene"/>
   <result pre="(c-Mpl) for the treatment of immune thrombocytopenic purpura and aplastic" exact="anemia" post="(eltrombopag), and an antiprotozoal agent (broxyquinoline). Of them, hexachlorophene"/>
   <result pre="2013), West Nile virus (Scherbik and Brinton, 2010), and Japanese" exact="encephalitis" post="virus (Wang et al., 2017) has been reported. Screening"/>
   <result pre="of the most widely used drugs for treating hypertension and" exact="atherosclerosis" post="in China. Thus, Li et al. (2019) performed a"/>
   <result pre="al., 2016), Crimean-Congo hemorrhagic fever virus (Welch et al., 2017)," exact="influenza" post="virus (Kumaki et al., 2011), and herpesviruses (Wohlrab et"/>
   <result pre="1999). It exerts a variety of biological effects, including the" exact="suppression" post="of cancer cells (Tang et al., 2017; Bułdak et"/>
   <result pre="exerts a variety of biological effects, including the suppression of" exact="cancer" post="cells (Tang et al., 2017; Bułdak et al., 2018)"/>
   <result pre="al., 2017). The mechanism of inhibitory activity of amodiaquine against" exact="malaria" post="and those viruses remains unclear. Baba et al. (2017)"/>
   <result pre="of the possible adverse events induced by ribavirin such as" exact="anemia" post="and hyperamylasemia (Lu et al., 2015). Favipiravir exhibited higher"/>
   <result pre="diseases caused by ebola virus (Mendoza et al., 2017) and" exact="influenza" post="(Nachbagauer and Krammer, 2017). Antibody drugs neutralize viruses or"/>
   <result pre="et al., 2019; Kwak et al., 2019). A recombinant vesicular" exact="stomatitis" post="virus expressing SFTSV antigen completely protected mice from SFTSV"/>
   <result pre="an antiviral assay system and identification of severe fever with" exact="thrombocytopenia" post="syndrome virus inhibitors. Antivir. Chem. Chemother.25, 83–89. 10.1177/204020661774030329096526 BajramovicJ."/>
   <result pre="its selected bioactive compounds on the development and progression of" exact="colorectal cancer" post="in vivo and in vitro. Molecules23:E3309. 10.3390/molecules2312330930551667 ChenX. P.CongM."/>
   <result pre="selected bioactive compounds on the development and progression of colorectal" exact="cancer" post="in vivo and in vitro. Molecules23:E3309. 10.3390/molecules2312330930551667 ChenX. P.CongM."/>
   <result pre="W.BaeI. G.KimS. H.RyuS. Y.KimH. A.et al.. (2016). Severe fever with" exact="thrombocytopenia" post="syndrome in South Korea, 2013-2015. PLoS Negl. Trop. Dis.10:e0005264."/>
   <result pre="Rev.29, 695–747. 10.1128/CMR.00102-1527281742 DelangL.GuerreroN. S.TasA.QuératG.PastorinoB.FroeyenM.et al.. (2014). Mutations in the" exact="chikungunya" post="virus non-structural proteins cause resistance to favipiravir (T-705), a"/>
   <result pre="channel blocker bepridil demonstrates efficacy in the murine model of" exact="marburg virus disease." post="J. Infect. Dis.22, S588–S591. 10.1093/infdis/jiy332 DingY.CaoZ.CaoL.DingG.WangZ.XiaoW. (2017). Antiviral activity"/>
   <result pre="S588–S591. 10.1093/infdis/jiy332 DingY.CaoZ.CaoL.DingG.WangZ.XiaoW. (2017). Antiviral activity of chlorogenic acid against" exact="influenza" post="A (H1N1/H3N2) virus and its inhibition of neuraminidase. Sci."/>
   <result pre="a rVSV-based vaccine elicits complete protection against severe fever with" exact="thrombocytopenia" post="syndrome virus. NPJ Vaccines4:5. 10.1038/s41541-018-0096-y30701094 FerrariG.HaynesB. F.KoenigS.NordstromJ. L.MargolisD. M.TomarasG."/>
   <result pre="GaiZ.LiangM.ZhangY.ZhangS.JinC.WangS. W.et al.. (2012). Person-to-person transmission of severe fever with" exact="thrombocytopenia" post="syndrome bunyavirus through blood contact. Clin. Infect. Dis.54, 249–252."/>
   <result pre="WettereA. J.RigasJ. D.HickersonB. T.et al.. (2017). Modeling severe fever with" exact="thrombocytopenia" post="syndrome virus infection in golden syrian hamsters: importance of"/>
   <result pre="10.1093/infdis/jiu56425326554 JinC.LiangM.NingJ.GuW.JiangH.WuW.et al.. (2012). Pathogenesis of emerging severe fever with" exact="thrombocytopenia" post="syndrome virus in C57/BL6 mouse model. Proc. Natl. Acad."/>
   <result pre="al.. (2016). Epidemiological and clinical features of severe fever with" exact="thrombocytopenia" post="syndrome in Japan, 2013-2014. PLoS ONE11:e0165207. 10.1371/journal.pone.016520727776187 KidaK.MatsuokaY.ShimodaT.MatsuokaH.YamadaH.SaitoT.et al.."/>
   <result pre="(2019). A case of cat-to-human transmission of severe fever with" exact="thrombocytopenia" post="syndrome virus. Jpn. J. Infect. Dis.72, 356–358. 10.7883/yoken.JJID.2018.52631366857 KimK."/>
   <result pre="convalescent patient potently inhibits the infection of severe fever with" exact="thrombocytopenia" post="syndrome virus. PLoS Pathog.15:e1007375. 10.1371/journal.ppat.100737530707748 KimK. H.YiJ.KimG.ChoiS. J.JunK. I.KimN."/>
   <result pre="KimK. H.YiJ.KimG.ChoiS. J.JunK. I.KimN. H.et al.. (2013). Severe fever with" exact="thrombocytopenia" post="syndrome, South Korea, 2012. Emerg. Infect. Dis.19, 1892–189410.3201/eid1911.13079224206586 KimbroughR."/>
   <result pre="and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic" exact="avian influenza" post="H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res.92,"/>
   <result pre="in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian" exact="influenza" post="H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res.92,"/>
   <result pre="of metal chelates of caffeic acid and similar compounds towards" exact="herpes simplex," post="VSV-Ebola pseudotyped and vaccinia viruses. Antiviral Res.160, 143–150. 10.1016/j.antiviral.2018.10.02130393014"/>
   <result pre="In vitro antiviral activity of ribavirin against severe fever with" exact="thrombocytopenia" post="syndrome virus. Korean J. Intern. Med.32, 731–737. 10.3904/kjim.2016.10927899013 LiH.LuQ.BinX."/>
   <result pre="(2018). Epidemiological and clinical features of laboratory-diagnosed severe fever with" exact="thrombocytopenia" post="syndrome in China, 2011–17: a prospective observational study. Lancet"/>
   <result pre="L.et al.. (2019). Calcium channel blockers reduce severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV) related fatality. Cell Res.29, 739–753. 10.1038/s41422-019-0214-z31444469"/>
   <result pre="among hospitalized patients in china who had severe fever with" exact="thrombocytopenia" post="syndrome. Clin. Infect. Dis.57, 1292–1299. 10.1093/cid/cit53023965284 LiuY.WuB.PaesslerS.WalkerD. H.TeshR. B.YuX."/>
   <result pre="H.TeshR. B.YuX. J. (2014). The pathogenesis of severe fever with" exact="thrombocytopenia" post="syndrome virus infection in alpha/beta interferon knockout mice: insights"/>
   <result pre="adverse events associated with ribavirin therapy for Severe fever with" exact="thrombocytopenia" post="syndrome. Antiviral Res.119, 19–22. 10.1016/j.antiviral.2015.04.00625892251 MendozaE. J.RacineT.KobingerG. P. (2017)."/>
   <result pre="(2011). Guideline for prevention and treatment of severe fever with" exact="thrombocytopenia" post="syndrome (2010 version). Chinese J. Clin. Infect. Dis.4, 193−194."/>
   <result pre="version). Chinese J. Clin. Infect. Dis.4, 193−194. NachbagauerR.KrammerF. (2017). Universal" exact="influenza" post="virus vaccines and therapeutic antibodies. Clin. Microbiol. Infect.23, 222–228."/>
   <result pre="10.1016/j.cmi.2017.02.00928216325 NakamuraS.AzumaM.MaruhashiT.SogabeK.SumitaniR.UemuraM.et al.. (2018). Steroid pulse therapy in patients with" exact="encephalopathy" post="associated with severe fever with thrombocytopenia syndrome. J. Infect."/>
   <result pre="therapy in patients with encephalopathy associated with severe fever with" exact="thrombocytopenia" post="syndrome. J. Infect. Chemother.24, 389–392. 10.1016/j.jiac.2017.11.00429428565 NingY.MoQ.FengK.MinY. Q.LiM.HouD.et al.."/>
   <result pre="STAT1. Front. Immunol.10:1182. 10.3389/fimmu.2019.0118231191546 NiuG.LiJ.LiangM.JiangX.JiangM.YinH.et al.. (2013). Severe fever with" exact="thrombocytopenia" post="syndrome virus among domesticated animals, China. Emerg. Infect. Dis.19,"/>
   <result pre="a coffee-related organic acid, inhibits infection by severe fever with" exact="thrombocytopenia" post="syndrome virus in vitro. J. Infect. Chemother.24, 597–601. 10.1016/j.jiac.2018.03.00529628386"/>
   <result pre="Plasma exchange and ribavirin for rapidly progressive severe fever with" exact="thrombocytopenia" post="syndrome. Int. J. Infect. Dis.18, 84–86. 10.1016/j.ijid.2013.08.01124161209 RamuJ.KonakT.PauleM. G.HanigJ."/>
   <result pre="Neurotoxicology56, 225–232. 10.1016/j.neuro.2016.08.01127555423 SaijoM. (2018). Pathophysiology of severe fever with" exact="thrombocytopenia" post="syndrome and development of specific antiviral therapy. J. Infect."/>
   <result pre="effect of post-exposure treatment with antiserum on severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) in a mouse model of SFTS virus"/>
   <result pre="Combination effects of ribavirin and interferons on severe fever with" exact="thrombocytopenia" post="syndrome virus infection. Virol. J.12:181. 10.1186/s12985-015-0412-326527529 ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014)."/>
   <result pre="ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014). Effects of ribavirin on severe fever with" exact="thrombocytopenia" post="syndrome virus in vitro. Jpn. J. Infect. Dis.67, 423–427."/>
   <result pre="The first identification and retrospective study of severe fever with" exact="thrombocytopenia" post="syndrome in Japan. J. Infect. Dis.209, 816–827. 10.1093/infdis/jit60324231186 TangH.YaoX.YaoC.ZhaoX.ZuoH.LiZ."/>
   <result pre="in Japan. J. Infect. Dis.209, 816–827. 10.1093/infdis/jit60324231186 TangH.YaoX.YaoC.ZhaoX.ZuoH.LiZ. (2017). Anti-colon" exact="cancer" post="effect of caffeic acid p-nitro-phenethyl ester in vitro and"/>
   <result pre="in the treatment of infections with lethal severe fever with" exact="thrombocytopenia" post="syndrome virus. mSphere1, e00061–e00015. 10.1128/mSphere.00061-1527303697 TaniH.KomenoT.FukumaA.FukushiS.TaniguchiS.ShimojimaM.et al.. (2018). Therapeutic"/>
   <result pre="al.. (2018). Therapeutic effects of favipiravir against severe fever with" exact="thrombocytopenia" post="syndrome virus infection in a lethal mouse model: dose-efficacy"/>
   <result pre="T. P.ManP. K. C.et al.. (2019). Endemic severe fever with" exact="thrombocytopenia" post="syndrome, Vietnam. Emerg. Infect. Dis.25, 1029–1031. 10.3201/eid2505.18146331002059 UtsunomiyaH.IchinoseM.IkedaK.UozakiM.MorishitaJ.KuwaharaT.et al.."/>
   <result pre="10.3201/eid2505.18146331002059 UtsunomiyaH.IchinoseM.IkedaK.UozakiM.MorishitaJ.KuwaharaT.et al.. (2014). Inhibition by caffeic acid of the" exact="influenza" post="a virus multiplication in vitro. Int. J. Mol. Med.34,"/>
   <result pre="al.. (2017). Screening of FDA-approved drugs for inhibitors of Japanese" exact="encephalitis" post="virus infection. J. Virol.91, e01055–e01017. 10.1128/JVI.01055-1728814523 WelchS. R.GuerreroL. W.ChakrabartiA."/>
   <result pre="of therapeutic plasma exchange in patients having severe fever with" exact="thrombocytopenia" post="syndrome. Korean J. Intern. Med.34, 902–909. 10.3904/kjim.2016.19429117665 YoshikawaR.SakabeS.UrataS.YasudaJ. (2019)."/>
   <result pre="902–909. 10.3904/kjim.2016.19429117665 YoshikawaR.SakabeS.UrataS.YasudaJ. (2019). Species-specific pathogenicity of severe fever with" exact="thrombocytopenia" post="syndrome virus is determined by anti-STAT2 activity of NSs."/>
   <result pre="YuX. J.LiangM. F.ZhangS. Y.LiuY.LiJ. D.SunY. L.et al.. (2011). Fever with" exact="thrombocytopenia" post="associated with a novel bunyavirus in China. N. Engl."/>
   <result pre="two-tier system identifies an entry inhibitor of severe fever with" exact="thrombocytopenia" post="syndrome virus. Viruses11:E385. 10.3390/v1104038531027241 ZhuL.YinF.MomingA.ZhangJ.WangB.GaoL.et al.. (2019). First case"/>
   <result pre="ZhuL.YinF.MomingA.ZhangJ.WangB.GaoL.et al.. (2019). First case of laboratory-confirmed severe fever with" exact="thrombocytopenia" post="syndrome disease revealed the risk of SFTSV infection in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7032198/results/search/disease/results.xml">
   <result pre="synergy between a high surface area (due to nanoparticles) and" exact="suppression" post="of crystallinity (due to amorphous dispersions of cellulose acetate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7087576/results/search/disease/results.xml">
   <result pre="in pathophysiological statesCell Cycle20111022924010.4161/cc.10.2.1447221220943 6.NiepmannM.Internal translation initiation of picornaviruses and" exact="hepatitis" post="C virusBiochim. Biophys. Acta2009178952954110.1016/j.bbagrm.2009.05.00219439208 7.BalvayL.Soto-RifoR.RicciE. P.DecimoD.OhlmannT.Structural and functional diversity"/>
   <result pre="ribosomal entry site (IRES) present within the 5'-nontranslated region of" exact="hepatitis" post="A virus RNA: comparison with the IRES of encephalomyocarditis"/>
   <result pre="of encephalomyocarditis virusJ. Virol.199468106610748289336 28.AliI. K.McKendrickL.MorleyS. J.JacksonR. J.Activity of the" exact="hepatitis" post="A virus IRES requires association between the cap-binding translation"/>
   <result pre="screening of respiratory tract infections in adults with and without" exact="asthma" post="reveals unexpected human coronavirus and human rhinovirus diversityJ. Infect."/>
   <result pre="49.GalassiF. M.HabichtM. E.RuhliF. J.Poliomyelitis in Ancient EgyptNeurol. Sci.20173837510.1007/s10072-016-2720-927665570 50.HorstmannD. M.YaleJ.The" exact="poliomyelitis" post="story: a scientific hegiraBiol. Med.1985587990 51.De JesusN. H.Epidemics to"/>
   <result pre="J.HowardR. S.PoliomyelitisPostgrad. Med. J.19967264164710.1136/pgmj.72.853.6418944203 54.ReznikB. I.KurakinaL. T.A pontine form of" exact="poliomyelitis" post="and isolated facial neuritisSov. Med.196125879113741125 55.MatzkeH. A.BakerA. B.Poliomyelitis. V."/>
   <result pre="62.GaaloulI.RiabiS.HarrathR.HunterT.HamdaK. B.GhzalaA. B.HuberS.AouniM.Coxsackievirus B detection in cases of myocarditis, myopericarditis," exact="pericarditis" post="and dilated cardiomyopathy in hospitalized patientsMol. Med. Rep.2014102811281810.3892/mmr.2014.257825241846 63.NovikovIu."/>
   <result pre="B detection in cases of myocarditis, myopericarditis, pericarditis and dilated" exact="cardiomyopathy" post="in hospitalized patientsMol. Med. Rep.2014102811281810.3892/mmr.2014.257825241846 63.NovikovIu. I.StulovaM. A.LavrovaI. K.Myocarditis"/>
   <result pre="E.ChoE. J.KimC. J.Acute viral myopericarditis presenting as a transient effusive-constrictive" exact="pericarditis" post="caused by coinfection with coxsackieviruses A4 and B3Korean J."/>
   <result pre="coxsackie B2 to blameActa Cardiol.201166798110.1080/AC.66.1.206497121446385 68.ChatterjeeS.QuarcoopomeC. O.ApentengA.Unusual type of epidemic" exact="conjunctivitis" post="in GhanaBr. J. Ophthalmol.19705462863010.1136/bjo.54.9.6285458256 69.LimK. H.Yin-MurphyM.An epidemic of conjunctivitis"/>
   <result pre="epidemic conjunctivitis in GhanaBr. J. Ophthalmol.19705462863010.1136/bjo.54.9.6285458256 69.LimK. H.Yin-MurphyM.An epidemic of" exact="conjunctivitis" post="in Singapore in 1970Singapore Med. J.1971122472495134044 70.WrightP. W.StraussG. H.LangfordM."/>
   <result pre="76.LeeB. E.DaviesH. D.Aseptic meningitisCurr. Opin. Infect. Dis.20072027227710.1097/QCO.0b013e3280ad467217471037 77.CuiA.YuD.ZhuZ.MengL.LiH.LiuJ.LiuG.MaoN.XuW.An outbreak of" exact="aseptic meningitis" post="caused by coxsackievirus A9 in Gansu, the People’s Republic"/>
   <result pre="E.DaviesH. D.Aseptic meningitisCurr. Opin. Infect. Dis.20072027227710.1097/QCO.0b013e3280ad467217471037 77.CuiA.YuD.ZhuZ.MengL.LiH.LiuJ.LiuG.MaoN.XuW.An outbreak of aseptic" exact="meningitis" post="caused by coxsackievirus A9 in Gansu, the People’s Republic"/>
   <result pre="in Gansu, the People’s Republic of ChinaVirol. J.201077210.1186/1743-422X-7-7220367886 78.IraniD. N.Aseptic" exact="meningitis" post="and viral myelitisNeurol. Clin.20082663510.1016/j.ncl.2008.03.00318657719 79.HuangC. C.LiuC. C.ChangY. C.ChenC. Y.WangS."/>
   <result pre="children during an epidemic in TaiwanPediatrics2002109e8810.1542/peds.109.6.e8812042582 83.LagaA. C.ShrobaS. M.HannaJ.A typical" exact="hand, foot and mouth disease" post="in adults associated with coxsackievirus A6: a clinicopathologic studyJ."/>
   <result pre="epidemic in TaiwanPediatrics2002109e8810.1542/peds.109.6.e8812042582 83.LagaA. C.ShrobaS. M.HannaJ.A typical hand, foot and" exact="mouth disease" post="in adults associated with coxsackievirus A6: a clinicopathologic studyJ."/>
   <result pre="a clinicopathologic studyJ. Cutan. Pathol.20164394094510.1111/cup.1277527445155 84.ChiuW. Y.LoY. H.YehT. C.Coxsackievirus associated" exact="hand, foot and mouth disease" post="in an adultQJM201610982382410.1093/qjmed/hcw15427634973 85.LeeK. Y.Enterovirus 71 infection and neurological"/>
   <result pre="Cutan. Pathol.20164394094510.1111/cup.1277527445155 84.ChiuW. Y.LoY. H.YehT. C.Coxsackievirus associated hand, foot and" exact="mouth disease" post="in an adultQJM201610982382410.1093/qjmed/hcw15427634973 85.LeeK. Y.Enterovirus 71 infection and neurological"/>
   <result pre="and neurological complicationsKorean J. Pediatr.20165939540110.3345/kjp.2016.59.10.39527826325 86.FowlkesA. L.HonarmandS.GlaserC.YagiS.SchnurrD.ObersteM. S.AndersonL.PallanschM. A.KhetsurianiN. J.Enterovirus-associated" exact="encephalitis" post="in the California encephalitis project, 1998-2005Infect. Dis.20081981685169110.1086/592988 87.ZhangL.YanJ.OjciusD. M.LvH.MiaoZ.ChenY.ZhangY.YanJ.Novel"/>
   <result pre="Pediatr.20165939540110.3345/kjp.2016.59.10.39527826325 86.FowlkesA. L.HonarmandS.GlaserC.YagiS.SchnurrD.ObersteM. S.AndersonL.PallanschM. A.KhetsurianiN. J.Enterovirus-associated encephalitis in the California" exact="encephalitis" post="project, 1998-2005Infect. Dis.20081981685169110.1086/592988 87.ZhangL.YanJ.OjciusD. M.LvH.MiaoZ.ChenY.ZhangY.YanJ.Novel and predominant pathogen responsible"/>
   <result pre="Dis.20081981685169110.1086/592988 87.ZhangL.YanJ.OjciusD. M.LvH.MiaoZ.ChenY.ZhangY.YanJ.Novel and predominant pathogen responsible for the enterovirus-associated" exact="encephalitis" post="in eastern ChinaPLoS One20138e8502310.1371/journal.pone.008502324386442 88.GusevE. A.BurdG. S.KonovalovA. N.Neurology and"/>
   <result pre="the treatment of neonates with enterovirus sepsis. National institute of" exact="allergy" post="and infectious diseases collaborative antiviral study groupJ. Pediatric Infect."/>
   <result pre="conserved inhibitory mechanism of a lycorine derivative against enterovirus and" exact="hepatitis" post="C virusAntimicrob. Agents Chemother.20166091392410.1128/AAC.02274-1526596952 115.LuG.QiJ.ChenZ.XuX.GaoF.LinD.QianW.LiuH.JiangH.YanJ.GaoG. F.Enterovirus 71 and coxsackievirus"/>
   <result pre="binding to rupintrivir and their substrates and anti-hand, foot, and" exact="mouth disease" post="virus drug designJ. Virol.201185103191033110.1128/JVI.00787-1121795339 116.ChenT. C.WengK. F.ChangS. C.LinJ. Y.HuangP."/>
   <result pre="of poliovirus type 3J. Virol.200478110971110710.1128/JVI.78.20.11097-11107.200415452230 125.Romero-LopezC.Barroso-DeljesusA.Berzal-HerranzA.The chaperone-like activity of the" exact="hepatitis" post="C virus IRES and CRE elements regulates genome dimerizationSci."/>
   <result pre="CRE elements regulates genome dimerizationSci. Rep.2017244341510.1038/srep43415 126.WakitaT.WandsJ. R.Specific inhibition of" exact="hepatitis" post="C virus expression by antisense oligodeoxynu-cleotides. In vitro model"/>
   <result pre="sequenceJ. Biol. Chem.199426914205142108188703 127.HanecakR.Brown-DriverV.FoxM. C.AzadR. F.FurusakoS.NozakiC.FordC.SasmorH.AndersonK. P.Antisense oligonucleotide inhibition of" exact="hepatitis" post="C virus gene expression in transformed hepatocytesJ. Virol.199670520352128764029 128.YangD.WilsonJ."/>
   <result pre="of recombinant oncolytic poliovirusCurr. Opin. Virol.201513818510.1016/j.coviro.2015.05.00726083317 130.NulfC. J.CoreyD.Intracellular inhibition of" exact="hepatitis" post="C virus (HCV) internal ribosomal entry site (IRES)-dependent translation"/>
   <result pre="nucleic acids (LNAs)Nucleic Acids Res.2004323792379810.1093/nar/gkh70615263060 131.Martinand-MariC.LebleuB.RobbinsI.Oligonucleotide-based strategies to inhibit human" exact="hepatitis" post="C virusOligonucleotides20031353954810.1089/15454570332286083415025918 132.DasguptaA.DasS.IzumiR.VenkatesanA.BaratB.Targeting internal ribosome entry site (IRES)-mediated translation"/>
   <result pre="virusOligonucleotides20031353954810.1089/15454570332286083415025918 132.DasguptaA.DasS.IzumiR.VenkatesanA.BaratB.Targeting internal ribosome entry site (IRES)-mediated translation to block" exact="hepatitis" post="C and other RNA virusesFEMS Microbiol. Lett.200423418919915135522 133.DibrovS. M.ParsonsJ.CarnevaliM.ZhouS.RynearsonK."/>
   <result pre="P.MeuseL.KarimiM.ContagC. H.KayM. A.A potent and specific morpholino antisense inhibitor of" exact="hepatitis" post="C translation in miceHepatology20033850350810.1053/jhep.2003.5033012883495 135.StoneJ. K.RijnbrandR.SteinD. A.MaY.YangY.IversenP. L.AndinoR.A morpholino"/>
   <result pre="of picornavirusAntimicrob. Agents Chemother.2008521970198110.1128/AAC.00011-0818347107 136.KandaT.SteeleR.RayR.RayR. B.Small interfering RNA targeted to" exact="hepatitis" post="C virus 5'-nontrans-lated region exerts potent antiviral effectJ. Virol.20078166967610.1128/JVI.01496-0617079316"/>
   <result pre="H.Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of" exact="hepatitis" post="C virus in mice with humanized liversGastroenterology2014146636510.1053/j.gastro.2013.09.04924076507 138.MaoX.LiX.MaoX.HuangZ.ZhangC.ZhangW.WuJ.LiG.Inhibition of"/>
   <result pre="hepatitis C virus in mice with humanized liversGastroenterology2014146636510.1053/j.gastro.2013.09.04924076507 138.MaoX.LiX.MaoX.HuangZ.ZhangC.ZhangW.WuJ.LiG.Inhibition of" exact="hepatitis" post="C virus by an M1GS ribozyme derived from the"/>
   <result pre="RNA recognition motif 2 of human La protein binds to" exact="hepatitis" post="C virus internal ribosome entry site, prevents ribosomal assembly,"/>
   <result pre="inhibits internal initiation of translationJ. Virol.2005799842985310.1128/JVI.79.15.9842-9853.200516014945 143.FontanesV.RaychaudhuriS.DasguptaA.A cell-permeable peptide inhibits" exact="hepatitis" post="C virus replication by sequestering IRES transacting factorsVirology2009394829010.1016/j.virol.2009.08.01219740508 144.De"/>
   <result pre="(HCV) therapyJ. Zhejiang University. Science. B201213568210.1631/jzus.B1100120 149.WakitaT.WandsJ. R.Specific inhibition of" exact="hepatitis" post="C virus expression by antisense oligodeoxynu-cleotides. In vitro model"/>
   <result pre="sequenceJ. Biol. Chem.199426914205142108188703 150.HanecakR.Brown-DriverV.FoxM. C.AzadR. F.FurusakoS.NozakiC.FordC.SasmorH.AndersonK. P.Antisense oligonucleotide inhibition of" exact="hepatitis" post="C virus gene expression in transformed hepatocytesJ. Virol.199670520352128764029 151.Martinand-MariC.LebleuB.RobbinsI.Oligonucleotide-based"/>
   <result pre="expression in transformed hepatocytesJ. Virol.199670520352128764029 151.Martinand-MariC.LebleuB.RobbinsI.Oligonucleotide-based strategies to inhibit human" exact="hepatitis" post="C virusOligonucleotides20031353954810.1089/15454570332286083415025918 152.NulfC. J.CoreyD.Intracellular inhibition of hepatitis C virus"/>
   <result pre="to inhibit human hepatitis C virusOligonucleotides20031353954810.1089/15454570332286083415025918 152.NulfC. J.CoreyD.Intracellular inhibition of" exact="hepatitis" post="C virus (HCV) internal ribosomal entry site (IRES)-dependent translation"/>
   <result pre="locked nucleic acids (LNAs)Nucleic Acids Res.2004323792379810.1093/nar/gkh70615263060 153.MutsoM.NikonovA.PihlakA.ZusinaiteE.ViruL.SelyutinaA.ReintammT.KelveM.SaarmaM.KarelsonM.MeritsA.RNA interference-guided targeting of" exact="hepatitis" post="C virus replication with antisense locked nucleic acid-based oligonucleotides"/>
   <result pre="Res.2014107354110.1016/j.antiviral.2014.04.00424769243 158.DasguptaA.DasS.IzumiR.VenkatesanA.BaratB.Targeting internal ribosome entry site (IRES)-mediated translation to block" exact="hepatitis" post="C and other RNA virusesFEMS Microbiol. Lett.200423418919915135522 159.HolochD.MoazedD.RNA-mediated epigenetic"/>
   <result pre="lipid nanoparticles as non-viral vector for the treatment of chronic" exact="hepatitis" post="C by RNA interferenceInt. J. Pharm.201547918118810.1016/j.ijpharm.2014.12.04725542984 162.SledzC. A.HolkoM.De VeerM."/>
   <result pre="deoxyri-bozymes in RNA researchMethods Enzymol.20094699511710.1016/S0076-6879(09)69005-420946786 164.RoyS.GuptaN.SubramanianN.MondaL. T.BanerjeaA. C.DasS.Sequence-specific cleavage of" exact="hepatitis" post="C virus RNA by DNAzymes: inhibition of viral RNA"/>
   <result pre="165.MacejakD. G.JensenK. L.JamisonS. F.DomenicoK.RobertsE. C.ChaudharyN.Von CarlowitzI.BellonL.TongM. J.ConradA.PavcoP. A.BlattL. M.Inhibition of" exact="hepatitis" post="C virus (HCV)-RNA-dependent translation and replication of a chimeric"/>
   <result pre="stabilized ribozymesHepatology20003176977610.1002/hep.51031033110706571 166.Romero-LopezC.Berzal-HerranzB.GomezJ.Berzal-HerranzA.An engineered inhibitor RNA that efficiently interferes with" exact="hepatitis" post="C virus translation and replicationAntiviral Res.20129413113810.1016/j.antiviral.2012.02.01522426470 167.KumarD.ChaudhuryI.KarP.DasR. H.Site-specific cleavage"/>
   <result pre="autoantigen is necessary for optimal function of the poliovirus and" exact="hepatitis" post="C virus internal ribosome entry site in vivo and"/>
   <result pre="entry sitesPLoS One20138e5295410.1371/journal.pone.005295423301007 176.RynearsonK. D.CharretteB.GabrielC.MorenoJ.BoernekeM. A.DibrovS. M.HermannT.2-Aminobenzoxazole ligands of the" exact="hepatitis" post="C virus internal ribosome entry siteBioorg. Med. Chem. Lett.2014243521352510.1016/j.bmcl.2014.05.08824930829"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7091927/results/search/disease/results.xml">
   <result pre="the current state of development of antiviral drugs that target" exact="influenza" post="virus and hepatitis B virus, and the future prospects"/>
   <result pre="of development of antiviral drugs that target influenza virus and" exact="hepatitis" post="B virus, and the future prospects for antivirals from"/>
   <result pre="drugs have been employed. As a result of global efforts," exact="smallpox" post="caused by variola virus infections was eradicated in 1979"/>
   <result pre="by variola virus infections was eradicated in 1979 because of" exact="smallpox" post="vaccination (by vaccinia virus). However, the development of effective"/>
   <result pre="diseases caused by the following nine viruses: HIV, human cytomegalovirus," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), herpes simplex"/>
   <result pre="following nine viruses: HIV, human cytomegalovirus, hepatitis B virus (HBV)," exact="hepatitis" post="C virus (HCV), herpes simplex virus, influenza virus, respiratory"/>
   <result pre="human cytomegalovirus, hepatitis B virus (HBV), hepatitis C virus (HCV)," exact="herpes simplex" post="virus, influenza virus, respiratory syncytial virus, varicella zoster virus"/>
   <result pre="B virus (HBV), hepatitis C virus (HCV), herpes simplex virus," exact="influenza" post="virus, respiratory syncytial virus, varicella zoster virus and human"/>
   <result pre="infections is emerging and re-emerging viruses, such as Ebola virus," exact="severe acute respiratory syndrome" post="coronavirus, Middle East respiratory syndrome coronavirus and Zika virus."/>
   <result pre="Institute of Microbial Chemistry (IMC) and discuss antiviral compounds against" exact="influenza" post="virus and HBV, because these two viruses threaten global"/>
   <result pre="in IMC Compound Viral infections Reference Formycins Influenza virus, poliovirus," exact="vaccinia virus," post="VSV 3, 4 Coformycin HIV 5 Oxanosine HIV 6,"/>
   <result pre="(HIV)d 27, 28 Siastatin B (Influenza virus)e 30 Abbreviations: HBV," exact="hepatitis" post="B virus; HCV, hepatitis C virus; HIV, human immunodeficiency"/>
   <result pre="B (Influenza virus)e 30 Abbreviations: HBV, hepatitis B virus; HCV," exact="hepatitis" post="C virus; HIV, human immunodeficiency virus; HSV, herpes simplex"/>
   <result pre="virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV," exact="herpes simplex" post="virus; IMC, Institute of Microbial Chemistry; VSV, vesicular stomatitis"/>
   <result pre="herpes simplex virus; IMC, Institute of Microbial Chemistry; VSV, vesicular" exact="stomatitis" post="virus. aInhibition of HIV reverse transcriptase. bInhibition of unknown"/>
   <result pre="anti-HIV drugs against HIV protease. eInhibition of sialidase activity of" exact="influenza" post="virus by epimeric analog of siastatin B. Table 2"/>
   <result pre="infections Reference Spongouridine Spongothymidine (HSV)a 1, 2 Statins HBV, HIV," exact="influenza" post="virus, DENV, HCMV, HCV 101, 102, 103, 104, 105,"/>
   <result pre="HCV 101, 102, 103, 104, 105, 106 Myriocin HCV, HBV," exact="influenza" post="virus 108, 109, 110 NA255 HCV 108 Cyclosporine A"/>
   <result pre="108, 109, 110 NA255 HCV 108 Cyclosporine A HIV, HPV," exact="influenza" post="virus, HBV, HCV, coronaviruses, HCMV 81, 82, 111, 112,"/>
   <result pre="112, 113, 114, 115, 116 Abbreviations: DENV, dengue virus; HBV," exact="hepatitis" post="B virus; HCMV, human cytomegalovirus; HCV, hepatitis C virus;"/>
   <result pre="dengue virus; HBV, hepatitis B virus; HCMV, human cytomegalovirus; HCV," exact="hepatitis" post="C virus; HIV, human immunodeficiency virus; HSV, herpes simplex"/>
   <result pre="cytomegalovirus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV," exact="herpes simplex" post="virus; HPV, human papillomavirus. aContributed to the synthesis of"/>
   <result pre="of vidarabine (arabinosyladenine), which is used for the treatment of" exact="herpes simplex" post="virus infections. Professor Umezawa and colleagues identified nucleoside analogs"/>
   <result pre="viruses: phleomycin (anti-poliovirus activity),14 fusaric acid (broad-spectrum antiviral activity against" exact="herpes simplex" post="virus, varicella-zoster virus, HBV, HCV and sindbis virus),15 aclacinomycin"/>
   <result pre="siastatin B showed no effect on the sialidase activity of" exact="influenza" post="virus neuraminidase (NA), its epimeric analog significantly inhibited this"/>
   <result pre="unique pharmacophores for antiviral drugs. Influenza virus Influenza virus Seasonal" exact="influenza" post="is acute respiratory infections caused by influenza viruses. There"/>
   <result pre="Influenza virus Seasonal influenza is acute respiratory infections caused by" exact="influenza" post="viruses. There are three types of seasonal influenza viruses—type"/>
   <result pre="caused by influenza viruses. There are three types of seasonal" exact="influenza" post="viruses—type A, B and C; influenza A and B"/>
   <result pre="three types of seasonal influenza viruses—type A, B and C;" exact="influenza" post="A and B viruses cause outbreaks and epidemics. The"/>
   <result pre="The World Health Organization estimates that annual epidemics caused by" exact="influenza" post="A(H1N1), A(H3N2) and B viruses result in ~3 to"/>
   <result pre="severe illness and 250 000 to 500 000 deaths, globally.31 Furthermore, an" exact="influenza" post="pandemic, such as those of the ‘Spanish’ influenza in"/>
   <result pre="Furthermore, an influenza pandemic, such as those of the ‘Spanish’" exact="influenza" post="in 1918 (H1N1),’ ‘Asian’ influenza in 1957 (H2N2),’ ‘Hong"/>
   <result pre="as those of the ‘Spanish’ influenza in 1918 (H1N1),’ ‘Asian’" exact="influenza" post="in 1957 (H2N2),’ ‘Hong Kong’ influenza in 1968 (H3N2),’"/>
   <result pre="in 1918 (H1N1),’ ‘Asian’ influenza in 1957 (H2N2),’ ‘Hong Kong’" exact="influenza" post="in 1968 (H3N2),’ ‘Russian’ influenza in 1977 (H1N1)’ and"/>
   <result pre="in 1957 (H2N2),’ ‘Hong Kong’ influenza in 1968 (H3N2),’ ‘Russian’" exact="influenza" post="in 1977 (H1N1)’ and 2009 H1N1 influenza (swine-origin H1N1),"/>
   <result pre="1968 (H3N2),’ ‘Russian’ influenza in 1977 (H1N1)’ and 2009 H1N1" exact="influenza" post="(swine-origin H1N1), occurs when new influenza A virus against"/>
   <result pre="(H1N1)’ and 2009 H1N1 influenza (swine-origin H1N1), occurs when new" exact="influenza" post="A virus against which the human population has no"/>
   <result pre="discovery and development of new antiviral drugs and vaccines against" exact="influenza" post="infections are required. A total of eight drugs (matrix"/>
   <result pre="(ribavirin and favipiravir) have been approved for the treatment of" exact="influenza" post="infections. M2 inhibitors 1-Adamantanamine (amantadine) was the first synthetic"/>
   <result pre="1-Adamantanamine (amantadine) was the first synthetic compound shown to inhibit" exact="influenza" post="virus propagation33 and was approved in 1966 to treat"/>
   <result pre="influenza virus propagation33 and was approved in 1966 to treat" exact="influenza" post="A virus infections. The target of amantadine is M2"/>
   <result pre="a derivative of amantadine, are not currently used to treat" exact="influenza" post="virus infections because drug-resistant viruses can emerge rapidly (both"/>
   <result pre="in patients treated with amantadine. Figure 1 Life cycle of" exact="influenza" post="virus and anti-influenza virus drugs. Influenza virus is incorporated"/>
   <result pre="(HA) and NA are two major glycoproteins expressed by both" exact="influenza" post="A and B viruses. HA mediates the binding of"/>
   <result pre="from host cells. NA activity facilitates the release of progeny" exact="influenza" post="virus by digesting sialic acids in the HA receptors"/>
   <result pre="of Clostridium perfrigens NAs, but does not inhibit that of" exact="influenza" post="virus (A/Aichi/2/68 strain) NA and Newcastle disease virus (Sato"/>
   <result pre="epimeric analog, 3-episiastatin B, can inhibit the sialidase activity of" exact="influenza" post="A and B viruses NA and propagation of influenza"/>
   <result pre="of influenza A and B viruses NA and propagation of" exact="influenza" post="A virus.30 A synthetic analog of neuraminic acid, 2,3-didehydro-2-deoxy-N-acetylneuraminic"/>
   <result pre="2,3-didehydro-2-deoxy-N-acetylneuraminic acid (Neu5Ac2en), was found to be an inhibitor of" exact="influenza" post="virus NA.36 Neu5Ac2en is considered to be a transition"/>
   <result pre="complex, analogs of Neu5Ac2en were synthesized and the specificity for" exact="influenza" post="virus NA and activity of these analogs were tested."/>
   <result pre="Among these analogs, 4-guanidino-Neu5Ac2en (zanamivir) exhibited antiviral activity against various" exact="influenza" post="A and B viruses.40 The guanidine group in zanamivir"/>
   <result pre="analysis of NA with key analogs.41 One analog, GS4071, inhibited" exact="influenza" post="A virus NA activity. The NA inhibition activity of"/>
   <result pre="These two drugs are used as a single-dose treatment for" exact="influenza" post="A and B viruses. Virus polymerase inhibitors Viral polymerase"/>
   <result pre="PB1 and PB2. At the initiation of viral mRNA transcription," exact="influenza" post="viral polymerase cannot synthesize the 5′-cap structure of mRNA"/>
   <result pre="represents an orally bioavailable compound that is only effective for" exact="influenza" post="A virus, not influenza B virus. S-03318 specifically inhibits"/>
   <result pre="compound that is only effective for influenza A virus, not" exact="influenza" post="B virus. S-03318 specifically inhibits the endonuclease activity of"/>
   <result pre="the cleavage of host pre-mRNAs. S-03318 is effective for both" exact="influenza" post="A and influenza B virus infections. Two approved drugs,"/>
   <result pre="host pre-mRNAs. S-03318 is effective for both influenza A and" exact="influenza" post="B virus infections. Two approved drugs, ribavirin and T-705"/>
   <result pre="virus infections. Two approved drugs, ribavirin and T-705 (favipiravir), inhibit" exact="influenza" post="viral RNA synthesis (Figure 1). Ribavirin is a synthetic"/>
   <result pre="triphosphate form (Ribavirin-TP).48 Ribavirin-TP inhibits the RNA polymerase complex of" exact="influenza" post="virus by competing with ATP and GTP.49 Ribavirin has"/>
   <result pre="ATP and GTP.49 Ribavirin has not been used to treat" exact="influenza" post="virus infection, but has been used for HCV infections"/>
   <result pre="in cells.50, 51 T705-4-ribofuranosyl-5′-triphosphate acts as a specific inhibitor of" exact="influenza" post="virus RNA synthesis. T705-4-ribofuranosyl-5′-triphosphate directly inhibits viral RNA synthesis"/>
   <result pre="exhibit infectivity. T-705 has been approved for use against pandemic" exact="influenza" post="infections in Japan. Natural products for anti-influenza virus infections"/>
   <result pre="estimates in 2016, the annual number of deaths resulting from" exact="viral hepatitis" post="is ~1.4 million, which is comparable to that of"/>
   <result pre="in 2016, the annual number of deaths resulting from viral" exact="hepatitis" post="is ~1.4 million, which is comparable to that of"/>
   <result pre="HBV worldwide and have an elevated risk of developing liver" exact="cirrhosis" post="and hepatocellular carcinoma.60 Current antiviral drugs approved by the"/>
   <result pre="to supply the cccDNA pool. Figure 2 Life cycle of" exact="hepatitis" post="B virus (HBV). HBV enters hepatocytes following binding to"/>
   <result pre="Although nucleos(t)ide analog inhibitors can be highly effective in preventing" exact="liver disease" post="progression, these drugs are not curative and require long-term"/>
   <result pre="HBsAg, which is correlated with dramatic reduction of incidence of" exact="hepatocellular carcinoma." post="However, current nucleos(t)ide inhibitors are ineffective in this regard,"/>
   <result pre="Australia, Hantavirus in the United States, Ebola virus in Africa," exact="severe acute respiratory syndrome" post="and Middle East respiratory syndrome coronaviruses in China and"/>
   <result pre="and Mideast, Zika virus in Oceania and Americas, and the" exact="influenza" post="virus H5N1, H1N1 and H7N2 subtypes. No efficient vaccine"/>
   <result pre="Antiviral effects of stains have been reported for HBV, HIV," exact="influenza" post="virus, dengue virus, human cytomegalovirus and HCV.101, 102, 103,"/>
   <result pre="incarnatum,108 can also inhibit the propagation of HCV, HBV and" exact="influenza" post="virus.108, 109, 110 Serine palmitoyltransferase acts in the sphingomyelin"/>
   <result pre="component of ‘lipid rafts’. Myriocin inhibits the intracellular transport of" exact="influenza" post="virus glycoproteins and NA255 disrupts the HCV replication complex."/>
   <result pre="CsA is effective against viruses such as HIV, human papillomavirus," exact="influenza" post="virus, HCV, coronaviruses and human cytomegalovirus.111, 112, 113, 114,"/>
   <result pre="simulation reveals a multifaceted mechanism of proton permeation through the" exact="influenza" post="A M2 proton channelProc. Natl Acad. Sci. USA20141119396940124979779 35HongMDegradoWFStructural"/>
   <result pre="USA20141119396940124979779 35HongMDegradoWFStructural basis for proton conduction and inhibition by the" exact="influenza" post="M2 proteinNature200845159659918235504 36MeindlPBodoGPalesePSchulmanJTuppyHInhibition of neuraminidase activity by derivatives of"/>
   <result pre="of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acidVirology1974584574634362431 37JanakiramanMNWhiteCLLaverWGAirGMLuoMStructure of" exact="influenza" post="virus neuraminidase B/Lee/40 complexed with sialic acid and a"/>
   <result pre="38TaylorNRvon ItzsteinMMolecular modeling studies on ligand binding to sialidase from" exact="influenza" post="virus and the mechanism of catalysisJ. Med. Chem.1994376166248126701 39ChongAKPeggMSvon"/>
   <result pre="ionisable group involved in binding and catalysis by sialidase from" exact="influenza" post="virusBiochem. Int.1991241651711768256 40von ItzsteinMRational design of potent sialidase-based inhibitors"/>
   <result pre="virusBiochem. Int.1991241651711768256 40von ItzsteinMRational design of potent sialidase-based inhibitors of" exact="influenza" post="virus replicationNature19933634184238502295 41KimCUInfluenza neuraminidase inhibitors possessing a novel hydrophobic"/>
   <result pre="anti-influenza activityJ. Am. Chem. Soc.199711968169016526129 42EisenbergEJBidgoodACundyKCPenetration of GS4071, a novel" exact="influenza" post="neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral"/>
   <result pre="activity of VX-787, a first-in-class, orally bioavailable inhibitor of the" exact="influenza" post="virus polymerase PB2 subunitAntimicrob. Agents Chemother.2015591569158225547360 47ClarkMPDiscovery of a"/>
   <result pre="of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of" exact="influenza" post="PB2J. Med. Chem.2014576668667825019388 48SidwellRWBroad-spectrum antiviral activity of virazole: 1-f8-"/>
   <result pre="antiviral activity of virazole: 1-f8- D-ribofuranosyl- 1,2,4-triazole- 3-carboxamideScience19721777057064340949 49ErikssonBInhibition of" exact="influenza" post="virus ribonucleic acid polymerase by ribavirin triphosphate inhibition of"/>
   <result pre="influenza virus ribonucleic acid polymerase by ribavirin triphosphate inhibition of" exact="influenza" post="virus ribonucleic acid polymerase by ribavirin triphosphateAntimicrob. Agents Chemother.197711946951879760"/>
   <result pre="compound T-705Antimicrob. Agents Chemother.20024697798111897578 51FurutaYMechanism of action of T-705 against" exact="influenza" post="virusAntimicrob. Agents Chemother.20054998198615728892 52JinZSmithLKRajwanshiVKKimBDevalJThe ambiguous base-pairing and high substrate"/>
   <result pre="and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5’-triphosphate towards" exact="influenza" post="A virus polymerasePLoS ONE20138e6834723874596 53BaranovichTT-705 (Favipiravir) induces lethal mutagenesis"/>
   <result pre="A virus polymerasePLoS ONE20138e6834723874596 53BaranovichTT-705 (Favipiravir) induces lethal mutagenesis in" exact="influenza" post="A H1N1 viruses in vitroJ. Virol.2013873741375123325689 54SangawaHMechanism of action"/>
   <result pre="vitroJ. Virol.2013873741375123325689 54SangawaHMechanism of action of T-705 ribosyl triphosphate against" exact="influenza" post="virus RNA polymeraseAntimicrob. Agents Chemother.2013575202520823917318 55GrienkeUInfluenza neuraminidase: a druggable"/>
   <result pre="63YanHSodium taurocholate cotransporting polypeptide is a functional receptor for human" exact="hepatitis" post="B and D virusElife20121128 64Hepatitis B Foundation. Treatment &amp;amp;"/>
   <result pre="oxetanocin G, a novel nucleoside analog, on DNA synthesis by" exact="hepatitis" post="B virus virionsAntimicrob. Agents Chemother.1994387077127518217 67NagahataTUedaKTsurimotoTChisakaOMatsubaraKAnti-hepatitis B virus activities"/>
   <result pre="oxetanocin AJ. Antibiot. (Tokyo)1989426446462722678 68WangXEmerging antivirals for the treatment of" exact="hepatitis" post="BWorld J. Gastroenterol.201420770724976708 69SummersJSmithPMHorwichALHepadnavirus envelope proteins regulate covalently closed"/>
   <result pre="closed circular DNA amplificationJ. Virol.199064281928242335817 70LevreroMControl of cccDNA function in" exact="hepatitis" post="B virus infectionJ. Hepatol.20095158159219616338 71YangLIsothiafludine, a novel non-nucleoside compound,"/>
   <result pre="B virus infectionJ. Hepatol.20095158159219616338 71YangLIsothiafludine, a novel non-nucleoside compound, inhibits" exact="hepatitis" post="B virus replication through blocking pregenomic RNA encapsidationActa Pharmacol."/>
   <result pre="through blocking pregenomic RNA encapsidationActa Pharmacol. Sin.20143541041824487969 72YangLEffect of a" exact="hepatitis" post="B virus inhibitor, NZ-4, on capsid formationAntiviral Res.2016125253326611395 73HuYChengXCaoFHuangATavisJEβ-Thujaplicinol"/>
   <result pre="B virus inhibitor, NZ-4, on capsid formationAntiviral Res.2016125253326611395 73HuYChengXCaoFHuangATavisJEβ-Thujaplicinol inhibits" exact="hepatitis" post="B virus replication by blocking the viral ribonuclease H"/>
   <result pre="blocking the viral ribonuclease H activityAntiviral Res.20139922122923796982 74LuGHydroxylated tropolones inhibit" exact="hepatitis" post="B virus replication by blocking viral ribonuclease H activityAntimicrob."/>
   <result pre="by Streptoverticillium hadanonense KY11449J. Antibiot. (Tokyo)1986395895933086266 76SuzukiMEfficient genome replication of" exact="hepatitis" post="B virus using adenovirus vector: a compact pregenomic RNA-expression"/>
   <result pre="adenovirus vector: a compact pregenomic RNA-expression unitSci. Rep.201774185128157182 77GehringABertolettiATavisJEHost factor-targeted" exact="hepatitis" post="B virus therapiesIntervirology20145715816225034483 78EzzikouriSRecent insights into hepatitis B virus-host"/>
   <result pre="Rep.201774185128157182 77GehringABertolettiATavisJEHost factor-targeted hepatitis B virus therapiesIntervirology20145715816225034483 78EzzikouriSRecent insights into" exact="hepatitis" post="B virus-host interactionsJ. Med. Virol.20148692593224604126 79GriponPCannieIUrbanSEfficient inhibition of hepatitis"/>
   <result pre="into hepatitis B virus-host interactionsJ. Med. Virol.20148692593224604126 79GriponPCannieIUrbanSEfficient inhibition of" exact="hepatitis" post="B virus infection by acylated peptides derived from the"/>
   <result pre="blocks intrahepatic virus spreading in humanized mice previously infected with" exact="hepatitis" post="B virusJ. Hepatol.20135886186723246506 81NkongoloSCyclosporin A inhibits hepatitis B and"/>
   <result pre="previously infected with hepatitis B virusJ. Hepatol.20135886186723246506 81NkongoloSCyclosporin A inhibits" exact="hepatitis" post="B and hepatitis D virus entry by cyclophilin-independent interference"/>
   <result pre="hepatitis B virusJ. Hepatol.20135886186723246506 81NkongoloSCyclosporin A inhibits hepatitis B and" exact="hepatitis" post="D virus entry by cyclophilin-independent interference with the NTCP"/>
   <result pre="the NTCP receptorJ. Hepatol.20146072373124295872 82WatashiKCyclosporin A and its analogs inhibit" exact="hepatitis" post="B virus entry into cultured hepatocytes through targeting a"/>
   <result pre="membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)Hepatology2014591726173724375637 83BlockTMSecretion of human" exact="hepatitis" post="B virus is inhibited by the imino sugar N-butyldeoxynojirimycinProc."/>
   <result pre="tick-borne flavivirusesAntiviral Res.2017142636728336346 97JulanderJGBCX4430, a novel nucleoside analog, effectively treats" exact="yellow fever" post="in a hamster modelAntimicrob. Agents Chemother.2014586607661425155605 98JulanderJGEfficacy of the"/>
   <result pre="for combination therapy with interferonHepatology20064411712516799963 103PengJProtective effect of fluvastatin on" exact="influenza" post="virus infectionMol. Med. Rep.201492221222624676773 104GiguèreJTremblayMJStatin compounds reduce human immunodeficiency"/>
   <result pre="arbomycesJ. Antibiot. (Tokyo)197222109115 108SakamotoHHost sphingolipid biosynthesis as a target for" exact="hepatitis" post="C virus therapyNat. Chem. Biol.2005133333716408072 109TatematsuKTanakaYSugiyamaMSudohMMizokamiMHost sphingolipid biosynthesis is"/>
   <result pre="biosynthesis is a promising therapeutic target for the inhibition of" exact="hepatitis" post="B virus replicationJ. Med. Virol.20118358759321328371 110TafesseFGIntact sphingomyelin biosynthetic pathway"/>
   <result pre="110TafesseFGIntact sphingomyelin biosynthetic pathway is essential for intracellular transport of" exact="influenza" post="virus glycoproteinsProc. Natl Acad. Sci. USA20131106406641123576732 111Bienkowska-HabaMWilliamsCKimSMGarceaRLSappMCyclophilins facilitate dissociation"/>
   <result pre="as target for pan-coronavirus inhibitorsPLoS Pathog.20117e100233122046132 114LiuXCyclosporin A inhibits the" exact="influenza" post="virus replication through cyclophilin A-dependent and -independent pathwaysPLoS ONE2012718"/>
   <result pre="replication and reactivationJ. Gen. Virol.20129372273222238232 116WatashiKHijikataMHosakaMYamajiMShimotohnoKCyclosporin A suppresses replication of" exact="hepatitis" post="C virus genome in cultured hepatocytesHepatology2003381282128814578868 117MatsudaSKoyasuSMechanisms of action"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7104000/results/search/disease/results.xml">
   <result pre="and colleagues is that all individuals with symptomatic infection with" exact="severe acute respiratory syndrome" post="(SARS) coronavirus 2 (SARS-CoV-2) are eventually tested and reported."/>
   <result pre="drug, hydroxychloroquine, is licensed for the chemoprophylaxis and treatment of" exact="malaria" post="and as a disease-modifying antirheumatic drug. It has a"/>
   <result pre="ameliorate viral shedding.5 Clinical trials of hydroxychloroquine treatment for COVID-19" exact="pneumonia" post="are underway in China (NCT04261517 and NCT04307693). We are"/>
   <result pre="close contactsmedRxiv2020published online March 4.10.1101/2020.03.03.20028423(preprint). 3WelliverRMontoASCarewiczOEffectiveness of oseltamivir in preventing" exact="influenza" post="in household contacts: a randomized controlled trialJAMA285200174875411176912 4YaoXYeFZhangMIn vitro"/>
   <result pre="of optimized dosing design of hydroxychloroquine for the treatment of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020published online March 9.10.1093/cid/ciaa237 5TettSECutlerDJDayROBrownKFBioavailability"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7114304/results/search/disease/results.xml">
   <result pre="(N-7 MTase) domain of protein D1 from the dsDNA virus" exact="vaccinia virus" post="(PDB accession code 2VDW) in complex with a molecule"/>
   <result pre="2′-O MTase: VP39, the 2′-O MTase of the dsDNA virus" exact="vaccinia virus," post="in complex with a capped RNA and AdoHcy (PDB"/>
   <result pre="Endonuclease fold: (I) endonuclease (N-terminal) domain of L protein of" exact="lymphocytic choriomeningitis" post="virus (PDB code 3JSB). Structures are colored cyan for"/>
   <result pre="help accommodate or stabilize the substrate. The N-7 MTase of" exact="vaccinia virus" post="(VV) serves as structural and reference model of N-7"/>
   <result pre="al., 1986). SAH analogues were shown to inhibit VV and" exact="herpes simplex" post="virus (HSV) and their respective MTases were proposed as"/>
   <result pre="cap structure. Since then, it has been demonstrated that vesicular" exact="stomatitis" post="virus (VSV, Mononegavirales) and alphaviruses (Togaviridae) can synthesize a"/>
   <result pre="non-segmented (NNS) RNA viruses comprises major human pathogens such as" exact="rabies" post="virus (Rhabdoviridae), measles virus (Paramyxovirinae), bornavirus (Bornaviridae) and Ebola/Marburg"/>
   <result pre="viruses comprises major human pathogens such as rabies virus (Rhabdoviridae)," exact="measles" post="virus (Paramyxovirinae), bornavirus (Bornaviridae) and Ebola/Marburg viruses (Filoviridae). RNA"/>
   <result pre="exemplified by some alphaviruses (Semliki Forest virus, sindbis virus and" exact="chikungunya" post="virus) synthesize their cap-0 structure through another non-conventional mechanism"/>
   <result pre="2001), tobacco mosaic virus P126 (Merits et al., 1999) and" exact="hepatitis" post="E virus p110 (Magden et al., 2001) were reported"/>
   <result pre="both mechanistic and structural studies. In the case of the" exact="influenza" post="virus, the replication complex is made of three proteins"/>
   <result pre="L-735,882 compound reached an IC50 value of 1.1 μM for" exact="influenza" post="in an in vitro endonuclease assay and an IC50"/>
   <result pre="value of 2 μM in a viral titer assay using" exact="influenza" post="virus infected cells. The La Crosse virus, a Bunyaviridae"/>
   <result pre="La Crosse virus replicates in the cytoplasm exclusively, unlike the" exact="influenza" post="virus. Therefore, RNA caps are likely snatched in different"/>
   <result pre="active site gave very interesting perspectives for effective drugs targeting" exact="influenza" post="RNA capping. 7 Conclusions The viral RNA capping machinery"/>
   <result pre="structure of the methylated mRNA synthesized in vitro by vesicular" exact="stomatitis" post="virusCell519755158165900 AbrahamG.RhodesD.P.BanerjeeA.K.Novel initiation of RNA synthesis in vitro by"/>
   <result pre="virusCell519755158165900 AbrahamG.RhodesD.P.BanerjeeA.K.Novel initiation of RNA synthesis in vitro by vesicular" exact="stomatitis" post="virusNature25519753740165428 AholaT.AhlquistP.Putative RNA capping activities encoded by brome mosaic"/>
   <result pre="involved in methyltransferase and guanylyltransferase-like activitiesJ. Virol.7119973923978985362 AlmazanF.DediegoM.L.GalanC.EscorsD.AlvarezE.OrtegoJ.SolaI.ZunigaS.AlonsoS.MorenoJ.L.NogalesA.CapiscolC.EnjuanesL.Construction of a" exact="severe acute respiratory syndrome" post="coronavirus infectious cDNA clone and a replicon to study"/>
   <result pre="Biol. Chem.2792004221242213015037606 BouloyM.PlotchS.J.KrugR.M.Globin mRNAs are primers for the transcription of" exact="influenza" post="viral RNA in vitroProc. Natl. Acad. Sci. USA75197848864890283399 BouvetM.DebarnotC.ImbertI.SeliskoB.SnijderE.J.CanardB.DecrolyE.In"/>
   <result pre="of the host-derived sequences present at the 5′ ends of" exact="influenza" post="virus mRNANucleic Acids Res.8198025916253885 ChangelaA.HoC.K.MartinsA.ShumanS.MondragónA.Structure and mechanism of the"/>
   <result pre="la PeñaM.KyrieleisO.J.P.CusackS.Structural insights into the mechanism and evolution of the" exact="vaccinia virus" post="mRNA cap N7 methyl-transferaseEMBO J.2620074913492517989694 DecrolyE.DebarnotC.FerronF.BouvetM.CoutardB.ImbertI.GluaisL.PapageorgiouN.SharffA.BricogneG.Ortiz-LombardiaM.LescarJ.CanardB.Crystal structure and functional"/>
   <result pre="cap (nucleoside-2′O)-methyltransferaseBioorg. Med. Chem.1520077795780217888664 MagdenJ.TakedaN.LiT.AuvinenP.AholaT.MiyamuraT.MeritsA.KaariainenL.Virus-specific mRNA capping enzyme encoded by" exact="hepatitis" post="E virusJ. Virol.7520016249625511413290 MalmgaardL.Induction and regulation of IFNs during"/>
   <result pre="of mRNA capping by the RNA-dependent RNA polymerase of vesicular" exact="stomatitis" post="virusMol. Cell252007859717218273 OginoT.BanerjeeA.K.The HR motif in the RNA-dependent RNA"/>
   <result pre="virusAntiviral Res.912011899321616094 PlotchS.J.BouloyM.KrugR.M.Transfer of 5′-terminal cap of globin mRNA to" exact="influenza" post="viral complementary RNA during transcription in vitroProc. Natl. Acad."/>
   <result pre="Cell Biol.3200261962512154373 SongJ.M.LeeK.H.SeongB.L.Antiviral effect of catechins in green tea on" exact="influenza" post="virusAntiviral Res.682005667416137775 SoulièreM.F.PerreaultJ.-P.BisaillonM.Kinetic and thermodynamic characterization of the RNA"/>
   <result pre="ThomasE.FeldJ.J.LiQ.HuZ.FriedM.W.LiangT.J.Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in" exact="hepatitis" post="C virus cell culture modelsHepatology532011324121254160 TomassiniJ.SelnickH.DaviesM.E.ArmstrongM.E.BaldwinJ.BourgeoisM.HastingsJ.HazudaD.LewisJ.McClementsW.Inhibition of cap (m7G"/>
   <result pre="cell culture modelsHepatology532011324121254160 TomassiniJ.SelnickH.DaviesM.E.ArmstrongM.E.BaldwinJ.BourgeoisM.HastingsJ.HazudaD.LewisJ.McClementsW.Inhibition of cap (m7G pppXm)-dependent endonuclease of" exact="influenza" post="virus by 4-substituted 2,4-dioxobutanoic acid compoundsAntimicrob. Agents Chemother.381994282728377695269 van"/>
   <result pre="Opin. Immunol.222010414720061127 ZhouS.LiuR.BaroudyB.M.MalcolmB.A.ReyesG.R.The effect of ribavirin and IMPDH inhibitors on" exact="hepatitis" post="C virus subgenomic replicon RNAVirology310200333334212781720 ZhouY.RayD.ZhaoY.DongH.RenS.LiZ.GuoY.BernardK.A.ShiP.Y.LiH.Structure and function of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7118541/results/search/disease/results.xml">
   <result pre="Gammacoronavirus[4]. Two infamous infectious coronaviruses in the genus Betacoronavirus are" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) [5] and Middle East respiratory syndrome coronavirus"/>
   <result pre="the previous outbreak due to a recent epidemic of atypical" exact="pneumonia" post="(designated as coronavirus disease 2019; COVID-19) caused by a"/>
   <result pre="latency on average after infection. This is relatively slower than" exact="severe acute respiratory syndrome" post="(SARS), which was caused by SARS-CoV [10]. During the"/>
   <result pre="drugs (rapamycin and everolimus) and a drug (tiotropium bromide) for" exact="asthma" post="and chronic obstructive pulmonary disease (COPD) were identified as"/>
   <result pre="and everolimus) and a drug (tiotropium bromide) for asthma and" exact="chronic obstructive pulmonary disease" post="(COPD) were identified as promising candidates by MT-DTI. In"/>
   <result pre="6ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med36720121814182023075143 7WHO. Summary of"/>
   <result pre="of optimized dosing design of hydroxychloroquine for the treatment of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 33HolshueM.L.DeBoltC.LindquistS.LofyK.H.WiesmanJ.BruceH.First case of 2019"/>
   <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci Trends1412020646832037389 35MaxmenA.More"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7127483/results/search/disease/results.xml">
   <result pre="Reports201774314310.1038/srep4314328220872 He, Duan &amp;amp; Tan (2007)HeYDuanWTanS-LEmerging host cell targets for" exact="hepatitis" post="C therapyDrug Discovery Today2007125–620921717331885 Hernaez, Escribano &amp;amp; Alonso (2008)HernaezBEscribanoJMAlonsoCAfrican"/>
   <result pre="antiviral drug developmentAntiviral Research201511814815810.1016/j.antiviral.2015.03.01425842996 Mak et al. (2019)MakL-YSetoW-KFungJYuenM-FNovel developments of" exact="hepatitis" post="B: treatment goals, agents and monitoring toolsExpert Review of"/>
   <result pre="(2013)RodríguezJMSalasMLAfrican swine fever virus transcriptionVirus Research20131731152810.1016/j.virusres.2012.09.01423041356 Rozenblatt-Rosen et al. (2012)Rozenblatt-RosenODeoRCPadiMAdelmantGCalderwoodMARollandTGraceMDricotAAskenaziMTavaresMPevznerSJAbderazzaqFByrdsongDCarvunisARChenAAChengJCorrellMDuarteMFanCFeltkampMCFicarroSBFranchiRGargBKGulbahceNHaoTHolthausAMJamesRKorkhinALitovchickLMarJCPakTRRabelloSRubioRShenYSinghSSpangleJMTasanMWanamakerSWebberJTRoecklein-CanfieldJJohannsenEBarabásiALBeroukhimRKieffECusickMEHillDEMüngerKMartoJAQuackenbushJRothFPDeCaprioJAVidalMInterpreting" exact="cancer" post="genomes using systematic host network perturbations by tumour virus"/>
   <result pre="virusVirus Research201926515015510.1016/j.virusres.2019.03.02230922809 Sánchez-Cordón et al. (2018)Sánchez-CordónPMontoyaMReisADixonLKAfrican swine fever: a re-emerging" exact="viral disease" post="threatening the global pig industryVeterinary Journal2018233414810.1016/j.tvjl.2017.12.025 Tan et al."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7127693/results/search/disease/results.xml">
   <result pre="to humankind. Every year, known viruses such as HIV-1 and" exact="hepatitis" post="B virus newly infect millions of people across the"/>
   <result pre="across the globe. In addition, recent outbreaks of Ebola virus," exact="influenza" post="virus, severe acute respiratory syndrome (SARS) coronavirus and Middle"/>
   <result pre="globe. In addition, recent outbreaks of Ebola virus, influenza virus," exact="severe acute respiratory syndrome" post="(SARS) coronavirus and Middle East respiratory syndrome-coronavirus (MERS-CoV) serve"/>
   <result pre="that over 1.34 million causalities per year are connected with" exact="hepatitis" post="B and almost 500,000 with hepatitis C. Occasional epidemic"/>
   <result pre="year are connected with hepatitis B and almost 500,000 with" exact="hepatitis" post="C. Occasional epidemic outbreaks of other viruses are also"/>
   <result pre="of noroviruses, flaviviruses (Zika and dengue viruses), new strains of" exact="influenza" post="viruses, the re-emergence of West Nile virus in Italy"/>
   <result pre="the United States. Despite relatively long pauses, viruses such as" exact="influenza" post="virus can re-emerge and cause global pandemic health problems."/>
   <result pre="Viruses can use either a single receptor (e.g. TIM-1 for" exact="hepatitis" post="A virus, GM1 for SV40, CD155 for poliovirus, low-density"/>
   <result pre="multiple receptors with equivalent roles (e.g., Nectin-1/2 or HVEM for" exact="herpes simplex" post="virus 1/2, ACE or L-SIGN for SARS coronavirus). For"/>
   <result pre="two types of endocytosis, such as clathrin-mediated endocytosis (e.g. VSV," exact="influenza" post="A virus, rhinovirus), caveolin-mediated uptake (echovirus, polyoma virus), clathrin/caveolin-independent"/>
   <result pre="or lipid raft-mediated (e.g. SV40, polyomavirus mouse), or macropinocytosis (e.g." exact="vaccinia virus," post="respiratory syncytial virus, Ebola virus, HIV-1) (Blaas, 2016, Cossart"/>
   <result pre="these events can occur in early endosomes (pH 6.5–6.0; e.g." exact="hepatitis" post="C virus, vesicular stomatitis virus), late endosomes (pH 6.0–5.0;"/>
   <result pre="in early endosomes (pH 6.5–6.0; e.g. hepatitis C virus, vesicular" exact="stomatitis" post="virus), late endosomes (pH 6.0–5.0; e.g. influenza A virus,"/>
   <result pre="C virus, vesicular stomatitis virus), late endosomes (pH 6.0–5.0; e.g." exact="influenza" post="A virus, dengue virus, SARS coronavirus), recycling endosomes, macropinosomes,"/>
   <result pre="only a few, very small viral capsid particles, such as" exact="hepatitis" post="B virus (HBV; 32–36 nm diameter), can pass through"/>
   <result pre="or ribonucleoprotein complexes (RNPs) of some larger viruses, such as" exact="influenza" post="A virus and HIV-1, disassemble within the cytoplasm. The"/>
   <result pre="Panté, 2015, Hutchinson and Fodor, 2013). Another mechanism, used by" exact="herpes simplex" post="virus (HSV) and adenoviruses, involves cellular (importins, Nup) or"/>
   <result pre="replication and transcription. The only exceptions are some hepadnaviruses (e.g." exact="hepatitis" post="B virus) that despite having small genomes (approximately 3"/>
   <result pre="protein/oncogene to re-program the host cell-cycle regulatory proteins p53 or" exact="retinoblastoma" post="protein (pRb), triggering entry into the S-phase (e.g. polyomaviruses"/>
   <result pre="Jackson et al., 2005), coxsackievirus (Alirezaei et al., 2012), and" exact="hepatitis" post="A virus (Feng et al., 2013). Another possibility is"/>
   <result pre="Interactions with ESCRT proteins have also been reported for vesicular" exact="stomatitis" post="virus (Chen et al., 2010, Luyet et al., 2008),"/>
   <result pre="(Feng et al., 2013), paramyxoviruses (Park et al., 2016), and" exact="hepatitis" post="C virus, a representative of the flavivirus family (Falcon"/>
   <result pre="(Hübner et al., 2009, Wang et al., 2017) and murine" exact="leukemia" post="virus (Sherer et al., 2010). Receptors on tight junctions"/>
   <result pre="et al., 2010). Receptors on tight junctions that specifically recognize" exact="hepatitis" post="C virus (Carloni et al., 2012, Ploss et al.,"/>
   <result pre="the BlaM reporter (Tscherne et al., 2010). Their assay uses" exact="influenza" post="virus-like particles (VLPs) bearing the influenza membrane proteins hemagglutinin"/>
   <result pre="2010). Their assay uses influenza virus-like particles (VLPs) bearing the" exact="influenza" post="membrane proteins hemagglutinin and neuraminidase. BlaM tagged with influenza"/>
   <result pre="the influenza membrane proteins hemagglutinin and neuraminidase. BlaM tagged with" exact="influenza" post="matrix protein (M1) is incorporated into the VLPs and"/>
   <result pre="Marburg virus glycoprotein, hemagglutinin and neuraminidase isolated from A/Goose/Qinghai/59/05 (H5N1)" exact="influenza" post="virus, Ebolavirus Zaire envelope glycoprotein, and Lassa virus envelope"/>
   <result pre="against entry of both Marburg and Ebola viruses in human" exact="cancer" post="cell lines, and confirmed their anti-Ebola activity in human"/>
   <result pre="A method to monitor the uncoating/disassembly of the capsid of" exact="influenza" post="A virus, which enters the cell by endocytosis, also"/>
   <result pre="be either acquired from the host cell mRNA (e.g. in" exact="influenza" post="virus) or newly synthesized (e.g. flaviviruses). The methylation of"/>
   <result pre="dengue virus (Dong et al., 2012); rhabdoviruses such as vesicular" exact="stomatitis" post="virus (VSV) (Rahmeh et al., 2009); coronaviruses such as"/>
   <result pre="2014). Some cellular methyltransferases regulate viral infections, as shown for" exact="herpes simplex" post="virus, for which epigenetic control is involved in viral"/>
   <result pre="been demonstrated for human cytomegalovirus (Gan et al., 2017) and" exact="herpes simplex" post="virus (Hill et al., 2014, Liang et al., 2013)."/>
   <result pre="from flaviviruses such as dengue virus, HCV, West Nile virus," exact="yellow fever" post="virus, and Japanese encephalitis virus (Cao et al., 2016,"/>
   <result pre="virus, HCV, West Nile virus, yellow fever virus, and Japanese" exact="encephalitis" post="virus (Cao et al., 2016, Gu and Rice, 2016,"/>
   <result pre="common in some DNA viruses, including poxviruses. These include the" exact="vaccinia virus" post="helicase-primase D5 (Bayliss and Smith, 1996, Hutin et al.,"/>
   <result pre="contrast to tyrosine kinases from oncogenic viruses, such as Rous" exact="sarcoma" post="virus src tyrosine kinase, viral S/T kinases share little"/>
   <result pre="replication. For example, polo-like kinases induce early stages in the" exact="influenza" post="virus life cycle (Pohl et al., 2017), and human"/>
   <result pre="kinase C regulates the assembly of the ribonucleoprotein complexes in" exact="influenza" post="virus (Mondal et al., 2017). Inhibitors of Abelson tyrosine-protein"/>
   <result pre="2000, Rumlova-Klikova et al., 1999, Ulbrich et al., 2006), Rous" exact="sarcoma" post="virus (Campbell and Vogt, 1995, Campbell and Vogt, 1997,"/>
   <result pre="Purdy et al., 2008, Purdy et al., 2009), and murine" exact="leukemia" post="virus (Dolezal et al., 2016, Hadravova et al., 2012,"/>
   <result pre="epithelial cells [reviewed in (Laporte and Naesens, 2017)] such as" exact="influenza" post="virus (Böttcher-Friebertshäuser et al., 2010, Kühn et al., 2016),"/>
   <result pre="inhibitorsBioorg. Med. Chem. Lett.161120063005300816530412 BaldickC.J.WichroskiM.J.PendriA.WalshA.W.FangJ.MazzuccoC.E.PokornowskiK.A.RoseR.E.EggersB.J.HsuM.ZhaiW.ZhaiG.GerritzS.W.PossM.A.MeanwellN.A.CockettM.I.TenneyD.J.A novel small molecule inhibitor of" exact="hepatitis" post="C virus entryPLoS Pathog.692010e100108620838466 BartonE.S.ForrestJ.C.ConnollyJ.L.ChappellJ.D.LiuY.SchnellF.J.NusratA.ParkosC.A.DermodyT.S.Junction adhesion molecule is a"/>
   <result pre="Pathog.692010e100108620838466 BartonE.S.ForrestJ.C.ConnollyJ.L.ChappellJ.D.LiuY.SchnellF.J.NusratA.ParkosC.A.DermodyT.S.Junction adhesion molecule is a receptor for reovirusCell1043200144145111239401 BartoschB.DubuissonJ.CossetF.L.Infectious" exact="hepatitis" post="C virus pseudo-particles containing functional E1-E2 envelope protein complexesJ."/>
   <result pre="I8R has both DNA and RNA helicase activities: implications for" exact="vaccinia virus" post="transcriptionJ. Virol.70219967948008551617 BeadleJ.R.ValiaevaN.YangG.YuJ.-H.BrokerT.R.AldernK.A.HardenE.A.KeithK.A.PrichardM.N.HartmanT.BuckheitR.W.ChowL.T.HostetlerK.Y.Synthesis and antiviral evaluation of octadecyloxyethyl benzyl"/>
   <result pre="componentsProc. Natl. Acad. Sci.111362014130811308625157142 BlaasD.Viral entry pathways: the example of" exact="common cold" post="virusesWiener Medizinische Wochenschrift (1946)166201621122627174165 BoehmerP.NimonkarA.Herpes virus replicationIUBMB Life5512003132212716057 BogomolovP.AlexandrovA.VoronkovaN.MacievichM.KokinaK.PetrachenkovaM.LehrT.LemppF.A.WedemeyerH.HaagM.SchwabM.HaefeliW.E.BlankA.UrbanS.Treatment"/>
   <result pre="Medizinische Wochenschrift (1946)166201621122627174165 BoehmerP.NimonkarA.Herpes virus replicationIUBMB Life5512003132212716057 BogomolovP.AlexandrovA.VoronkovaN.MacievichM.KokinaK.PetrachenkovaM.LehrT.LemppF.A.WedemeyerH.HaagM.SchwabM.HaefeliW.E.BlankA.UrbanS.Treatment of chronic" exact="hepatitis" post="D with the entry inhibitor myrcludex B: First results"/>
   <result pre="Mason-Pfizer monkey virus and human immunodeficiency virusJ. Virol.84420101977198820007269 Böttcher-FriebertshäuserE.FreuerC.SielaffF.SchmidtS.EickmannM.UhlendorffJ.SteinmetzerT.KlenkH.-D.GartenW.Cleavage of" exact="influenza" post="virus hemagglutinin by airway proteases TMPRSS2 and HAT differs"/>
   <result pre="type-1J. Virol.69101995648764977666550 CampbellS.VogtV.M.In vitro assembly of virus-like particles with Rous" exact="sarcoma" post="virus Gag deletion mutants: identification of the p10 domain"/>
   <result pre="anti-filoviral entry inhibitorAntivir. Res.1452017243228645623 CheslockS.R.PoonD.T.FuW.RhodesT.D.HendersonL.E.NagashimaK.McGrathC.F.HuW.S.Charged assembly helix motif in murine" exact="leukemia" post="virus capsid: an important region for virus assembly and"/>
   <result pre="Emerging Drugs133200839341618764719 CliffeA.R.WilsonA.C.Restarting lytic gene transcription at the onset of" exact="herpes simplex" post="virus reactivationJ. Virol.9122017e0141901416 CoatesJ.A.CammackN.JenkinsonH.J.JowettA.J.JowettM.I.PearsonB.A.PennC.R.RouseP.L.VinerK.C.CameronJ.M.(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective"/>
   <result pre="Molecular Cell Research1813920111634164521167871 ColemanC.M.SiskJ.M.MingoR.M.NelsonE.A.WhiteJ.M.FriemanM.B.Abelson kinase inhibitors are potent inhibitors of" exact="severe acute respiratory syndrome" post="coronavirus and middle east respiratory syndrome coronavirus fusionJ. Virol.901920168924893327466418"/>
   <result pre="NS5 methyltransferase from Zika virusCell Rep.161220163097310227633330 ColpittsC.C.El-SaghireH.PochetN.SchusterC.BaumertT.F.High-throughput approaches to unravel" exact="hepatitis" post="C virus-host interactionsVirus Res.2182016182426410623 CondezoG.N.San MartínC.Localization of adenovirus morphogenesis"/>
   <result pre="of linker connecting capsid and nucleocapsid protein domains in murine" exact="leukemia" post="virusJ. Biol. Chem.291392016206302064227514744 DongH.ChangD.C.HuaM.H.C.LimS.P.ChionhY.H.HiaF.LeeY.H.KukkaroP.LokS.-M.DedonP.C.ShiP.-Y.2′-O methylation of internal adenosine by"/>
   <result pre="vitroJ. Virol.6681992487448831629958 ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.PrabhakarB.S.Identification of a broad-spectrum antiviral small molecule against" exact="severe acute respiratory syndrome" post="coronavirus and ebola, hendra, and nipah viruses by using"/>
   <result pre="for clinical kinase inhibitorsNat. Biotechnol.233200532933615711537 FalconV.Acosta-RiveroN.GonzalezS.Duenas-CarreraS.Martinez-DonatoG.MenendezI.GarateixR.SilvaJ.A.AcostaE.KouriJ.Ultrastructural and biochemical basis for" exact="hepatitis" post="C virus morphogenesisVirus Genes532201715116428233195 FayN.PantéN.Nuclear entry of DNA virusesFront."/>
   <result pre="picornavirus acquires an envelope by hijacking cellular membranesNature4967445201336737123542590 FengJ.Y.ChengG.PerryJ.BarauskasO.XuY.FenauxM.EngS.TirunagariN.PengB.YuM.TianY.LeeY.-J.StepanG.LagpacanL.L.JinD.HungM.KuK.S.HanB.KitrinosK.PerronM.BirkusG.WongK.A.ZhongW.KimC.U.CareyA.ChoA.RayA.S.Inhibition of" exact="hepatitis" post="C virus replication by GS-6620, a potent C-nucleoside monophosphate"/>
   <result pre="signalingJ. Virol.831320096689670519369340 FromentinR.MajeauN.Laliberte GagneM.E.BoivinA.DuvignaudJ.B.LeclercD.A method for in vitro assembly of" exact="hepatitis" post="C virus core protein and for screening of inhibitorsAnal."/>
   <result pre="and H3K27 histone demethylasesPLoS One1242017e017539028407004 GastaminzaP.Whitten-BauerC.ChisariF.V.Unbiased probing of the entire" exact="hepatitis" post="C virus life cycle identifies clinical compounds that target"/>
   <result pre="Immunol.325200818720418637507 GlebeD.AliakbariM.KrassP.KnoopE.V.ValeriusK.P.GerlichW.H.Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human" exact="hepatitis" post="B virusJ. Virol.771720039511952112915565 GlebeD.UrbanS.KnoopE.V.ÇaǧN.KrassP.GrünS.BulavaiteA.SasnauskasK.GerlichW.H.Mapping of the Hepatitis B Virus"/>
   <result pre="Virol.62111988413641433172341 GriponP.RuminS.UrbanS.Le SeyecJ.GlaiseD.CannieI.GuyomardC.LucasJ.TrepoC.Guguen-GuillouzoC.Infection of a human hepatoma cell line by" exact="hepatitis" post="B virusProc. Natl. Acad. Sci.99242002156551566012432097 GriponP.CannieI.UrbanS.Efficient inhibition of Hepatitis"/>
   <result pre="vitro assembly of virus-like particles of a gammaretrovirus, the murine" exact="leukemia" post="virus XMRVJ. Virol.86320121297130622090120 HadravovaR.RumlovaM.RumlT.FAITH - fast assembly inhibitor test"/>
   <result pre="LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic" exact="suppression" post="of viral genomes. Sci. Transl. Med. 6(265), 265ra169-265ra169. HiltonB.J.WolkowiczR.An"/>
   <result pre="viral infectionPLoS One1222017e017174628207819 HurleyJ.H.ESCRTs are everywhereEMBO J.341920152398240726311197 HutchinsonE.C.FodorE.Transport of the" exact="influenza" post="virus genome from nucleus to nucleusViruses51020132424244624104053 HutinS.LingW.L.RoundA.EffantinG.ReichS.IseniF.TarbouriechN.SchoehnG.BurmeisterW.P.Domain organization of"/>
   <result pre="influenza virus genome from nucleus to nucleusViruses51020132424244624104053 HutinS.LingW.L.RoundA.EffantinG.ReichS.IseniF.TarbouriechN.SchoehnG.BurmeisterW.P.Domain organization of" exact="vaccinia virus" post="Helicase-Primase D5J. Virol.90920164604461326912611 InoueT.TsaiB.How viruses use the endoplasmic reticulum"/>
   <result pre="Naffakh, N., 2016. Experimental approaches to study genome packaging of" exact="influenza" post="A viruses. Viruses 8(8). JacksonW.T.Poliovirus-induced changes in cellular membranes"/>
   <result pre="mechanism by which Us3 protein kinase regulates the pathogenicity of" exact="herpes simplex" post="virus type-1Uirusu6612016839028484184 KatoT.DateT.MurayamaA.MorikawaK.AkazawaD.WakitaT.Cell culture and infection system for hepatitis"/>
   <result pre="herpes simplex virus type-1Uirusu6612016839028484184 KatoT.DateT.MurayamaA.MorikawaK.AkazawaD.WakitaT.Cell culture and infection system for" exact="hepatitis" post="C virusNat. Protoc.1520062334233917406476 KatzR.A.MerkelG.KulkoskyJ.LeisJ.SkalkaA.M.The avian retroviral IN protein is"/>
   <result pre="KobilerO.DraymanN.Butin-IsraeliV.OppenheimA.Virus strategies for passing the nuclear envelope barrierNucleus36201252653922929056 KokorisM.S.BlackM.E.Characterization of" exact="herpes simplex" post="virus type 1 thymidine kinase mutants engineered for improved"/>
   <result pre="as antiviral targetsNat. Rev. Drug Discov.410200584585316184083 LadnerS.K.OttoM.J.BarkerC.S.ZaifertK.WangG.H.GuoJ.T.SeegerC.KingR.W.Inducible expression of human" exact="hepatitis" post="B virus (HBV) in stably transfected hepatoblastoma cells: a"/>
   <result pre="expression of human hepatitis B virus (HBV) in stably transfected" exact="hepatoblastoma" post="cells: a novel system for screening potential inhibitors of"/>
   <result pre="in vitroJ. Virol.761420026900690812072491 LaporteM.NaesensL.Airway proteases: an emerging drug target for" exact="influenza" post="and other respiratory virus infectionsCurr. Opin. Virol.242017162428414992 LathiaU.S.OrnatskyO.BaranovV.NitzM.Multiplexed protease"/>
   <result pre="by proximity ligationMol. Cell. Proteomics91201017818319864249 LeungK.-H.HeH.-Z.HeB.ZhongH.-J.LinS.WangY.-T.MaD.-L.LeungC.-H.Label-free luminescence switch-on detection of" exact="hepatitis" post="C virus NS3 helicase activity using a G-quadruplex-selective probe"/>
   <result pre="LiJ.Fontaine-RodriguezE.C.WhelanS.P.J.Amino acid residues within conserved domain VI of the vesicular" exact="stomatitis" post="virus large polymerase protein essential for mRNA cap methyltransferase"/>
   <result pre="polymerase protein essential for mRNA cap methyltransferase activityJ. Virol.79212005133731338416227259 LiJ.ChorbaJ.S.WhelanS.P.Vesicular" exact="stomatitis" post="viruses resistant to the methylase inhibitor sinefungin upregulate RNA"/>
   <result pre="from latencyNat. Med.151120091312131719855399 LiangY.QuenelleD.VogelJ.L.MascaroC.OrtegaA.KristieT.M.A novel selective LSD1/KDM1A inhibitor epigenetically blocks" exact="herpes simplex" post="virus lytic replication and reactivation from latencyMBio412013e00512e00558 Liao, C.,"/>
   <result pre="LinC.T.TritschlerF.LeeK.S.GuM.RiceC.M.HaT.Single-molecule imaging reveals the translocation and DNA looping dynamics of" exact="hepatitis" post="C virus NS3 helicaseProtein Sci.26720171391140328176403 Lindsten, K., Uhlíková, T.á.,"/>
   <result pre="Soc.130382008128211282718759402 LütgehetmannM.ManckeL.V.VolzT.HelbigM.AllweissL.BornscheuerT.PollokJ.M.LohseA.W.PetersenJ.UrbanS.DandriM.Humanized chimeric uPA mouse model for the study of" exact="hepatitis" post="B and D virus interactions and preclinical drug evaluationHepatology553201268569422031488"/>
   <result pre="Opin. Drug Discovery362008607621 MaY.WeiY.ZhangX.ZhangY.CaiH.ZhuY.ShiloK.OglesbeeM.KrakowkaS.WhelanS.P.J.LiJ.mRNA cap methylation influences pathogenesis of vesicular" exact="stomatitis" post="virus in vivoJ. Virol.88520142913292624371058 MadhviA.HinganeS.SrivastavR.JoshiN.SubramaniC.MuthumohanR.KhasaR.VarshneyS.KaliaM.VratiS.SurjitM.Ranjith-KumarC.T.A screen for novel hepatitis"/>
   <result pre="vesicular stomatitis virus in vivoJ. Virol.88520142913292624371058 MadhviA.HinganeS.SrivastavR.JoshiN.SubramaniC.MuthumohanR.KhasaR.VarshneyS.KaliaM.VratiS.SurjitM.Ranjith-KumarC.T.A screen for novel" exact="hepatitis" post="C virus RdRp inhibitor identifies a broad-spectrum antiviral compoundSci."/>
   <result pre="their use in kinetic analyses of wild-type and mutant Rous" exact="sarcoma" post="virus integrasesProc. Natl. Acad. Sci. U. S. A.9024199311633116378265600 MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.JoshiS.K.Advances"/>
   <result pre="and protease activitiesJ. Enzyme Inhibition Med. Chem.321201710911101 PetersenJ.DandriM.MierW.LutgehetmannM.VolzT.von WeizsackerF.HaberkornU.FischerL.PollokJ.M.ErbesB.SeitzS.UrbanS.Prevention of" exact="hepatitis" post="B virus infection in vivo by entry inhibitors derived"/>
   <result pre="envelope proteinNat. Biotechnol.263200833534118297057 PflugA.LukarskaM.Resa-InfanteP.ReichS.CusackS.Structural insights into RNA synthesis by the" exact="influenza" post="virus transcription-replication machineVirus Res.234201710311728115197 PietiläM.K.HellströmK.AholaT.Alphavirus polymerase and RNA replicationVirus"/>
   <result pre="Methods and Protocols2012Humana PressTotowa, NJ2131 PlossA.EvansM.J.GaysinskayaV.A.PanisM.YouH.de JongY.P.RiceC.M.Human occludin is a" exact="hepatitis" post="C virus entry factor required for infection of mouse"/>
   <result pre="HIV-1 integrase strand transfer inhibitorsClin. Pharmacokinet.5612017254027317415 PohlM.O.LanzC.StertzS.Late stages of the" exact="influenza" post="A virus replication cycle-a tight interplay between virus and"/>
   <result pre="Identification of Polo-like kinases as potential novel drug targets for" exact="influenza" post="A virus. Sci. Rep. 7(1), 8629. PrasadB.V.V.SchmidM.F.Principles of virus"/>
   <result pre="the CA dimer in initiationJ. Mol. Biol.3892200943845119361521 RabeB.VlachouA.PanteN.HeleniusA.KannM.Nuclear import of" exact="hepatitis" post="B virus capsids and release of the viral genomeProc."/>
   <result pre="virus capsid structuresTrends Microbiol.256201743844628094093 RahmehA.A.LiJ.KranzuschP.J.WhelanS.P.Ribose 2'-O methylation of the vesicular" exact="stomatitis" post="virus mRNA cap precedes and facilitates subsequent guanine-N-7 methylation"/>
   <result pre="disassemblyJ. Virol.91122017 RasmussenI.VilhardtF.Macropinocytosis is the entry mechanism of amphotropic murine" exact="leukemia" post="virusJ. Virol.89320151851186625428868 RayD.ShahA.TilgnerM.GuoY.ZhaoY.DongH.DeasT.S.ZhouY.LiH.ShiP.-Y.West Nile Virus 5′-Cap structure is formed"/>
   <result pre="promotes maturation of infectious poliovirus particlesPLoS Pathog.8112012e100304623209416 RoeT.ReynoldsT.C.YuG.BrownP.O.Integration of murine" exact="leukemia" post="virus DNA depends on mitosisEMBO J.1251993209921088491198 RossignolE.D.YangJ.E.BullittE.the role of"/>
   <result pre="measurement of protein kinase activityAssay Drug Dev Technol76200961562220105027 SatoY.KoshizukaT.IshibashiK.HashimotoK.IshiokaK.IkutaK.YokotaS.I.FujiiN.SuzutaniT.Involvement of" exact="herpes simplex" post="virus type 1 UL13 protein kinase in induction of"/>
   <result pre="in cell biology and viral replicationBiochem. Soc. Trans.453201761363428620025 SellsM.A.ChenM.L.AcsG.Production of" exact="hepatitis" post="B virus particles in Hep G2 cells transfected with"/>
   <result pre="B virus particles in Hep G2 cells transfected with cloned" exact="hepatitis" post="B virus DNAProc. Natl. Acad. Sci. U. S. A.8441987100510093029758"/>
   <result pre="of SV40 large tumor antigenEMBO J.581986193919443019672 StaufferS.NebiogluF.HeleniusA.In vitro disassembly of" exact="influenza" post="A virus capsids by gradient centrifugationJ. Vis. Exp.1092016e53909 StichtJ.HumbertM.FindlowS.BodemJ.MullerB.DietrichU.WernerJ.KrausslichH.G.A"/>
   <result pre="StrayS.J.JohnsonJ.M.KopekB.G.ZlotnickA.An in vitro fluorescence screen to identify antivirals that disrupt" exact="hepatitis" post="B virus capsid assemblyNat. Biotechnol.243200635836216474383 StremlauM.PerronM.LeeM.LiY.SongB.JavanbakhtH.Diaz-GrifferoF.AndersonD.J.SundquistW.I.SodroskiJ.Specific recognition and accelerated"/>
   <result pre="of inhibitors of coronavirus RNA cap guanine-N7-methyltransferaseAntivir. Res.104201415616424530452 SureauC.Romet-LemonneJ.-L.MullinsJ.I.EssexM.Production of" exact="hepatitis" post="B virus by a differentiated human hepatoma cell line"/>
   <result pre="assay for sensitive detection of virus entryJ. Virol. Methods1632201033634319879300 UdukalaD.N.WangH.WendelS.O.MalalasekeraA.P.SamarakoonT.N.YapaA.S.AbayaweeraG.BaselM.T.MaynezP.OrtegaR.ToledoY.BossmannL.RobinsonC.JanikK.E.KoperO.B.LiP.MotamediM.HigginsD.A.GadburyG.ZhuG.TroyerD.L.BossmannS.H.Early" exact="breast cancer" post="screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of"/>
   <result pre="for sensitive detection of virus entryJ. Virol. Methods1632201033634319879300 UdukalaD.N.WangH.WendelS.O.MalalasekeraA.P.SamarakoonT.N.YapaA.S.AbayaweeraG.BaselM.T.MaynezP.OrtegaR.ToledoY.BossmannL.RobinsonC.JanikK.E.KoperO.B.LiP.MotamediM.HigginsD.A.GadburyG.ZhuG.TroyerD.L.BossmannS.H.Early breast" exact="cancer" post="screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of"/>
   <result pre="UtamaA.ShimizuH.MorikawaS.HasebeF.MoritaK.IgarashiA.HatsuM.TakamizawaK.MiyamuraT.Identification and characterization of the RNA helicase activity of Japanese" exact="encephalitis" post="virus NS3 proteinFEBS Lett.46512000747810620709 VeeslerD.JohnsonJ.E.Virus maturationAnnu. Rev. Biophys.41201247349622404678 VlachJ.LipovJ.RumlovaM.VeverkaV.LangJ.SrbP.KnejzlikZ.PichovaI.HunterE.HrabalR.RumlT.D-retrovirus"/>
   <result pre="blocks intrahepatic virus spreading in humanized mice previously infected with" exact="hepatitis" post="B virusJ. Hepatol.585201386186723246506 VyseS.DesmondH.HuangP.H.Advances in mass spectrometry based strategies"/>
   <result pre="and pathogenesisJ. Virol.891620158416842726041293 WangZ.ZhaoF.GaoQ.LiuZ.ZhangY.LiX.LiY.MaW.DengT.ZhangZ.CenS.Establishment of a high-throughput assay to monitor" exact="influenza" post="A virus RNA transcription and replicationPLoS One1072015e013355826196128 WangF.ChenC.TanW.YangK.YangH.Structure of"/>
   <result pre="and proteolytic processingJ. Virol.79162005102681027716051820 XingY.ChenJ.TuJ.ZhangB.ChenX.ShiH.BakerS.C.FengL.ChenZ.The papain-like protease of porcine epidemic" exact="diarrhea" post="virus negatively regulates type I interferon pathway by acting"/>
   <result pre="YanH.ZhongG.XuG.HeW.JingZ.GaoZ.HuangY.QiY.PengB.WangH.FuL.SongM.ChenP.GaoW.RenB.SunY.CaiT.FengX.SuiJ.LiW.Sodium taurocholate cotransporting polypeptide is a functional receptor for human" exact="hepatitis" post="B and D viruselife12012e0004923150796 YangL.MohrI.FoutsE.LimD.A.NohaileM.BotchanM.The E1 protein of bovine"/>
   <result pre="function of the Zika virus full-length NS5 proteinNat. Commun.820171476228345656 ZhongJ.GastaminzaP.ChengG.KapadiaS.KatoT.BurtonD.R.WielandS.F.UprichardS.L.WakitaT.ChisariF.V.Robust" exact="hepatitis" post="C virus infection in vitroProc. Natl. Acad. Sci. U."/>
   <result pre="conjugatesAnalyst139520141178118324445423 ZhouY.VedanthamP.LuK.AgudeloJ.CarrionR.NunneleyJ.W.BarnardD.PöhlmannS.McKerrowJ.H.RensloA.R.SimmonsG.Protease inhibitors targeting coronavirus and filovirus entryAntivir. Res.1162015768425666761 ZieglerC.M.EisenhauerP.BruceE.A.WeirM.E.KingB.R.KlausJ.P.KrementsovD.N.ShirleyD.J.BallifB.A.BottenJ.The" exact="lymphocytic choriomeningitis" post="virus matrix protein PPXY late domain drives the production"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7145266/results/search/disease/results.xml">
   <result pre="is gaining considerable attention [1]. USUV belongs to the Japanese" exact="encephalitis" post="virus (JEV) antigenic complex, similar to West Nile virus"/>
   <result pre="endemic for flaviviruses with reported transmission to humans such as" exact="tick-borne encephalitis" post="virus (TBEV) and WNV [28] (National surveillance and response"/>
   <result pre="for flaviviruses with reported transmission to humans such as tick-borne" exact="encephalitis" post="virus (TBEV) and WNV [28] (National surveillance and response"/>
   <result pre="of Usutu virus, an African mosquito-borne flavivirus of the Japanese" exact="encephalitis" post="virus group, central Europe. Emerg Infect Dis. 2002;8(7):652–6. 10.3201/eid0807.02009412095429"/>
   <result pre="LuzzatiR, SantonD, MerelliM, et al.Persistent viremia and urine shedding of" exact="tick-borne encephalitis" post="virus in an infected immunosuppressed patient from a new"/>
   <result pre="SantonD, MerelliM, et al.Persistent viremia and urine shedding of tick-borne" exact="encephalitis" post="virus in an infected immunosuppressed patient from a new"/>
   <result pre="WilliamsJ, LewisJ, et al.Evidence of arbovirus co-infection in suspected febrile" exact="malaria" post="and typhoid patients in Nigeria. J Infect Dev Ctries."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7171712/results/search/disease/results.xml">
   <result pre="G-ORi ORi supplemented with gentamycin NMR nuclear magnetic resonance SARS" exact="severe acute respiratory syndrome" post="S1 test solution without Ba2+ S2 test solution with"/>
   <result pre="channel activity blocks virus release; this could be demonstrated by" exact="suppression" post="of 3a expression as well as pharmacological inhibition of"/>
   <result pre="MZhangM MHeLLiY PKangY KChinese herbs combined with Western medicine for" exact="severe acute respiratory syndrome" post="(SARS)Cochrane Database Syst Rev20061CD004882 4FischerW BThielGFinkR HAViral membrane proteinsEur"/>
   <result pre="A comprehensive reviewMinirev Med Chem2008811061133 17LyuS-YRhimJ-YParkW-BAntiherpetic activities of flavonoids against" exact="herpes simplex" post="virus type 1 (HSV-1) and type 2 (SV-2) in"/>
   <result pre="Med Chem2006148295830617046271 24LyuS YRhimJ YParkW BAntiherpetic activities of flavonoids against" exact="herpes simplex" post="virus type 1 (HSV-1) and type 2 (HSV-2) in"/>
   <result pre="25LiuA LWangH DLeeS MYWangY TDuG HStructure-activity relationship of flavonoids as" exact="influenza" post="virus neuraminidase inhibitors and their in vitro anti-viral activitiesBioorg"/>
   <result pre="C virus p 7 ion channel inhibitor, BIT225, inhibits bovine viral" exact="diarrhea" post="virus in vitro and shows synergism with recombinant interferon-α-2b"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7190394/results/search/disease/results.xml">
   <result pre="pharmacological interactions between direct-acting antivirals for the treatment of chronic" exact="hepatitis" post="C and psychotropic drugs. Expert Rev Clin Pharmacol2018; 11(10):"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7201615/results/search/disease/results.xml">
   <result pre="cited. Abstract Aim To assess the effect of treating chronic" exact="hepatitis" post="C virus (HCV) infection with direct acting antiviral drugs"/>
   <result pre="antiviral drugs (DAAs) on glycemic control in patients with concomitant" exact="diabetes mellitus" post="(DM). Methods We performed a retrospective case-control study in"/>
   <result pre="(DM). Methods We performed a retrospective case-control study in a" exact="viral hepatitis" post="ambulatory clinic in Shreveport, Louisiana, during the period 11/01/2014"/>
   <result pre="Methods We performed a retrospective case-control study in a viral" exact="hepatitis" post="ambulatory clinic in Shreveport, Louisiana, during the period 11/01/2014"/>
   <result pre="clinic patient ages 18 years and above with treatment-naïve/biopsy-proven chronic" exact="hepatitis" post="C and DM (hemoglobin A1C level ≥ 6.5%) who were eligible"/>
   <result pre="group of 59 patients did not receive treatment for their" exact="hepatitis" post="C and was followed in the clinic. Patients in"/>
   <result pre="receive treatment either due to insurance issues or refusal of" exact="hepatitis" post="C treatment. Results Fifty-five of the 59 patients treated"/>
   <result pre="0.2%). Conclusion This controlled study demonstrated that treatment of chronic" exact="hepatitis" post="C with DAAs results in statistically significant and meaningful"/>
   <result pre="1. Introduction Diabetes mellitus (DM) is strongly associated with chronic" exact="hepatitis" post="C virus (HCV) infection. It has been estimated that"/>
   <result pre="cohort of HCV patients with overt DM seen at a" exact="viral hepatitis" post="clinic in Shreveport, Louisiana. An untreated group of patients"/>
   <result pre="of HCV patients with overt DM seen at a viral" exact="hepatitis" post="clinic in Shreveport, Louisiana. An untreated group of patients"/>
   <result pre="in Shreveport, Louisiana. An untreated group of patients with chronic" exact="hepatitis" post="C was included as controls. 2. Methods 2.1. Study"/>
   <result pre="adult patients (age ≥ 18 years) with treatment-naïve, biopsy-proven chronic" exact="hepatitis" post="C and concomitant DM (hemoglobin A1C (HbA1C) level ≥ 6.5% [12]) seen"/>
   <result pre="and concomitant DM (hemoglobin A1C (HbA1C) level ≥ 6.5% [12]) seen in a" exact="viral hepatitis" post="clinic in Shreveport, Louisiana, clinic between November 1, 2014,"/>
   <result pre="concomitant DM (hemoglobin A1C (HbA1C) level ≥ 6.5% [12]) seen in a viral" exact="hepatitis" post="clinic in Shreveport, Louisiana, clinic between November 1, 2014,"/>
   <result pre="eligible for inclusion in the study. Clinic patients with chronic" exact="hepatitis" post="C and with DM were identified by ICD-10-CM codes"/>
   <result pre="with DAAs and 59 controls who were not treated for" exact="hepatitis" post="C (because of insurance or refusal of hepatitis C"/>
   <result pre="treated for hepatitis C (because of insurance or refusal of" exact="hepatitis" post="C treatment) and were followed in the clinic. Clinic"/>
   <result pre="were excluded from the study. All patients were screened for" exact="hepatocellular carcinoma" post="(HCC), and none were found to have HCC. We"/>
   <result pre="RNA was checked at 4, 8, and 12 weeks during" exact="hepatitis" post="C treatment and at 6 months after completion of"/>
   <result pre="whereas in the 25 patients with either severe fibrosis or" exact="cirrhosis" post="at baseline (F3-F4), mean HbA1C decreased 0.9 ± 0.3%"/>
   <result pre="is (are) unclear. Matsui et al. demonstrated in vitro that" exact="hepatitis" post="C viral replication suppresses GLUT2 expression and hence cellular"/>
   <result pre="[16]. Conversely, there has been speculation that insulin resistance and" exact="hyperglycemia" post="promote hepatitis C viral replication and are associated with"/>
   <result pre="there has been speculation that insulin resistance and hyperglycemia promote" exact="hepatitis" post="C viral replication and are associated with worse clinical"/>
   <result pre="achieved with interferon alpha plus ribavirin in patients with chronic" exact="hepatitis" post="C could improve glycemic control and insulin sensitivity [19]"/>
   <result pre="effects of the medications used to achieve a SVR, including" exact="hemolytic anemia" post="from ribavirin which can falsely lower HbA1C levels and"/>
   <result pre="of the medications used to achieve a SVR, including hemolytic" exact="anemia" post="from ribavirin which can falsely lower HbA1C levels and"/>
   <result pre="direct acting antiviral drugs (DAAs) on the severity of coexisting" exact="diabetes mellitus" post="(DM) [2–6]. In the largest study, Hum et al."/>
   <result pre="was only seen in veterans without severe hepatic fibrosis or" exact="cirrhosis" post="[2]. In contrast, in our study with roughly equal"/>
   <result pre="on their reduced HbA1C levels. Because the patients with chronic" exact="hepatitis" post="C treated with DAAs in our study did not"/>
   <result pre="should be aware that glycemia will probably improve and that" exact="hypoglycemia" post="might occur, particularly if the patient is receiving insulin,"/>
   <result pre="blood glucose monitoring at home and in the clinic. However," exact="hypoglycemia" post="has not been commonly reported in HCV treatment studies"/>
   <result pre="manuscript. References 1GastaldiG.GoossensN.ClémentS.NegroF.Current level of evidence on causal association between" exact="hepatitis" post="C virus and type 2 diabetes: a reviewJournal of"/>
   <result pre="glycemic control of type 2 diabetes after successful treatment of" exact="hepatitis" post="C virusDiabetes Care20174091173118010.2337/dc17-048528659309 3Abdel AlemS.ElsharkawyA.FouadR.et al.Improvement of glycemic state"/>
   <result pre="2 diabetes following direct acting antiviral treatment of genotype 1" exact="hepatitis" post="CCase Reports in Hepatology20162016310.1155/2016/7807921 8DrazilovaS.JanickoM.SkladanyL.et al.Glucose metabolism changes in"/>
   <result pre="in Hepatology20162016310.1155/2016/7807921 8DrazilovaS.JanickoM.SkladanyL.et al.Glucose metabolism changes in patients with chronic" exact="hepatitis" post="C treated with direct acting antiviralsCanadian Journal of Gastroenterology"/>
   <result pre="glucose metabolism and reduction of pre-diabetes in patients with chronic" exact="hepatitis" post="CJournal of Gastrointestinal and Liver Diseases201827328128910.15403/jgld.2014.1121.273.daa30240472 10MoralesA. L.JungaZ.SinglaM. B.SjogrenM.TorresD.Hepatitis"/>
   <result pre="interobserver variations in liver biopsy interpretation in patients with chronic" exact="hepatitis" post="CHepatology199429p. 15 14BedossaP.PoynardT.An algorithm for the grading of activity"/>
   <result pre="15 14BedossaP.PoynardT.An algorithm for the grading of activity in chronic" exact="hepatitis" post="CHepatology199624228929310.1002/hep.5102402018690394 15ChungR. T.GhanyM. G.KimA. Y.et al.Hepatitis C guidance 2018"/>
   <result pre="guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating" exact="hepatitis" post="C virus infectionClinical Infectious Diseases201867101477149210.1093/cid/ciy58530215672 16MatsuiC.ShojiI.KanedaS.SianiparI. R.DengL.HottaH.Hepatitis C virus"/>
   <result pre="Virology20128623129031291110.1128/JVI.01418-1222993150 17NegroF.FortonD.CraxìA.SulkowskiM. S.FeldJ. J.MannsM. P.Extrahepatic morbidity and mortality of chronic" exact="hepatitis" post="CGastroenterology201514961345136010.1053/j.gastro.2015.08.03526319013 18NegroF.Facts and fictions of HCV and comorbidities: steatosis,"/>
   <result pre="hepatitis CGastroenterology201514961345136010.1053/j.gastro.2015.08.03526319013 18NegroF.Facts and fictions of HCV and comorbidities: steatosis," exact="diabetes mellitus," post="and cardiovascular diseasesJournal of Hepatology2014611 SupplS69S7810.1016/j.jhep.2014.08.00325443347 19TahraniA.BowlerL.SinghP.CoatesP.Resolution of diabetes"/>
   <result pre="type 2 diabetic patient treated with IFN-?? and ribavirin for" exact="hepatitis" post="CEuropean journal of gastroenterology &amp;amp; hepatology200618329129310.1097/00042737-200603000-0001116462544 20AraseY.SuzukiF.SuzukiY.et al.Sustained virological"/>
   <result pre="reduces incidence of onset of type 2 diabetes in chronic" exact="hepatitis" post="CHepatology200949373974410.1002/hep.2270319127513 21GrossB. N.CrossL. B.FoardJ. C.WoodY. A.Falsely low hemoglobin A1c"/>
   <result pre="levels in a patient receiving ribavirin and peginterferon alfa-2b for" exact="hepatitis" post="CPharmacotherapy200929112112310.1592/phco.29.1.12119113800 22GreenbergP. D.RosmanA. S.EldeiryL. S.NaqviZ.BräuN.Decline in haemoglobin A1c values"/>
   <result pre="values in diabetic patients receiving interferon-alpha and ribavirin for chronic" exact="hepatitis" post="CJournal of Viral Hepatitis200613961361710.1111/j.1365-2893.2006.00729.x16907848 23StineJ. G.WynterJ. A.NiccumB.KellyV.CaldwellS. H.ShahN. L.Effect"/>
   <result pre="with direct acting antiviral on glycemic control in patients with" exact="diabetes mellitus" post="and chronic hepatitis CAnnals of Hepatology201716221522010.5604/16652681.123158131153414 24ChaudhuryC. S.SheehanJ.ChairezC.et al.No"/>
   <result pre="on glycemic control in patients with diabetes mellitus and chronic" exact="hepatitis" post="CAnnals of Hepatology201716221522010.5604/16652681.123158131153414 24ChaudhuryC. S.SheehanJ.ChairezC.et al.No improvement in hemoglobin"/>
   <result pre="of Hepatology201716221522010.5604/16652681.123158131153414 24ChaudhuryC. S.SheehanJ.ChairezC.et al.No improvement in hemoglobin a1c following" exact="hepatitis" post="c viral clearance in patients with and without HIVThe"/>
   <result pre="Infectious Diseases20172171475010.1093/infdis/jix51729161418 25HuangJ.-F.HuangC.-F.YehM.-L.et al.The outcomes of glucose abnormalities in chronic" exact="hepatitis" post="C patients receiving interferon-free direct antiviral agentsThe Kaohsiung Journal"/>
   <result pre="glycaemic control in patients with type 2 diabetes and chronic" exact="hepatitis" post="CLiver International20193961027103210.1111/liv.1403130570808 27GiladA.FrickerZ. P.HsiehA.ThomasD. D.ZahorianT.NunesD. P.Sustained improvement in type"/>
   <result pre="CLiver International20193961027103210.1111/liv.1403130570808 27GiladA.FrickerZ. P.HsiehA.ThomasD. D.ZahorianT.NunesD. P.Sustained improvement in type 2" exact="diabetes mellitus" post="is common after treatment of hepatitis C virus with"/>
   <result pre="in type 2 diabetes mellitus is common after treatment of" exact="hepatitis" post="C virus with direct-acting antiviral therapyJournal of Clinical Gastroenterology201953861662010.1097/mcg.000000000000116830614943"/>
   <result pre="control by direct-acting antiviral agent treatment in egyptian type 2" exact="diabetes mellitus" post="patients with chronic hepatitis C genotype 4Diabetes &amp;amp; Metabolism"/>
   <result pre="treatment in egyptian type 2 diabetes mellitus patients with chronic" exact="hepatitis" post="C genotype 4Diabetes &amp;amp; Metabolism Journal201741431632110.4093/dmj.2017.41.4.31628868829 29MadaP. K.MalusM. E.ChenB.et"/>
   <result pre="sustained virologic response achieved through newer direct acting antivirals in" exact="hepatitis" post="C infection on diabetes mellitusOpen Forum Infectious Diseases20185suppl_1p. S65610.1093/ofid/ofy210.1875"/>
   <result pre="BMI (kg/m2)a 30.8 ± 0.8 29.1 ± 0.8 NS Cirrhosis/no" exact="cirrhosis" post="27/32 26/33 NS Viral load (copies × 106)a 3.8"/>
   <result pre="BMI: body mass index; HbA1C: hemoglobin A1C level (%); HCV:" exact="hepatitis" post="C virus; NS: P value not statistically significant (P"/>
   <result pre="regression model predicting final HbA1C levels in 118 patients with" exact="hepatitis" post="C and diabetes mellitus (n = 118). Covariate (1)"/>
   <result pre="final HbA1C levels in 118 patients with hepatitis C and" exact="diabetes mellitus" post="(n = 118). Covariate (1) Reference variable (0) Estimate"/>
   <result pre="0.460 0.497 Genotype 1 Non-1 -0.104 0.080 0.772 Moderate/severe chronic" exact="hepatitis" post="Minimal/mild chronic hepatitis 0.474 0.960 0.326 Baseline serum ALT"/>
   <result pre="1 Non-1 -0.104 0.080 0.772 Moderate/severe chronic hepatitis Minimal/mild chronic" exact="hepatitis" post="0.474 0.960 0.326 Baseline serum ALT level — -0.026"/>
   <result pre="0.131 Pretreatment HbA1C — 0.209 1.730 0.189 Severe fibrosis or" exact="cirrhosis" post="No, mild, or significant fibrosis 0.066 0.020 0.889 Treatment"/>
   <result pre="antiviral agents for HCV; HbA1C: hemoglobin A1C level (%); HCV:" exact="hepatitis" post="C virus; P: probability."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7219522/results/search/disease/results.xml">
   <result pre="of Human Immunodeficiency Virus (HIV) infection can successfully maintain long-term" exact="suppression" post="of HIV-1 replication in plasma. Still, none of these"/>
   <result pre="virus replication, thus being responsible for the onset of HIV-associated" exact="dementia" post="and the neuropathological features of HIV encephalitis [7–10]. Tissue"/>
   <result pre="onset of HIV-associated dementia and the neuropathological features of HIV" exact="encephalitis" post="[7–10]. Tissue macrophages are critical contributors to HIV pathogenesis,"/>
   <result pre="specific conditions, monocytes can stimulate or inhibit T-cell responses during" exact="cancer" post="as well as infectious and autoimmune diseases. They are"/>
   <result pre="first fusion inhibitor in clinical use [121] even under viral" exact="suppression" post="by antiretroviral therapy. Taken together, overall findings support the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7232184/results/search/disease/results.xml">
   <result pre="pathogenesis results in symptoms like fever, acute pneumonia, and, eventually," exact="respiratory failure." post="The death rate, the long time needed for a"/>
   <result pre="developed for antiviral therapy against other viruses, such as the" exact="hepatitis" post="C virus (HCV) and the human immunodeficiency virus (HIV)."/>
   <result pre="antiviral drugs included in our screening show activity against the" exact="hepatitis" post="C virus and good oral bioavailability. One of the"/>
   <result pre="The last one is Pleconaril [39], used for prevention of" exact="asthma" post="exacerbations and common cold symptoms in asthmatic subjects exposed"/>
   <result pre="is Pleconaril [39], used for prevention of asthma exacerbations and" exact="common cold" post="symptoms in asthmatic subjects exposed to respiratory infections; Pleconaril"/>
   <result pre="contribute to characterize the peculiarity of SARS-CoV-2 from coronavirus and" exact="influenza" post="virus belonging to an old-scenario of virology taxonomy. It"/>
   <result pre="Human Coronavirus InfectionsViruses202012E19410.3390/v1202019432050635 3.HöferC.T.Di LellaS.DahmaniI.JungnickN.BordagN.BoboneS.HuangQ.KellerS.HerrmannA.ChiantiaS.Structural determinants of the interaction between" exact="influenza" post="A virus matrix protein M1 and lipid membranesBiochim. Biophys."/>
   <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg. Microb. Infect.2020922123610.1080/22221751.2020.1719902 7.WanY.ShangJ.GrahamR.BaricR.S.LiF.Receptor recognition by novel"/>
   <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitorsAntivir. Res.201714110110610.1016/j.antiviral.2017.02.00728216367 15.ChenL.ChenS.GuiC.ShenJ.ShenX.JiangH.Discovering" exact="severe acute respiratory syndrome" post="coronavirus 3CL protease inhibitors: Virtual screening, surface plasmon resonance,"/>
   <result pre="with the AutoDock suiteNat. Protoc.20161190591910.1038/nprot.2016.05127077332 22.YangH.YangM.DingY.LiuY.LouZ.ZhouZ.SunL.MoL.YeS.PangH.et al.The crystal structures of" exact="severe acute respiratory syndrome" post="virus main protease and its complex with an inhibitorProc."/>
   <result pre="Dependent RNA Polymerases: Insights from Structure, Function and EvolutionViruses201810e7610.3390/v1002007629439438 34.TaharaS.M.DietlinT.A.NelsonG.W.StohlmanS.A.MannoD.J.Mouse" exact="hepatitis" post="virus nucleocapsid protein as a translational effector of viral"/>
   <result pre="CD4 lymphocytesNat. Rev. Drug Discov.2004321522510.1038/nrd133115031735 38.PshenichnayaN.Y.BulgakovaV.A.LvovN.I.PoromovA.A.SelkovaE.P.GrekovaA.I.ShestakovaI.V.MaleevV.V.LenevaI.A.Clinical efficacy of umifenovir in" exact="influenza" post="and ARVI (study ARBITR)Ter. Arkhiv201991566310.26442/00403660.2019.03.000127 39.FloreaN.R.MaglioD.NicolauD.P.Pleconaril, a novel antipicornaviral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7232887/results/search/disease/results.xml">
   <result pre="cause disease in humans. These include HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1," exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)"/>
   <result pre="the cause of a large and rapidly spreading outbreak of" exact="respiratory disease," post="including pneumonia. According to the isolation and viral genome"/>
   <result pre="al., 2012). Unlike viruses such as human immunodeficiency virus and" exact="herpes simplex" post="virus, Sendai virus that can fuse the plasma membrane"/>
   <result pre="prevent coronavirus fusion as shown in a study using mouse" exact="hepatitis" post="virus (MHV) a safe model of coronavirus (de Haan"/>
   <result pre="VaddeR. (2020). In-silico approaches to detect inhibitors of the human" exact="severe acute respiratory syndrome" post="coronavirus envelope protein ion channel. Journal of Biomolecular Structure"/>
   <result pre="J. (2014). Clathrin- and serine proteases-dependent uptake of porcine epidemic" exact="diarrhea" post="virus into Vero cells. Virus Research, 191, 21–29. 10.1016/j.virusres.2014.07.02225086180"/>
   <result pre="D., &amp;amp; FauciA. S. (2020). Coronavirus infections—more than just the" exact="common cold." post="JAMA, 323(8), 707–708. 10.1001/jama.2020.0757 PiresD. E. V., BlundellT. L.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7241459/results/search/disease/results.xml">
   <result pre="The current pandemic coronavirus disease 2019 (COVID-19) caused by the" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial"/>
   <result pre="current outbreak of coronavirus disease 2019 (COVID-19) caused by the" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) poses a serious threat to global"/>
   <result pre="widely used for treating certain rheumatic diseases such as rheumatic" exact="arthritis" post="(RA) and systemic lupus erythematosus (SLE), and it also"/>
   <result pre="treating certain rheumatic diseases such as rheumatic arthritis (RA) and" exact="systemic lupus erythematosus" post="(SLE), and it also demonstrates a strong immunomodulatory capacity,"/>
   <result pre="certain rheumatic diseases such as rheumatic arthritis (RA) and systemic" exact="lupus erythematosus" post="(SLE), and it also demonstrates a strong immunomodulatory capacity,"/>
   <result pre="(CQ) is a drug widely used in the treatment of" exact="malaria" post="and autoimmune diseases, reportedly having broad-spectrum antiviral potential [4]."/>
   <result pre="vs 12.5%; P&amp;lt;0.001) [2]. In our opinion, patients before having" exact="shortness" post="of breath or in the high-risk category even with"/>
   <result pre="the patients to HCQ can cause side effects such as" exact="retinopathy" post="and cardiomyopathy. Although HCQ has a low level of"/>
   <result pre="of HCQ is likely to contribute to the development of" exact="retinopathy" post="[11]. However, a study that focused on the dose"/>
   <result pre="induced by the association of the two drugs and viral" exact="myocarditis" post="caused by SARS-CoV-2 infection should be considered. This side"/>
   <result pre="of optimized dosing design of Hydroxychloroquine for the treatment of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2). Clin Infect Dis202010.1093/cid/ciaa237. 4SavarinoA, Di TraniL,"/>
   <result pre="et al.Discovery of a novel coronavirus associated with the recent" exact="pneumonia" post="outbreak in humans and its potential bat origin. Nature."/>
   <result pre="11LaaksonenAL, KoskiahdeV, JuvaK.Dosage of antimalarial drugs for children with juvenile" exact="rheumatoid arthritis" post="and systemic lupus erythematosus. A clinical study with determination"/>
   <result pre="KoskiahdeV, JuvaK.Dosage of antimalarial drugs for children with juvenile rheumatoid" exact="arthritis" post="and systemic lupus erythematosus. A clinical study with determination"/>
   <result pre="of antimalarial drugs for children with juvenile rheumatoid arthritis and" exact="systemic lupus erythematosus." post="A clinical study with determination of serum concentrations of"/>
   <result pre="antimalarial drugs for children with juvenile rheumatoid arthritis and systemic" exact="lupus erythematosus." post="A clinical study with determination of serum concentrations of"/>
   <result pre="signature is a risk factor for the development of autoimmune" exact="congenital heart block." post="Ann. Rheum. Dis. 2017;10.1136/annrheumdis-2016-210927. 15MisraDP, AgarwalV, GasparyanAY, et al.Rheumatologists’"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7292951/results/search/disease/results.xml">
   <result pre="spectrometry of small-molecule antiviral drugs: 3. antiviral agents against herpes," exact="influenza" post="and other viral infections NiessenW.M.A.mail@hyphenms.nl[], pmc-release: 2020-6-6ppub: 2020-9epub: 2020-6-6455116377116377received:"/>
   <result pre="fragmentation in MS–MS of small-molecule antiviral drugs against herpes and" exact="influenza" post="viruses is reviewed. In this way, insight is gained"/>
   <result pre="is paid to small-molecule antiviral agents used against herpes and" exact="influenza" post="virus infections. In addition, some attention is paid to"/>
   <result pre="•Detailed study on the fragmentation of 15 Herpes-related and 9" exact="influenza" post="A-related antiviral drugs in MS–MS. •MS–MS of nucleoside analogues"/>
   <result pre="the fragmentation in MS–MS of antiviral agents against herpes and" exact="influenza" post="viruses. Thus, structures of relevant compounds were searched on"/>
   <result pre="compounds are nucleoside analogues. There are several types of the" exact="influenza" post="virus that affect humans [4,5]. Influenza A and B"/>
   <result pre="deaths. Larger outbreaks of pandemic nature are less frequent. Well-known" exact="influenza" post="pandemics, all related to the Influenza A virus, are"/>
   <result pre="all related to the Influenza A virus, are the Spanish" exact="influenza" post="(H1N1) in 1918, the Asian influenza (H2N2) in 1957,"/>
   <result pre="virus, are the Spanish influenza (H1N1) in 1918, the Asian" exact="influenza" post="(H2N2) in 1957, the Hong Kong influenza (H3N2) in"/>
   <result pre="1918, the Asian influenza (H2N2) in 1957, the Hong Kong" exact="influenza" post="(H3N2) in 1968, and the Mexican influenza (H7N9) in"/>
   <result pre="the Hong Kong influenza (H3N2) in 1968, and the Mexican" exact="influenza" post="(H7N9) in 2018. Influenza may also affect animals like"/>
   <result pre="to mutations in the virus. The most common treatment of" exact="influenza" post="is the use of acetaminophen to relieve fever and"/>
   <result pre="of antiviral drugs used against influenza, the antagonists of the" exact="influenza" post="virus A Matrix-2 proton channel (adamantane derivatives) and the"/>
   <result pre="a pandemic due to a new corona virus, the so-called" exact="severe acute respiratory syndrome" post="(SARS) corona virus 2 (SARS-CoV-2). Therefore, a short section"/>
   <result pre="and pritelivir used against Herpes viruses. 4 Antiviral agents against" exact="influenza" post="viruses In this section, the MS–MS fragmentation of the"/>
   <result pre="this section, the MS–MS fragmentation of the antiviral agents against" exact="influenza" post="viruses is reviewed. There are two classes of antiviral"/>
   <result pre="of antiviral drugs used against influenza, the antagonists of the" exact="influenza" post="virus A Matrix-2 proton channel (adamantane derivatives) and the"/>
   <result pre="2 . Table 2 SRM transitions for antiviral drugs against" exact="influenza" post="in positive-ion mode. Table 2 Compound m/z of [M+H]+"/>
   <result pre="[44], [45]] 121.028 [C7H5O2]+ [45] 4.1 M2 protein inhibitors against" exact="influenza" post="A Amantadine and rimantadine are inhibitors of the Matrix-2"/>
   <result pre="a proton-selective viroprotein, integral in the viral envelope of the" exact="influenza" post="A virus. They have been used against influenza A,"/>
   <result pre="of the influenza A virus. They have been used against" exact="influenza" post="A, but because of their antagonistic properties to the"/>
   <result pre="they are also used in the treatment of parkinsonism and" exact="multiple sclerosis" post="(like the structural analogue memantine). In order to prevent"/>
   <result pre="m/z 81 ([C6H9]+) (Fig. 4) [33]. 4.2 Neuraminidase inhibitors against" exact="influenza" post="A The initial fragmentation of the neuraminidase inhibitors laninamivir,"/>
   <result pre="confirmed by accurate-m/z data [47]. 4.3 Other antiviral agents against" exact="influenza" post="A viruses Umifenovir (arbidol) is only approved for use"/>
   <result pre="A viruses Umifenovir (arbidol) is only approved for use against" exact="influenza" post="in Russia and China. It inhibits membrane fusion, and"/>
   <result pre="virus infections took place, causing serious health problems, e.g., the" exact="severe acute respiratory syndrome" post="(SARS), caused by SARS-CoV in 2002 and 2003, mainly"/>
   <result pre="RNA polymerase and is applied as antiviral agent against new" exact="influenza" post="strains in Japan. Favipiravir ([M−H]– with m/z 156) is"/>
   <result pre="30 antiviral agents involved in the treatment of Herpes and" exact="influenza" post="infections has been reviewed. MS–MS spectra and SRM transitions"/>
   <result pre="treatment of wild-type or pritelivir-resistant virus infection in a murine" exact="herpes simplex" post="virus 1 infection modelAntimicrob. Agents Chemother.5820143843385210.1128/AAC.02641-1424752278 23QuenelleD.C.BirkmannA.GoldnerT.PfaffT.ZimmermannH.BonsmannS.CollinsD.J.RiceT.L.PrichardM.N.Efficacy of pritelivir"/>
   <result pre="Chemother.5820143843385210.1128/AAC.02641-1424752278 23QuenelleD.C.BirkmannA.GoldnerT.PfaffT.ZimmermannH.BonsmannS.CollinsD.J.RiceT.L.PrichardM.N.Efficacy of pritelivir and acyclovir in the treatment of" exact="herpes simplex" post="virus infections in a mouse model of herpes simplex"/>
   <result pre="of herpes simplex virus infections in a mouse model of" exact="herpes simplex" post="encephalitisAntivir. Res.14920181610.1016/j.antiviral.2017.11.00229113740 24LinC.C.YehL.T.LauJ.Y.Specific, sensitive and accurate liquid chromatographic-tandem mass"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7308127/results/search/disease/results.xml">
   <result pre="with an excellent safety profile since revolutionized the management of" exact="hepatitis" post="c virus (HCV) patients. Published papers have suggested a"/>
   <result pre="patients. Published papers have suggested a possible increased incidence of" exact="hepatocellular carcinoma" post="(HCC) after successful DAAs treatment. Other papers have been"/>
   <result pre="the de novo occurrence of HCC in patients with liver" exact="cirrhosis" post="(LC). Patients and Methods A prospective cohort study has"/>
   <result pre="with the HCV get chronic hepatitis, which may progress to" exact="cirrhosis" post="in 20% of patients within 2–3 decades; a quarter"/>
   <result pre="a quarter of these patients will develop complications, such as" exact="hepatocellular carcinoma" post="(HCC), portal hypertension, and liver decompensation, with an average"/>
   <result pre="these patients will develop complications, such as hepatocellular carcinoma (HCC)," exact="portal hypertension," post="and liver decompensation, with an average 5-year survival rate"/>
   <result pre="50%.3 Hepatocellular carcinoma is the fifth most frequent form of" exact="cancer" post="worldwide, and it holds the second cause of malignancy-related"/>
   <result pre="most parts of the world (about 2–3% per year). Liver" exact="cirrhosis" post="(LC) is the major risk factor or HCC in"/>
   <result pre="management of HCV patients.7 Interferon era teaches us that after" exact="cirrhosis" post="has been established, eradication of HCV infection is not"/>
   <result pre="the de novo occurrence of HCC in patients with liver" exact="cirrhosis" post="who are treated by DAAs. Materials and Methods Study"/>
   <result pre="from March 2016 till March 2019 in Assiut center for" exact="viral hepatitis" post="mangment (one of the national established centers in every"/>
   <result pre="March 2016 till March 2019 in Assiut center for viral" exact="hepatitis" post="mangment (one of the national established centers in every"/>
   <result pre="and Alrajhi University Hospital for Liver on 350 HCV-related liver" exact="cirrhosis" post="patients who are seeking for HCV treatment by direct-acting"/>
   <result pre="from every included patient. Patients with HBV co-infection, renal impairment," exact="hepatocellular carcinoma" post="have been excluded from the study. A complete history"/>
   <result pre="have analyzed data from 350 consecutive patients with HCV-related liver" exact="cirrhosis" post="who have been treated with direct-acting antivirals between March"/>
   <result pre="55.4% of patients were males. As high as 30.3% had" exact="diabetes mellitus" post="(D.M), and 84.3% of patients are naïve. PCR Median"/>
   <result pre="± 0.56 mg/dL. Ascites is in 12.3% of patients and" exact="hepatic encephalopathy" post="in 2.6% of patients. The baseline characteristics of the"/>
   <result pre="0.56 mg/dL. Ascites is in 12.3% of patients and hepatic" exact="encephalopathy" post="in 2.6% of patients. The baseline characteristics of the"/>
   <result pre="± 1.07 (3–6) PCR Median (range) 511,897 (52–815,000,000) Abbreviations: DM," exact="diabetes mellitus;" post="HTN, hypertension; S+R, sofosbuvir+ribavirin; S+S, sofosbuvir+Semiprevir; s+d±r, sofosbuvir+daclatasvir±ribavirin. Table"/>
   <result pre="27.0 (5.0–157.0) Note: *Significant. Abbreviations: SVR, sustained virological response; HE," exact="hepatic encephalopathy;" post="BIL, bilirubin; ALB, albumin; INR, international normalized ratio; AFP,"/>
   <result pre="4.8% 1.000 Note: *Significant. Abbreviations: SVR, sustained virological response; DM," exact="diabetes mellitus;" post="HTN, hypertension; HE, hepatic encephalopathy. Evolution of Liver Function"/>
   <result pre="SVR, sustained virological response; DM, diabetes mellitus; HTN, hypertension; HE," exact="hepatic encephalopathy." post="Evolution of Liver Function Significant improvement in liver enzymes"/>
   <result pre="16 (76.2%) Note: *Significant. Abbreviations: SVR, sustained virological response; HCC," exact="hepatocellular carcinoma." post="Table 5 Characteristics of HCC Patients with SVR and"/>
   <result pre="27 17 10 22 5 8 Abbreviations: No, number; HCC," exact="hepatocellular carcinoma;" post="SVR, sustained virological response; Non-SVR, non-sustained virological response; TTT,"/>
   <result pre="non-sustained virological response; TTT, treatment; m, month; AFP, alpha-fetoprotein; DM," exact="diabetes mellitus." post="Figure 1 Kaplan–Meier curve for HCC occurrence after treatment."/>
   <result pre="curve for HCC occurrence after treatment. Discussion The therapy of" exact="hepatitis" post="C has dramatically changed since 2013. Direct-acting antivirals against"/>
   <result pre="appears to be high in some real-world studies, regardless of" exact="cirrhosis" post="status.14 Resolution of HCV infection in these patients leads"/>
   <result pre="to evaluate the impact of DAAs on patients with liver" exact="cirrhosis" post="in our locality regarding the outcome and development of"/>
   <result pre="colleagues have reported that SVR is 95.2% in their liver" exact="cirrhosis" post="patients,21 Also the ALLY-1 trial looks at the effects"/>
   <result pre="Daclatasvir/Sofosbuvir with ribavirin on patients with advanced cirrhosis, including decompensated" exact="cirrhosis" post="across 5 of the 6 major HCV genotypes, only"/>
   <result pre="noted a high treatment response with Child-Pugh A or B" exact="cirrhosis" post="(93%); SVR is 100% in genotype 4 patients.22 In"/>
   <result pre="have shown an epidemiological association between HCV and type 2" exact="diabetes mellitus" post="(T2DM). The data from the National Health and Nutrition"/>
   <result pre="also have demonstrated that in patients with risk factors for" exact="metabolic syndrome," post="the presence of chronic HCV infection has increased the"/>
   <result pre="study of 564 noncirrhotic HCV‐infected patients and control‐matched with noncirrhotic" exact="hepatitis" post="B virus-infected patients has demonstrated an increased prevalence rate"/>
   <result pre="SVR have shown a significant reduction in the frequency of" exact="hepatic encephalopathy" post="episodes, improvement in the management of ascites. De-novo HCC"/>
   <result pre="have shown a significant reduction in the frequency of hepatic" exact="encephalopathy" post="episodes, improvement in the management of ascites. De-novo HCC"/>
   <result pre="patients who have achieved a SVR after IFN-free treatment with" exact="cirrhosis" post="with no history of liver cancer and they have"/>
   <result pre="SVR after IFN-free treatment with cirrhosis with no history of" exact="liver cancer" post="and they have found that HCC occurrence rate is"/>
   <result pre="after IFN-free treatment with cirrhosis with no history of liver" exact="cancer" post="and they have found that HCC occurrence rate is"/>
   <result pre="of data from a large prospective study of patients with" exact="hepatitis" post="C virus–associated compensated or decompensated cirrhosis, Calvaruso et al"/>
   <result pre="et al. The current and future disease burden of chronic" exact="hepatitis" post="C virus infection in Egypt. Arab J Gastroenterol. 2014;15(2):45–52."/>
   <result pre="doi:10.1016/j.ajg.2014.04.00325097045 3.PlanasR, BallestéB, AlvarezMA, et al. Natural history of decompensated" exact="hepatitis" post="C virus-related cirrhosis. A study of 200 patients. J"/>
   <result pre="Hepatol. 2004;40(5):823–830. doi:10.1016/j.jhep.2004.01.00515094231 4.JemalA, BrayF, CenterMM, FerlayJ, WardE, FormanD. Global" exact="cancer" post="statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855 5.RyersonAB, EhemanCR,"/>
   <result pre="the Status of Cancer, 1975–2012, featuring the increasing incidence of" exact="liver cancer." post="Cancer. 2016;122(9):1312–1337. doi:10.1002/cncr.2993626959385 6.MoriyaK, FujieH, ShintaniY, et al. The"/>
   <result pre="doi:10.1002/cncr.2993626959385 6.MoriyaK, FujieH, ShintaniY, et al. The core protein of" exact="hepatitis" post="C virus induces hepatocellular carcinoma in transgenic mice. Nat"/>
   <result pre="et al. The core protein of hepatitis C virus induces" exact="hepatocellular carcinoma" post="in transgenic mice. Nat Med. 1998;4(9):1065. doi:10.1038/20539734402 7.BurraP, GianniniEG,"/>
   <result pre="Liver Int. 2018;38(8):1338–1362. doi:10.1111/liv.1375529637743 8.BuonfiglioliF, BrillantiS. Direct antiviral therapy for" exact="hepatitis" post="C and hepatocellular carcinoma: facing the conundrum. Hepatoma Res."/>
   <result pre="9.SangiovanniA, PratiGM, FasaniP, et al. The natural history of compensated" exact="cirrhosis" post="due to hepatitis C virus: a 17-year cohort study"/>
   <result pre="et al. The natural history of compensated cirrhosis due to" exact="hepatitis" post="C virus: a 17-year cohort study of 214 patients."/>
   <result pre="Suarez-CuervoC, NelsonDR, FriedMW, SegalJB, SulkowskiMS. Oral direct-acting agent therapy for" exact="hepatitis" post="C virus infection: a systematic review. Ann Intern Med."/>
   <result pre="2017;166(9):637–648. doi:10.7326/M16-257528319996 12.ZanettoA, ShalabyS, FerrareseA, et al. Direct-acting antivirals and" exact="hepatocellular carcinoma" post="occurrence and recurrence in hepatitis C virus-related liver cirrhosis:"/>
   <result pre="al. Direct-acting antivirals and hepatocellular carcinoma occurrence and recurrence in" exact="hepatitis" post="C virus-related liver cirrhosis: fact or fiction. Hepatoma Res."/>
   <result pre="13.MessinaJP, HumphreysI, FlaxmanA, et al. Global distribution and prevalence of" exact="hepatitis" post="C virus genotypes. Hepatology. 2015;61(1):77–87. doi:10.1002/hep.2725925069599 14.GayamV, KhalidM, MandalAK,"/>
   <result pre="doi:10.1002/hep.2725925069599 14.GayamV, KhalidM, MandalAK, et al. Direct-acting antivirals in chronic" exact="hepatitis" post="C genotype 4 infection in community care setting. Gastroenterol"/>
   <result pre="doi:10.14740/gr999w 15.KanwalF, KramerJ, AschSM, ChayanupatkulM, CaoY, El-SeragHB. Risk of hepatocellular" exact="cancer" post="in HCV patients treated with direct-acting antiviral agents. Gastroenterology."/>
   <result pre="doi:10.1053/j.gastro.2017.06.01228642197 16.LiDK, RenY, FiererDS, et al. The short-term incidence of" exact="hepatocellular carcinoma" post="is not increased after hepatitis C treatment with direct-acting"/>
   <result pre="The short-term incidence of hepatocellular carcinoma is not increased after" exact="hepatitis" post="C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology."/>
   <result pre="eradication induced by direct-acting antiviral agents reduces the risk of" exact="hepatocellular carcinoma." post="J Hepatol. 2017;pii: S0168–8278 (17)32273–0. 18.RinaldiL, Di FranciaR, CoppolaN,"/>
   <result pre="18.RinaldiL, Di FranciaR, CoppolaN, et al. Hepatocellular carcinoma in HCV" exact="cirrhosis" post="after viral clearance with direct acting antiviral therapy: preliminary"/>
   <result pre="19.ContiF, BuonfiglioliF, ScuteriA, et al. Early occurrence and recurrence of" exact="hepatocellular carcinoma" post="in HCV-related cirrhosis treated with direct acting antivirals. J"/>
   <result pre="al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related" exact="cirrhosis" post="treated with direct acting antivirals. J Hepatol. 2016;65:727–733. doi:10.1016/j.jhep.2016.06.01527349488"/>
   <result pre="doi:10.1016/j.jhep.2016.06.01527349488 20.KozbialK, MoserS, SchwarzerR, et al. Unexpected high incidence of" exact="hepatocellular carcinoma" post="in cirrhotic patients with sustained virologic response following interferon-free"/>
   <result pre="Hepatol. 2016;65(4):856–858. doi:10.1016/j.jhep.2016.06.00927318327 21.CalvarusoV, CabibboG, CacciolaI, et al. Incidence of" exact="hepatocellular carcinoma" post="in patients with HCV-associated cirrhosis treated with direct-acting antiviral"/>
   <result pre="et al. Incidence of hepatocellular carcinoma in patients with HCV-associated" exact="cirrhosis" post="treated with direct-acting antiviral agents. Gastroenterology. 2018;155(2):411–421. doi:10.1053/j.gastro.2018.04.00829655836 22.PoordadF,"/>
   <result pre="SchiffER, VierlingJM, et al. Daclatasvir with sofosbuvir and ribavirin for" exact="hepatitis" post="C virus infection with advanced cirrhosis or post-liver transplantation"/>
   <result pre="sofosbuvir and ribavirin for hepatitis C virus infection with advanced" exact="cirrhosis" post="or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–1505. doi:10.1002/hep.2844626754432 23.MehtaSH, BrancatiFL,"/>
   <result pre="doi:10.1002/hep.2844626754432 23.MehtaSH, BrancatiFL, SulkowskiMS, et al. Prevalence of type 2" exact="diabetes mellitus" post="among persons with hepatitis C virus infection in the"/>
   <result pre="al. Prevalence of type 2 diabetes mellitus among persons with" exact="hepatitis" post="C virus infection in the United States. Ann Intern"/>
   <result pre="Clinical outcomes of direct-acting antiviral therapy in patients with compensated" exact="hepatitis" post="C virus-related cirrhosis. Hepatoma Res. 2017;3(9):209–214. doi:10.20517/2394-5079.2017.28 27.RomanoA, AngeliP,"/>
   <result pre="Res. 2017;3(9):209–214. doi:10.20517/2394-5079.2017.28 27.RomanoA, AngeliP, PiovesanS, et al. Newly diagnosed" exact="hepatocellular carcinoma" post="in patients with advanced hepatitis C treated with DAAs:"/>
   <result pre="et al. Newly diagnosed hepatocellular carcinoma in patients with advanced" exact="hepatitis" post="C treated with DAAs: a prospective population study. J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7315692/results/search/disease/results.xml">
   <result pre="compound combined with the contact tracing process. Results For an" exact="infectious disease" post="in which asymptomatic and presymptomatic infections are plausible, an"/>
   <result pre="mers-cov. Nature Communications 11(1), 222 (2020). 9.RhodesPHHalloranMELonginiIMJrCounting process models for" exact="infectious disease" post="data: distinguishing exposure to infection from susceptibilityJ R Stat"/>
   <result pre="Med. 2020;382(12):1177-9. 14.DonnellyCAGhaniACLeungGMHedleyAJFraserCRileySAbu-RaddadLJHoL-MThachT-QChauPChanK-PLamT-HTseL-YTsangTLiuS-HKongJHLauEMFergusonNMAndersonRMEpidemiological determinants of spread of causal agent of" exact="severe acute respiratory syndrome" post="in Hong KongLancet200336193711761176610.1016/S0140-6736(03)13410-112781533 15.Flahault A. Has China faced only"/>
   <result pre="B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7318677/results/search/disease/results.xml">
   <result pre="as an antiviral drug against human immunodeficiency virus (HIV) and" exact="hepatitis" post="B virus (HBV) infections.11 It is administered as a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7335219/results/search/disease/results.xml">
   <result pre="visit http://creativecommons.org/licenses/by-nc/4.0/. The emergence of a novel coronavirus, designated as" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), in Wuhan (China) at the end"/>
   <result pre="in the last 30 years, including coronaviruses SARS-CoV and MERS-CoV," exact="influenza" post="viruses H1N1 and H7N9 and Ebola viruses. The emergence"/>
   <result pre="approved antiviral drugs and 40 million doses of vaccines against" exact="influenza" post="virus subtypes considered to pose a substantial pandemic risk"/>
   <result pre="by the WHO’s Regional Office for Europe [3], after the" exact="influenza" post="pandemic of 2009, found the following weaknesses: poor seasonal"/>
   <result pre="influenza pandemic of 2009, found the following weaknesses: poor seasonal" exact="influenza" post="vaccination coverage, inequitable access to vaccines across Europe, lack"/>
   <result pre="care and paediatric services, poor use of antivirals to treat" exact="influenza" post="patients and lack of effectiveness of new interventions introduced"/>
   <result pre="insufficient stockpiling of antiviral drugs, insufficient production and distribution of" exact="influenza" post="vaccines and insufficient research on treatments against potential new"/>
   <result pre="evaluative studies have found that stockpiling of antiviral drugs against" exact="influenza" post="is a cost-effective intervention. Milne et al. [5] assessed"/>
   <result pre="terms of cost per life-year saved (LYS) of interventions against" exact="influenza" post="pandemics including school closure, antiviral drugs for treatment and"/>
   <result pre="Three antiviral drug strategies were examined: (1) antiviral treatment of" exact="influenza" post="cases, (2) antiviral treatment of influenza cases and antiviral"/>
   <result pre="(1) antiviral treatment of influenza cases, (2) antiviral treatment of" exact="influenza" post="cases and antiviral prophylaxis of household contacts of influenza"/>
   <result pre="of influenza cases and antiviral prophylaxis of household contacts of" exact="influenza" post="cases and (3) antiviral treatment of influenza cases, antiviral"/>
   <result pre="household contacts of influenza cases and (3) antiviral treatment of" exact="influenza" post="cases, antiviral prophylaxis of household contacts of influenza cases"/>
   <result pre="treatment of influenza cases, antiviral prophylaxis of household contacts of" exact="influenza" post="cases and antiviral prophylaxis of school or workplace contacts"/>
   <result pre="cases and antiviral prophylaxis of school or workplace contacts of" exact="influenza" post="cases. The study assumed that influenza pandemics were associated"/>
   <result pre="or workplace contacts of influenza cases. The study assumed that" exact="influenza" post="pandemics were associated with clinical attack rates (percentage of"/>
   <result pre="number, Ro) of 1.8. The most cost-effective intervention against severe" exact="influenza" post="pandemics (0.75–2.5% case fatality rate) included continuous school closure,"/>
   <result pre="antiviral treatment of symptomatic patients, prophylaxis of household contacts of" exact="influenza" post="cases and 50% community contact reduction. The cost effectiveness"/>
   <result pre="in moderate severity pandemics. The most cost-effective intervention against low-severity" exact="influenza" post="pandemics (0.03–0.25% case fatality rate) included the same combined"/>
   <result pre="intervention plus antiviral prophylaxis of school or workplace contacts of" exact="influenza" post="cases. The cost-effectiveness ratio for this intervention was US$26,726"/>
   <result pre="effectiveness of stockpiling the neuraminidase inhibitor oseltamivir for a potential" exact="influenza" post="pandemic in the UK in 2004. The study selected"/>
   <result pre="(amantadine and rimantadine) were not included in the analysis because" exact="influenza" post="viruses can be resistant to cyclic amines. The study"/>
   <result pre="(treat only intervention) and (3) test all influenza-like patients for" exact="influenza" post="and treat only individuals with a positive test result"/>
   <result pre="study assumed 25% for the clinical attack rate over one" exact="influenza" post="wave lasting 15 weeks, case fatality rates of 0.3%"/>
   <result pre="fatality scenario. In pandemics due to air-transmitted infections, such as" exact="influenza" post="and coronavirus, ventilators in intensive care units are of"/>
   <result pre="Pandemic Plan of the United States considered that a severe" exact="influenza" post="pandemic would require mechanical ventilators for 740,000 critically ill"/>
   <result pre="ill people [2]. Ventilator support and intensive care for acute" exact="respiratory failure" post="due to acute respiratory distress syndrome is a cost-effective"/>
   <result pre="support and intensive care for acute respiratory failure due to" exact="acute respiratory distress syndrome" post="is a cost-effective intervention [8], but the cost effectiveness"/>
   <result pre="Seqirus. References References 1.ZhuNZhangDWangWLiXYangBSongJet al.A Novel Coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med202038272773310.1056/NEJMoa200101731978945 2.US Department of"/>
   <result pre="ONE201384e6150410.1371/journal.pone.006150423585906 6.SiddiquiMREdmundsWJCost-effectiveness of antiviral stockpiling and near-patient testing for potential" exact="influenza" post="pandemicEmerg Infect Dis20081426727410.3201/eid1402.07047818258120 7.RubinsonLVaughnFNelsonSet al.Mechanical ventilators in US acute"/>
   <result pre="of ventilator support and aggressive care for patients with acute" exact="respiratory failure" post="due to pneumonia or acute respiratory distress syndromeAm J"/>
   <result pre="aggressive care for patients with acute respiratory failure due to" exact="pneumonia" post="or acute respiratory distress syndromeAm J Med200010961462010.1016/s0002-9343(00)00591-x11099680"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7366079/results/search/disease/results.xml">
   <result pre="al., 2012). While Alpha-coronaviruses and Beta-coronaviruses are known to cause" exact="gastroenteritis" post="in animals, in humans, they commonly cause respiratory distress"/>
   <result pre="Hepatitis C Famciclovir DB00426 Herpes virus infections Simeprevir DB06290 Chronic" exact="hepatitis" post="C virus Lopinavir DB01601 Human immunodeficiency virus type 1"/>
   <result pre="A and B infections Baloxavir marboxil DB13997 Influenza A and" exact="influenza" post="B infections Didanosine DB00900 HIV infection Bictegravir DB11799 HIV-1"/>
   <result pre="Amantadine DB00915 Influenza A infection Vidarabine DB00194 Herpes viruses, the" exact="vaccinia virus" post="and varicella zoster virus infection Daclatasvir DB09102 Hepatitis C"/>
   <result pre="DB09102 Hepatitis C Virus (HCV) infection Tenofovir alafenamide DB09299 Chronic" exact="hepatitis" post="B and HIV-1 infection Ritonavir DB00503 HIV infection Trifluridine"/>
   <result pre="Ritonavir DB00503 HIV infection Trifluridine DB00432 Keratoconjunctivitis and recurrent epithelial" exact="keratitis" post="Zanamivir DB00558 Influenza A and B virus infection Acyclovir"/>
   <result pre="and B virus infection Acyclovir DB00787 Herpes simplex, Varicella zoster," exact="herpes zoster" post="infection Ganciclovir DB01004 AIDS-associated cytomegalovirus infections. Entecavir DB00442 Hepatitis"/>
   <result pre="disoproxil DB00300 HIV infection and Hepatitis B Cidofovir DB00369 CMV" exact="retinitis" post="Voxilaprevir DB12026 Chronic Hepatitis C Asunaprevir DB11586 HCV infection"/>
   <result pre="Hepatitis C Indinavir DB00224 HIV infection Lamivudine DB00709 HIV-1 and" exact="hepatitis" post="B virus (HBV) infection Atazanavir DB01072 HIV infection Rilpivirine"/>
   <result pre="While Glecaprevir, Daclatasvir and Paritaprevir have been used against chronic" exact="hepatitis" post="C (For the Study of the Liver (KASL, K.A.,"/>
   <result pre="K.A., others, 2018. 2017 KASL clinical practice guidelines management of" exact="hepatitis" post="C: Treatment of chronic hepatitis C. Clin. Mol. Hepatol."/>
   <result pre="clinical practice guidelines management of hepatitis C: Treatment of chronic" exact="hepatitis" post="C. Clin. Mol. Hepatol. 24, 169-229. ForniD.CaglianiR.ClericiM.SironiM.Molecular evolution of"/>
   <result pre="scope, parameterization, and performance of MMFF94J. Comput. Chem.17199649051910.1002/(SICI)1096-987X(199604)17:5/6&amp;lt;490::AID-JCC1&amp;gt;3.0.CO;2-P HézodeC.Treatment of" exact="hepatitis" post="C: results in real lifeLiver Int.382018212729427481 JoS.KimS.ShinD.H.KimM.-S.Inhibition of SARS-CoV"/>
   <result pre="coronavirus in Brazil related to appalachian ridge and Porcine epidemic" exact="diarrhea" post="virusesEmerg. Infect. Dis.21201572973125811911 SuS.WongG.ShiW.LiuJ.LaiA.C.K.ZhouJ.LiuW.BiY.GaoG.F.Epidemiology, genetic recombination, and pathogenesis of"/>
   <result pre="drug candidatesJ. Med. Chem.4520022615262312036371 WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen" exact="severe acute respiratory syndrome" post="coronavirusMicrobiol. Mol. Biol. Rev.69200563566416339739 WishartD.S.KnoxC.GuoA.C.ChengD.ShrivastavaS.TzurD.GautamB.HassanaliM.DrugBank: a knowledgebase for drugs,"/>
   <result pre="gammacoronavirus and deltacoronaviJ. Virol.8620123995400822278237 WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.HuY.TaoZ.-W.TianJ.-H.PeiY.-Y.A new coronavirus associated with human" exact="respiratory disease" post="in ChinaNature579202026526932015508 ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.A pneumonia outbreak associated with a new"/>
   <result pre="new coronavirus associated with human respiratory disease in ChinaNature579202026526932015508 ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7376526/results/search/disease/results.xml">
   <result pre="and the SARS-CoV-2 spike protein. Caulerpin exhibited antiviral activities against" exact="chikungunya" post="virus and herpes simplex virus type 1. Caulerpin and"/>
   <result pre="spike protein. Caulerpin exhibited antiviral activities against chikungunya virus and" exact="herpes simplex" post="virus type 1. Caulerpin and some of its derivatives"/>
   <result pre="cough, and fatigue [4], but it may lead to severe" exact="pneumonia" post="and pulmonary edema [5]. Until now, there is no"/>
   <result pre="fatigue [4], but it may lead to severe pneumonia and" exact="pulmonary edema" post="[5]. Until now, there is no specific effective drug"/>
   <result pre="regulator [14–17], and anti-inflammatory [18]. Caulerpin exhibited antiviral activities against" exact="chikungunya" post="virus [19] and herpes simplex virus type 1 [11]."/>
   <result pre="[18]. Caulerpin exhibited antiviral activities against chikungunya virus [19] and" exact="herpes simplex" post="virus type 1 [11]. Caulerpin and some of its"/>
   <result pre="consensus statementWorld J Pediatr2020719 3.ZhuNZhangDWangWLiXYangBSongJZhaoXHuangBShiWLuRNiuPA novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med202038272773310.1056/NEJMoa200101731978945 4.WangTDuZZhuFCaoZAnYGaoYJiangBComorbidities and multi-organ"/>
   <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 6.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and chloroquine"/>
   <result pre="Alternat Med:1–3. 10.1155/2018/1945179 11.MacedoNRPVRibeiroMSVillaçaRCFerreiraWPintoAMTeixeiraVLCirne-SantosCPaixãoICNPGiongoVCaulerpin as a potential antiviral drug against" exact="herpes simplex" post="virus type 1Rev Bras Farmacogn Braz J Pharmacogn20122286186710.1590/S0102-695X2012005000072 12.AyyadSENBadriaFACaulerpin,"/>
   <result pre="seaweeds of the genus Caulerpa, attenuated colon damage in murine" exact="colitis" post="modelMar Drugs201816931810.3390/md16090318 18.De SouzaÉTPereira de LiraDCavalcanti de QueirozACosta da"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7391054/results/search/disease/results.xml">
   <result pre="investigating drugs from different pharmaceutical classes with antiviral activity against" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) and SARS-CoV. Remarkably, at least four"/>
   <result pre="that confers drug resistance, representing a key obstacle to effective" exact="cancer" post="treatment [2]. Likewise, the antiparasitic drug nitazoxanide induces cancer"/>
   <result pre="effective cancer treatment [2]. Likewise, the antiparasitic drug nitazoxanide induces" exact="cancer" post="cell cytotoxicity under hypoxic conditions and could be an"/>
   <result pre="conditions and could be an excellent candidate to target dormant" exact="cancer" post="cells in hypoxic regions of tumours in combination with"/>
   <result pre="agents [3]. Metformin, an effective medication used in type 2" exact="diabetes mellitus," post="is able to modulate tumour cell signalling and metabolism."/>
   <result pre="treatment of patients with severe COVID-19 at risk for acute" exact="respiratory disease" post="syndrome (ARDS). Clinically approved drugs could be used to"/>
   <result pre="particular, lovastatin holds promise for the clinical management of triple-negative" exact="breast cancer" post="[8]. The compound reduces membrane localisation of Rho proteins,"/>
   <result pre="lovastatin holds promise for the clinical management of triple-negative breast" exact="cancer" post="[8]. The compound reduces membrane localisation of Rho proteins,"/>
   <result pre="response by manipulating the renin–angiotensin system might attenuate the destructive" exact="lung disease" post="associated with COVID-19 [12,16]. The well-known antiparasitic drug ivermectin"/>
   <result pre="In this regard, nuclear transport plays a central role in" exact="cancer" post="by moving key mediators of carcinogenesis across the nuclear"/>
   <result pre="repurposed drugs with antitumour effects and potential antiviral activity against" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) Table 1 Drug Original indication Potential"/>
   <result pre="defined. Induces cell cytotoxicity under hypoxic conditions [1,3] ARDS, acute" exact="respiratory disease" post="syndrome. aOther lipophilic statins such as simvastatin and atorvastatin"/>
   <result pre="inducer and an autophagy inhibitor: a smarter strategy emerging in" exact="cancer" post="therapyFront Pharmacol11202040810.3389/fphar.2020.0040832322202 3SenkowskiWZhangXOlofssonMHIsacsonRHöglundUGustafssonMThree-dimensional cell culture-based screening identifies the anthelmintic"/>
   <result pre="U S A11720209932994110.1073/pnas.191370711732312819 6LiCCWangXJWangHRRepurposing host-based therapeutics to control coronavirus and" exact="influenza" post="virusDrug Discov Today24201972673610.1016/j.drudis.2019.01.01830711575 7AlonsoDFFarinaHGSkiltonGGabriMRDe LorenzoMSGomezDEReduction of mouse mammary tumor"/>
   <result pre="13TikooKPatelGKumarSKarpePASanghaviMMalekVTissue specific up regulation of ACE2 in rabbit model of" exact="atherosclerosis" post="by atorvastatin: role of epigenetic histone modificationsBiochem Pharmacol93201534335110.1016/j.bcp.2014.11.01325482567 14FerrarioCMJessupJChappellMCAverillDBBrosnihanKBTallantEAEffect"/>
   <result pre="ATP via ivermectin induces a non-apoptotic and inflammatory form of" exact="cancer" post="cell deathSci Rep520151622210.1038/srep1622226552848 20WagstaffKMSivakumaranHHeatonSMHarrichDJansDAIvermectin is a specific inhibitor of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7392152/results/search/disease/results.xml">
   <result pre="approved for indications such as influenza, acute respiratory viral infection," exact="viral hepatitis," post="viral encephalitis and myelitis. Arbidol is registered in Russia"/>
   <result pre="such as influenza, acute respiratory viral infection, viral hepatitis, viral" exact="encephalitis" post="and myelitis. Arbidol is registered in Russia and China"/>
   <result pre="is registered in Russia and China for the treatment of" exact="influenza" post="[24]. It is claimed to inhibit the membrane fusion"/>
   <result pre="effective against a wide variety of viruses: Herpes simplex, SARS-CoV," exact="hepatitis" post="C, dengue and Chikungunya [23] (DrugVirus database). It is"/>
   <result pre="A. D. Drugs@FDA: FDA-Approved Drugs [Online] Available: https://www.accessdata.fda.gov/scripts/cder/daf/ [Accessed]. 46BjorneboeM.IversenO.OlsenS.Infective" exact="hepatitis" post="and toxic jaundice in a municipal hospital during a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7399655/results/search/disease/results.xml">
   <result pre="as the COVID-19 resource centre remains active. Abstract Recently, scary" exact="viral pneumonia" post="is known as (COVID-19) has swept the whole world."/>
   <result pre="the COVID-19 resource centre remains active. Abstract Recently, scary viral" exact="pneumonia" post="is known as (COVID-19) has swept the whole world."/>
   <result pre="appearance of highly pathogenic three coronaviruses which cause human fatal" exact="pneumonia" post="including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle-East respiratory"/>
   <result pre="highly pathogenic three coronaviruses which cause human fatal pneumonia including" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV), Middle-East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2"/>
   <result pre="of December 2019 [[7], [8], [9]] as an outbreak of" exact="pneumonia" post="with a mysterious etiological agent responsible for the viral"/>
   <result pre="of pneumonia with a mysterious etiological agent responsible for the" exact="viral pneumonia" post="outbreak that swept the world [4,8,[10], [11], [12], [13],"/>
   <result pre="pneumonia with a mysterious etiological agent responsible for the viral" exact="pneumonia" post="outbreak that swept the world [4,8,[10], [11], [12], [13],"/>
   <result pre="symptoms include respiratory distress, malaise, fever, dry cough, dyspnea, and" exact="shortness" post="of breath [8,14]. In advanced serious cases, the infection"/>
   <result pre="[8,14]. In advanced serious cases, the infection can cause pneumonia," exact="kidney failure," post="severe acute respiratory disorder, and even death [1]. The"/>
   <result pre="4 Antiviral drug [46] 5 Aminoquinoline Image 5 Used in" exact="malaria" post="treatment [9] 6 Azithromycin Image 6 Broad spectrum antibiotic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7403393/results/search/disease/results.xml">
   <result pre="mostly involved in gastrointestinal and respiratory tract infections. Among them," exact="severe acute respiratory syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) CoVs that"/>
   <result pre="opioids plus non-opioid CNS drugs, neuromuscular-blocking drugs, respiratory system drugs," exact="allergy" post="medications, antiparasitic drugs and few unrelated drugs. Among these"/>
   <result pre="capping enzyme nsP1: a novel target for the inhibition of" exact="chikungunya" post="virus infectionSci. Rep.201663181910.1038/srep3181927545976 11.TouretFet al.Phylogenetically based establishment of a"/>
   <result pre="17.Efficacy and safety of darunavir and cobicistat for treatment of" exact="pneumonia" post="caused by 2019-nCoV. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT042522745 (2020). 18.Hydroxychloroquine vs. Azithromycin"/>
   <result pre="Integr. Comp. Physiol.2018315R895R90610.1152/ajpregu.00099.201830088946 27.TranDHet al.Azithromycin, a 15-membered macrolide antibiotic, inhibits" exact="influenza" post="A(H1N1)pdm09 virus infection by interfering with virus internalization processJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7404195/results/search/disease/results.xml">
   <result pre="peptide 1. Alzheimer’s Epidemiology Alzheimer’s disease (AD) is a progressive" exact="neurological disorder" post="that accounts for the greatest number of dementia cases."/>
   <result pre="progressive neurological disorder that accounts for the greatest number of" exact="dementia" post="cases. As of 2019, 5.8 million people were living"/>
   <result pre="appears to be more responsible for subsequent cognitive impairment and" exact="dementia" post="symptoms associated with AD [8]. Indeed, tau hyperphosphorylation and"/>
   <result pre="clinical studies, with one study seeing 6% of participants develop" exact="meningoencephalitis" post="[21,22]. Tarenflurbil, for instance, had been administered clinically, after"/>
   <result pre="the latter have been shown to be able to detect" exact="neurodegeneration" post="in presymptomatic AD [36]. Other highly sensitive methods that"/>
   <result pre="in AD brains [45,46,47,48,49,50]. This notion draws parallels with the" exact="measles" post="virus, which can lead to the development of the"/>
   <result pre="lead to the development of the neurological disease known as" exact="subacute sclerosing panencephalitis" post="[51]. These findings include the identification of viral [52]"/>
   <result pre="samples [68]. Interestingly, fungal infection from species primarily associated with" exact="periodontal disease" post="has recently been suggested to be involved in AD"/>
   <result pre="having a role in innate immunity as an AMP that" exact="aids" post="in the entrapment and degradation of invading bacteria and"/>
   <result pre="they has been associated with the development of plaques in" exact="atherosclerosis" post="and other non-infectious diseases [98]. Protein analyses comparing known"/>
   <result pre="shown to have antiviral activity against both HSV-1 and the" exact="influenza" post="virus A by inhibiting the infectivity of HSV-1 [82],"/>
   <result pre="influenza virus A by inhibiting the infectivity of HSV-1 [82]," exact="influenza" post="virus A [103], H3N2 [103] and H1N1 [103]. Researchers"/>
   <result pre="object learning, verbal memory and working memory in patients with" exact="schizophrenia" post="[115]. Due to its effects on working memory, its"/>
   <result pre="enzyme BBB blood brain barrier CNS central nervous system HSV-1" exact="herpes simplex" post="virus-1 MBP-1 major basic protein-1 NFTS neurofibrillary tangles References"/>
   <result pre="miceNeuron20054719119910.1016/j.neuron.2005.06.03016039562 20.KimJ.OnsteadL.RandleS.PriceR.SmithsonL.ZwizinskiC.DicksonD.W.GoldeT.McGowanE.Abeta40 inhibits amyloid deposition in vivoJ. Neurosci.20072762763310.1523/JNEUROSCI.4849-06.200717234594 21.OrgogozoJ.M.GilmanS.DartiguesJ.F.LaurentB.PuelM.KirbyL.C.JouannyP.DuboisB.EisnerL.FlitmanS.et al.Subacute" exact="meningoencephalitis" post="in a subset of patients with AD after Abeta42"/>
   <result pre="of an Infectious Etiology of Alzheimer DiseaseMol. Neurobiol.2019564479449110.1007/s12035-018-1388-y30338482 51.MurphyJ.V.YunisE.J.Encephalopathy following" exact="measles" post="infection in children with chronic illnessJ. Pediatrics19768893794210.1016/S0022-3476(76)81045-1 52.DobsonC.B.ItzhakiR.F.Herpes simplex"/>
   <result pre="of Alzheimer’s Disease DevelopmentJ. Alzheimer’s Dis.20186193994510.3233/JAD-16130529254081 56.LinardM.LetenneurL.GarrigueI.DoizeA.DartiguesJ.F.HelmerC.Interaction between APOE4 and" exact="herpes simplex" post="virus type 1 in Alzheimer’s diseaseAlzheimer’s Dement. J. Alzheimer’s"/>
   <result pre="in Alzheimer’s diseaseAlzheimer’s Dement. J. Alzheimer’s Assoc.20201620020810.1002/alz.12008 57.De ChiaraG.PiacentiniR.FabianiM.MastrodonatoA.MarcocciM.E.LimongiD.NapoletaniG.ProttoV.ColuccioP.CelestinoI.et al.Recurrent" exact="herpes simplex" post="virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits"/>
   <result pre="57.De ChiaraG.PiacentiniR.FabianiM.MastrodonatoA.MarcocciM.E.LimongiD.NapoletaniG.ProttoV.ColuccioP.CelestinoI.et al.Recurrent herpes simplex virus-1 infection induces hallmarks of" exact="neurodegeneration" post="and cognitive deficits in micePLoS Pathog.201915e100761710.1371/journal.ppat.100761730870531 58.WozniakM.A.ShipleyS.J.CombrinckM.WilcockG.K.ItzhakiR.F.Productive herpes simplex"/>
   <result pre="hallmarks of neurodegeneration and cognitive deficits in micePLoS Pathog.201915e100761710.1371/journal.ppat.100761730870531 58.WozniakM.A.ShipleyS.J.CombrinckM.WilcockG.K.ItzhakiR.F.Productive" exact="herpes simplex" post="virus in brain of elderly normal subjects and Alzheimer’s"/>
   <result pre="elderly normal subjects and Alzheimer’s disease patientsJ. Med. Virol.20057530030610.1002/jmv.2027115602731 59.JamiesonG.A.MaitlandN.J.WilcockG.K.CraskeJ.ItzhakiR.F.Latent" exact="herpes simplex" post="virus type 1 in normal and Alzheimer’s disease brainsJ."/>
   <result pre="Cell Culture ModelJ. Alzheimer’s Dis.2016501227124110.3233/JAD-15065226836158 83.De ChiaraG.MarcocciM.E.CivitelliL.ArgnaniR.PiacentiniR.RipoliC.ManservigiR.GrassiC.GaraciE.PalamaraA.T.APP processing induced by" exact="herpes simplex" post="virus type 1 (HSV-1) yields several APP fragments in"/>
   <result pre="compartments and the inhibition of the non-amyloidogenic pathway in human" exact="neuroblastoma" post="cellsNeurobiol. Aging201233430.e19430.e3310.1016/j.neurobiolaging.2010.12.01021272962 85.Li PumaD.D.PiacentiniR.LeoneL.GironiK.MarcocciM.E.De ChiaraG.PalamaraA.T.GrassiC.Herpes Simplex Virus Type-1 Infection"/>
   <result pre="accumulationSci. Rep.201551544410.1038/srep1544426487282 87.KristenH.SantanaS.SastreI.RecueroM.BullidoM.J.AldudoJ.Herpes simplex virus type 2 infection induces AD-like" exact="neurodegeneration" post="markers in human neuroblastoma cellsNeurobiol. Aging2015362737274710.1016/j.neurobiolaging.2015.06.01426163986 88.MiklossyJ.KisA.RadenovicA.MillerL.ForroL.MartinsR.ReissK.DarbinianN.DarekarP.MihalyL.et al.Beta-amyloid deposition"/>
   <result pre="virus type 2 infection induces AD-like neurodegeneration markers in human" exact="neuroblastoma" post="cellsNeurobiol. Aging2015362737274710.1016/j.neurobiolaging.2015.06.01426163986 88.MiklossyJ.KisA.RadenovicA.MillerL.ForroL.MartinsR.ReissK.DarbinianN.DarekarP.MihalyL.et al.Beta-amyloid deposition and Alzheimer’s type changes"/>
   <result pre="92.KhanM.B.LangM.J.HuangM.B.RaymondA.BondV.C.ShiramizuB.PowellM.D.Nef exosomes isolated from the plasma of individuals with HIV-associated" exact="dementia" post="(HAD) can induce Aβ(1-42) secretion in SH-SY5Y neural cellsJ."/>
   <result pre="95.BurgosJ.S.RamirezC.SastreI.BullidoM.J.ValdiviesoF.ApoE4 is more efficient than E3 in brain access by" exact="herpes simplex" post="virus type 1Neuroreport2003141825182710.1097/00001756-200310060-0001314534428 96.WozniakM.A.MeeA.P.ItzhakiR.F.Herpes simplex virus type 1 DNA"/>
   <result pre="upregulated in Alzheimer’s brainJ. Neuroinflamm.20131012710.1186/1742-2094-10-127 103.WhiteM.R.KandelR.TripathiS.CondonD.QiL.TaubenbergerJ.HartshornK.L.Alzheimer’s associated β-amyloid protein inhibits" exact="influenza" post="A virus and modulates viral interactions with phagocytesPLoS ONE20149e10136410.1371/journal.pone.010136424988208"/>
   <result pre="key Alzheimer’s disease molecules in cell cultures acutely infected with" exact="herpes simplex" post="virus type 1PLoS ONE20116e2515210.1371/journal.pone.002515222003387 113.ZambranoA.SolisL.SalvadoresN.CortesM.LerchundiR.OtthC.Neuronal cytoskeletal dynamic modification and"/>
   <result pre="simplex virus type 1PLoS ONE20116e2515210.1371/journal.pone.002515222003387 113.ZambranoA.SolisL.SalvadoresN.CortesM.LerchundiR.OtthC.Neuronal cytoskeletal dynamic modification and" exact="neurodegeneration" post="induced by infection with herpes simplex virus type 1J."/>
   <result pre="113.ZambranoA.SolisL.SalvadoresN.CortesM.LerchundiR.OtthC.Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with" exact="herpes simplex" post="virus type 1J. Alzheimer’s Dis.20081425926910.3233/JAD-2008-1430118599953 114.HuiZ.ZhijunY.YushanY.LipingC.YiyingZ.DifanZ.ChunglitC.T.WeiC.The combination of acyclovir"/>
   <result pre="inhibitor BAY 57-1293 reduces the Alzheimer’s disease-related molecules induced by" exact="herpes simplex" post="virus type 1Antivir. Res.20139940140410.1016/j.antiviral.2013.07.00323867133 118.BaumeisterJ.FischerR.EckenbergP.HenningerK.Ruebsamen-WaigmannH.KleymannG.Superior efficacy of helicase-primase inhibitor"/>
   <result pre="diseaseAntivir. Chem. Chemother.200718354810.1177/09563202070180010417354650 119.BetzU.A.FischerR.KleymannG.HendrixM.Rubsamen-WaigmannH.Potent in vivo antiviral activity of the" exact="herpes simplex" post="virus primase-helicase inhibitor BAY 57-1293Antimicrob. Agents Chemother.2002461766177210.1128/AAC.46.6.1766-1772.200212019088 120.KleymannG.Helicase primase:"/>
   <result pre="57-1293Antimicrob. Agents Chemother.2002461766177210.1128/AAC.46.6.1766-1772.200212019088 120.KleymannG.Helicase primase: Targeting the Achilles heel of" exact="herpes simplex" post="virusesAntivir. Chem. Chemother.20041513514010.1177/09563202040150030315266895 121.KleymannG.FischerR.BetzU.A.HendrixM.BenderW.SchneiderU.HandkeG.EckenbergP.HewlettG.PevznerV.et al.New helicase-primase inhibitors as drug"/>
   <result pre="al.New helicase-primase inhibitors as drug candidates for the treatment of" exact="herpes simplex" post="diseaseNat. Med.2002839239810.1038/nm0402-39211927946 122.HayashiK.HayashiT.MoritaN.Mechanism of action of the antiherpesvirus biflavone"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7406694/results/search/disease/results.xml">
   <result pre="copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The ongoing pandemic of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), referred to as coronavirus disease 2019"/>
   <result pre="DHODH is an attractive therapeutic target for multiple diseases including" exact="cancer" post="and autoimmune diseases (Lolli et al., 2018; Boschi et"/>
   <result pre="et al., 2018). Leflunomide was approved for the therapy of" exact="rheumatoid arthritis" post="many years ago (Herrmann et al., 2000). Figure 1"/>
   <result pre="al., 2018). Leflunomide was approved for the therapy of rheumatoid" exact="arthritis" post="many years ago (Herrmann et al., 2000). Figure 1"/>
   <result pre="the enzyme. Moreover, two inhibitors exhibited significant antiviral activities against" exact="influenza" post="A (H1N1, H3N2 and H9N2), Zika, Ebola, and SARS-CoV-2"/>
   <result pre="advantage over oseltamivir to treat the late phase of the" exact="infectious disease." post="These results together demonstrated the feasibility of DHODH inhibitors"/>
   <result pre="and teriflunomide are used to treat autoimmune diseases such as" exact="rheumatoid arthritis" post="and multiple sclerosis by regulating lymphocytes and the release"/>
   <result pre="teriflunomide are used to treat autoimmune diseases such as rheumatoid" exact="arthritis" post="and multiple sclerosis by regulating lymphocytes and the release"/>
   <result pre="used to treat autoimmune diseases such as rheumatoid arthritis and" exact="multiple sclerosis" post="by regulating lymphocytes and the release of cytokines and"/>
   <result pre="COVID-19 virusScience202036877978210.1126/science.abb749832277040 HerrmannMLSchleyerbachRKirschbaumBJLeflunomide: an immunomodulatory drug for the treatment of" exact="rheumatoid arthritis" post="and other autoimmune diseasesImmunopharmacology20004727328910.1016/S0162-3109(00)00191-010878294 JiXLiZMedicinal chemistry strategies toward host"/>
   <result pre="virusScience202036877978210.1126/science.abb749832277040 HerrmannMLSchleyerbachRKirschbaumBJLeflunomide: an immunomodulatory drug for the treatment of rheumatoid" exact="arthritis" post="and other autoimmune diseasesImmunopharmacology20004727328910.1016/S0162-3109(00)00191-010878294 JiXLiZMedicinal chemistry strategies toward host"/>
   <result pre="dehydrogenase (hDHODH) inhibitors in autoimmune diseases and new perspectives in" exact="cancer" post="therapyRecent Pat Anticancer Drug Discov2018138610510.2174/157489281266617110812421829119937 MadakJTBankheadA3rdCuthbertsonCRShowalterHDNeamatiNRevisiting the role of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7409489/results/search/disease/results.xml">
   <result pre="As for acute rejection (Additional file 1: Figure S5A) and" exact="leukopenia" post="(Additional file 1: Figure S5B), it was found a"/>
   <result pre="(0.60), valganciclovir (0.47) and valacyclovir (0.63). Concerning the inducement of" exact="leukopenia" post="(Additional file 1: Figure S8B), the safest antiviral drug"/>
   <result pre="may have the weakest therapeutic effect, with minimum chance of" exact="leukopenia" post="occurrence. Compared to ganciclovir, valganciclovir is the most efficient"/>
   <result pre="disease, but it is also the most likely to induce" exact="leukopenia" post="among the four antiviral drugs. Nowadays, universal prophylaxis and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7436731/results/search/disease/results.xml">
   <result pre="identified 24 FDA‐approved drugs which exhibited substantial antiviral effect against" exact="severe acute respiratory syndrome" post="coronavirus 2 in Vero cells. Since antiviral efficacy could"/>
   <result pre="10.1002/jmv.2639731502247 1 INTRODUCTION Coronavirus disease 2019 (COVID‐19) is an emerging" exact="infectious disease" post="caused by a coronavirus.1 The causative virus was named"/>
   <result pre="caused by a coronavirus.1 The causative virus was named as" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS‐CoV‐2) because it is very similar to"/>
   <result pre="indicates cell viability, and the blue line indicates inhibition of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS‐CoV‐2) infection. SARS‐CoV‐2 infectivity was measured by"/>
   <result pre="as an anticoagulant to remove blood clots frequently associated with" exact="acute respiratory distress syndrome." post="A recent case report on the treatment of three"/>
   <result pre="half maximal cytotoxic concentration; IC50, half maximal inhibitory concentration; SARS‐CoV‐2," exact="severe acute respiratory syndrome" post="coronavirus 2; SI, selective index Table 3 List of"/>
   <result pre="reasonable request. References REFERENCES 1ZhouP, YangX‐L, WangX‐G, et al. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="of chloroquine diphosphate as adjunctive therapy for patients hospitalized with" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS‐CoV‐2) infection. JAMA Netw Open.2020;3(4):e20885710.1001/jamanetworkopen.2020.8857 9CaoB, WangY,"/>
   <result pre="bronchial epithelial cells with serine and cysteine protease inhibitors prevents" exact="severe acute respiratory syndrome" post="coronavirus entry. J Virol. 2012;86(12):6537‐6545. 10.1128/JVI.00094-1222496216 14KlokFA, KruipM, van"/>
   <result pre="cases of treatment with nafamostat in elderly patients with COVID‐19" exact="pneumonia" post="who need oxygen therapy. Int J Infect Dis. 2020;96:500‐502."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7437450/results/search/disease/results.xml">
   <result pre="a cluster of artemisinin-related drugs developed for the treatment of" exact="malaria" post="and have been reported to have multiple pharmacological activities,"/>
   <result pre="acid are artemisinin derivatives reported to have therapeutic efficacy against" exact="malaria" post="in vivo.12,13 Previous studies have reported the broad-spectrum antiviral"/>
   <result pre="of DNA and RNA viruses, including human cytomegalovirus (HCMV), human" exact="herpes simplex" post="virus (HSV), hepatitis B virus (HBV), hepatitis C virus"/>
   <result pre="viruses, including human cytomegalovirus (HCMV), human herpes simplex virus (HSV)," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), human immunodeficiency"/>
   <result pre="(HCMV), human herpes simplex virus (HSV), hepatitis B virus (HBV)," exact="hepatitis" post="C virus (HCV), human immunodeficiency virus (HIV), and polyomavirus"/>
   <result pre="broad-spectrum antiviral potential in recent years. Chloroquine is effective against" exact="influenza" post="virus, dengue virus, and SARS-CoV-2 in vitro and has"/>
   <result pre="observed in antiviral research, including HCMV, HBV, and bovine viral" exact="diarrhea" post="virus.29−31 Facing the global outbreak of SARS-CoV-2, the combination"/>
   <result pre="C.; BarenholzY.; HaynesR. K.; GolenserJ. (2010) Artemisone effective against murine" exact="cerebral malaria." post="Malar. J.9, 22710.1186/1475-2875-9-227.20691118 CaiT. Y.; ZhangY. R.; JiJ. B.;"/>
   <result pre="MarinJ. J. G. (2005) Effect of artemisinin/artesunate as inhibitors of" exact="hepatitis" post="B virus production in an &quot;in vitro&quot; replicative system."/>
   <result pre="ZhanF. X.; WangY. Y.; XiaoG. F.; ShiZ. L. (2020) A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7438026/results/search/disease/results.xml">
   <result pre="of calcium in endoplasmic reticulum (ER) and Golgi apparatus, further" exact="aids" post="in the inhibition of host protein trafficking and viral"/>
   <result pre="receptor potential channel (TRP) is known to be associated with" exact="hypersensitivity" post="induced by chemical or thermal stimuli. Infection of human"/>
   <result pre="epithelial cells by respiratory viruses including respiratory syncytial virus (RSV)," exact="measles" post="virus (MV) and rhinovirus (RV) was found to increase"/>
   <result pre="et al. 2019; Omar et al. 2017). Infections caused by" exact="influenza" post="A virus was successfully contained by Verapamil, a drug"/>
   <result pre="was successfully contained by Verapamil, a drug to treat hypertension," exact="atrial fibrillation" post="and angina. Compounds blocking L-type calcium channels such as"/>
   <result pre="of polyomavirus endosomal traffickingAntivir Res2020710481910.1016/j.antiviral.2020.104819 FangLKarakiulakisGRothMAre patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir Med20208e2110.1016/S2213-2600(20)30116-832171062 KaiHKaiMInteractions"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7441766/results/search/disease/results.xml">
   <result pre="Daclatasvir) that are previously used for human immunodeficiency virus (HIV)," exact="hepatitis" post="C virus (HCV), Ebola, and Marburg virus show higher"/>
   <result pre="discoveries of potential drugs against several diseases such as Ebola," exact="hepatitis" post="C, and zika virus infection (Barrows et al., 2016;"/>
   <result pre="synthesis and has been accepted for the treatment of chronic" exact="hepatitis" post="C infection, genotype 1 (Talwani et al., 2013). Simpeprevir"/>
   <result pre="of novel subgenomic RNAs and noncanonical transcription initiation signals of" exact="severe acute respiratory syndrome" post="coronavirus. Journal of Virology, (9), 5288–5295. 10.1128/JVI.79.9.5288-5295.200515827143 IslamM. J.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7441777/results/search/disease/results.xml">
   <result pre="2020). The symptoms of SARS-CoV-2 infection include fever, dry cough," exact="shortness" post="of breath, runny nose, and sore throat (Wu et"/>
   <result pre="drug target for several other RNA viruses, spanning from the" exact="hepatitis" post="C virus, zika virus to coronaviruses (Elfiky, 2017, 2019;"/>
   <result pre="that green tea catechins, by disrupting the membrane of the" exact="influenza" post="virus, inhibited neuraminidase in the crude system (Song et"/>
   <result pre="a green tea polyphenol can inhibit the endonuclease activity of" exact="influenza" post="A virus RNA polymerase. EGCG is also reported to"/>
   <result pre="shown to exert antiviral activity against many viruses such as" exact="hepatitis" post="virus and influenza A and B viruses (Chowdhury et"/>
   <result pre="antiviral activity against many viruses such as hepatitis virus and" exact="influenza" post="A and B viruses (Chowdhury et al., 2018). Hesperidin"/>
   <result pre="altering the immune system mainly via regulating interferons in the" exact="influenza" post="A virus (Randall &amp;amp; Goodbourn, 2008). EGCG, a major"/>
   <result pre="coronavirus helicase (Yu et al., 2012). Quercetagetin also showed strong" exact="hepatitis" post="C virus replication inhibitory activity in vitro (Ahmed-Belkacem et"/>
   <result pre="HernandezE., PallierC., &amp;amp; PawlotskyJ.-M. (2014). Inhibition of RNA binding to" exact="hepatitis" post="C virus RNA-dependent RNA polymerase: A new mechanism for"/>
   <result pre="SéronK. (2018). Theaflavins, polyphenols of black tea, inhibit entry of" exact="hepatitis" post="C virus in cell culture. PloS One, (11), e019822610.1371/journal.pone.019822630485282"/>
   <result pre="BarakatK. (2017). Applications of computer-aided approaches in the development of" exact="hepatitis" post="C antiviral agents. Expert Opinion on Drug Discovery, (4),"/>
   <result pre="Mutation-induced loop opening and energetics for binding of tamiflu to" exact="influenza" post="N8 neuraminidase. The Journal of Physical Chemistry B, (21),"/>
   <result pre="EchigoN. (2009). Green tea catechins inhibit the endonuclease activity of" exact="influenza" post="A virus RNA polymerase. PLoS Currents, , RRN105210.1371/currents.RRN105220025206 LarregieuC."/>
   <result pre="SeongB.-L. (2005). Antiviral effect of catechins in green tea on" exact="influenza" post="virus. Antiviral Research, (2), 66–74. 10.1016/j.antiviral.2005.06.01016137775 SubissiL., PosthumaC. C.,"/>
   <result pre="GorbalenyaA. E., DecrolyE., SnijderE. J., CanardB., &amp;amp; ImbertI. (2014). One" exact="severe acute respiratory syndrome" post="coronavirus protein complex integrates processive RNA polymerase and exonuclease"/>
   <result pre="C., &amp;amp; ZhangY.-Z. (2020). A new coronavirus associated with human" exact="respiratory disease" post="in China. Nature, (7798), 265–269. 10.1038/s41586-020-2008-3 WuJ., &amp;amp; GongP."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7448857/results/search/disease/results.xml">
   <result pre="ABSTRACT The emerging SARS-CoV-2 infection associated with the outbreak of" exact="viral pneumonia" post="in China is ongoing worldwide. There are no approved"/>
   <result pre="The emerging SARS-CoV-2 infection associated with the outbreak of viral" exact="pneumonia" post="in China is ongoing worldwide. There are no approved"/>
   <result pre="worldwide. There are no approved antiviral therapies to treat this" exact="viral disease." post="Here we examined the antiviral abilities of three broad-spectrum"/>
   <result pre="ref-count: page-count: Since the late 2019 when a cluster of" exact="pneumonia" post="associated with the emerging novel coronavirus, SARS-CoV-2 was reported"/>
   <result pre="RNA viruses which include Middle East respiratory syndrome coronavirus (MERS-CoV)," exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) [4], Zika virus [5], influenza virus [6]"/>
   <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) [4], Zika virus [5]," exact="influenza" post="virus [6] and enterovirus. Gemcitabine inhibits both MERS-CoV and"/>
   <result pre="immunity, at least in the cases of enterovirus [7] and" exact="influenza" post="virus [6]. To examine whether it acts by the"/>
   <result pre="concentration of gemcitabine observed in patients with advanced non-small cell" exact="lung cancer" post="(NSCLC) could reach 17 µM after bronchial artery infusion or"/>
   <result pre="of gemcitabine observed in patients with advanced non-small cell lung" exact="cancer" post="(NSCLC) could reach 17 µM after bronchial artery infusion or"/>
   <result pre="assays have shown that oxysophoridine has various pharmacological activities, including" exact="suppression" post="of the growth of hepatocellular carcinoma [10] and colorectal"/>
   <result pre="has various pharmacological activities, including suppression of the growth of" exact="hepatocellular carcinoma" post="[10] and colorectal cancer cells [11] by regulating apoptosis"/>
   <result pre="including suppression of the growth of hepatocellular carcinoma [10] and" exact="colorectal cancer" post="cells [11] by regulating apoptosis associated with the Bcl-2/Bax/caspase-3"/>
   <result pre="suppression of the growth of hepatocellular carcinoma [10] and colorectal" exact="cancer" post="cells [11] by regulating apoptosis associated with the Bcl-2/Bax/caspase-3"/>
   <result pre="in Amaryllidaceae with a wide range of biological functions for" exact="cancer" post="and infectious diseases treatment [13]. Unlike oxysophoridine, lycorine has"/>
   <result pre="to exhibit antiviral activities against enterovirus, flaviviruses, HIV-1, SARS-CoV and" exact="hepatitis" post="C virus. Regarding the exact antiviral mechanism of lycorine,"/>
   <result pre="that lycorine was able to (i) inhibit the export of" exact="influenza" post="virus nucleoprotein from the nucleus [14], and (ii) downregulate"/>
   <result pre="ZhengXS, ZhaoK, ChenQJ, DengF, LiuLL, YanB, ZhanFX, WangYY, XiaoGF, ShiZL.2020A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="10.1016/j.antiviral.2016.12.02228049006 6DenisovaOV, KakkolaL, FengL, et al.Obatoclax, saliphenylhalamide, and gemcitabine inhibit" exact="influenza" post="a virus infection. J Biol Chem. 2012;287:35324–32. doi: 10.1074/jbc.M112.39214222910914"/>
   <result pre="and related active compounds: a review of their role on" exact="hepatitis" post="B virus infection. Drug Discov Ther. 2013;7:212–24. doi: 10.5582/ddt.2013.v7.6.21224423652"/>
   <result pre="10.5582/ddt.2013.v7.6.21224423652 10YaoXQ, ZhangYH, LongW, et al.Oxysophoridine suppresses the growth of" exact="hepatocellular carcinoma" post="in mice: in vivo and cDNA microarray studies. Chin"/>
   <result pre="in vitro induction of the apoptotic effects of oxysophoridine on" exact="colorectal cancer" post="cells via the Bcl-2/Bax/caspase-3 signaling pathway. Oncol Lett. 2017;14:8000–8006.29344242"/>
   <result pre="vitro induction of the apoptotic effects of oxysophoridine on colorectal" exact="cancer" post="cells via the Bcl-2/Bax/caspase-3 signaling pathway. Oncol Lett. 2017;14:8000–8006.29344242"/>
   <result pre="inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic" exact="avian influenza" post="virus H5N1. Infl Other Respir Viruses. 2013;7:922–31. doi: 10.1111/irv.12035"/>
   <result pre="nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic avian" exact="influenza" post="virus H5N1. Infl Other Respir Viruses. 2013;7:922–31. doi: 10.1111/irv.12035"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7451411/results/search/disease/results.xml">
   <result pre="of diabetes Type 2, for the prevention and treatment of" exact="cancer" post="[4]. There have also been attempts to repurpose metformin"/>
   <result pre="SARS-CoV and SARS-CoV-2 are known to induce apoptosis and resulting" exact="lymphocytopenia" post="is a common laboratory finding (&amp;gt;60 of patients and"/>
   <result pre="patients would be particularly welcome. Preclinical studies suggest that experimental" exact="viral pneumonia" post="may be ameliorated by anti-TNF therapy. As increased levels"/>
   <result pre="would be particularly welcome. Preclinical studies suggest that experimental viral" exact="pneumonia" post="may be ameliorated by anti-TNF therapy. As increased levels"/>
   <result pre="levels in serum and lungs of mice with experimental acute" exact="pneumonia" post="[43,44]. Interestingly, clinical phage therapy may reduce TNF production"/>
   <result pre="Eur. J. Pharmacol.866, 172784 (2020).31730760 5.RenaG , LangCCRepurposing metformin for" exact="cardiovascular disease." post="Circulation137(5), 422–424 (2018).29378754 6.KapoorY , SharmaR , KumarARepurposing of"/>
   <result pre="primary epithelial cell screening tool to investigate phage therapy in" exact="cystic fibrosis." post="Front. Pharmacol.9, 1330 (2018).30546305 14.BocianK , BorysowskiJ , ZarzyckiMet"/>
   <result pre="bacteriophages T4 and M13 down-regulates Hsp90 gene expression in human" exact="prostate cancer" post="cells (PC-3) representing a potential nanoparticle against cancer. Virol."/>
   <result pre="T4 and M13 down-regulates Hsp90 gene expression in human prostate" exact="cancer" post="cells (PC-3) representing a potential nanoparticle against cancer. Virol."/>
   <result pre="ChinBS , KangCKet al.Clinical course and outcomes of patients with" exact="severe acute respiratory syndrome" post="coronavirus 2 infection: a preliminary report of the first"/>
   <result pre="stress associated with SARS-Cov-2 (COVID-19) increases the severity of the" exact="lung disease" post="- a systematic review. J. Infect. Dis. Epidemiol.6, 121"/>
   <result pre="eaat9691 (2019).30923196 37.DufourN , DelattreR , ChevallereauAet al.Phage therapy of" exact="pneumonia" post="is not associated with an overstimulation of the inflammatory"/>
   <result pre=", SidorovIet al.The respiratory virome and exacerbations in patients with" exact="chronic obstructive pulmonary disease." post="PLoS ONE14(10), e0223952 (2019).31647831 40.GogokhiaL , BuhrkeK , BellRet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7452913/results/search/disease/results.xml">
   <result pre="centre remains active. Abstract The high mortality rate from the" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) infections in humans and the lack"/>
   <result pre="mean square deviation RTC, replication-transcription complex SAH, S-adenosyl homocysteine SARS-CoV," exact="severe acute respiratory syndrome" post="coronavirus SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 SAVES,"/>
   <result pre="SAH, S-adenosyl homocysteine SARS-CoV, severe acute respiratory syndrome coronavirus SARS-CoV-2," exact="severe acute respiratory syndrome" post="coronavirus 2 SAVES, Structure Analysis and Verification Server SF,"/>
   <result pre="modelling 1 Introduction The coronavirus disease 2019 (COVID-19) caused by" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) has posed a serious health emergency"/>
   <result pre="from Wuhan, China where the clinical symptoms showed resemblance to" exact="viral pneumonia" post="(Huang et al., 2020). Coronaviruses have a history of"/>
   <result pre="Wuhan, China where the clinical symptoms showed resemblance to viral" exact="pneumonia" post="(Huang et al., 2020). Coronaviruses have a history of"/>
   <result pre="of causing severe epidemics such as the infections caused by" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) during 2002–2003 in Guangdong province of China"/>
   <result pre="lead molecules are accepted drugs which are potent inhibitors of" exact="hepatitis" post="C virus (HCV) NS3/4A protease (De Clercq and Li,"/>
   <result pre="Agents Chemother.5620124718472822733076 AdedejiA.O.SinghK.KassimA.ColemanC.M.ElliottR.WeissS.R.FriemanM.B.SarafianosS.G.Evaluation of SSYA10-001 as a replication inhibitor of" exact="severe acute respiratory syndrome," post="mouse hepatitis, and Middle East respiratory syndrome coronavirusesAntimicrob. Agents"/>
   <result pre="globular proteinsJ. Biochem.881980189518987462208 IvanovK.A.ThielV.DobbeJ.C.van der MeerY.SnijderE.J.ZiebuhrJ.Multiple enzymatic activities associated with" exact="severe acute respiratory syndrome" post="coronavirus helicaseJ. Virol.7820045619563215140959 JangK.J.LeeN.-R.YeoW.-S.JeongY.-J.KimD.-E.Isolation of inhibitory RNA aptamers against"/>
   <result pre="syndrome coronavirus helicaseJ. Virol.7820045619563215140959 JangK.J.LeeN.-R.YeoW.-S.JeongY.-J.KimD.-E.Isolation of inhibitory RNA aptamers against" exact="severe acute respiratory syndrome" post="(SARS) coronavirus NTPase/HelicaseBiochem. Biophys. Res. Commun.366200873874418082623 JiaZ.YanL.RenZ.WuL.WangJ.GuoJ.ZhengL.MingZ.ZhangL.LouZ.Delicate structural coordination"/>
   <result pre="coronavirus NTPase/HelicaseBiochem. Biophys. Res. Commun.366200873874418082623 JiaZ.YanL.RenZ.WuL.WangJ.GuoJ.ZhengL.MingZ.ZhangL.LouZ.Delicate structural coordination of the" exact="severe acute respiratory syndrome" post="coronavirus Nsp13 upon ATP hydrolysisNucleic Acids Res.4720196538655031131400 KimS.ThiessenP.A.BoltonE.E.ChenJ.FuG.GindulyteA.HanL.HeJ.HeS.ShoemakerB.A.WangJ.YuB.ZhangJ.BryantS.H.PubChem substance"/>
   <result pre="exploratory research and analysisJ. Comput. Chem.2520041605161210.1002/jcc.2008415264254 PrenticeE.McAuliffeJ.LuX.SubbaraoK.DenisonM.R.Identification and characterization of" exact="severe acute respiratory syndrome" post="coronavirus replicase proteinsJ. Virol.7820049977998615331731 SinghalT.A review of coronavirus disease-2019"/>
   <result pre="Pediatr.87202028128610.1007/s12098-020-03263-632166607 SipplM.J.Recognition of errors in three-dimensional structures of proteinsProteins17199335536210.1002/prot.3401704048108378 TannerJ.A.WattR.M.ChaiY.-B.LuL.-Y.LinM.C.PeirisJ.S.M.PoonL.L.M.KungH.-F.HuangJ.-D.The" exact="severe acute respiratory syndrome" post="(SARS) coronavirus NTPase/helicase belongs to a distinct class of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7461398/results/search/disease/results.xml">
   <result pre="drugs for treatment of SARS‐CoV‐2 (the new virus causing COVID‐19)" exact="pneumonia" post="remains unclear.10 However, according to the previous studies, the"/>
   <result pre="could be suggested to relatively high risk groups of 2019‐nCoV" exact="pneumonia" post="(elderly patients or patients with underlying diseases) from the"/>
   <result pre="to hospital. After treatment, three patients showed significant improvement in" exact="pneumonia" post="associated symptoms, two of whom were confirmed to be"/>
   <result pre="inhibited virus infection efficiently in a human cell line (human" exact="liver cancer" post="Huh‐7 cells), which is sensitive to 2019‐nCoV. As these"/>
   <result pre="virus infection efficiently in a human cell line (human liver" exact="cancer" post="Huh‐7 cells), which is sensitive to 2019‐nCoV. As these"/>
   <result pre="to evaluate the safety and efficacy of remdesivir against 2019‐nCoV" exact="respiratory disease." post="5 ARBIDOL Arbidol (known as umifenovir) is a broad‐spectrum"/>
   <result pre="China for prophylaxis and can effectively block the fusion of" exact="influenza" post="virus with host cells.25 Arbidol not only stimulated overexpression"/>
   <result pre="that selectively and potently inhibits the RNA‐dependent RNA polymerase of" exact="influenza" post="and many other RNA viruses. As described below, it"/>
   <result pre="has been found to inhibit all serotypes and strains of" exact="influenza" post="A, B and C viruses against which it has"/>
   <result pre="phosphate has shown apparent efficacy in treatment of COVID‐19 associated" exact="pneumonia" post="in clinical studies. Biosci Trends. 2020;14:72‐73.32074550 12YaoX, YeF, ZhangM,"/>
   <result pre="of optimized dosing Design of Hydroxychloroquine for the treatment of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS‐CoV‐2). Clin Infect Dis. 2020;71(15):732‐739. 32150618 13ZhouD,"/>
   <result pre="the application of lopinavir/ritonavir for the treatment of COVID‐19 infected" exact="pneumonia" post="monitored by quantitative RT‐PCR. J Korean Med Sci. 2020;35(6):35."/>
   <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatment. Biosci Trends."/>
   <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507‐513.32007143 21HassanHA,"/>
   <result pre="DieboldSS, SmythLA, WaltersAA, LombardiG, Al‐JamalKT. Application of carbon nanotubes in" exact="cancer" post="vaccines: achievements, challenges and chances. J Control Release. 2019;297:79‐90.30659906"/>
   <result pre="Remdesivir attenuates high fat diet (HFD)‐induced NAFLD by regulating hepatocyte" exact="dyslipidemia" post="and inflammation via the suppression of STING. Biochem Biophys"/>
   <result pre="(HFD)‐induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the" exact="suppression" post="of STING. Biochem Biophys Res Commun. 2020;526(2):381‐388. 32223926 23WangM,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7463695/results/search/disease/results.xml">
   <result pre="MACUGEN, was meant for the treatment of the wet age-related" exact="macular degeneration" post="[15,16,17]. Nevertheless, the full therapeutic potential of the aptamers"/>
   <result pre="the entire aptamer activity. 3.2. Anti HCV RNA Aptamers The" exact="hepatitis" post="C virus (HCV) has been another favorite virus for"/>
   <result pre="RNA elementsJ. Biol. Chem.2016291157881579510.1074/jbc.M116.73561327226636 3.KendraJ.A.AdvaniV.M.ChenB.BriggsJ.W.ZhuJ.BressH.J.PathyS.M.DinmanJ.D.Functional and structural characterization of the" exact="chikungunya" post="virus translational recoding signalsJ. Biol. Chem.2018293175361754510.1074/jbc.RA118.00560630242123 4.EllingtonA.D.SzostakJ.W.In vitro selection"/>
   <result pre="acids estimated by a gel retardation assayAnal. Biochem.19891799810510.1016/0003-2697(89)90207-82474260 23.Romero-LópezC.Barroso-delJesusA.Puerta-FernándezE.Berzal-HerranzA.Interfering with" exact="hepatitis" post="C virus IRES activity using RNA molecules identified by"/>
   <result pre="antiviral targetPharmaceuticals2019123810.3390/ph12010038 28.Romero-LópezC.Berzal-HerranzA.The role of the RNA-RNA interactome in the" exact="hepatitis" post="C virus life cycleInt. J. Mol. Sci.202021147910.3390/ijms21041479 29.Romero-LópezC.Berzal-HerranzA.The 5BSL3.2"/>
   <result pre="29.Romero-LópezC.Berzal-HerranzA.The 5BSL3.2 functional RNA domain connects distant regions in the" exact="hepatitis" post="C virus genomeFront. Microbiol.20178209310.3389/fmicb.2017.0209329163393 30.Fernández-SanlésA.Berzal-HerranzB.González-MatamalaR.Ríos-MarcoP.Romero-LópezC.Berzal-HerranzA.RNA aptamers as molecular tools"/>
   <result pre="aptamers as molecular tools to study the functionality of the" exact="hepatitis" post="C virus CRE regionMolecules201520160301604710.3390/molecules20091603026364632 31.MartonS.Romero-LópezC.Berzal-HerranzA.RNA aptamer-mediated interference of HCV"/>
   <result pre="replication by targeting the CRE-5BSL3.2 domainJ. Viral Hepat.20132010311210.1111/j.1365-2893.2012.01629.x23301545 32.Romero-LópezC.Díaz-GonzálezR.Berzal-HerranzA.Inhibition of" exact="hepatitis" post="C virus internal ribosome entry site-mediated translation by an"/>
   <result pre="targeting the conserved IIIf domainCell Mol. Life Sci.2007642994300610.1007/s00018-007-7345-y17938858 33.Romero-LópezC.Díaz-GonzálezR.Barroso-delJesusA.Berzal-HerranzA.Inhibition of" exact="hepatitis" post="C virus replication and internal ribosome entry site-dependent translation"/>
   <result pre="Gen. Virol.2009901659166910.1099/vir.0.008821-019264618 34.Romero-LópezC.Berzal-HerranzB.GómezJ.Berzal-HerranzA.An engineered inhibitor RNA that efficiently interferes with" exact="hepatitis" post="C virus translation and replicationAntivir. Res.20129413113810.1016/j.antiviral.2012.02.01522426470 35.Romero-LópezC.LahlaliT.Berzal-HerranzB.Berzal-HerranzA.Development of optimized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7463888/results/search/disease/results.xml">
   <result pre="(COVID-19) represents a global concern of public health caused by" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2). Its clinical manifestations are characterized by"/>
   <result pre="pictures (ranging from asymptomatic to lethal courses). The prevalence of" exact="conjunctivitis" post="in patients with COVID-19 is at present controversial. Although"/>
   <result pre="thus suggesting potential broad-spectrum applications. coronavirus disease 2019 (COVID-19) coronavirus" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) eye drop therapy treatment antiviral repurposing"/>
   <result pre="The origin of this disease is infectious, being caused by" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), and its clinical manifestations are characterized"/>
   <result pre="of human tears and ocular surface epithelia, the appearance of" exact="conjunctivitis" post="in COVID-19 may be presumed to be not uncommon"/>
   <result pre="eyes are not the main transmission routes of SARS-CoV-2 [4]," exact="conjunctivitis" post="can be the first presenting symptom of COVID-19, before"/>
   <result pre="symptoms, such as cough and fever [5,6,7]. The prevalence of" exact="conjunctivitis" post="in patients with COVID-19 is, at present, controversial. Although"/>
   <result pre="been reported that only 0.9% of patients developed signs of" exact="conjunctivitis" post="[8], another report indicates that up to 31.6% (12"/>
   <result pre="(12 cases out of 32 patients) of hospitalized patients had" exact="conjunctivitis" post="[9]. Considering the widespread use of topical ophthalmic medications"/>
   <result pre="Roche, Genentech, South San Francisco, CA, USA) for wet age-related" exact="macular degeneration" post="(original indication: colorectal cancer). Despite the fact that specific"/>
   <result pre="sodium hypochlorite (at least 0.21%) has shown efficacy against mouse" exact="hepatitis" post="virus (a species of coronavirus) and, consequently, should also"/>
   <result pre="[19,20,21,22]. 6. Artificial Tears Considering that the prevalence of dry" exact="eye disease" post="ranges from 5 to 50% in the general population,"/>
   <result pre="leading cause of global irreversible blindness. Present estimates of global" exact="glaucoma" post="prevalence are not up-to-date and focus mainly on European"/>
   <result pre="focus mainly on European ancestry populations. The global prevalence of" exact="glaucoma" post="for the population aged 40–80 years is 3.54% and"/>
   <result pre="3.54% and rises progressively by age. Some drugs used for" exact="glaucoma" post="have been shown to affect the clinical course of"/>
   <result pre="is used in the treatment of viral infections, such as" exact="herpes simplex" post="infections [58]. Of interest, dorzolamide showed antiviral action against"/>
   <result pre="infections [58]. Of interest, dorzolamide showed antiviral action against oseltamivir-resistant" exact="influenza" post="by an in silico screening, specifically targeting mutant viral"/>
   <result pre="inhibitor of viral growth of the H3N2 virus and H1N1" exact="influenza" post="viruses and a weak inhibitor of avian H5N2 and"/>
   <result pre="viruses and a weak inhibitor of avian H5N2 and H7N1" exact="influenza" post="viruses [60]. Overall, glaucoma drugs may have a synergistic"/>
   <result pre="inhibitor of avian H5N2 and H7N1 influenza viruses [60]. Overall," exact="glaucoma" post="drugs may have a synergistic action against viral infections,"/>
   <result pre="levofloxacin, ofloxacin, which have shown efficacy against polyomavirus BK and" exact="influenza" post="virus), aminoglycosides (e.g., on Japanese encephalitis and influenza A"/>
   <result pre="against polyomavirus BK and influenza virus), aminoglycosides (e.g., on Japanese" exact="encephalitis" post="and influenza A virus infection), chloramphenicol (e.g., on human"/>
   <result pre="BK and influenza virus), aminoglycosides (e.g., on Japanese encephalitis and" exact="influenza" post="A virus infection), chloramphenicol (e.g., on human Herpesviridae family),"/>
   <result pre="as chlorcyclizine, chlorpheniramine, and diphenhydramine, have demonstrated antiviral action against" exact="hepatitis" post="C virus (HCV), filoviruses (consisting of Ebola virus, Marburg"/>
   <result pre="of antihistamines in antiviral effects appear to be associated with" exact="herpes simplex" post="virus (HSV) infection [82]. A group of Flavonoids, plant"/>
   <result pre="treatment of different ocular diseases, including allergic eye disorders, dry" exact="eye disease," post="diabetic retinopathy, macular degeneration, and cataracts [83,84]. In particular,"/>
   <result pre="different ocular diseases, including allergic eye disorders, dry eye disease," exact="diabetic retinopathy," post="macular degeneration, and cataracts [83,84]. In particular, antiviral effects"/>
   <result pre="diseases, including allergic eye disorders, dry eye disease, diabetic retinopathy," exact="macular degeneration," post="and cataracts [83,84]. In particular, antiviral effects have been"/>
   <result pre="therapy), have also shown antiviral action against HCV, Flavivirus and" exact="influenza" post="virus [85,86,87]. 10. Anti-Inflammatory Ophthalmic Preparations Another interesting category"/>
   <result pre="uveitis) or to control ocular pain (e.g., discomfort symptoms after" exact="cataract" post="surgery). Interestingly, some NSAIDs have shown antiviral action. However,"/>
   <result pre="be useful for patients with acute, presumed, and aspecific viral" exact="conjunctivitis" post="[90,91,92]. 11. Discussion and Conclusions Although systemic and topical"/>
   <result pre="some controversial and unclear data. First, a patient with this" exact="conjunctivitis" post="as an earlier symptom may have a negative conjunctival"/>
   <result pre="a recent meta-analysis on 1167 patients, the overall rate of" exact="conjunctivitis" post="appears to be 1.1% (13/1149), of which 3% (6/195)"/>
   <result pre="forms of COVID-19, respectively [93]. Nevertheless, an increasing number of" exact="conjunctivitis" post="case reports are continuously appearing in literature. Second, SARS-CoV-2"/>
   <result pre="conjunctivitis case reports are continuously appearing in literature. Second, SARS-CoV-2" exact="conjunctivitis" post="has been described as a mild follicular conjunctivitis otherwise"/>
   <result pre="Second, SARS-CoV-2 conjunctivitis has been described as a mild follicular" exact="conjunctivitis" post="otherwise indistinguishable from other viral causes [94]. In addition,"/>
   <result pre="epiphora, and mild eyelid edema. Another unresolved question is whether" exact="conjunctivitis" post="is directly related to virus infection or represents an"/>
   <result pre="an allergic immune response to the virus [95]. Generally, viral" exact="conjunctivitis" post="(of unknown origin) does not require treatment, although antibiotics,"/>
   <result pre="symptoms. Most medicines currently available for the treatment of viral" exact="conjunctivitis" post="are directed against herpes and adenovirus infections, and infectious"/>
   <result pre="other drugs for treatment and prevention during the onset of" exact="conjunctivitis" post="symptoms or a history of eye contact [96]. According"/>
   <result pre="contact [96]. According to Zhou [97], the rarity of viral" exact="conjunctivitis" post="in SARS-CoV-2 infection may exist in three interpretations. Firstly,"/>
   <result pre="ocular surface must not be ignoredLancet2020395e3910.1016/S0140-6736(20)30313-532035510 6.LiX.J.WangM.DaiJ.WangW.YangY.JinW.Novel coronavirus disease with" exact="conjunctivitis" post="and conjunctivitis as first symptom: Two cases reportChin. J."/>
   <result pre="must not be ignoredLancet2020395e3910.1016/S0140-6736(20)30313-532035510 6.LiX.J.WangM.DaiJ.WangW.YangY.JinW.Novel coronavirus disease with conjunctivitis and" exact="conjunctivitis" post="as first symptom: Two cases reportChin. J. Exp. Ophthalmol.20203810.0376/cma.j.cn.115989-20200303-00133"/>
   <result pre="Ophthalmol.20203810.0376/cma.j.cn.115989-20200303-00133 7.LiX.J.WangM.ChenC.Z.YangA.JinW.Ophthalmologists’ strategy for the prevention and control of coronavirus" exact="pneumonia" post="with conjunctivitis or with conjunctivitis as the first symptomChin."/>
   <result pre="strategy for the prevention and control of coronavirus pneumonia with" exact="conjunctivitis" post="or with conjunctivitis as the first symptomChin. J. Exp."/>
   <result pre="prevention and control of coronavirus pneumonia with conjunctivitis or with" exact="conjunctivitis" post="as the first symptomChin. J. Exp. Ophthalmol.20203827628010.3760/cma.j.issn.2095-0160.2020.0002 8.GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-L.HuiD.S.et al.Clinical"/>
   <result pre="activities of lactoferrinAntivir. Res.20015222523910.1016/S0166-3542(01)00195-411675140 29.KochC.ReichlingJ.SchneeleJ.SchnitzlerP.Inhibitory effect of essential oils against" exact="herpes simplex" post="virus type 2Phytomedicine200815717810.1016/j.phymed.2007.09.00317976968 30.KochC.ReichlingJ.KehmR.SharafM.M.ZentgrafH.SchneeleJ.SchnitzlerP.Efficacy of anise oil, dwarf-pine oil"/>
   <result pre="simplex Virus (HSV-I)Planta Med.20026878078310.1055/s-2002-3439712357386 32.DanaherR.J.WangC.DaiJ.MumperR.J.MillerC.S.Antiviral effects of blackberry extract against" exact="herpes simplex" post="virus type 1Oral Surg. Oral Med. Oral Pathol. Oral"/>
   <result pre="A H3N2 and Hepatitis B Virus in VitroMolecules2015205137515110.3390/molecules2003513725808155 35.LeeJ.-H.ParkJ.-S.LeeS.-W.HwangS.-Y.YoungB.-E.ChoiH.-J.Porcine epidemic" exact="diarrhea" post="virus infection: Inhibition by polysaccharide from Ginkgo biloba exocarp"/>
   <result pre="al.Vitamin D supplementation improves response to antiviral treatment for recurrent" exact="hepatitis" post="CTranspl. Int.201024435010.1111/j.1432-2277.2010.01141.x 50.Gal-TanamyM.BachmetovL.RavidA.KorenR.ErmanA.Tur-KaspaR.ZemelR.Vitamin D: An innate antiviral agent suppressing"/>
   <result pre="hepatitis CTranspl. Int.201024435010.1111/j.1432-2277.2010.01141.x 50.Gal-TanamyM.BachmetovL.RavidA.KorenR.ErmanA.Tur-KaspaR.ZemelR.Vitamin D: An innate antiviral agent suppressing" exact="hepatitis" post="C virus in human hepatocytesHepatology2011541570157910.1002/hep.2457521793032 51.HubbardG.B.HerronB.E.AndrewsJ.S.ElliottJ.H.Influence of topical and"/>
   <result pre="Mild to Moderate Dry Eye DiseaseCurr. Eye Res.2019441306131210.1080/02713683.2019.164182431283891 53.WandM.GilbertC.M.LiesegangT.J.Latanoprost and" exact="herpes simplex" post="keratitisAm. J. Ophthalmol.199912760262410.1016/S0002-9394(99)00050-110334356 54.KaufmanH.E.VarnellE.D.ThompsonH.W.Latanoprost increases the severity and recurrence"/>
   <result pre="J. Ophthalmol.199912760262410.1016/S0002-9394(99)00050-110334356 54.KaufmanH.E.VarnellE.D.ThompsonH.W.Latanoprost increases the severity and recurrence of herpetic" exact="keratitis" post="in the rabbitAm. J. Ophthalmol.199912753153610.1016/S0002-9394(99)00089-610334345 55.ParkH.G.ChoiS.A Case of Herpetic"/>
   <result pre="of 0.015% Tafluprost Eye DropsJ. Korean Ophthalmol. Soc.201354195010.3341/jkos.2013.54.12.1950 56.KrollD.M.SchumanJ.S.Reactivation of" exact="herpes simplex" post="virus keratitis after initiating bimatoprost treatment for glaucomaAm. J."/>
   <result pre="Eye DropsJ. Korean Ophthalmol. Soc.201354195010.3341/jkos.2013.54.12.1950 56.KrollD.M.SchumanJ.S.Reactivation of herpes simplex virus" exact="keratitis" post="after initiating bimatoprost treatment for glaucomaAm. J. Ophthalmol.200213340140310.1016/S0002-9394(01)01360-511860979 57.YangH.S.ParkH.G.ChoiS.Reactivation"/>
   <result pre="Virus Prophylaxis Following Kidney TransplantationJAMA2014312210610.1001/jama.2014.1472125399012 65.KimH.LeeM.-K.KoJ.ParkC.-J.KimM.JeongY.HongS.VaraniG.ChoiB.-S.Aminoglycoside antibiotics bind to the" exact="influenza" post="a virus RNA promoterMol. BioSyst.201282857285910.1039/c2mb25333j22990985 66.TopnoR.KhanS.A.ChowdhuryP.MahantaJ.Pharmacodynamics of aminoglycosides and"/>
   <result pre="promoterMol. BioSyst.201282857285910.1039/c2mb25333j22990985 66.TopnoR.KhanS.A.ChowdhuryP.MahantaJ.Pharmacodynamics of aminoglycosides and tetracycline derivatives against Japanese" exact="encephalitis" post="virusAsian Pac. J. Trop. Med.2016924124610.1016/j.apjtm.2016.01.03326972394 67.ZegarelliE.V.BudowskyJ.SilversH.F.KutscherA.H.Chloramphenicol in Treatment of"/>
   <result pre="EsterAntimicrob. Agents Chemother.19781319920410.1128/AAC.13.2.199206201 73.SchloerS.GoretzkoJ.KühnlA.BrunotteL.LudwigS.RescherU.The clinically licensed antifungal drug itraconazole inhibits" exact="influenza" post="virus in vitro and in vivoEmerg. Microbes Infect.20198809310.1080/22221751.2018.155970930866762 74.TakamuraE.UchioE.EbiharaN.OhnoS.OhashiY.OkamotoS.KumagaiN.SatakeY.ShojiJ.NakagawaY.et"/>
   <result pre="allergic conjunctival diseases 2017Allergol. Int.20176622022910.1016/j.alit.2016.12.00428209324 75.LeonardiA.BogackaE.FauquertJ.-L.KowalskiM.L.GroblewskaA.Jedrzejczak-CzechowiczM.DoanS.MarmouzF.DemolyP.DelgadoL.Ocular allergy: Recognizing and diagnosing" exact="hypersensitivity" post="disorders of the ocular surfaceAllergy2012671327133710.1111/all.1200922947083 76.BronA.J.De PaivaC.S.ChauhanS.K.BoniniS.GabisonE.E.JainS.KnopE.MarkoulliM.OgawaY.PerezV.et al.TFOS DEWS"/>
   <result pre="of the antihistamine chlorcyclizine and related compounds for treatment of" exact="hepatitis" post="C virus infectionSci. Transl. Med.20157282ra4910.1126/scitranslmed.3010286 79.XuW.XiaS.PuJ.WangQ.LiP.LuL.JiangS.The Antihistamine Drugs Carbinoxamine"/>
   <result pre="using in vitro model of DENV3-induced RBL-2H3 cellsBiosci. Rep.20193910.1042/BSR20181273 82.ZawarV.P.GodseK.SankalechaS.Chronic" exact="urticaria" post="associated with recurrent genital herpes simplex infection and success"/>
   <result pre="DENV3-induced RBL-2H3 cellsBiosci. Rep.20193910.1042/BSR20181273 82.ZawarV.P.GodseK.SankalechaS.Chronic urticaria associated with recurrent genital" exact="herpes simplex" post="infection and success of antiviral therapy—A report of two"/>
   <result pre="on human virusesJ. Med. Virol.198515717910.1002/jmv.18901501102981979 85.RabieR.MumtazK.RennerE.L.Efficacy of antiviral therapy for" exact="hepatitis" post="C after liver transplantation with cyclosporine and tacrolimus: A"/>
   <result pre="of indometacin, prostaglandin E2 and interferon on the multiplication of" exact="herpes simplex" post="virus type 1 in human lymphoid cellsAntivir. Res.19901416117210.1016/0166-3542(90)90032-31964373 89.HigakiS.WatanabeK.ItahashiM.ShimomuraY.Cyclooxygenase"/>
   <result pre="topical steroid in presumed viral conjunctivitisBr. J. Ophthalmol.2011951299130310.1136/bjo.2010.18862321252084 92.KhanJ.MackH.G.Management of" exact="conjunctivitis" post="during the COVID-19 pandemic 2020Aust. J. Gen. Pract.20204910.31128/AJGP-COVID-1832362106 93.LoffredoL.PacellaF.PacellaE.TiscioneG.OlivaA.VioliF.Conjunctivitis"/>
   <result pre="activity of Australian tea tree oil and eucalyptus oil against" exact="herpes simplex" post="virus in cell cultureDie Pharm.200156343347 110.BishopC.D.Antiviral Activity of the"/>
   <result pre="have a broad-spectrum action, possibly including inhibition of replication/diffusion of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) on the ocular surface. Abbreviations were"/>
   <result pre="viruses (notable for its ability to infect M. tuberculosis); Mouse" exact="hepatitis" post="virus (MHV); Encephalomyocarditis virus (EMC).H(X)N(Y): Influenza A viruses. Based"/>
   <result pre="classified into different subtypes: H1N1 (the common cause of human" exact="influenza" post="and generally associated with the Spanish flu), H3N2 (commonly"/>
   <result pre="or seasonal H3N2 flu), H5N2 or H7N1 (generally associated with" exact="avian influenza" post="virus or bird flu virus). e.g., -exempli gratia."/>
   <result pre="seasonal H3N2 flu), H5N2 or H7N1 (generally associated with avian" exact="influenza" post="virus or bird flu virus). e.g., -exempli gratia."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7464166/results/search/disease/results.xml">
   <result pre="Flaviviridae (including many different diseases such as Hepatitis-C, bovine viral" exact="diarrhea" post="virus, and more), Picornaviridae (including the rhinoviruses, which causes"/>
   <result pre="RNA viruses&quot;. This class includes Filoviridae, Arenaviridae, Rhabdoviridae (include the" exact="rabies" post="virus), Orthomyxoviridae, Paramyxoviridae, and Bunyaviridae. Class VI contains viruses"/>
   <result pre="antiviral properties, the entire co-polymer gains antiviral effect against the" exact="influenza" post="virus. An increase attraction between viruses and polymer enhanced"/>
   <result pre="(Zn(AC)2) to carrageenan-based gels. The combination possessed antiviral properties against" exact="herpes simplex" post="virus 2 (HSV-2) and simian immunodeficiency virus (SIVs) both"/>
   <result pre="her group proposed several organotin polymers with antiviral effects against" exact="vaccinia virus" post="and Zika virus [92]. Those polymers, as shown in"/>
   <result pre="on HSV-1 and HSV-2 viruses (see also Figure 6) [98]," exact="influenza" post="A virus [99] and on poliovirus and rotavirus [100]."/>
   <result pre="chitosan (and chitin) can induce interferon synthesis, which leads to" exact="suppression" post="of the virus replication by causing damage to the"/>
   <result pre="TMS, most likely due to several mechanisms, such as a" exact="suppression" post="effect of the viral RNA, an effect on the"/>
   <result pre="cytomegalovirus, human papillomavirus-16, respiratory syncytial virus, human rhinovirus, and vesicular" exact="stomatitis" post="virus. Other amine-containing polymers were synthesized by Xiao et"/>
   <result pre="antiviral effect of several hyperbranched quaternary ammonium containing polymers on" exact="influenza" post="A (an envelope virus) and poliovirus Sabin1 (a non-envelop"/>
   <result pre="of bacteria and virusesCrit. Rev. Environ. Control19891829531510.1080/10643388909388351 10.BishopN.E.AndersonD.A.Early interactions of" exact="hepatitis" post="A virus with cultured cells: Viral elution and the"/>
   <result pre="of metal ion binding on the structural stability of the" exact="hepatitis" post="C virus RNA polymeraseJ. Biol. Chem.2004279497554976110.1074/jbc.M40965720015375162 21.JavidpourL.Lošdorfer BožičA.NajiA.PodgornikR.Multivalent ion"/>
   <result pre="in Escherichia coliJ. Virol.1999731649165410.1128/JVI.73.2.1649-1654.19999882374 27.YuasaK.NaganumaA.SatoK.IkedaM.KatoN.TakagiH.MoriM.Zinc is a negative regulator of" exact="hepatitis" post="C virus RNA replicationLiver Int.2006261111111810.1111/j.1478-3231.2006.01352.x17032412 28.ReadS.A.ParnellG.BoothD.DouglasM.W.GeorgeJ.AhlenstielG.The antiviral role of"/>
   <result pre="replicationLiver Int.2006261111111810.1111/j.1478-3231.2006.01352.x17032412 28.ReadS.A.ParnellG.BoothD.DouglasM.W.GeorgeJ.AhlenstielG.The antiviral role of zinc and metallothioneins in" exact="hepatitis" post="C infectionJ. Viral Hepat.20182549150110.1111/jvh.1284529239069 29.TurnerR.B.CetnarowskiW.E.Effect of Treatment with Zinc"/>
   <result pre="virucidal activities of hyperbranched quaternary ammonium coatings on poliovirus and" exact="influenza" post="virusAppl. Environ. Microbiol.2012782456245810.1128/AEM.07738-1122287007 41.WeiL.LiQ.ChenY.ZhangJ.MiY.DongF.LeiC.GuoZ.Enhanced antioxidant and antifungal activity of"/>
   <result pre="antiviral activity, antiviral mechanisms and optimization for the treatment of" exact="hepatitis" post="B and hepatitis D infectionAntiviral Res.2016133324010.1016/j.antiviral.2016.07.00427400989 51.GazinaE.V.HarrisonD.N.JefferiesM.TanH.WilliamsD.AndersonD.A.PetrouS.Ion transport blockers"/>
   <result pre="mechanisms and optimization for the treatment of hepatitis B and" exact="hepatitis" post="D infectionAntiviral Res.2016133324010.1016/j.antiviral.2016.07.00427400989 51.GazinaE.V.HarrisonD.N.JefferiesM.TanH.WilliamsD.AndersonD.A.PetrouS.Ion transport blockers inhibit human rhinovirus"/>
   <result pre="overviewJ. Eng. Technol. Res.2013510411110.5897/JETR2013.0309 54.SokolovaA.S.YarovayaO.I.KorchaginaD.V.ZarubaevV.V.TretiakT.S.AnfimovP.M.KiselevO.I.SalakhutdinovN.F.Camphor-based symmetric diimines as inhibitors of" exact="influenza" post="virus reproductionBioorganic Med. Chem.2014222141214810.1016/j.bmc.2014.02.038 55.SokolovaA.S.YarovayaO.I.ShernyukovA.V.GatilovY.V.RazumovaY.V.ZarubaevV.V.TretiakT.S.PokrovskyA.G.KiselevO.I.SalakhutdinovN.F.Discovery of a new class"/>
   <result pre="inhibiting action of novel camphor-based compound with anti-hemagglutinin activity against" exact="influenza" post="viruses in vitro and in vivoAntiviral Res.201512012613310.1016/j.antiviral.2015.06.00426072310 57.BassiP.KaurG.Polymeric films"/>
   <result pre="polymersomes by controlling the surface density of cell-targeting groups for" exact="influenza" post="A virus treatmentPolym. Chem.201892116212310.1039/C8PY00116B 62.LeeC.M.WeightA.K.HaldarJ.WangL.KlibanovA.M.ChenJ.Polymer-attached zanamivir inhibits synergistically both"/>
   <result pre="62.LeeC.M.WeightA.K.HaldarJ.WangL.KlibanovA.M.ChenJ.Polymer-attached zanamivir inhibits synergistically both early and late stages of" exact="influenza" post="virus infectionProc. Natl. Acad. Sci. USA2012109203852039010.1073/pnas.121915510923185023 63.AgostoniV.ChalatiT.HorcajadaP.WillaimeH.AnandR.SemiramothN.BaatiT.HallS.MaurinG.ChacunH.et al.Towards an"/>
   <result pre="ActivityJ. Pharm. Sci.20121013896390510.1002/jps.2325322786697 70.GambaryanA.S.BoravlevaE.Y.MatrosovichT.Y.MatrosovichM.N.KlenkH.D.MoiseevaE.V.TuzikovA.B.ChinarevA.A.PazyninaG.V.BovinN.V.Polymer-bound 6′ sialyl-N-acetyllactosamine protects mice infected by" exact="influenza" post="virusAntiviral Res.20056811612310.1016/j.antiviral.2005.07.00816214231 71.RonerM.R.CarraherC.E.DhanjiS.BarotG.Antiviral and anticancer activity of cisplatin derivatives"/>
   <result pre="FiberU.S. PatentApplication No. 10/591,4602672007 75.ImaiK.OgawaH.BuiV.N.InoueH.FukudaJ.OhbaM.YamamotoY.NakamuraK.Inactivation of high and low pathogenic" exact="avian influenza" post="virus H5 subtypes by copper ions incorporated in zeolite-textile"/>
   <result pre="PatentApplication No. 10/591,4602672007 75.ImaiK.OgawaH.BuiV.N.InoueH.FukudaJ.OhbaM.YamamotoY.NakamuraK.Inactivation of high and low pathogenic avian" exact="influenza" post="virus H5 subtypes by copper ions incorporated in zeolite-textile"/>
   <result pre="Biomed. Nanotechnol.20084149158 81.RogersJ.V.ParkinsonC.V.ChoiY.W.SpeshockJ.L.HussainS.M.A preliminary assessment of silver nanoparticle inhibition of" exact="monkeypox" post="virus plaque formationNanoscale Res. Lett.2008312913310.1007/s11671-008-9128-2 82.SpeshockJ.L.MurdockR.C.Braydich-StolleL.K.SchrandA.M.HussainS.M.Interaction of silver nanoparticles"/>
   <result pre="virusJ. Nanobiotechnol.201081910.1186/1477-3155-8-1920718972 83.MoriY.OnoT.MiyahiraY.NguyenV.Q.MatsuiT.IshiharaM.Antiviral activity of silver nanoparticle/chitosan composites against H1N1" exact="influenza" post="A virusNanoscale Res. Lett.201389310.1186/1556-276X-8-9323421446 84.BalagnaC.PereroS.PercivalleE.NepitaE.V.FerrarisM.Virucidal effect against Coronavirus SARS-CoV-2"/>
   <result pre="microbicide, is safe and effective against simian-human immunodeficiency virus and" exact="herpes simplex" post="virus 2 infection in vivoAntimicrob. Agents Chemother.2013574001400910.1128/AAC.00796-1323752515 86.BotequimD.MaiaJ.LinoM.M.F.LopesL.M.F.SimõesP.N.IlharcoL.M.FerreiraL.Nanoparticles and"/>
   <result pre="properties of polymeric aziridine- and biguanide-modified core-shell magnetic nanoparticlesLangmuir2012284548455810.1021/la205127x22313053 98.LarsonA.M.OhH.S.KnipeD.M.KlibanovA.M.Decreasing" exact="herpes simplex" post="viral infectivity in solution by surface-immobilized and suspended N,N-dodecyl,methyl-polyethyleniminePharm."/>
   <result pre="and AnimalsJ. Med. Chem.19772035635910.1021/jm00213a009845868 107.HaldarJ.AnD.De CienfuegosL.Á.ChenJ.KlibanovA.M.Polymeric coatings that inactivate both" exact="influenza" post="virus and pathogenic bacteriaProc. Natl. Acad. Sci. USA2006103176671767110.1073/pnas.060880310317101983 108.WangY.CanadyT.D.ZhouZ.TangY.PriceD.N.BearD.G.ChiE.Y.SchanzeK.S.WhittenD.G.Cationic"/>
   <result pre="of cinnamaldehyde, derived from Cinnamomi cortex, on the growth of" exact="influenza" post="A/PR/8 virus in vitro and in vivoAntiviral Res.2007741810.1016/j.antiviral.2007.01.00317303260 115.RandazzoW.FabraM.J.FalcóI.López-RubioA.SánchezG.Polymers"/>
   <result pre="155.YamayaM.NishimuraH.Lusamba KalonjiN.DengX.MommaH.ShimotaiY.NagatomiR.Effects of high temperature on pandemic and seasonal human" exact="influenza" post="viral replication and infection-induced damage in primary human tracheal"/>
   <result pre="Springer, Larson AM, Oh HS, Knipe DM, Klibanov AM. Decreasing" exact="herpes simplex" post="viral infectivity in solution by surface-immobilized and suspended N,N-dodecyl,methyl-polyethylenimine."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7465925/results/search/disease/results.xml">
   <result pre="sleeping to severe complications such as depression, psychosis, and painful" exact="peripheral neuropathy," post="side effects which may necessitate discontinuation of treatment. The"/>
   <result pre="reverse transcriptase inhibitors, which are associated with the development of" exact="peripheral neuropathy" post="after prolonged use (an effect strongly associated with older"/>
   <result pre="transcriptase inhibitors, which are associated with the development of peripheral" exact="neuropathy" post="after prolonged use (an effect strongly associated with older"/>
   <result pre="occur and manage them appropriately. central nervous system antiviral efavirenz" exact="peripheral neuropathy" post="monoamine oxidase The content published in Cureus is the"/>
   <result pre="and manage them appropriately. central nervous system antiviral efavirenz peripheral" exact="neuropathy" post="monoamine oxidase The content published in Cureus is the"/>
   <result pre="side effects include flu-like symptoms and hematologic abnormalities such as" exact="anemia" post="and neutropenia. Moreover, some antiviral drugs cause significant neuropsychiatric"/>
   <result pre="but also discuss, in some cases, peripheral neurotoxicities such as" exact="neuropathy" post="and myopathy. By being aware of the neuropsychiatric side"/>
   <result pre="independently by all authors. Neuropsychiatric effects of antiviral therapy in" exact="influenza" post="Oseltamivir and zanamivir are neuraminidase inhibitors, used for treating"/>
   <result pre="influenza Oseltamivir and zanamivir are neuraminidase inhibitors, used for treating" exact="influenza" post="by shortening the duration of the disease, relieving the"/>
   <result pre="relieving the symptoms and reducing the complications and transmission of" exact="influenza" post="[1]. Neuraminidase inhibition prevents the virus from spreading within"/>
   <result pre="use, no major neuropsychiatric adverse events are described. Headache (9-23%)," exact="migraine" post="(&amp;lt;3%), and paresthesia (&amp;lt;3%) are occasionally reported. Foscarnet (trisodium"/>
   <result pre="investigational pyrophosphate analog is increasingly used to treat refractory cytomegalovirus" exact="retinitis" post="and mucocutaneous herpes simplex virus infections in immunocompromised patients."/>
   <result pre="is increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous" exact="herpes simplex" post="virus infections in immunocompromised patients. Foscarnet has been reported"/>
   <result pre="to hypocalcemia [9]. Neuropsychiatric effects of antiviral therapy for chronic" exact="hepatitis" post="B (CHB) Chronic hepatitis B requires long-term treatment with"/>
   <result pre="effects of antiviral therapy for chronic hepatitis B (CHB) Chronic" exact="hepatitis" post="B requires long-term treatment with antiviral drugs, so side"/>
   <result pre="the drugs used. Antiviral agents indicated for the treatment of" exact="hepatitis" post="B include lamivudine, telbivudine, and entecavir (classified as nucleoside"/>
   <result pre="tenofovir alafenamide [10]. Lamivudine and telbivudine have been associated with" exact="myopathy" post="and peripheral neuropathy, with the incidence of these effects"/>
   <result pre="[10]. Lamivudine and telbivudine have been associated with myopathy and" exact="peripheral neuropathy," post="with the incidence of these effects being similar across"/>
   <result pre="another study, three of six patients with lamivudine or telbivudine­associated" exact="myopathy" post="had a complaint of numbness in the distal end"/>
   <result pre="complaint of numbness in the distal end of limbs, suggesting" exact="peripheral neuropathy." post="The presence of neuropathy was confirmed by the electrophysiological"/>
   <result pre="distal end of limbs, suggesting peripheral neuropathy. The presence of" exact="neuropathy" post="was confirmed by the electrophysiological studies and nerve biopsies"/>
   <result pre="monotherapy in clinical trials, 10 (0.28%) were reported to have" exact="peripheral neuropathy" post="compared to nine of 48 (18.75%) patients who received"/>
   <result pre="in clinical trials, 10 (0.28%) were reported to have peripheral" exact="neuropathy" post="compared to nine of 48 (18.75%) patients who received"/>
   <result pre="of nucleoside analogues (NAs), but they are not specific for" exact="myopathy" post="and may be associated with strenuous exercise and many"/>
   <result pre="1-10% of patients treated with entecavir suffer from insomnia. Entecavir­-associated" exact="myopathy" post="and peripheral neuropathy cases were very rarely reported in"/>
   <result pre="patients treated with entecavir suffer from insomnia. Entecavir­-associated myopathy and" exact="peripheral neuropathy" post="cases were very rarely reported in the literature. Patients"/>
   <result pre="treated with entecavir suffer from insomnia. Entecavir­-associated myopathy and peripheral" exact="neuropathy" post="cases were very rarely reported in the literature. Patients"/>
   <result pre="reported in the literature. Patients receiving entecavir presenting with severe" exact="lactic acidosis," post="complain of weakness, reduced general physical condition, and impaired"/>
   <result pre="and impaired consciousness [10]. Neuropsychiatric effects of antiviral therapy in" exact="hepatitis" post="C The management of patients with hepatitis C is"/>
   <result pre="antiviral therapy in hepatitis C The management of patients with" exact="hepatitis" post="C is very complex. Psychiatric symptoms during antiviral therapy"/>
   <result pre="symptoms during antiviral therapy are reported in 30-40% of chronic" exact="hepatitis" post="C (CHC) patients treated for 6-12 months and are"/>
   <result pre="pegylated interferon and ribavirin was the mainstay of treatment for" exact="hepatitis" post="C infection until the approval of direct-acting antivirals. The"/>
   <result pre="direct-acting antiviral (DAA) regimens has dramatically changed the approach to" exact="hepatitis" post="C virus (HCV) infection management. New antivirals have been"/>
   <result pre="effects of DAAs may be more pronounced in patients with" exact="liver cancer," post="as one study found an association between their use"/>
   <result pre="course of treatment with a sofosbuvir (SOF)-based regimen, patients with" exact="cirrhosis" post="exhibited an increase in extra-slow EEG activity and a"/>
   <result pre="and usually transient as a result of DAA treatment for" exact="hepatitis" post="C, but further research is required in larger patient"/>
   <result pre="a chronic toxidrome reminiscent of inherited mitochondrial disorders, which include" exact="peripheral neuropathy," post="myopathy [27]. All drugs of this category have been"/>
   <result pre="toxidrome reminiscent of inherited mitochondrial disorders, which include peripheral neuropathy," exact="myopathy" post="[27]. All drugs of this category have been associated"/>
   <result pre="varies. Didanosine and stavudine have been more strongly associated with" exact="peripheral neuropathy," post="whereas zidovudine has more commonly been associated with myopathy"/>
   <result pre="peripheral neuropathy, whereas zidovudine has more commonly been associated with" exact="myopathy" post="and myelotoxicity. The pro-drug tenofovir alafenamide, which leads to"/>
   <result pre="first-line treatment since the 1990s. It has been associated with" exact="peripheral neuropathy" post="attributed to depletion of mitochondrial DNA by the mechanism"/>
   <result pre="treatment since the 1990s. It has been associated with peripheral" exact="neuropathy" post="attributed to depletion of mitochondrial DNA by the mechanism"/>
   <result pre="mechanism that is common for all NRTIs. The risk of" exact="neuropathy" post="seems to be dependent upon the total cumulative exposure"/>
   <result pre="zidovudine discontinuation [28]. In contemporary clinical settings, the incidence of" exact="peripheral neuropathy" post="or myopathy during treatment with zidovudine could be managed"/>
   <result pre="discontinuation [28]. In contemporary clinical settings, the incidence of peripheral" exact="neuropathy" post="or myopathy during treatment with zidovudine could be managed"/>
   <result pre="In contemporary clinical settings, the incidence of peripheral neuropathy or" exact="myopathy" post="during treatment with zidovudine could be managed by drug"/>
   <result pre="disiproxil fumarate is the first-line treatment for both HIV and" exact="hepatitis" post="B virus (HBV) infection, due to its similar efficacy"/>
   <result pre="and significantly improved safety profile compared to other NRTIs. Peripheral" exact="neuropathy" post="is less common with tenofovir compared to other NRTIs"/>
   <result pre="although it does occur. Eight percent of participants developed sensory" exact="neuropathy" post="in a South African cohort of 120 treatment-naive individuals"/>
   <result pre="the drug. Nevirapine has, however, been associated with hepatotoxicity and" exact="peripheral neuropathy," post="similar to nucleoside reverse transcriptase inhibitors, as evidenced by"/>
   <result pre="CYP3A4 metabolism for inactivation. They have been associated with a" exact="lipodystrophy" post="syndrome characterized by insulin resistance, dyslipidemia, central adiposity, and"/>
   <result pre="disease [40]. Prolonged use may contribute to the development of" exact="dementia" post="by promoting the pathogenesis of cerebral small vessel disease"/>
   <result pre="of an NRTI by a fusion inhibitor may partially attenuate" exact="peripheral neuropathy" post="and myopathy without compromising treatment efficacy [50]. Further research"/>
   <result pre="an NRTI by a fusion inhibitor may partially attenuate peripheral" exact="neuropathy" post="and myopathy without compromising treatment efficacy [50]. Further research"/>
   <result pre="by a fusion inhibitor may partially attenuate peripheral neuropathy and" exact="myopathy" post="without compromising treatment efficacy [50]. Further research is, however,"/>
   <result pre="correct electrolyte abnormalities. Ribavirin Depressed mood, irritability, anxiety, sleep disturbances," exact="sexual dysfunction" post="- gradual onset Unclear Consider treatment discontinuation (direct-acting antiviral"/>
   <result pre="effects are attributable to ribavirin alone. Direct-acting antiviral agents for" exact="hepatitis" post="C Depression, insomnia, irritability, anxiety Unclear Address symptoms if"/>
   <result pre="ribavirin use may exacerbated NPAEs. Nucleoside / Nucleotide analogues Peripheral" exact="neuropathy" post="and myopathy. Idiosyncratic manic or psychotic reactions to treatment"/>
   <result pre="zidovudine) compared to the ones currently recommended (lamivudine, tenofovir) Peripheral" exact="neuropathy" post="is more pronounced with increased duration of exposure and"/>
   <result pre="dosing at night. In patients with a psychiatric history or" exact="substance abuse," post="alternative agents may be preferred. Psychotropic effects likely present"/>
   <result pre="may predispose to the development of dementia, cerebrovascular disease. Peripheral" exact="neuropathy" post="Direct psychotropic effects unlikely, may cause NPAEs via promoting"/>
   <result pre="exist. References References 1Neuropsychiatric events in an adult patient with" exact="influenza" post="a (H3N2) treated with oseltamivir (Tamiflu): a case reportBMC"/>
   <result pre="Endocrinol MetabJacobsonMAGambertoglioJGAweekaFTCauseyDMPortaleAA113011357219911827127 10Adverse effects of oral antiviral therapy in chronic" exact="hepatitis" post="BWorld J HepatolKayaaslanBGunerR2272419201728261380 11Longitudinal analysis of the associations between"/>
   <result pre="pegylated interferon-alpha and ribavirin therapy in Iranian patients with chronic" exact="hepatitis" post="C: a meta-analysisExp Ther MedDavoodiLMasoumBMoosazadehMJafarpourHHaghshenasMRMousaviT97197816201830116347 14A case report of"/>
   <result pre="symptoms following direct-acting antiviral and ribavirin combination therapy for chronic" exact="hepatitis" post="C in a patient with innate anxietyBMC GastroenterolSakamakiAKamimuraKFukuiNet al.8519201931195993"/>
   <result pre="anxietyBMC GastroenterolSakamakiAKamimuraKFukuiNet al.8519201931195993 15Neuropsychiatric toxicity of antiviral treatment in chronic" exact="hepatitis" post="CDig DisFontanaRJ10711618200011279329 16Efficacy and tolerability of interferon-free regimen for"/>
   <result pre="HCV infectionExp Ther MedTakedaKNoguchiRNamisakiTet al.2743275016201830210615 17Neuropsychiatric performance and treatment of" exact="hepatitis" post="C with direct-acting antivirals: a prospective studyBMJ Open GastroenterolVolpatoSMontagneseSZanettoAet"/>
   <result pre="boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic" exact="hepatitis" post="C genotype 1: a combined analysis of 3 phase"/>
   <result pre="III results of Boceprevir in treatment naive patients with chronic" exact="hepatitis" post="C genotype 1Liver IntMannsMPMarkovaAACalle SerranoBCornbergM273132201222212568 21Efficacy and safety outcomes"/>
   <result pre="SerranoBCornbergM273132201222212568 21Efficacy and safety outcomes of sofosbuvir-based treatment regimens for" exact="hepatitis" post="C virus-infected patients with or without cirrhosis from phase"/>
   <result pre="treatment regimens for hepatitis C virus-infected patients with or without" exact="cirrhosis" post="from phase III clinical trialsTher Clin Risk ManagYangY-MChoiEJ47749713201728442915 22Neurologic"/>
   <result pre="phase III clinical trialsTher Clin Risk ManagYangY-MChoiEJ47749713201728442915 22Neurologic manifestations of" exact="hepatitis" post="C virus infectionClin Liver DisIrianaSCurryMPAfdhalNH53554221201728689591 23Impact of treatment with"/>
   <result pre="treatment with direct-acting antivirals on anxiety and depression in chronic" exact="hepatitis" post="CPLoS OneGallachMVergaraMda CostaJPet al.208112132018 24The next generation of the"/>
   <result pre="vs. single (zidovudine) nucleoside reverse transcriptase inhibitorsHIV MedReissPCasulaMde RondeAWeverlingGJGoudsmitJLangeJMA11145200414731163 28Prevalent" exact="neuropathy" post="in a cohort of HIV-infected Kenyan sex workers using"/>
   <result pre="reporting system in NigeriaPerspect Clin ResAguKAOparahAC1171244201323833736 30Clinical diagnosis of sensory" exact="neuropathy" post="in HIV patients treated with tenofovir: a 6-month follow-up"/>
   <result pre="GriensvenJZachariahRRasschaertFMugaboJAtteEFReidT148153104201019732926 40Brain injury caused by HIV protease inhibitors: role of" exact="lipodystrophy" post="and insulin resistanceAntiviral ResGuptaSKnightAGLossoBYIngramDKKellerJNBruce-KellerAJ192995201222580130 41Potential drug-drug interactions in HIV-perinatally"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7473106/results/search/disease/results.xml">
   <result pre="Center, Jerusalem, Israel First three authors contributed equally Abbreviations: SARS-CoV-2:" exact="severe acute respiratory syndrome" post="coronavirus 2; IFNα: S: spike protein; RAS: renin angiotensin"/>
   <result pre="RAS: renin angiotensin system; Interferon α; IL-6: interleukin 6; ARDS:" exact="acute respiratory distress syndrome;" post="IL-10: interleukin 10; TNFα: tumor necrosis factor alpha; IFNγ:"/>
   <result pre="protease serine 2; S protein: spike glycoprotein; LPS: lipopolysaccharide; COPD:" exact="chronic obstructive pulmonary disease;" post="IL-8: interleukin 8; NF-kappaB: nuclear factor–kappa B; ARB: angiotensin"/>
   <result pre="original work is properly cited. http://creativecommons.org/licenses/by/4.0/TEMI_9_1776161.pdf Abstract ABSTRACT The ongoing" exact="severe acute respiratory syndrome" post="pandemic caused by the novel coronavirus 2 (SARS-CoV-2) is"/>
   <result pre="DPP4 fig-count: table-count: equation-count: ref-count: page-count: 1. Introduction The ongoing" exact="severe acute respiratory syndrome" post="pandemic caused by the coronavirus 2 (SARS-CoV-2), which causes"/>
   <result pre="drawn global attention, by causing potentially lethal epidemic outbreaks: the" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV), and the Middle East respiratory syndrome coronavirus"/>
   <result pre="fever, myalgia, and respiratory symptoms including throat pain, cough, and" exact="shortness" post="of breath [11]. The innate immune response is mediated"/>
   <result pre="progresses to a severe form which most commonly manifests as" exact="acute respiratory distress syndrome" post="(ARDS) followed by respiratory failure, acute myocardial injury, cardiac"/>
   <result pre="commonly manifests as acute respiratory distress syndrome (ARDS) followed by" exact="respiratory failure," post="acute myocardial injury, cardiac dysfunction, shock, and multiple organ"/>
   <result pre="diseases such as hypertension, heart failure, and obstructive or inflammatory" exact="lung disease" post="are more susceptible to SARS-CoV-2 infection [31]. This may"/>
   <result pre="inflammatory responses and tissue fibrosis. Viral respiratory infections such as" exact="influenza" post="strains, the respiratory syncytial virus, and SARS-CoV-2 can mediate"/>
   <result pre="These effects affect additional inflammatory processes in the lungs, including" exact="pulmonary fibrosis," post="chronic obstructive pulmonary disease (COPD), asthma, and acute lung"/>
   <result pre="affect additional inflammatory processes in the lungs, including pulmonary fibrosis," exact="chronic obstructive pulmonary disease" post="(COPD), asthma, and acute lung injury due to potentiation"/>
   <result pre="fibrosis-associated signaling pathways in models of atherosclerosis, cerebral ischemia, obesity," exact="chronic kidney disease," post="liver disease, and asthma [39]. Loss of ACE2 is"/>
   <result pre="in models of atherosclerosis, cerebral ischemia, obesity, chronic kidney disease," exact="liver disease," post="and asthma [39]. Loss of ACE2 is associated with"/>
   <result pre="atherosclerosis, cerebral ischemia, obesity, chronic kidney disease, liver disease, and" exact="asthma" post="[39]. Loss of ACE2 is associated with increased neutrophil,"/>
   <result pre="vascular endothelial cells, lymphatics, and pleural mesothelia. Patients with chronic" exact="lung disease" post="manifest increased DPP4 immunostaining in alveolar epithelia, type I"/>
   <result pre="B cell activation, and its inhibitors suppress that activation via" exact="suppression" post="of DNA synthesis in mitogenic active B cells [57]."/>
   <result pre="[58]. Sitagliptin is a DPP4 inhibitor used for treatment of" exact="diabetes mellitus." post="It can inhibit proliferation of phytohemagglutinin-stimulated peripheral blood mononuclear"/>
   <result pre="virus, which allows viral entry into the cell. GRP78 inhibits" exact="hepatitis" post="B virus replication by reducing viral production and protein"/>
   <result pre="cyclic peptide that binds to GRP78 at the surface of" exact="cancer" post="cells. Sequence and structural alignments have shown that four"/>
   <result pre="[84]. Models have been developed to describe the development of" exact="influenza" post="resistance using semi-stochastic simulations which determine the emergence of"/>
   <result pre="against protease or polymerase inhibitors used for the treatment of" exact="hepatitis" post="C viral infections have been linked to a lower"/>
   <result pre="a clinical Update. JAMA. 2020;323(18):1767–1768. 2ZhouP, YangXL, WangXG, et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
   <result pre="2020;11:1620. doi: 10.1038/s41467-020-15562-932221306 17JiaH.Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory" exact="lung disease." post="Shock. 2016;46:239–248. doi: 10.1097/SHK.000000000000063327082314 18JiaH, SodhiCP, YamaguchiY, et al.Pulmonary"/>
   <result pre="doi: 10.1038/nature0371216001071 22JiaHP, LookDC, ShiL, et al.ACE2 receptor expression and" exact="severe acute respiratory syndrome" post="coronavirus infection depend on differentiation of human airway epithelia."/>
   <result pre="10.1016/j.bbrc.2020.03.04432199615 35YangP, GuH, ZhaoZ, et al.Angiotensin-converting enzyme 2 (ACE2) mediates" exact="influenza" post="H7N9 virus-induced acute lung injury. Sci Rep. 2014;4:7027. doi:"/>
   <result pre="36ZouZ, YanY, ShuY, et al.Angiotensin-converting enzyme 2 protects from lethal" exact="avian influenza" post="A H5N1 infections. Nat Commun. 2014;5:3594. doi: 10.1038/ncomms459424800825 37SodhiCP,"/>
   <result pre="YanY, ShuY, et al.Angiotensin-converting enzyme 2 protects from lethal avian" exact="influenza" post="A H5N1 infections. Nat Commun. 2014;5:3594. doi: 10.1038/ncomms459424800825 37SodhiCP,"/>
   <result pre="syndrome coronavirus receptor, is Upregulated in lungs of Smokers and" exact="chronic obstructive pulmonary disease" post="patients. Clinical Infectious Diseases: an Official Publication of the"/>
   <result pre="protein 78 demonstrates antiviral effects but is more suitable for" exact="hepatocellular carcinoma" post="prevention in hepatitis B. Virol J. 2017;14:77. doi: 10.1186/s12985-017-0747-z28407787"/>
   <result pre="effects but is more suitable for hepatocellular carcinoma prevention in" exact="hepatitis" post="B. Virol J. 2017;14:77. doi: 10.1186/s12985-017-0747-z28407787 66LiaoY, FungTS, HuangM,"/>
   <result pre="ChinKT, et al.Modulation of the unfolded protein response by the" exact="severe acute respiratory syndrome" post="coronavirus spike protein. J Virol. 2006;80:9279–9287. doi: 10.1128/JVI.00659-0616940539 69IbrahimIM,"/>
   <result pre="J Infect. 2020;80:554–562. doi: 10.1016/j.jinf.2020.02.02632169481 70LiT.Diagnosis and clinical management of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking"/>
   <result pre="of chloroquine Diphosphate as Adjunctive therapy for patients hospitalized With" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) infection: A Randomized clinical trial. JAMA"/>
   <result pre="to treat COVID-19 causes fears of shortages among people with" exact="systemic lupus erythematosus." post="Nat Med. 2020;26:632. doi: 10.1038/s41591-020-0853-0 80YazdanyJ, KimAHJ.Use of Hydroxychloroquine"/>
   <result pre="treat COVID-19 causes fears of shortages among people with systemic" exact="lupus erythematosus." post="Nat Med. 2020;26:632. doi: 10.1038/s41591-020-0853-0 80YazdanyJ, KimAHJ.Use of Hydroxychloroquine"/>
   <result pre="antivirals. F1000Res. 2019;8:1628. doi: 10.12688/f1000research.19694.1 85DobrovolnyHM, BeaucheminCAA.Modelling the emergence of" exact="influenza" post="drug resistance: The roles of surface proteins, the immune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7473320/results/search/disease/results.xml">
   <result pre="of Record : Review: Review In vivo expressed biologics for" exact="infectious disease" post="prophylaxis: rapid delivery of DNA-based antiviral antibodies Emerging Microbes"/>
   <result pre="KEYWORDS Neutralizing antibodies DNA therapeutics antivirals electroporation gene transfer emerging" exact="infectious disease" post="antibody cocktail fig-count: table-count: equation-count: ref-count: page-count: Introduction Unmet"/>
   <result pre="fig-count: table-count: equation-count: ref-count: page-count: Introduction Unmet needs of emerging" exact="infectious disease" post="outbreaks Fuelled by multiple factors, including the growing urbanization"/>
   <result pre="outbreaks have caused significant damage with wide-reaching ramifications. From the" exact="severe acute respiratory syndrome" post="(SARS) outbreak in 2003, the H1N1 influenza A virus"/>
   <result pre="severe acute respiratory syndrome (SARS) outbreak in 2003, the H1N1" exact="influenza" post="A virus (IAV) pandemic in 2009, the Middle East"/>
   <result pre="recurring Ebola virus outbreaks in 2014–2016, to the expansion of" exact="chikungunya" post="virus and the rapid spreading of Zika virus infections"/>
   <result pre="and private sectors [6]. Because of the existing infrastructure for" exact="influenza" post="vaccine development, vaccines against the 2009 H1N1 pandemic IAV"/>
   <result pre="authorization from the FDA [14]. Antibodies as drugs for fighting" exact="infectious disease" post="Monoclonal antibodies (mAbs) represent a unique class of biologic"/>
   <result pre="diseases. A few, however, have been approved for use in" exact="infectious disease" post="settings, such as palivizumab for respiratory syncytial virus and"/>
   <result pre="mAb Fc domain [20]. This is of particular importance in" exact="infectious disease" post="settings that are susceptible to Fc receptor-mediated antibody dependent"/>
   <result pre="major barrier to the more widespread use of mAbs for" exact="infectious disease" post="[17]. However, the use of mAbs as therapeutics in"/>
   <result pre="not the least of which is the global eradication of" exact="smallpox" post="and massive reductions in the number of other viral"/>
   <result pre="in the number of other viral diseases like polio and" exact="measles" post="through vaccination [28]. Similarly, the development of a vast"/>
   <result pre="inert [31]. And although historically the delivery of mAbs for" exact="infectious disease" post="prevention and therapy has been a much smaller area"/>
   <result pre="first clinical use was in 1995 for the treatment of" exact="cystic fibrosis." post="The first regulatory approval didn’t come until 2012, however,"/>
   <result pre="by Moderna (www.clinicaltrials.gov Identifier: NCT03829384), for an antibody directed against" exact="chikungunya" post="virus. In contrast to the long-lived expression often seen"/>
   <result pre="LNP-mRNA has successfully been used to deliver NAbs against HIV-1," exact="influenza" post="B virus, or rabies virus in mice, resulting in"/>
   <result pre="used to deliver NAbs against HIV-1, influenza B virus, or" exact="rabies" post="virus in mice, resulting in peak titers of ∼10–150 µg/mL"/>
   <result pre="antibodies, either as therapeutic agents or for the prevention of" exact="infectious disease" post="(Table 1) [48,49]. Table 1. DNA/EP-mediated delivery of antiviral"/>
   <result pre="1) [48,49]. Table 1. DNA/EP-mediated delivery of antiviral mAbs for" exact="infectious disease" post="prophylaxis. Virus Antibody Reference Influenza A rHA Yamazaki et"/>
   <result pre="subsequent study revealed the benefit of cardiotrophin-1 delivery for progressive" exact="motor neuron disease" post="[47,57]. It was nearly a decade later, however, before"/>
   <result pre="lethal IAV challenge [58]. In another important model of DNA/EP-mediated" exact="infectious disease" post="prophylaxis, the delivery of an anti-dengue virus NAb bearing"/>
   <result pre="the prevention of infectious diseases, including not only IAV, but" exact="influenza" post="B virus, chikungunya virus, Ebola virus, and Zika virus"/>
   <result pre="infectious diseases, including not only IAV, but influenza B virus," exact="chikungunya" post="virus, Ebola virus, and Zika virus [60–65.] Importantly, the"/>
   <result pre="An important advantage revealed by some of these studies of" exact="infectious disease" post="prophylaxis, but with relevance to other disease indications that"/>
   <result pre="makes this highly attractive strategy of administering NAb cocktails for" exact="infectious disease" post="a much more realistic possibility, particularly when the goal"/>
   <result pre="References References 1SmithKF, GoldbergM, RosenthalS, et al.Global rise in human" exact="infectious disease" post="outbreaks. J Roy Soc Interface. 2014;11:20140950. doi: 10.1098/rsif.2014.095025401184 2FindlaterA,"/>
   <result pre="2002;11:1615–1625. doi: 10.1093/hmg/11.14.161512075006 58YamazakiT, NagashimaM, NinomiyaD, et al.Passive immune-prophylaxis against" exact="influenza" post="virus infection by the expression of neutralizing anti-hemagglutinin monoclonal"/>
   <result pre="al.DMAb inoculation of synthetic cross reactive antibodies protects against lethal" exact="influenza" post="A and B infections. npj Vaccines. 2017;2:18. doi: 10.1038/s41541-017-0020-x29263874"/>
   <result pre="immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against" exact="chikungunya" post="virus. J Infect Dis. 2016;214:369–378. doi: 10.1093/infdis/jiw11127001960 62AndrewsCD, LuoY,"/>
   <result pre="monoclonal antibodies by gene transfer via electroporation protects against lethal" exact="influenza" post="and Ebola infections. Mol Ther Methods Clin Dev. 2017;7:74–82."/>
   <result pre="et al.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19," exact="acute respiratory distress syndrome," post="and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7475736/results/search/disease/results.xml">
   <result pre="We report successful recovery in an elderly patient with severe" exact="pneumonia" post="requiring mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Despite"/>
   <result pre="the ship. Two days later, he was transferred to the" exact="infectious disease" post="ward at our hospital. He had a history of"/>
   <result pre="hospital. He had a history of bronchial asthma, hypertension, and" exact="dyslipidemia" post="and showed no respiratory symptoms including cough, sputum, and"/>
   <result pre="were negative. Simple inspection kit results were negative for both" exact="influenza" post="virus types A and B. Oral administration of lopinavir/ritonavir,"/>
   <result pre="of favipiravir, which was developed for treating RNA viruses including" exact="influenza" post="virus, was started. On the first day, 1600 mg was"/>
   <result pre="not be prevented during its administration. Moreover, the appearance of" exact="diarrhea" post="and inability to eat seemed to be side effects"/>
   <result pre="(Fujifilm group) of Japan and was approved for stockpiling against" exact="influenza" post="pandemics. Favipiravir is currently being studied in China for"/>
   <result pre="the administration of favipiravir, it might have a modest virus" exact="suppression" post="effect. Although favipiravir did not cause any adverse events"/>
   <result pre="five-day course, as has been prescribed for the treatment of" exact="influenza" post="virus infection, might be too short to achieve sufficient"/>
   <result pre="have given favipiravir to a patient with severe fever with" exact="thrombocytopenia" post="syndrome and that its duration can be extended up"/>
   <result pre="in animal models of Middle East respiratory syndrome (MERS) and" exact="severe acute respiratory syndrome" post="(SARS), which are caused by other coronaviruses [13]. We"/>
   <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA2020323111061106910.1001/jama.2020.158532031570 4LiG.ClercqE. D.Therapeutic options for the 2019"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="ribavirin/PMC7498411/results/search/disease/results.xml">
   <result pre="emergencies and socioeconomic losses (Fig. 1 a). For instance, the" exact="severe acute respiratory syndrome" post="(SARS) outbreak in 2003 induced 774 deaths and 8096"/>
   <result pre="treatment of 9 types of human transmissible diseases, namely HIV," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), herpesvirus, influenza"/>
   <result pre="of human transmissible diseases, namely HIV, hepatitis B virus (HBV)," exact="hepatitis" post="C virus (HCV), herpesvirus, influenza virus, human cytomegalovirus, varicella-zoster"/>
   <result pre="HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), herpesvirus," exact="influenza" post="virus, human cytomegalovirus, varicella-zoster virus, respiratory syncytial virus (RSV),"/>
   <result pre="antibody to neutralizing DENV. [38] aDENV: dengue virus; VSV: vesicular" exact="stomatitis" post="virus; BV: baculovirus; ED III: domain III of envelope"/>
   <result pre="an approved antiviral drug, acyclovir can be used to treat" exact="herpes simplex" post="virus (HSV) infection through disruption of the viral DNA"/>
   <result pre="used clinical route, especially for treating an infection due to" exact="influenza" post="virus. However, for gastrointestinal infections caused by rotavirus or"/>
   <result pre="influenza virus. However, for gastrointestinal infections caused by rotavirus or" exact="hepatitis" post="virus, oral administration is better, while intranodal administration may"/>
   <result pre="- Two-dimensional nanoparticles for the delivery of anticancer drugs and" exact="cancer" post="therapyParakW.J.FeliuN.Frontiers of Nanoscience2020Elsevier151199 33PalmieriV.PapiM.Nano Today332020100883 34JoungY.K.SonS.JangJ.Y.KwonM.H.ParkK.D.Pharm. Res.29201293294222139535 35TaharaK.KobayashiM.YoshidaS.OnoderaR.InoueN.TakeuchiH.Int. J."/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
